Drug Name,Brand Name,Generic Name,PDF Links,Therapeutic Area,Recommendation,Status,Submission Date,Recommendation Date,Project Number
Dabrafenib trametinibOpens in new tab,N/A,Dabrafenib trametinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373_Dabrafeninb_FINAL_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373-Dabrafanib-Trametinib_DPI_Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0373-Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0373-Supplemental_Material.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373_Dabrafenib_consolidated_feedback.pdf']",Head and neck cancer,Reimburse with clinical criteria and/or conditions,Complete,07-Oct-24,16-May-25,PX0373-000
ruxolitinibOpens in new tab,Opzelura,ruxolitinib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0807-Opzelura_Recommendation.pdf'],atopic dermatitis,Do not reimburse,Active,27-Oct-23,06-May-25,SR0807-000
pemigatinibOpens in new tab,Pemazyre,pemigatinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0391-Pemazyre_FINAL_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0391_Pemazyre_Patient_Clinician_Input.pdf']",Cholangiocarcinoma,Reimburse with clinical criteria and/or conditions,Active,18-Oct-24,05-May-25,PC0391-000
"durvalumab, carboplatin, pacli...Opens in new tab",Imfinzi,"durvalumab, carboplatin, paclitaxel","['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0366-Imfinzi_FINAL_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0366-000_Imfinz_Patient_Group_Clinician_Group_Input.pdf']",Endometrial cancer that is mismatch repair deficient (dMMR),Reimburse with clinical criteria and/or conditions,Active,16-Oct-24,05-May-25,PC0366-000
daratumumabOpens in new tab,Darzalex SC,daratumumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0388_Darzalex_SC_Final_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0388_Patient_and_Clinician_Group_Input.pdf']","Multiple myeloma, eligible for autologous stem cell transplant",Reimburse with clinical criteria and/or conditions,Active,01-Oct-24,02-May-25,PC0388-000
blinatumomabOpens in new tab,Blincyto,blinatumomab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0365-Blincyto_Recommendation-e.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0365_Blincyto_Patient_and_Clinician_Input.pdf']",B-cell precursor acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Active,18-Oct-24,01-May-25,PC0365-000
ferric carboxymaltoseOpens in new tab,Ferinject,ferric carboxymaltose,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0852-Ferinject_FINAL_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0852%20ferric%20carboxymaltose%20HF%20consolidated%20Patient%20and%20Clinician%20Group%20Input.pdf']",Iron deficiency in adult patients with heart failure,Reimburse with clinical criteria and/or conditions,Active,01-Mar-24,16-Apr-25,SR0852-000
olopatadine hydrochloride and ...Opens in new tab,Ryaltris,olopatadine hydrochloride and mometasone,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0848_Ryaltris_FINAL_Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0848_Patient_and_Clinician_Input.pdf']",Seasonal allergic rhinitis,Do not reimburse,Active,21-Jun-24,08-Apr-25,SR0848-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0385_Keytruda_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0385_Patient_Clinician_Group_Input.pdf']","Non-Small Cell Lung Cancer, neoadjuvant",Reimburse with clinical criteria and/or conditions,Active,17-Sep-24,04-Apr-25,PC0385-000
MyelofibrosisOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0069-Rapid_Algorithm_Report_for_Myelofibrosis.pdf'],Myelofibrosis,,Complete,,04-Apr-25,PH0069-000
Non-small-cell lung cancer (NS...Opens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025//PH0071-NSCLC-EGFR.pdf'],Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations,,Complete,,04-Apr-25,PH0071-000
trastuzumab deruxtecanOpens in new tab,Enhertu,trastuzumab deruxtecan,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0367_Enhertu_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0367-Enhertu_Patient_Clinician_Group_Input.pdf']",Gastric or gastroesophageal junction (GEJ) adenocarcinoma,Time-limited reimbursement recommendation,Active,16-Sep-24,03-Apr-25,PC0367-000
trametinibOpens in new tab,N/A,trametinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372%20Trametinib_FMEC_Nonsponsored_Review_Final_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372-Trametinib_FMEC_Nonsponsored_Review_DPI_Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0372_trametinib_Combined_Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0372_trametinib_Stakeholder_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372_trametinib_Supplemental_Material.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372_consolidated_feedback_on_draft_recs.pdf']",Gynecological cancers,Reimburse with clinical criteria and/or conditions,Complete,28-Aug-24,02-Apr-25,PX0372-000
Urothelial carcinomaOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0070-MUC_Rapid_Algorithm_Report.pdf'],Urothelial carcinoma,,Complete,,01-Apr-25,PH0070-000
Cladribine and Natalizumab for...Opens in new tab,,,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/TS0004_cladribine_natalizumab_Final%20Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/attachments/2025-03/TS0004-Cladribine-Natalizumab_Updated_Recommendations_1.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/TS0004-Cladribine-Natalizumab_DPI-Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/TS0004-Natalizumab_Clinical_and_Pharmacoeconomic_Combined_Report%20.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/TS0004-Cladribine-Natalizumab_SF_DR_Redacted.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/TS0004-Natalizumab_and_Cladribine_Combined_Review_Stakeholder_Input.pdf']",,,Active,,28-Mar-25,TS0004-000
iptacopanOpens in new tab,Fabhalta,iptacopan,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0851_Fabhalta_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0851_Patient_and_Clinician_Group_Input.pdf']",paroxysmal nocturnal hemoglobinuria (PNH),Reimburse with clinical criteria and/or conditions,Active,15-Aug-24,12-Mar-25,SR0851-000
tarlatamabOpens in new tab,Imdelltra,tarlatamab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0351_Imdelltra_FINAL_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0351_Patient_and_Clinician_Group_Input.pdf']",Extensive stage small cell lung cancer,Reimburse with clinical criteria and/or conditions,Active,14-Aug-24,28-Feb-25,PC0351-000
talquetamabOpens in new tab,Talvey,talquetamab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0363-Talvey_FINAL_Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2025/PC0363_Talvey_Patient_Clinician_Input.pdf']",Relapsed or refractory multiple myeloma,Do not reimburse,Active,01-May-24,27-Feb-25,PC0363-000
faricimabOpens in new tab,Vabysmo,faricimab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0832-Vabysmo_FINAL_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0832_Patient_and_Clinician_Input.pdf']",Retinal vein occlusion,Reimburse with clinical criteria and/or conditions,Active,31-Jul-24,13-Feb-25,SR0832-000
Large B cell lymphomaOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0064-Rapid_Algorithm_Report_LBCL.pdf'],Large B cell lymphoma/  Lymphome B à grandes cellules,,Complete,,11-Feb-25,PH0064-000
clascoteroneOpens in new tab,Winlevi,clascoterone,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0863_Winlevi_FINAL_Reconsideration.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0863_Patient_and_Clinician_Group_Input.pdf']",Acne vulgaris,Do not reimburse,Active,06-Aug-24,06-Feb-25,SR0863-000
Colorectal cancerOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0062-mCRC_Rapid_Algorithm_Report.pdf'],Colorectal cancer,,Complete,,06-Feb-25,PH0062-000
blinatumomabOpens in new tab,N/A,blinatumomab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-FMEC_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-DPI_Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-Blinatumomab_Supplemental.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0367_consolidated_input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-Feedback_DRAFT_REC.pdf']","Acute lymphoblastic leukemia, pediatrics",Reimburse with clinical criteria and/or conditions,Complete,11-Jun-24,04-Feb-25,PX0367-000
dimethyl fumarateOpens in new tab,N/A,dimethyl fumarate,"['https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Dimethyl_FMEC_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Dimethyl-DPI_Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0751-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0751-Supplemental_Material.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Feedback_%20DRAFT_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Feedback_Input.pdf']",Multiple Sclerosis (MS),Reimburse with clinical criteria and/or conditions,Complete,21-Jun-24,04-Feb-25,SX0751-000
teriflunomideOpens in new tab,N/A,teriflunomide,"['https://cda-amc.ca/sites/default/files/DRR/2025/SX0752_Teriflunomide_FMEC_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0752-DPI_Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0752-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0752-Supplemental_Material.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0752_Feedback_%20DRAFT_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SX0752_Feedback_input.pdf']",Multiple Sclerosis (MS),Reimburse with clinical criteria and/or conditions,Complete,21-Jun-24,04-Feb-25,SX0752-000
nivolumab ipilimumabOpens in new tab,N/A,nivolumab ipilimumab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PX0371_FMEC_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0371-DPI_table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0371-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0371-Supplemental_Material.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0371_input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0371_Feedback_%20DRAFT_REC.pdf']",Melanoma,Reimburse with clinical criteria and/or conditions,Complete,25-Jun-24,04-Feb-25,PX0371-000
Chronic lymphocytic leukemia (...Opens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0063-CLL_Rapid_Algorithm_Report.pdf'],Chronic lymphocytic leukemia (CLL),,Complete,,31-Jan-25,PH0063-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0377_Keytruda_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0377-Keytruda_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0377-Keytruda_Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0377_Patient_and_Clinician_Group_Input.pdf']",Unresectable or metastatic MSI-H or dMMR solid tumors,Reimburse with clinical criteria and/or conditions,Complete,16-Jul-24,31-Jan-25,PC0377-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0369-Keytruda-NSCLC_FINAL_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0369-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0369-Feedback_Draft_Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0369_Combined_Patient_Clinician_Group_Input.pdf']",Non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,15-Jul-24,30-Jan-25,PC0369-000
zolbetuximabOpens in new tab,Vyloy,zolbetuximab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0338_Vyloy_Final_Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0338_zolbetuximab-Patient_Clinician_Input.pdf']",Gastric or gastroesophageal junction (GEJ) adenocarcinoma,Reimburse with clinical criteria and/or conditions,Active,28-Jun-24,29-Jan-25,PC0338-000
zilucoplanOpens in new tab,Zilbrysq,zilucoplan,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0838_Zilbrysq_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0838-Zilucoplan_Patient%20Clinician_Group_Input.pdf']",Generalized myasthenia gravis (gMG),Reimburse with clinical criteria and/or conditions,Active,29-Feb-24,23-Jan-25,SR0838-000
Prostate cancerOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0057-Prostate_Cancer_Rapid_Algorithm.pdf'],Prostate cancer,,Complete,,22-Jan-25,PH0057-000
Anaplastic Lymphoma Kinase (AL...Opens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0058-ALK_Positive_NSCLC.pdf'],Anaplastic Lymphoma Kinase (ALK) -Positive Non-small Cell Lung Cancer (NSCLC),,Complete,,21-Jan-25,PH0058-000
amivantamabOpens in new tab,Rybrevant,amivantamab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0376_Rybrevant_FINAL_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0376-Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0376-Rybrevant_Draft_Rec_Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0376_Patient_and_Clinician_Input.pdf']",Locally advanced or metastatic non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,21-Jun-24,10-Jan-25,PC0376-000
erdafitinibOpens in new tab,Balversa,erdafitinib,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0375-Balversa_Final_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0375_Combined_Patient_and_Clinician_Group_Input.pdf']",locally advanced unresectable or metastatic urothelial carcinoma (UC),Reimburse with clinical criteria and/or conditions,Active,14-Jun-24,09-Jan-25,PC0375-000
momelotinibOpens in new tab,Ojjaara,momelotinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0355_Ojjaara_FINAL_REC.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0355_Patient_and_Clinician_Group_Input.pdf']",Myelofibrosis,Reimburse with clinical criteria and/or conditions,Active,19-Jun-24,08-Jan-25,PC0355-000
ravulizumabOpens in new tab,Ultomiris,ravulizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0855_Ultomiris_FINAL_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0855_Patient_and_Clinician_Group_Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/SR0855_Ultomiris-Combined_Review.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/SR0855_Ultomiris_Feedback_Redacted.pdf']",Generalized Myasthenia Gravis,Reimburse with clinical criteria and/or conditions,Complete,04-Jun-24,17-Dec-24,SR0855-000
spesolimabOpens in new tab,Spevigo,spesolimab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0844_Spevigo_Final_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0844_Patient_and_Clinician_Group_Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/SR0844-Spevigo-Combined_Review.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/SR0844-Spevigo-Stakeholder_Feedback.pdf']",generalized pustular psoriasis (GPP),Reimburse with clinical criteria and/or conditions,Complete,04-Jun-24,12-Dec-24,SR0844-000
exagamglogene autotemcelOpens in new tab,Casgevy,exagamglogene autotemcel,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SG0831_Casgevy_FINAL_Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SG0831_Patient_Clinician_Group_Input.pdf']",Transfusion-dependent β-thalassemia,Reimburse with clinical criteria and/or conditions,Active,27-May-24,11-Dec-24,SG0831-000
exagamglogene autotemcelOpens in new tab,Casgevy,exagamglogene autotemcel,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SG0830_Casgevy_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SG0830-Casgevy-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SG0830-Casgevy-Feedback.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0830-exa-cel-SCD_Patient_Clinician_Group_Input_Revised.pdf']",Sickle cell disease (SCD),Reimburse with clinical criteria and/or conditions,Complete,27-May-24,11-Dec-24,SG0830-000
ferric carboxymaltoseOpens in new tab,Ferinject,ferric carboxymaltose,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0842-Ferinject-IDA_FINAL_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0842-Ferinject-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0842-Ferinject-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0842%20ferric%20carboxymaltose%20IDA%20consolidated%20Patient%20and%20Clinician%20Group%20Input.pdf']",Iron deficiency anemia,Reimburse with clinical criteria and/or conditions,Complete,10-May-24,11-Dec-24,SR0842-000
"HR positive, HER2 negative bre...Opens in new tab",,,['https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0053-HRPositive-HER2-Breast-Cancer.pdf'],"HR positive, HER2 negative breast cancer",,Complete,,10-Dec-24,PH0053-000
Non-small cell lung cancer (NS...Opens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2024/PH0054-FINAL_NSCLC_EGFR.pdf'],Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation,,Complete,,05-Dec-24,PH0054-000
Advanced or metastatic gastric...Opens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0051-Rapid_Algorithm_Report.pdf'],Gastric Cancer,,Complete,,03-Dec-24,PH0051-000
everolimusOpens in new tab,N/A,everolimus,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836-Everolimus-SEGA_FINAL_REC.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836-DPI_Table.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836_Reimbursement_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836_consolidated_FEEDBACK_DRAFT_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SX0836-Patient_Clinician_Industry_Group_Input.pdf']",Tuberous Sclerosis Complex (TSC),Reimburse with clinical criteria and/or conditions,Complete,13-Dec-23,03-Dec-24,SX0836-000
enfortumab vedotinOpens in new tab,Padcev,enfortumab vedotin,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0353-Padcev_FINAL_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0353_Padcev-Patient_and_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0353-Padcev_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0353-Padcev_Stakeholder_Feedback.pdf']",Metastatic urothelial cancer,Reimburse with clinical criteria and/or conditions,Complete,22-May-24,29-Nov-24,PC0353-000
venetoclaxOpens in new tab,Venclexta,venetoclax,"['https://cda-amc.ca/sites/default/files/DRR/2024/PC0362-Venclexta_Reassessment.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0362_Patient_and_Clinician_Group_Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0362_Venclexta-Combined_Review.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0362_Venclexta-Stakeholder_Feedback.pdf']",Chronic lymphocytic leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,22-May-24,28-Nov-24,PC0362-000
fruquintinibOpens in new tab,Fruzaqla,fruquintinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0352_Fruzaqla_FINAL_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0352%20fruquintinib%20Patient%20and%20Clinician%20Group%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0352_fruquintinib-Combined_Review.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0352_fruquintinib-Stakeholder_Feedback.pdf']",Metastatic colorectal cancer (mCRC),Reimburse with clinical criteria and/or conditions,Complete,22-May-24,27-Nov-24,PC0352-000
lisocabtagene maraleucelOpens in new tab,Breyanzi,lisocabtagene maraleucel,"['https://cda-amc.ca/sites/default/files/DRR/2024/PG0358-Breyanz_FINAL_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PG0358-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PG0358-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PG0358%20Breyanzi%20-%20Patient%20and%20Clinician%20Group%20Input.pdf']",Relapsed or refractory large B-cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,08-May-24,27-Nov-24,PG0358-000
EnzalutamideOpens in new tab,N/A,Enzalutamide,"['https://cda-amc.ca/sites/default/files/DRR/2024/PX0366_Enzalutamide_FINAL_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0366_Enzalutamide_DPI_Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0366-Enzalutamide-nmCSPC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0366-Patient_Clinician_input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0366_Enzalutamide_consolidated_SF_Redacted.pdf']",Genito-urinary cancer (prostate cancer),Reimburse with clinical criteria and/or conditions,Complete,30-Apr-24,26-Nov-24,PX0366-000
MepolizumabOpens in new tab,N/A,Mepolizumab,"['https://cda-amc.ca/sites/default/files/DRR/2024/SX0839-FINAL_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SX0839-DPI-Table_FINAL.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0839_Clinical_and_Pharmacoeconomic_Combined_Report.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0839_stakeholder_input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SX0839_Feedback_DRAFT_REC.pdf']",Eosinophilic Granulomatosis with Polyangiitis,Reimburse with clinical criteria and/or conditions,Complete,19-Dec-23,25-Nov-24,SX0839-000
Adult Classical Hodgkin Lympho...Opens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2024/PH0052-Adult_Classical_Hodgkin_Lymphoma.pdf'],Adult Classical Hodgkin Lymphoma,,Complete,,15-Nov-24,PH0052-000
ciltacabtagene autoleucelOpens in new tab,Carvykti,ciltacabtagene autoleucel,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PG0361REC_Carvykti_Final.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PG0361-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PG0361-Carvykti_Feedback.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PG0361_Carvykt_Patient_Clinician_Group_Input.pdf']",Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,18-Apr-24,01-Nov-24,PG0361-000
avapritinibOpens in new tab,Ayvakyt,avapritinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0335-Ayvakyt_FINAL_Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0335%20avapritinib%20-%20Patient%20and%20Clinicain%20input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0335_Ayvakyt-Combined_Review.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2025/PC0335-Ayvakyt-Stakeholder_Feedback.pdf']",Advanced Systemic Mastocytosis,Reimburse with clinical criteria and/or conditions,Complete,19-Apr-24,31-Oct-24,PC0335-000
alectinibOpens in new tab,Alecensaro,alectinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0350_FINAL_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0350-Alecensaro_Patient_Clinician_Group_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0350-Alecensaro_Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0350-Alecensaro_Stakeholder_Feedback.pdf']",ALK-positive NSCLC,Reimburse with clinical criteria and/or conditions,Complete,18-Apr-24,30-Oct-24,PC0350-000
sotaterceptOpens in new tab,Winrevair,sotatercept,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0828REC-Winrevair.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0828_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0828-Winrevair_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0828_Winrevair_Stakeholder_Feedback.pdf']",Pulmonary arterial hypertension (WHO group 1),Reimburse with clinical criteria and/or conditions,Complete,08-Apr-24,21-Oct-24,SR0828-000
eplontersenOpens in new tab,Wainua,eplontersen,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0826REC-Wainua_FINAL.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0826_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0826-Wainua_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0826-Wainua_Stakeholder_Feedback.pdf']",Polyneuropathy in hereditary transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,09-Apr-24,21-Oct-24,SR0826-000
clindamycin plus benzoyl perox...Opens in new tab,Cabtreo,clindamycin plus benzoyl peroxide and adapalene,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0794_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0794_Cabtreo_Patient_and_Clinician_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0794-Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0794_Cabtreo_Stakeholder_Feedback.pdf']",acne vulgaris,Reimburse with clinical criteria and/or conditions,Complete,08-Mar-24,18-Oct-24,SR0794-000
danicopanOpens in new tab,Voydeya,danicopan,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0815_Voydeya_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0815-Voydeya_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0815_Voydeya_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0815_Voydeya_Stakeholder_Feedback.pdf']",Paroxysmal nocturnal hemoglobinuria (PNH),Reimburse with clinical criteria and/or conditions,Complete,04-Apr-24,18-Oct-24,SR0815-000
elexacaftor/tezacaftor/ivacaft...Opens in new tab,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0837_Trikafta_%20Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0837-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0837-Trikafta%20_Feedback.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0837_Trikaft_Patient_and_Clinician_Input.pdf']","Cystic fibrosis, F508del or responsive CFTR mutation,  2 years and older",Reimburse with clinical criteria and/or conditions,Complete,05-Mar-24,17-Oct-24,SR0837-000
burosumabOpens in new tab,Crysvita,burosumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0818_Reassessment_Final_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0818_Crysvita_Patient_Clinician_Group_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0818-Crysvita_Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0818-Crysvita_Stakeholder_Feedback.pdf']",Treatment of X-Linked Hypophosphatemia,Reimburse with clinical criteria and/or conditions,Complete,02-Jan-24,10-Oct-24,SR0818-000
lebrikizumabOpens in new tab,Ebglyss,lebrikizumab,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0819_Ebglyss_FINAL_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0819-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0819-Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0819_Ebglyss_Patient_Clinician_Input.pdf']",atopic dermatitis,Do not reimburse,Complete,01-Nov-23,09-Oct-24,SR0819-000
Prostate CancerOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2024/PH0050-Prostate-Cancer.pdf'],Prostate Cancer,,Active,,09-Oct-24,PH0050-000
ivosidenibOpens in new tab,Tibsovo,ivosidenib,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0349_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0349-Tibsovo_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0349_Tibsovo_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0349_Tibsovo_Stakeholder_Feedback.pdf']",Acute myeloid leukemia (AML),Reimburse with clinical criteria and/or conditions,Complete,19-Mar-24,04-Oct-24,PC0349-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0356_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0356-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0356-Keytruda-Gastric_Feedback.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0356-Keytruda-Gastric_Patient_Clinician_Group.pdf']",Gastric or gastroesophageal junction (GEJ) adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,13-Mar-24,04-Oct-24,PC0356-000
abemaciclibOpens in new tab,Verzenio,abemaciclib,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0345_Final_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0345_Verzenio_Patient_and_Clinician_Group_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0345-Verzenio-Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0345-Verzenio-Stakeholder_Feedback.pdf']","Adjuvant treatment of HR-positive, HER2-negative early breast cancer",Reimburse with clinical criteria and/or conditions,Complete,09-Feb-24,03-Oct-24,PC0345-000
osimertinibOpens in new tab,Tagrisso,osimertinib,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0336_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0336-Tagrisso_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0336-Tagrisso_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0336-Tagrisso_Stakeholder_Feedback.pdf']",Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,11-Dec-23,03-Oct-24,PC0336-000
baricitinibOpens in new tab,Olumiant,baricitinib,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0843REC-Olumiant.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0843_Patient_and_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0843-Olumiant-Combined_Review.pdf', 'https://cda-amc.ca/sites/default//files/DRR/2025/SR0843-Olumiant-Stakeholder-Feedback.pdf']","Alopecia areata, severe",Reimburse with clinical criteria and/or conditions,Complete,04-Mar-24,13-Sep-24,SR0843-000
secukinumabOpens in new tab,Cosentyx,secukinumab,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0781REC-Cosentyx-HS.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0781_Patient_Group_and_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0781-Cosentyx_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0781_Cosentyx_Stakeholder_Feedback.pdf']",Hidradenitis suppurativa,Reimburse with clinical criteria and/or conditions,Complete,10-May-23,12-Sep-24,SR0781-000
capivasertibOpens in new tab,Truqap,capivasertib,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0341_Truqap-Final_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0341-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PC0341-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0341-Truqap_Patient_Clinician_Group_Input.pdf']","HR-positive, HER2-negative locally advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,14-Feb-24,30-Aug-24,PC0341-000
Brentuximab vedotinOpens in new tab,Adcetris,Brentuximab vedotin,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0371REC-Adectris.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0371-Adcetris-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0371-Adcetris_Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0371-Adcetris_Patient_Clinician_Input.pdf']",Hodgkin lymphoma,Reimburse with clinical criteria and/or conditions,Complete,18-Apr-24,29-Aug-24,PC0371-000
remdesivirOpens in new tab,Veklury,remdesivir,"['https://cadth.ca/sites/default/files/DRR/2024/SR0833_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0833-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0833-Veklury_Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0833-Veklury_Patient_Clinician_Group_Input.pdf']",COVID-19 in hospitalized patients,Reimburse with clinical criteria and/or conditions,Complete,01-Mar-24,16-Aug-24,SR0833-000
remdesivirOpens in new tab,Veklury,remdesivir,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0834_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0834_Veklury_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0834-Veklury_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0834_Veklury_Stakeholder_Feedback.pdf']",COVID-19 in non-hospitalized patients,Reimburse with clinical criteria and/or conditions,Complete,01-Mar-24,16-Aug-24,SR0834-000
inclisiranOpens in new tab,Leqvio,inclisiran,"['https://cadth.ca/sites/default/files/DRR/2024/SR0791-000REC-Leqvio_HeFH.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0791-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Patient_Clinician_Group_Input.pdf']",Primary hypercholesterolemia,Reimburse with clinical criteria and/or conditions,Complete,19-Sep-23,15-Aug-24,SR0791-000
cariprazineOpens in new tab,Vraylar,cariprazine,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0827_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0827-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0827-Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0827-Vraylar-Resub_Patient_Clinician_Group_Input.pdf']",Schizophrenia,Reimburse with clinical criteria and/or conditions,Complete,20-Dec-23,15-Aug-24,SR0827-000
etrasimodOpens in new tab,Velsipity,etrasimod,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0795_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0795-Velsipity_Patient_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0795_Velsipity_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0795_Velsipity_Stakeholder_Feedback.pdf']",Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,05-Feb-24,14-Aug-24,SR0795-000
cabotegravirOpens in new tab,Apretude,cabotegravir,"['https://cadth.ca/sites/default/files/DRR/2024/SR0825_Final_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0825-Apretude_Patient_Clinician_Group_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0825_Apretude_Combined_Review.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0825_Apretude_Stakeholder_Feedback.pdf']","HIV-1 infection, pre-exposure prophylaxis",Reimburse with clinical criteria and/or conditions,Complete,01-Feb-24,14-Aug-24,SR0825-000
evolocumabOpens in new tab,Repatha,evolocumab,"['https://cadth.ca/sites/default/files/DRR/2024/SR0821_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0821-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0821-Feedback.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0821-Repatha-Patient_Clinicia_%20Group_Input.pdf']",Primary hyperlipidemia,Reimburse with clinical criteria and/or conditions,Complete,29-Nov-23,08-Aug-24,SR0821-000
Multiple MyelomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf'],Multiple Myeloma,,Complete,,01-Aug-24,PH0047-000
Large B cell lymphomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0048_Rapid_Algorithm_Report_LBCL_Final.pdf'],Large B cell lymphoma,,Complete,,01-Aug-24,PH0048-000
Cutaneous MelanomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0049_Rapid_Algorithm_Report_Melanoma_Final.pdf'],Cutaneous Melanoma,,Complete,,01-Aug-24,PH0049-000
PembrolizumabOpens in new tab,N/A,Pembrolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_Final_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_Report_DPI.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_%20Clinical_and_Pharmacoeconomic_Combined_Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_stakeholder_input.pdf']",Melanoma (Skin),Reimburse with clinical criteria and/or conditions,Complete,16-Oct-23,01-Aug-24,PX0346-000
Nivolumab and IpilimumabOpens in new tab,N/A,Nivolumab and Ipilimumab,"['https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_Final_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_DPI_table.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_Combine_Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_Stakeholder_consolidated_input.pdf']",Melanoma (Skin),Reimburse with clinical criteria and/or conditions,Complete,16-Oct-23,01-Aug-24,PX0347-000
Nab-paclitaxelOpens in new tab,N/A,Nab-paclitaxel,"['https://www.cadth.ca/sites/default/files/DRR/2024/PX0348_Final_Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0348_DPI_Table.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0348_Nab-Paclitaxel_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0348_consolidated_input_Redacted.pdf']",Solid tumours,Reimburse with clinical criteria and/or conditions,Complete,16-Oct-23,24-Jul-24,PX0348-000
relugolixOpens in new tab,Orgovyx,relugolix,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0342_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0342-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0342-Orgovyx_Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0342_Patient_and_Clinician_Group_Input.pdf']",Advanced prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,14-Nov-23,22-Jul-24,PC0342-000
atogepantOpens in new tab,Qulipta,atogepant,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0817_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0817-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0817-Feedback.pdf', 'http://www.cda-amc.ca/sites/default/files/DRR/2024/SR0817_Patient_and_Clinician_Group_Input.pdf']","Migraine, prevention",Reimburse with clinical criteria and/or conditions,Complete,21-Dec-23,15-Jul-24,SR0817-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0344_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0344-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0344_Feedback.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0344_Patient_and_Clinician_Group_Input.pdf']",Biliary tract carcinoma,Reimburse with clinical criteria and/or conditions,Complete,07-Dec-23,11-Jul-24,PC0344-000
Endometrial CancerOpens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2024/PH0045-Endometrial-Cancer_Final.pdf'],Endometrial Cancer,,Complete,,27-Jun-24,PH0045-000
NSCLC without actionable oncog...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2024/PH0046_Final_Report_NSCLC.pdf'],NSCLC without actionable oncogenic alteration,,Complete,,27-Jun-24,PH0046-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343_Final_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343_%20Patient_and_Clinician_Group_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343-Combined_Report.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343_Stakeholder_Feedback.pdf']",Gastric or gastroesophageal junction adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,22-Nov-23,26-Jun-24,PC0343-000
aflibercept 8mg/0.07mLOpens in new tab,Eylea HD,aflibercept 8mg/0.07mL,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0813_Eylea_HD_DME-Final_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/SR0813_Eylea_HD_Patient_Clinician.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0813_Eylea_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0813_Eylea_Stakeholder_Feedback.pdf']",diabetic macular edema,Reimburse with clinical criteria and/or conditions,Complete,18-Aug-23,05-Jun-24,SR0813-000
aflibercept 8mg/0.07mLOpens in new tab,Eylea HD,aflibercept 8mg/0.07mL,"['https://cda-amc.ca/sites/default/files/DRR/2024/SR0812_Eylea_HD_nAMD-Final_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0812_Patient_and_Clinician_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0812-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0812_Stakeholder_Feedback.pdf']","macular degeneration, age related",Reimburse with clinical criteria and/or conditions,Complete,18-Aug-23,05-Jun-24,SR0812-000
Cutaneous MelanomaOpens in new tab,,,"['https://cadth.ca/sites/default/files/DRR/2024/PH0042-Cutaneous-Melanoma.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PH0042%20Algorithm%20Panel%20Scope_Melanoma_final.pdf']",Cutaneous Melanoma,,Complete,,04-Jun-24,PH0042-000
elranatamabOpens in new tab,Elrexfio,elranatamab,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315_Final_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315_Patient_and_Clinician_Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315-Combined_Report.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315-Stakeholder_Feedback.pdf']",Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,09-Nov-23,31-May-24,PC0315-000
epcoritamabOpens in new tab,Epkinly,epcoritamab,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0334_Epkinly-Final_Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0334_Patient_and_Clinician_Group_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0334-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0334%20Epkinly-Feedback.pdf']",Relapsed or refractory diffuse large B-cell lymphoma,Time-limited reimbursement recommendation,Complete,14-Nov-23,31-May-24,PC0334-000
nivolumabOpens in new tab,Opdivo,nivolumab,"['https://cadth.ca/sites/default/files/DRR/2024/PC0339_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0339-Opdivo-Melanoma-Combined-Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0339-Opdivo-Melanoma-DRAFT_REC.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0339_Patient_and_clinician_input.pdf']","Stage IIB or IIC melanoma, adjuvant",Reimburse with clinical criteria and/or conditions,Complete,06-Nov-23,29-May-24,PC0339-000
Colorectal cancerOpens in new tab,,,['https://cadth.ca/sites/default//files/DRR/2024/PH0044-Metastatic_Colorectal_Cancer.pdf'],Colorectal cancer,,Complete,,22-May-24,PH0044-000
insulin icodecOpens in new tab,Awiqli,insulin icodec,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0790REC-Awiqli.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0790-Awiqli-combined.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0790-Awiqli_Feedback_DRAFT_REC.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0790_Patient_and_Clinician_Group_Input.pdf']","Diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,18-Oct-23,17-May-24,SR0790-000
bimekizumabOpens in new tab,Bimzelx,bimekizumab,"['https://cadth.ca/sites/default/files/DRR/2024/SR0809REC-Bimzelx.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0809-Combined_Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0809-Bimzelx_Feedback.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0809_Patient_Clinician_Group_Input.pdf']",Ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,19-Oct-23,16-May-24,SR0809-000
bimekizumabOpens in new tab,Bimzelx,bimekizumab,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0803%20Bimzelx%20PsA_Rec_final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0803-Bimzelx-PsA-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0803-Bimzelx-PsA-Stakeholder-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0803%20Bimzelx%20PsA%20-%20Patient%20and%20Clinician%20Group%20Input.pdf']",Psoriatic arthritis,Reimburse with clinical criteria and/or conditions,Complete,05-Oct-23,15-May-24,SR0803-000
metreleptinOpens in new tab,Myalepta,metreleptin,"['https://cadth.ca/sites/default/files/DRR/2024/SR0784REC-Myalepta.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0784-Combined.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0784-Myalepta-Feedback.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0784_Patient_and_Clinician_Group_Input.pdf']",Leptin deficiency in lipodystrophy,Reimburse with clinical criteria and/or conditions,Complete,25-Jul-23,09-May-24,SR0784-000
tralokinumabOpens in new tab,Adtralza,tralokinumab,"['https://cadth.ca/sites/default/files/DRR/2024/SR0787REC-Adtralza.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0787-Adtralza-Combined-Report.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0787-Adtralza-Stakeholder-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0787%20Adtralza%20-%20Patient%20and%20Clinician%20Group%20Input.pdf']",atopic dermatitis (AD),Do not reimburse,Complete,05-Jun-23,08-May-24,SR0787-000
avatrombopagOpens in new tab,Doptelet,avatrombopag,"['https://cadth.ca/sites/default/files/DRR/2024/SR0721%20Doptelet_Rec_final.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0721-Doptelet-Combined-Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0721-Doptelet-Feedback.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0721_Patient_and_Clinician_Group_Input.pdf']",Chronic immune thrombocytopenia (ITP),Do not reimburse,Complete,03-Feb-22,08-May-24,SR0721-000
dostarlimabOpens in new tab,Jemperli,dostarlimab,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0325%20Jemperli_Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0325%20Jemperli%20-%20Patient%20and%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0325_Combined_Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0325_Stakeholder_Feedback.pdf']",Endometrial cancer,Reimburse with clinical criteria and/or conditions,Complete,18-Oct-23,03-May-24,PC0325-000
cemiplimabOpens in new tab,Libtayo,cemiplimab,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0331-Libtayo_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0331-Libtayo-combined.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0331-Libtayo_%20Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0331%20Libtayo%20-%20Patient%20and%20Clinician%20Input.pdf']",Locally advanced or metastatic NSCLC (first line),Reimburse with clinical criteria and/or conditions,Complete,27-Sep-23,02-May-24,PC0331-000
infliximabOpens in new tab,Remsima,infliximab,"['https://cadth.ca/sites/default/files/DRR/2024/SR0816-000%20Remsima%20SC%20(CD)%20-%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0816-000%20%26%20SR0816-001%20Remsima%20SC%20-%20Patient%20and%20Clinician%20Group%20Input.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0816-000_Clinical_and_Pharmacoeconomic_Combined_Report.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0816-000_Stakeholder_Feedback.pdf']",Crohn’s disease,Reimburse with clinical criteria and/or conditions,Complete,04-Oct-23,22-Apr-24,SR0816-000
inclisiranOpens in new tab,Leqvio,inclisiran,"['https://cadth.ca/sites/default/files/DRR/2024/SR0791-001_Resubmission_Final_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0791-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Patient_Clinician_Group_Input.pdf']",Primary hypercholesterolemia,Do not reimburse,Complete,19-Sep-23,22-Apr-24,SR0791-001
infliximabOpens in new tab,Remsima,infliximab,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0816-001%20Remsima%20SC%20(UC)%20-%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0816-000%20&%20SR0816-001%20Remsima%20SC%20-%20Patient%20and%20Clinician%20Group%20Input.pdf']",Ulcerative Colitis,Reimburse with clinical criteria and/or conditions,Complete,04-Oct-23,22-Apr-24,SR0816-001
maralixibatOpens in new tab,Livmarli,maralixibat,"['https://cadth.ca/sites/default/files/DRR/2024/SR0780-Livmarli_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0780-Livmarli-Combined-Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0780-Livmarli-Stakeholder-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0780%20Livmarli%20-%20Patient%20and%20Clinician%20input.pdf']",Alagille syndrome,Reimburse with clinical criteria and/or conditions,Complete,05-May-23,22-Apr-24,SR0780-000
etranacogene dezaparvovecOpens in new tab,Hemgenix,etranacogene dezaparvovec,"['https://cadth.ca/sites/default/files/DRR/2024/SG0805%20Hemgenix%20-%20Final%20Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SG0805-Hemgenix_combined.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SG0805-Hemgenix-Feedback_DRAFT_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SG0805_Patient_Clinician_Group_Input.pdf']",Hemophilia B,Reimburse with clinical criteria and/or conditions,Complete,04-Oct-23,19-Apr-24,SG0805-000
everolimusOpens in new tab,N/A,everolimus,"['https://cadth.ca/sites/default/files/DRR/2024/SX0814%20Everolimus%20Recommendation_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SX0814-Everolimus_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SX0814%20DPI%20Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SX0814-Stakeholder-Input.pdf']",Renal angiomyolipoma associated with tuberous sclerosis,Reimburse with clinical criteria and/or conditions,Complete,06-Jul-23,18-Apr-24,SX0814-000
panitumumabOpens in new tab,N/A,panitumumab,"['https://cadth.ca/sites/default/files/DRR/2024/PX0333REC-Panitumumab.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0333-DPI-table.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0333_Combine_Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0333_Stakeholder_Input.pdf']",Left-sided metastatic colorectal cancer (mCRC),Reimburse with clinical criteria and/or conditions,Complete,19-May-23,18-Apr-24,PX0333-000
cannabidiolOpens in new tab,Epidiolex,cannabidiol,"['https://cadth.ca/sites/default/files/DRR/2024/SR0800%20Epidiolex%20LGS%20-%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0800%20Epidiolex%20LGS%20-%20Patient%20and%20Clinician%20Group%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0800CL-Epidiolex-LGS-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0800-Epidiolex-LGS-Stakeholder-Feedback.pdf']",Lennox-Gastaut Syndrome (LGS),Reimburse with clinical criteria and/or conditions,Complete,20-Sep-23,18-Apr-24,SR0800-000
cannabidiolOpens in new tab,Epidiolex,cannabidiol,"['https://cadth.ca/sites/default/files/DRR/2024/SR0799%20Epidiolex%20DS%20-%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0799%20Epidiolex%20DS%20-%20Patient%20and%20Clinician%20Group%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0799_Combine_Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0799_Stakeholder_Feedback.pdf']",Dravet Syndrome (DS),Reimburse with clinical criteria and/or conditions,Complete,25-Sep-23,18-Apr-24,SR0799-000
cannabidiolOpens in new tab,Epidiolex,cannabidiol,"['https://cadth.ca/sites/default/files/DRR/2024/SR0798%20Epidiolex%20TSC%20-%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0798%20Epidiolex%20TSC%20-%20Patient%20and%20Clinician%20Group%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0798-Epidiolex-TSC-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0798-Epidiolex-TSC-Stakeholder-Feedback.pdf']",Seizures associated with Tuberous Sclerosis Complex (TSC),Reimburse with clinical criteria and/or conditions,Complete,29-Sep-23,18-Apr-24,SR0798-000
nirmatrelvir/ritonavirOpens in new tab,Paxlovid,nirmatrelvir/ritonavir,"['https://cadth.ca/sites/default/files/DRR/2024/SR0808%20Paxlovid%20-%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0808%20Paxlovid%20-%20Patient%20and%20Clinician%20Group%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0808_Combine_Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0808_Stakeholder_Feedback.pdf']","Mild-to-moderate COVID-19, treatment",Reimburse with clinical criteria and/or conditions,Complete,15-Sep-23,11-Apr-24,SR0808-000
"HR positive, HER2 negative bre...Opens in new tab",,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0041-HR%2BHER2-Breast-Cancer.pdf'],"HR positive, HER2 negative breast cancer",,Complete,,10-Apr-24,PH0041-000
Large B cell lymphomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0040%20LBCL.pdf'],Large B cell lymphoma,,Complete,,09-Apr-24,PH0040-000
teclistamabOpens in new tab,Tecvayli,teclistamab,"['https://cadth.ca/sites/default/files/DRR/2024/PC0332%20Tecvayli%20-%20Final_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0332-Tecvayli-Combined-Report-meta.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0332-Tecvayli-Stakeholder-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0332%20Tecvayli%20-%20Patient%20and%20Clinican%20input.pdf']",Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,31-Aug-23,08-Apr-24,PC0332-000
Prostate CancerOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0039-Prostate-Cancer-Rapid-Algorithm-Report.pdf'],Prostate Cancer,,Completed,,28-Mar-24,PH0039-000
Chronic Lymphocytic LeukemiaOpens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2024/PH0038-Chronic%20Lymphocytic%20Leukemia_Rapid%20Algorithm%20Report_final.pdf'],Chronic Lymphocytic Leukemia,,Complete,,21-Mar-24,PH0038-000
drospirenoneOpens in new tab,Slynd,drospirenone,"['https://cadth.ca/sites/default/files/DRR/2024/SR0806REC-Slynd.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0806-Slynd-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0806-Slynd-Stakeholder-Feedback.pdf']","Contraceptive, oral",Reimburse with clinical criteria and/or conditions,Complete,14-Aug-23,18-Mar-24,SR0806-000
ravulizumabOpens in new tab,Ultomiris,ravulizumab,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0785%20Ultomiris%20NMOSD%20-%20Confidential%20Final%20CADTH%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0785%20Ultomiris%20NMOSD%20-%20Patient%20and%20Clinician%20Group.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0785_Combined_Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0785_Stakeholder_Feedback.pdf']",Neuromyelitis optica spectrum disorder (NMOSD),Reimburse with clinical criteria and/or conditions,Complete,29-Aug-23,13-Mar-24,SR0785-000
inebilizumabOpens in new tab,Uplizna,inebilizumab,"['https://cadth.ca/sites/default/files/DRR/2024/SR0793_Uplizna-Final_Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0793%20Uplizna%20-%20Patient%20and%20Clinician%20Input%20(with%20Redactions).pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0793-Uplizna-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0793-Uplizna-Stakeholder-Feedback.pdf']",Neuromyelitis optica spectrum disorders (NMOSD),Reimburse with clinical criteria and/or conditions,Complete,18-Aug-23,13-Mar-24,SR0793-000
trifluridine and tipiracilOpens in new tab,Lonsurf,trifluridine and tipiracil,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0330%20Lonsurf%20-%20Confidential%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0330_Combined_Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0330_Stakeholder_Feedback.pdf']",Metastatic colorectal cancer,Reimburse with clinical criteria and/or conditions,Complete,15-Aug-23,29-Feb-24,PC0330-000
sotorasibOpens in new tab,Lumakras,sotorasib,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0300%20Lumakras%20-%20CADTH%20Final%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0300%20Lumakras%20-%20Patient%20and%20Clinician%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0300-Lumakras-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0300-Lumakras-Stakeholder-Feedback.pdf']",KRAS G12C-mutated advanced NSCLC,Do not reimburse,Complete,19-Aug-22,29-Feb-24,PC0300-000
treosulfanOpens in new tab,Trecondyv,treosulfan,"['https://www.cadth.ca/sites/default/files/DRR/2024/PC0324REC-Trecondyv.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0324-Trecondyv-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0324-Trecondyv-Stakeholder-Feedback.pdf']",Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS),Reimburse with clinical criteria and/or conditions,Complete,14-Jul-23,28-Feb-24,PC0324-000
Renal cell carcinomaOpens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2024/PH0037-Renal-Cell-Carcinoma.pdf'],Renal cell carcinoma,,Complete,,21-Feb-24,PH0037-000
fidanacogene elaparvovecOpens in new tab,Beqvez,fidanacogene elaparvovec,"['https://www.cadth.ca/sites/default/files/DRR/2024/SG0802%20Beqvez%20Final%20CADTH%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SG0802-Beqvez.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SG0802-Beqvez-Stakeholder-Feedback.pdf']",Hemophilia B,Reimburse with clinical criteria and/or conditions,Complete,01-Aug-23,16-Feb-24,SG0802-000
belumosudilOpens in new tab,Rezurock,belumosudil,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0789%20Rezurock%20-%20Confidential%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0789-Rezurock_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0789%20Rezurock%20-%20Stakeholder%20Feedback.pdf']",Graft-versus-host disease,Reimburse with clinical criteria and/or conditions,Complete,26-Jul-23,15-Feb-24,SR0789-000
odevixibatOpens in new tab,Bylvay,odevixibat,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0788%20Bylvay%20-%20Confidential%20Final%20CADTH%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0788-Bylvay-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0788-Bylvay-Stakeholder-Feedback.pdf']",Progressive familial intrahepatic cholestasis (PFIC),Reimburse with clinical criteria and/or conditions,Complete,23-Jun-23,13-Feb-24,SR0788-000
nivolumab and relatlimabOpens in new tab,Opdualag,nivolumab and relatlimab,"['https://cadth.ca/sites/default/files/DRR/2024/PC0329REC-Opdaulag.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0329-Opdualag_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0329%20Opdualag%20-%20Stakeholder%20Feedback%20February%202%2C%202024.pdf']",unresectable or metastatic melanoma,Reimburse with clinical criteria and/or conditions,Complete,10-Jul-23,02-Feb-24,PC0329-000
glofitamabOpens in new tab,Columvi,glofitamab,"['https://cadth.ca/sites/default/files/DRR/2024/PC0320REC-Columvi.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0320-Columvi-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0320-Columvi-Stakeholder-Feedback.pdf']",Relapsed or refractory diffuse large B-cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,18-Jul-23,02-Feb-24,PC0320-000
sacituzumab govitecanOpens in new tab,Trodelvy,sacituzumab govitecan,"['https://cadth.ca/sites/default/files/DRR/2024/PC0323REC-Trodelvy-HR.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0323-Trodelvy%20HR%2B.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0323%20Trodelvy%20HR%2B%20-%20Stakeholder%20Feedback%20February%201%2C%202024.pdf']","HR+, HER2− advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,18-Jul-23,01-Feb-24,PC0323-000
niraparib abiraterone acetateOpens in new tab,Akeega,niraparib abiraterone acetate,"['https://cadth.ca/sites/default/files/DRR/2024/PC0326%20Akeega%20Final%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0326-Akeega-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0326-AKeega-Stakeholder-Feedback.pdf']",Metastatic castration-resistant prostate cancer (mCRPC),Reimburse with clinical criteria and/or conditions,Complete,14-Jun-23,01-Feb-24,PC0326-000
olaparibOpens in new tab,Lynparza,olaparib,"['https://cadth.ca/sites/default/files/DRR/2024/PC0319REC-Lynparza.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0319-Lynparza-PC-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0319-Lynparza-PC-Stakeholder-Feedback.pdf']",Metastatic castration-resistant prostate cancer (mCRPC),Reimburse with clinical criteria and/or conditions,Complete,19-May-23,31-Jan-24,PC0319-000
vutrisiranOpens in new tab,Amvuttra,vutrisiran,"['https://cadth.ca/sites/default/files/DRR/2024/SR0801REC-Amvuttra%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0801-Amvuttra-combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0801%20Amvuttra%20-%20Stakeholder%20Feedback.pdf']",Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis),Reimburse with clinical criteria and/or conditions,Complete,04-Jul-23,29-Jan-24,SR0801-000
Unresectable Hepatocellular Ca...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2024/PH0036-Hepatocellular-Carcinoma.pdf'],Unresectable Hepatocellular Carcinoma,,Complete,,24-Jan-24,PH0036-000
evinacumabOpens in new tab,Evkeeza,evinacumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0778%20Evkeeza%20-%20Final%20CADTH%20Recommendation%20-%20Revised%20version%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0778-Evkeeza-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0778-Evkeeza-Stakeholder-Feedback.pdf']",Homozygous familial hypercholesterolemia (HoFH),Reimburse with clinical criteria and/or conditions,Complete,10-May-23,12-Jan-24,SR0778-000
eltrombopagOpens in new tab,N/A,eltrombopag,"['https://www.cadth.ca/sites/default/files/DRR/2024/SX0777/SX0777REC-Eltrombopag-for-SAA.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SX0777/SX0777-Eltrombopag-DPI-Table.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SX0777CL-Eltrombopag_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SX0777eltrombopag%20%20-%20Clinician%20and%20Patient%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SX0777%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20FOR%20POSTING.pdf']",Severe Aplastic Anemia (SAA),Reimburse with clinical criteria and/or conditions,Complete,03-Mar-23,10-Jan-24,SX0777-000
ibrutinibOpens in new tab,Imbruvica,ibrutinib,"['https://cadth.ca/sites/default/files/DRR/2024/PC0328%20Imbruvica%20WM%20-%20Final%20CADTH%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0328-Imbruvica-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PC0328%20Imbruvica-Stakeholder-Feedback.pdf']",Waldenström’s Macroglobulinemia,Reimburse with clinical criteria and/or conditions,Complete,20-Jun-23,05-Jan-24,PC0328-000
calaspargase pegolOpens in new tab,Asparlas,calaspargase pegol,"['https://cadth.ca/sites/default/files/DRR/2024/PC0321REC-Asparlas.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0321-Asparlas-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0321-Asparlas-Stakeholder-Feedback.pdf']",Acute lymphoblastic leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,12-May-23,04-Jan-24,PC0321-000
bevacizumab and lomustineOpens in new tab,N/A,bevacizumab and lomustine,"['https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX318-FMEC-REC.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318-FMEC-DPI-Table.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318CL-Bevacizumab-and-Lomustine.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318-Stakeholder-Input-Clinicians.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318-Stakeholder-Input-Industry.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/PX0318%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20FOR%20POSTING.pdf']",Recurrent glioblastoma multiform,Reimburse with clinical criteria and/or conditions,Complete,17-Feb-23,20-Dec-23,PX0318-000
polatuzumab vedotinOpens in new tab,Polivy,polatuzumab vedotin,"['https://cadth.ca/sites/default/files/DRR/2024/PC0313%20Polivy%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0313-Polivy.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0313%20Polivy%20-%20Stakeholder%20Feedback.pdf']",Large B-cell lymphoma,Do not reimburse,Complete,01-Mar-23,20-Dec-23,PC0313-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,"[""https://www.cadth.ca/sites/default/files/DRR/2024/SR0775REC-Rinvoq-(Crohn's)-meta.pdf"", 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0775-Rinvoq-Crohn-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0775-Rinvoq-Crohn-Stakeholder-Feedback.pdf']",Crohns disease,Reimburse with clinical criteria and/or conditions,Complete,05-Jun-23,14-Dec-23,SR0775-000
efgartigimod alfaOpens in new tab,Vyvgart,efgartigimod alfa,"['https://www.cadth.ca/sites/default/files/DRR/2024/SR0782REC-Vyvgart-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0782-Vyvgart.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0782%20Vyvgart%20-%20Stakeholder%20Feedback%20December%2014%2C%202023.pdf']",Generalized myasthenia gravis (gMG),Reimburse with clinical criteria and/or conditions,Complete,09-May-23,14-Dec-23,SR0782-000
HR+ HER2- Breast Cancer and Tr...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0033-HRplus-HER2-BC-and-TNBC-with-HER2-Low-Inclusion.pdf'],"HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer",,Complete,,07-Dec-23,PH0033-000
andexanet alfaOpens in new tab,Ondexxya,andexanet alfa,"['https://cadth.ca/sites/default/files/DRR/2023/ST0772%20Ondexxya%20-%20Confidential%20Final%20CADTH%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/ST0772-Ondexxya-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/ST0772-Ondexxya-Stakeholder-Feedback.pdf']",Reversal of FXa inhibitor anticoagulant effects,Do not reimburse,Complete,02-Mar-23,05-Dec-23,ST0772-000
NSCLC without actionable oncog...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0015%20Rapid%20Algorithm%20Report%20for%20NSCLC%20without%20actionable%20oncogenic%20alterations_%20Final%20Report%20for%20CAPCA%20Endorsement.pdf'],Non-Small Cell Lung Cancer,,Completed,,01-Dec-23,PH0015-000
elexacaftor/tezacaftor/ivacaft...Opens in new tab,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0776%20Trikafta%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0776-Trikafta-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0776-Trikafta-Stakeholder-Feedback.pdf']","Cystic fibrosis, F508del CFTR mutation, 2 years and older",Reimburse with clinical criteria and/or conditions,Complete,10-May-23,24-Nov-23,SR0776-000
somapacitanOpens in new tab,Sogroya,somapacitan,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0779REC-Sogroya-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0779-Sogroya-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0779-Sogroya-Stakeholder-Feedback.pdf']",Growth Hormone Deficiency (GHD),Reimburse with clinical criteria and/or conditions,Complete,27-Apr-23,17-Nov-23,SR0779-000
mirikizumabOpens in new tab,Omvoh,mirikizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2023/SR0773REC-Omvoh.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0773-Omvoh-Combined-Report.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0773-Omvoh-Stakeholder-Feedback.pdf']",Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,07-Mar-23,16-Nov-23,SR0773-000
cabozantinibOpens in new tab,Cabometyx,cabozantinib,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0312%20Cabometyx%20-%20Final%20CADTH%20Revised.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0312-Cabometyx-RCC-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PC0312-Cabometyx-RCC-Stakeholder-Feedback.pdf']",Advanced or metastatic renal cell carcinoma,Reimburse with clinical criteria and/or conditions,Complete,17-Feb-23,03-Nov-23,PC0312-000
durvalumab and tremelimumabOpens in new tab,Imfinzi and Imjudo,durvalumab and tremelimumab,"['https://cda-amc.ca/sites/default/files/DRR/2023/PC0308%20Imjudo%20and%20Imfinzi%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2023/PC0308-Imfinzi-and-Imjudo-Combined-Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2023/PC0308-Imfinzi-and-Imjudo-Stakeholder-Feedback.pdf']",unresectable hepatocellular carcinoma,Reimburse with clinical criteria and/or conditions,Complete,15-Dec-22,03-Nov-23,PC0308-000
ibrutinibOpens in new tab,Imbruvica,ibrutinib,"['https://cda-amc.ca/sites/default/files/DRR/2023/PC0317REC-Imbruvica-Final-Recommendation-meta.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0317-Imbruvica_combined.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0317%20Imbruvica%20Stakeholder%20Feedback.pdf']",Chronic lymphocytic leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,21-Apr-23,02-Nov-23,PC0317-000
rivaroxabanOpens in new tab,N/A,rivaroxaban,"['https://www.cadth.ca/sites/default/files/DRR/2023/SX0750/SX0750-Rivaroxaban_final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SX0750/SX0750-DPI-Table.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SX0750/SR0750CL-Rivaroxaban-rev-njcover.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0750%20Stakeholder%20Input%20FOR%20POSTING.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/SR0750%20Stakeholder%20Feedback%20on%20Draft%20Recommendations%20FOR%20POSTING.pdf']",Venous thromboembolic events (VTE),Reimburse with clinical criteria and/or conditions,Complete,29-Jun-22,02-Nov-23,SX0750-000 - SR0750-000
axicabtagene ciloleucelOpens in new tab,Yescarta,axicabtagene ciloleucel,"['https://cadth.ca/sites/default/files/DRR/2023/PG0314%20Yescarta%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PG0314-Yescarta.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PG0314%20Yescarta%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20November%202%2C%202023.pdf']",Relapsed or refractory follicular lymphoma,Reimburse with clinical criteria and/or conditions,Complete,13-Apr-23,02-Nov-23,PG0314-000
Prostate CancerOpens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0034%20Rapid%20Algorithm%20Report%20Prostate%20Cancer_final.pdf'],Prostate Cancer,,Complete,,27-Oct-23,PH0034-000
Chronic Lymphocytic LeukemiaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2023/PH0035-Rapid-Algorithm-Report-for-CLL3.pdf'],Chronic Lymphocytic Leukemia,,Complete,,27-Oct-23,PH0035-000
setmelanotideOpens in new tab,Imcivree,setmelanotide,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0769%20Imcivree%20%E2%80%93%20CADTH%20Final%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0769-Imcivree-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0769-Imcivree-Stakeholder-Feedback.pdf']",Bardet-Biedl syndrome,Reimburse with clinical criteria and/or conditions,Complete,07-Mar-23,16-Oct-23,SR0769-000
dupilumabOpens in new tab,Dupixent,dupilumab,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0774%20Dupixent%20Peds%20%E2%80%93%20CADTH%20Final%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0774-Dupixent-Peds.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0774%20Dupixent%20Peds%20-%20Stakeholder%20Feedback%20October%2013%2C%202023.pdf']","Atopic dermatitis, pediatrics",Reimburse with clinical criteria and/or conditions,Complete,29-Mar-23,13-Oct-23,SR0774-000
nelarabineOpens in new tab,Atriance,nelarabine,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0307%20Atriance%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0307-Atriance-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0307-Atriance-Stakeholder-Feedback.pdf']",T-cell acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Complete,06-Mar-23,29-Sep-23,PC0307-000
abiraterone acetate and predni...Opens in new tab,n/a,abiraterone acetate and prednisolone,"['https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Recommendation%20and%20Reasons.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Stakeholder Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Stakeholder Feedback on Draft Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Responses to Questions From the Drug Programs.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Clinical and Pharmacoeconomic Combined Report.pdf']",High-risk non-metastatic prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,23-Mar-22,08-Sep-23,PX0291-000 - PC0291-000
"abiraterone, prednisone, docet...Opens in new tab",N/A,"abiraterone, prednisone, docetaxel","['https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Recommendation%20and%20Reasons.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Responses to Questions From the Drug Programs.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Clinical and Pharmacoeconomic Combined Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Stakeholder Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Stakeholder Feedback on Draft Recommendation.pdf']",Metastatic castration sensitive prostate cancer (mCSPC),Reimburse,Complete,13-Jun-22,08-Sep-23,PX0298-000 - PC0298-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,"['https://cadth.ca/sites/default/files/DRR/2023/SR0730%20Rinvoq%20UC%20-%20Final%20CADTH%20Recommendation%20Final-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0730-Rinvoq-UC-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0730Rinvoq-Stakeholder-Feedback.pdf']",Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,18-Apr-22,01-Sep-23,SR0730-000
tisagenlecleucelOpens in new tab,Kymriah,tisagenlecleucel,"['https://www.cadth.ca/sites/default/files/DRR/2023/PG0306%20Kymriah%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PG0306-Kymriah_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PG0306%20Kymriah%20-%20Stakeholder%20Feedback.pdf']",Relapsed or refractory follicular lymphoma,Reimburse with clinical criteria and/or conditions,Complete,01-Feb-23,01-Sep-23,PG0306-000
zanubrutinibOpens in new tab,Brukinsa,zanubrutinib,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0310REC-Brukinsa_KT%20-%20MFJ_KT-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0310-Brukinsa_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0310%20Brukinsa%20-%20Stakeholder%20Feedback%20September%201%2C%202023.pdf']",Chronic lymphocytic leukemia /small lymphocytic lymphoma.,Reimburse with clinical criteria and/or conditions,Complete,20-Jan-23,01-Sep-23,PC0310-000
belzutifanOpens in new tab,Welireg,belzutifan,"['https://cadth.ca/sites/default/files/DRR/2023/PC0309%20Welireg%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0309-Welireg-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0309-Welireg-Stakeholder-Feedback.pdf']",von Hippel-Lindau disease-associated tumours,Reimburse with clinical criteria and/or conditions,Complete,23-Jan-23,01-Sep-23,PC0309-000
cenobamateOpens in new tab,Xcopri,cenobamate,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0770%20Xcopri%20-%20Final%20CADTH%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0770-Xcopri.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0770-Xcopri%20-Stakeholder-Feedback.pdf']","Epilepsy, partial-onset seizures",Reimburse with clinical criteria and/or conditions,Complete,07-Feb-23,29-Aug-23,SR0770-000
dapagliflozinOpens in new tab,N/A,dapagliflozin,"['https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Recommendation%20and%20Reasons.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Responses%20to%20Questions%20From%20the%20Drug%20Programs.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Clinical%20and%20Pharmacoeconomic%20Combined%20Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Stakeholder%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Chronic kidney disease,Reimburse with clinical criteria and/or conditions,Complete,17-Jun-22,23-Aug-23,SX0749-000 - SR0749-000
roflumilastOpens in new tab,Zoryve,roflumilast,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0771REC-Zoryve.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0771-Zoryve-Combined-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0771-Zoryve-Stakeholder-Feedback.pdf']",Plaque psoriasis,Reimburse with clinical criteria and/or conditions,Complete,02-Feb-23,16-Aug-23,SR0771-000
Non-Small Cell Lung Cancer wit...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0029-Algorithm_secured.pdf'],Non-Small Cell Lung Cancer without actionable oncogenic alterations,,Complete,,10-Aug-23,PH0029-000
avacopanOpens in new tab,Tavneos,avacopan,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0732REC-Tavneos-KH_BF-KH-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0732-Tavneos_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0732-Tavneos-Stakeholder-Feedback.pdf']",Antineutrophil cytoplasmic antibody-associated vasculitis,Do not reimburse,Complete,14-Oct-22,10-Aug-23,SR0732-000
cariprazineOpens in new tab,Vraylar,cariprazine,"['https://cadth.ca/sites/default/files/DRR/2022/SR0708_Memorandum%2C%20Panel%20Report%20%E2%80%93%20cariprazine_Vraylar%20-%20Procedural%20Review.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0708-Response-to-Procedural-Review-Panel-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0708REC-Cariprazine.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0708-Cariprazine.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0708%20vraylar%20-%20Stakeholder%20Feedback%20on%20draft%20recommendation.pdf']",Schizophrenia,Do not reimburse,Complete,29-Oct-21,10-Aug-23,SR0708-000
ravulizumabOpens in new tab,Ultomiris,ravulizumab,"['https://cadth.ca/sites/default/files/DRR/2023/SR0765Ultomiris%20-%20Confidential%20Final%20CADTH%20Recommendation%20August%2024%2C%202023%20revised.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0765_Ultomiris_Combined_Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0765_Ultomiris_Stakeholder_Feedback.pdf']",AChR antibody-positive generalized Myasthenia Gravis,Do not reimburse,Complete,25-Oct-22,08-Aug-23,SR0765-000
deucravacitinibOpens in new tab,Sotyktu,deucravacitinib,"['https://cadth.ca/sites/default//files/DRR/2023/SR0756%20Sotyktu%20-%20CADTH%20Final%20Recommendation%20-%20KH%20-%20MFJ%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0756-Sotyktu.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0756%20Sotyktu%20-%20Stakeholder%20Feedback.pdf']","Psoriasis, moderate to severe plaque",Do not reimburse,Complete,27-Sep-22,08-Aug-23,SR0756-000
Multiple MyelomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2023/PH0031%20Multiple%20Myeloma_Algorithm-Secured.pdf'],Multiple myeloma,,Complete,,27-Jul-23,PH0031-000
difelikefalinOpens in new tab,Korsuva,difelikefalin,"['https://cadth.ca/sites/default//files/DRR/2023/SR0752%20Korsuva%20-%20CADTH%20Final%20Recommendation%20(with%20correction%20notice.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0752-Korsuva.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0752%20Korsuva%20-%20Stakeholder%20Feedback.pdf']",Chronic kidney disease,Do not reimburse,Complete,22-Sep-22,13-Jul-23,SR0752-000
trastuzumab deruxtecanOpens in new tab,Enhertu,trastuzumab deruxtecan,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0305%20Enhertu%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20June%2029%2C%202023%20-%20KH_KAS%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0305-Enhertu.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0305-Enhertu-Stakeholder-Feedback.pdf']",unresectable or metastatic HER2-low breast cancer,Reimburse with clinical criteria and/or conditions,Complete,13-Dec-22,29-Jun-23,PC0305-000
Adult B-Cell Precursor Acute L...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2023/PH0030%20Rapid%20Algorithm%20Report-Adult%20B-Cell%20Precursor%20Acute%20Lymphoblastic%20Leukemia%20Philadelphia%20Chromosome%20Negative%20and%20Positive_SECURED.pdf'],"Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and Positive",,Complete,,28-Jun-23,PH0030-000
foslevodopa foscarbidopaOpens in new tab,Vyalev,foslevodopa foscarbidopa,"['https://cadth.ca/sites/default/files/DRR/2023/SR0768%20Vyalev%20-%20Confidential%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0768-Vyalev.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0768-Vyalev-Stakeholder-Feedback.pdf']",Parkinson’s disease,Reimburse with clinical criteria and/or conditions,Complete,23-Nov-22,16-Jun-23,SR0768-000
Triple Negative Breast CancerOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2023/PH0024-Rapid%20Algorithm%20Report%20for%20Triple%20Negative%20Breast%20Cancer_FINAL.pdf'],Triple Negative Breast Cancer,,Complete,,14-Jun-23,PH0024-000
atogepantOpens in new tab,Qulipta,atogepant,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0724%20Qulipta%20-%20Final%20CADTH%20Recommendation%20June%202023%20Final.pdf', 'https://cadth.ca/sites/default//files/DRR/2023/SR0724-Qulipta_combined.pdf', 'https://cadth.ca/sites/default//files/DRR/2023/SR0724-Qulipta-Stakeholder-Feedback.pdf']","Migraine, prevention",Reimburse with clinical criteria and/or conditions,Complete,23-Feb-22,14-Jun-23,SR0724-000
vericiguatOpens in new tab,Verquvo,vericiguat,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0758%20Verquvo%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0758-Verquvo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0758-Verquvo-Stakeholder-Feedback.pdf']",Heart failure,Reimburse with clinical criteria and/or conditions,Complete,14-Oct-22,14-Jun-23,SR0758-000
RET fusion-positive non-small ...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0026-Implementation-Advice-Report-Algorithm-RET-Positive-NSCLC.pdf'],RET fusion-positive non-small cell lung cancer,,Complete,,01-Jun-23,PH0026-000
Non-Small Cell Lung Cancer (NS...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0028-NSCLC-EGFR.pdf'],Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations,,Complete,,01-Jun-23,PH0028-000
risankizumabOpens in new tab,Skyrizi,risankizumab,"['https://cadth.ca/sites/default//files/DRR/2023/SR0767REC-Skyrizi_August%2022%2C2023-meta.pdf', 'https://cadth.ca/sites/default//files/DRR/2023/SR0767-Skyriz_combined.pdf', 'https://cadth.ca/sites/default//files/DRR/2023/SR0767%20Skyrizi%20Stakeholder%20Feedback.pdf']",Crohn's disease,Reimburse with clinical criteria and/or conditions,Complete,28-Oct-22,12-May-23,SR0767-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0759REC-Rinvoq_KT.CY_MFJ_KT_KT-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0759%20Rinvoq%20AS.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0759%20Rinvoq%20-%20Stakeholder%20Feedback%20June%202023.pdf']",ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,17-Oct-22,11-May-23,SR0759-000
palovaroteneOpens in new tab,Sohonos,palovarotene,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0761%20Sohonos%20-%20CADTH%20Final%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0761-Sohonos_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0761%20Sohonos%20-%20Stakeholder%20Feedback.pdf']",Fibrodysplasia Ossificans Progressiva,Reimburse with clinical criteria and/or conditions,Complete,21-Oct-22,11-May-23,SR0761-000
selumetinibOpens in new tab,Koselugo,selumetinib,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0764REC-Koselugo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0764-Koselugo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0764-Koselugo-Stakeholder-Feedback.pdf']",Neurofibromatosis type 1,Reimburse with clinical criteria and/or conditions,Complete,28-Oct-22,10-May-23,SR0764-000
fostemsavirOpens in new tab,Rukobia,fostemsavir,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0760REC-Rukobia.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0760-Rukobia.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0760%20Rubokia%20Stakeholder%20Feedback.pdf']",Human immunodeficiency virus type 1 (HIV-1),Reimburse with clinical criteria and/or conditions,Complete,28-Oct-22,10-May-23,SR0760-000
Prostate cancerOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2023/PH0023-000-Prostate-Cancer.pdf'],Prostate Cancer,,Complete,,03-May-23,PH0023-000
ciltacabtagene autoleucelOpens in new tab,Carvykti,ciltacabtagene autoleucel,"['https://cadth.ca/sites/default/files/DRR/2023/PG0302-Carvykti.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PG0302-Carvykti_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PG0302-Carvykti-Stakeholder-Feedback.pdf']",Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,23-Sep-22,01-May-23,PG0302-000
crisantaspase recombinantOpens in new tab,Rylaze,crisantaspase recombinant,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0301%20Rylaze%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0301-Rylaze.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0301%20Rylaze%20-%20CADTH%20Consolidated%20Stakeholder%20Feedback.pdf']",Acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Complete,18-Aug-22,26-Apr-23,PC0301-000
mavacamtenOpens in new tab,Camzyos,mavacamten,"['https://cadth.ca/sites/default/files/DRR/2023/SR0755_Camzyos-FinalCADTHRecommendation-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0755-Camzyos.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0755-Camzyos-Stakeholder-Feedback.pdf']",Obstructive hypertrophic cardiomyopathy,Reimburse with clinical criteria and/or conditions,Complete,22-Sep-22,14-Apr-23,SR0755-000
Large B-Cell LymphomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/DRR/2023/PH0027-LBCL.pdf'],Large B-Cell Lymphoma,,Completed,,11-Apr-23,PH0027-000
caplacizumabOpens in new tab,Cablivi,caplacizumab,"['https://cadth.ca/sites/default/files/DRR/2023/SR0736%20Cablivi%20Resubmission%20-%20Final%20CADTH%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0736-Cablivi%20Resubmission_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0736%20Cablivi%20Resubmission%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation_Redacted.pdf']",Acquired thrombotic thrombocytopenic purpura (aTTP),Do not reimburse,Complete,07-Jun-22,05-Apr-23,SR0736-000
nivolumabOpens in new tab,Opdivo,nivolumab,"['https://cadth.ca/sites/default/files/DRR/2023/PC0303%20Opdivo%20NSCLC%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0303-Opdivo-NSCLC.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0303-Opdivo-NSCLC-Stakeholder-Feedback.pdf']",Resectable Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,13-Sep-22,30-Mar-23,PC0303-000
brexucabtagene autoleucelOpens in new tab,Tecartus,brexucabtagene autoleucel,"['https://www.cadth.ca/sites/default/files/DRR/2023/PG0304%20Tecartus%20ALL%20%E2%80%93%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PG0304-Tecartus-ALL.pdf', 'https://www.cadth.ca/sites/default/files//DRR/2023/PG0304-Tecartus-ALL-Stakeholder-Feedback.pdf']",Acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Complete,16-Sep-22,29-Mar-23,PG0304-000
pegcetacoplanOpens in new tab,Empaveli,pegcetacoplan,"['https://cadth.ca/sites/default/files/DRR/2023/SR0748REC-Empaveli_KT-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0748-Empaveli_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0748-Empaveli-Stakeholder-Feedback.pdf']",Paroxysmal nocturnal hemoglobinuria,Reimburse with clinical criteria and/or conditions,Complete,26-Aug-22,20-Mar-23,SR0748-000
finerenoneOpens in new tab,Kerendia,finerenone,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0737REC-Kerendia.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0737-Kerendia.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0737%20Kerendia%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20March%208%2C%202023.pdf']",Chronic kidney disease,Reimburse with clinical criteria and/or conditions,Complete,20-May-22,08-Mar-23,SR0737-000
Hormone receptor (HR) positive...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0018%20HRplus_HER2neg_Implementation%20Advice%20Report%20Algorithm.pdf'],"Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer",,Complete,,08-Mar-23,PH0018-000
lutetium vipivotide tetraxetanOpens in new tab,Pluvicto,lutetium vipivotide tetraxetan,"['https://cadth.ca/sites/default/files/DRR/2023/PC0297%20Pluvicto%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20March%203%2C%202023_For%20publishing_JH_BMc-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0297-Pluvicto_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0297-Pluvicto-Stakeholder-Feedback.pdf']",Metastatic castration-resistant prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,21-Jul-22,03-Mar-23,PC0297-000
amivantamabOpens in new tab,Rybrevant,amivantamab,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0289%20Rybrevant%20-%20Confidential%20CADTH%20Final%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0289-Rybrevant_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0289%20Rybrevant%20-%20Final%20Stakeholder%20Feedback%20May%2011%2C%202023.pdf']",Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,21-Apr-22,01-Mar-23,PC0289-000
olaparibOpens in new tab,Lynparza,olaparib,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0299%20Lynparza%20%E2%80%93%20CADTH%20Final%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0299-Lynparza_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0299-Lynparza-Stakeholder-Feedback.pdf']","gBRCAm, HER2-negative high-risk early breast cancer",Reimburse with clinical criteria and/or conditions,Complete,03-Aug-22,01-Mar-23,PC0299-000
ravulizumabOpens in new tab,Ultomiris,ravulizumab,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0740%20Ultomiris%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0740-Ultomiris_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0740-Ultomiris-Stakeholder-Feedback.pdf']",Atypical hemolytic uremic syndrome,Reimburse with clinical criteria and/or conditions,Complete,08-Jun-22,27-Feb-23,SR0740-000
berotralstatOpens in new tab,Orladeyo,berotralstat,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0723%20Orladeyo%20-%20Final%20CADTH%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0723-Orladeyo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0723-Orladeyo-Stakeholder-Feedback.pdf']",hereditary angioedema (HAE),Reimburse with clinical criteria and/or conditions,Complete,22-Feb-22,17-Feb-23,SR0723-000
lumasiranOpens in new tab,Oxlumo,lumasiran,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0734%20Oxlumo%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0734-Oxlumo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0734-Oxlumo-Stakeholder-Feedback.pdf']",Primary hyperoxaluria type 1,Reimburse with clinical criteria and/or conditions,Complete,10-May-22,08-Feb-23,SR0734-000
MelanomaOpens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0022%20Rapid%20Algorithm%20Report%20for%20Melanoma_with%20CAPCA%20Endorsement_FINAL.pdf'],Melanoma,,Complete,,06-Feb-23,PH0022-000
Differentiated Thyroid Carcino...Opens in new tab,,,['https://cadth.ca/sites/default/files/DRR/2023/PH0021%20Differentiated%20Thyroid%20Carcinoma%20Rapid%20Algorithm_for%20CAPCA%20Endorsement.pdf'],Differentiated Thyroid Carcinoma,,Complete,,06-Feb-23,PH0021-000
axicabtagene ciloleucelOpens in new tab,Yescarta,axicabtagene ciloleucel,"['https://www.cadth.ca/sites/default/files/DRR/2023/PG0293REC-Yescarta-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PG0293-Yescarta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PG0293%20Yescarta%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20February%203%2C%202023.pdf']",Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL),Reimburse with clinical criteria and/or conditions,Complete,09-Jun-22,03-Feb-23,PG0293-000
durvalumabOpens in new tab,Imfinzi,durvalumab,"['https://cadth.ca/sites/default/files/DRR/2023/PC0296REC-Imfinzi_JH_GP1_KAS.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0296-Imfinzi_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0296-Imfinzi-Stakeholder-Feedback.pdf']",Biliary tract cancer,Reimburse with clinical criteria and/or conditions,Complete,14-Jul-22,03-Feb-23,PC0296-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0280%20Keytruda%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0280-Keytruda_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0280-Keytruda-Stakeholder-Feedback.pdf']",Advanced endometrial cancer,Reimburse with clinical criteria and/or conditions,Complete,15-Dec-21,03-Feb-23,PC0280-000
dupilumabOpens in new tab,Dupixent,dupilumab,"['https://cadth.ca/sites/default/files/DRR/2023/SR0745%20Dupixent%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0745-Dupixent.pdf', 'http://www.cadth.ca/sites/default/files/DRR/2023/SR0745-Dupixent-Stakeholder-Feedback.pdf']",Asthma,Reimburse with clinical criteria and/or conditions,Complete,28-Jun-22,20-Jan-23,SR0745-000
anifrolumabOpens in new tab,Saphnelo,anifrolumab,"['https://cadth.ca/sites/default/files/DRR/2023/SR0717%20Saphnelo%20-%20CADTH%20Final%20Rec_JH_BF.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0717-Saphnelo_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0717%20Saphnelo%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Systemic lupus erythematosus,Reimburse with clinical criteria and/or conditions,Complete,28-Jan-22,20-Jan-23,SR0717-000
deferiproneOpens in new tab,Ferriprox,deferiprone,"['https://cadth.ca/sites/default/files/DRR/2023/SR0741%20Ferriprox%20-%20Final%20CADTH%20Recommendation%20Final-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0741-Ferriprox_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0741%20Ferriprox%20-%20Stakeholder%20Feedback%20January%2019%2C%202023.pdf']",Transfusional iron overload,Reimburse with clinical criteria and/or conditions,Complete,08-Jun-22,19-Jan-23,SR0741-000
belimumabOpens in new tab,Benlysta,belimumab,"['https://cadth.ca/sites/default/files/DRR/2023/SR0746%20Benlysta-%20CADTH%20Final%20Recommendation%20February%207%2C%202023_For%20Publishing_KT_NA_BF_KT_BF-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0746-Benlysta_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0746-Benlysta-Stakeholder-Feedback.pdf']",Lupus nephritis,Reimburse with clinical criteria and/or conditions,Complete,07-Jul-22,19-Jan-23,SR0746-000
brolucizumabOpens in new tab,Beovu,brolucizumab,"['https://cadth.ca/sites/default/files/DRR/2023/SR0747%20Beovu%20-%20CADTH%20%20Final%20Recommendation%20KH_SC%20-%20KH-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0747-Beovu_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0747%20Beovu%20-%20Stakeholder%20feedback.pdf']",Diabetic macular edema,Reimburse with clinical criteria and/or conditions,Complete,30-Jun-22,18-Jan-23,SR0747-000
dupilumabOpens in new tab,Dupixent,dupilumab,"['https://cadth.ca/sites/default/files/DRR/2023/SF0754REC-Dupixent-RfA.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SF0754-Dupixent-RfA_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SF0754%20Dupixent%20RfA%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20January%2018%2C%202023.pdf']",atopic dermatitis,Reimburse with clinical criteria and/or conditions,Complete,15-Jul-22,18-Jan-23,SF0754-000
HER2 Positive Metastatic Breas...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0016-HER2-mBC-CAPCA-Endorsement_FINAL.pdf'],HER2 Positive Metastatic Breast Cancer,,Complete,,13-Jan-23,PH0016-000
Renal Cell CarcinomaOpens in new tab,,,['https://cadth.ca/sites/default/files/pdf/PH0019-Adjuvant%20RCC-CAPCA%20Endorsement.pdf'],Renal Cell Carcinoma,,Complete,,11-Jan-23,PH0019-000
Metastatic Urothelial Carcinom...Opens in new tab,,,['https://cadth.ca/sites/default/files/pdf/PH0017-mUC-CAPCA-Endorsement.pdf'],Metastatic Urothelial Carcinoma,,Complete,,11-Jan-23,PH0017-000
lemborexantOpens in new tab,Dayvigo,lemborexant,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0716%20Dayvigo%20-%20Confidential%20Final%20CADTH%20Rec%20DM%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0716-Dayvigo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0716-Dayvigo-Stakeholder-Feedback.pdf']",Insomnia,Do not reimburse,Complete,28-Feb-22,10-Jan-23,SR0716-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://cadth.ca/sites/default/files/DRR/2023/PC0295%20Keytruda%20mTNBC%20-%20Final%20CADTH%20Recommendation_for%20Publishing-KH%20-%20KW%20-%20KH-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0295-Keytruda-mTNBC_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0295-Keytruda-mTNBC-Stakeholder-Feedback.pdf']",Triple-negative breast cancer,Reimburse with clinical criteria and/or conditions,Complete,20-Jun-22,06-Jan-23,PC0295-000
darolutamideOpens in new tab,Nubeqa,darolutamide,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0294%20Nubeqa%20-%20CADTH%20Final%20Recommendation_KT_DM_KT-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0294-Nubeqa.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0294-Nubeqa-Stakeholder-Feedback.pdf']",Metastatic castration-sensitive prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,16-Jun-22,05-Jan-23,PC0294-000
tebentafuspOpens in new tab,Kimmtrak,tebentafusp,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0290%20Kimmtrak%20-%20CADTH%20Final%20Recommendation%20January%204%2C%202023_JH_KAS%20(clean)-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0290-Kimmtrak.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0290-Kimmtrak-Stakeholder-Feedback.pdf']",unresectable or metastatic uveal melanoma,Reimburse with clinical criteria and/or conditions,Complete,21-Apr-22,04-Jan-23,PC0290-000
edaravoneOpens in new tab,Radicava,edaravone,"['https://cadth.ca/sites/default/files/DRR/2023/SR0727%20Radicava%20-%20CADTH%20Final%20Recommendation_for%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0727-Radicava_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0727-Radicava-Stakeholder-Feedback.pdf']",Amyotrophic lateral sclerosis,Reimburse with clinical criteria and/or conditions,Complete,10-Mar-22,22-Dec-22,SR0727-000
lurbinectedinOpens in new tab,Zepzelca,lurbinectedin,"['https://www.cadth.ca/sites/default/files/DRR/2023/PC0281%20Zepzelca%20-%20Confidental%20Final%20CADTH%20Recommendation%20(Redacted)-KH_SC%20-%20KH-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0281-Zepzelca_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0281%20Zepzelca%20-%20Stakholder%20Feedback%20January%2030%2C%202023.pdf']",metastatic small cell lung cancer (SCLC),Do not reimburse,Complete,24-Feb-22,19-Dec-22,PC0281-000
eptinezumabOpens in new tab,Vyepti,eptinezumab,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0743%20Vyepti%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20final%20-%20KH%20-%20DM%20-%20KH2-meta%20(1).pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0743-Vyepti-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0743-Vyepti-Stakeholder-Feedback.pdf']",Migraine,Reimburse with clinical criteria and/or conditions,Complete,08-Jun-22,15-Dec-22,SR0743-000
dexamethasone intravitreal imp...Opens in new tab,Ozurdex,dexamethasone intravitreal implant,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0739%20Ozurdex%20-%20Final%20CADTH%20Recommendation_RW_SC_RW_RW-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0739-Ozurdex.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0739-Ozurdex-Stakeholder-Feedback.pdf']",Diabetic macular edema,Do not reimburse,Complete,08-Jun-22,13-Dec-22,SR0739-000
pitolisant hydrochlorideOpens in new tab,Wakix,pitolisant hydrochloride,"['https://cadth.ca/sites/default/files/DRR/2022/SR0715%20Wakix%20-%20Final%20CADTH%20Recommendation%20for%20publishing-KH_BMc%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0715-Wakix.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0715-Wakix-Stakeholder-Feedback.pdf']",Narcolepsy,Do not reimburse,Complete,08-Dec-21,06-Dec-22,SR0715-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0292%20Keytruda%20Cervical%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)_Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0292-Keytruda-Cervical.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0292-Keytruda-Cervical-Stakeholder-Feedback.pdf']","recurrent, or metastatic cervical cancer",Reimburse with clinical criteria and/or conditions,Complete,20-May-22,01-Dec-22,PC0292-000
guselkumabOpens in new tab,Tremfya,guselkumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0733%20Tremfya%20PsA%20-%20CADTH%20Final%20Recommendation_KAS-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0733-Tremfya.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0733%20Tremfya%20PsA%20-%20Stakeholder%20Feedback%20December%202022.pdf']",Psoriatic arthritis,Reimburse with clinical criteria and/or conditions,Complete,02-May-22,17-Nov-22,SR0733-000
ozanimodOpens in new tab,Zeposia,ozanimod,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0714%20Zeposia%20-%20Final%20CADTH%20Recommendation%20SC%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0714-Zeposia-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0714-Zeposia-UC-Stakeholder-Feedback.pdf']",Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,05-Jan-22,17-Nov-22,SR0714-000
tezepelumabOpens in new tab,Tezspire,tezepelumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0731%20Tezspire%20-%20Confidential%20CADTH%20Final%20Recommendation%20(with%20redactions)_RW_DM_RW-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0731-Tezspire.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0731-Tezspire-Stakeholder-Feedback-on-Draft-Rec.pdf']",Asthma,Reimburse with clinical criteria and/or conditions,Complete,14-Apr-22,16-Nov-22,SR0731-000
dalbavancinOpens in new tab,Xydalba,dalbavancin,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0728%20Xydalba%20-%20CADTH%20Final%20Recommendation%20JH_SC_ready%20for%20formatting-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0728-Xydalba_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0728%20Xydalba%20-%20Stakeholder%20Feedback%20November%2016%2C%202022.pdf']",Acute bacterial skin and skin structure infections,Reimburse with clinical criteria and/or conditions,Complete,11-Apr-22,16-Nov-22,SR0728-000
mepolizumabOpens in new tab,Nucala,mepolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0735%20Nucala%20-%20CADTH%20Final%20Recommendation%20(with%20corrections)_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0735-Nucala_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0735%20Nucala%20-%20Stakeholder%20feedback%20on%20Draft%20Recommendation.pdf']",Severe chronic rhinosinusitis with nasal polyps,Reimburse with clinical criteria and/or conditions,Complete,11-May-22,16-Nov-22,SR0735-000
Multiple Myeloma (MM)Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0014%20Rapid%20Algorithm%20Report%20Multiple%20Myeloma.pdf'],Multiple Myeloma (MM),,Complete,,15-Nov-22,PH0014-000
cariprazineOpens in new tab,Vraylar,cariprazine,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0718%20Vraylar%20BPD%20-%20CADTH%20Final%20Recommendation%20(with%20redactions)_RW_DM_RW-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0718-Vraylar-BPD.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0718-Vraylar-BPD-Stakeholder-Feedback.pdf']",Bipolar Disorder,Do not reimburse,Complete,28-Jan-22,09-Nov-22,SR0718-000
pegvaliaseOpens in new tab,Palynziq,pegvaliase,"['https://www.cadth.ca/sites/default/files/DRR/2023/SR0712%20Palynziq%20Procedural%20Review%20Panel%20report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0712-Response-to-Procedural-Review-Panel.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0712%20Palynziq%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0712-Palynziq_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0712%20Palynziq%20-%20Stakeholder%20Feedback%20.pdf']",Phenylketonuria,Reimburse with clinical criteria and/or conditions,Complete,22-Dec-21,09-Nov-22,SR0712-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0286%20Keytruda%20Melanoma%20-%20CADTH%20Final%20Rec%20Revised%20Jan.%2031.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0286-Keytruda-Melanoma_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0286-Keytruda-Melanoma-Stakeholder-Feedback.pdf']",Melanoma Adjuvant Treatment,Reimburse with clinical criteria and/or conditions,Complete,26-Apr-22,04-Nov-22,PC0286-000
maribavirOpens in new tab,Livtencity,maribavir,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0720%20Livtencity%20%E2%80%93%20CADTH%20Final%20Recommendation%20(with%20redactions)%20KH2_SY%20-%20KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0720-Livtencity.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/SR0720-Livtencity-Stakeholder-Feedback.pdf']",Post-transplant cytomegalovirus infection,Reimburse with clinical criteria and/or conditions,Complete,31-Mar-22,04-Nov-22,SR0720-000
entrectinibOpens in new tab,Rozlytrek,entrectinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0278%20Rozlytrek%20-%20CADTH%20Final%20Recommendation%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0278-Rozlytrek.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0278-Rozlytrek-Stakeholder-Feedback.pdf']",Extracranial solid tumours with NTRK gene fusion,Reimburse with clinical criteria and/or conditions,Complete,25-Jan-22,03-Nov-22,PC0278-000
cabozantinibOpens in new tab,Cabometyx,cabozantinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0287%20Cabometyx%20-%20CADTH%20Final%20Recommendation%20for%20formatting-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0287-Cabometyx_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0287-Cabometyx-Stakeholder-Feedback.pdf']",Differentiated thyroid carcinoma,Reimburse with clinical criteria and/or conditions,Complete,27-Apr-22,02-Nov-22,PC0287-000
empagliflozinOpens in new tab,Jardiance,empagliflozin,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0726%20Jardiance%20-%20Final%20CADTH%20Recommendation.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0726-Jardiance_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0726%20Jardiance%20-%20Stakeholder%20Feedback%20October%2014%2C%202022.pdf']",Heart failure,Reimburse with clinical criteria and/or conditions,Complete,06-Apr-22,14-Oct-22,SR0726-000
faricimabOpens in new tab,Vabysmo,faricimab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0729%20Vabysmo%20-%20Confidential%20Final%20CADTH%20Recommendation-KH_BF%20-%20KH-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0729-Vabysmo_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0729-Vabysmo-Stakeholder-Feedback.pdf']",Diabetic Macular Edema,Reimburse with clinical criteria and/or conditions,Complete,24-Mar-22,14-Oct-22,SR0729-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0273%20Keytruda%20RCC%20-%20CADTH%20Final%20Recommendation_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0273-Keytruda-RCC_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0273-Keytruda-RCC-Stakeholder-Feedback.pdf']","Renal cell carcinoma, adjuvant",Reimburse with clinical criteria and/or conditions,Complete,03-Mar-22,29-Sep-22,PC0273-000
pralsetinibOpens in new tab,Gavreto,pralsetinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0283%20Gavreto%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0283-Gavreto_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0283-Gavreto-Stakeholder-Feedback.pdf']",RET fusion-positive non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,09-Mar-22,29-Sep-22,PC0283-000
abemaciclibOpens in new tab,Verzenio,abemaciclib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0282%20Verzenio%20-%20CADTH%20Final%20Recommendation%20(With%20Redactions)_Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0282-Verzenio.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0282-Verzenio-Stakeholder-Feedback.pdf']","Adjuvant treatment of HR-positive, HER2-negative early breast cancer",Reimburse with clinical criteria and/or conditions,Complete,23-Mar-22,29-Sep-22,PC0282-000
tafasitamabOpens in new tab,Minjuvi,tafasitamab,"['https://cadth.ca/sites/default/files/DRR/2023/PC0266%20Minjuvi%20Procedural%20Review%20Panel%20report_Redacted.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0266%20Response%20to%20the%20Procedural%20Review%20Panel.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0266%20Minjuvi%20-%20CADTH%20Final%20Recommendation-Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0266-Minjuvi_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0266-Minjuvi-Stakeholder-Feedback.pdf']",Diffuse large B-cell lymphoma (DLBCL),Do not reimburse,Complete,19-Nov-21,29-Sep-22,PC0266-000
nivolumabOpens in new tab,Opdivo,nivolumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0272%20Opdivo%20UC%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0272-Opdivo-combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0272-Opdivo-UC-Stakeholder-Feedback.pdf']",Urothelial carcinoma,Reimburse with clinical criteria and/or conditions,Complete,22-Feb-22,28-Sep-22,PC0272-000
lutetium oxodotreotideOpens in new tab,Lutathera,lutetium oxodotreotide,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0284%20Lutathera%20-CADTH%20Final%20Recommendation%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0284-Lutathera_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/PC0284%20Lutathera%20-%20Stakeholder%20Feedback%20.pdf']",Gastroenteropancreatic neuroendocrine tumours (GEP-NETs),Reimburse with clinical criteria and/or conditions,Complete,23-Mar-22,28-Sep-22,PC0284-000
trastuzumab deruxtecanOpens in new tab,Enhertu,trastuzumab deruxtecan,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0285%20Enhertu%20-%20Confidential%20Final%20CADTH%20Recommendation-KH%20-%20Validated-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0285-Enhertu.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/PC0285-Enhertu-Stakeholder-Feedback.pdf']",Metastatic HER2 positive breast cancer,Reimburse with clinical criteria and/or conditions,Complete,23-Mar-22,28-Sep-22,PC0285-000
selpercatinibOpens in new tab,Retevmo,selpercatinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0264%20Retevmo%20MTC%20-%20Final%20CADTH%20Recommendation%20for%20Posting%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0264-Retevmo-MTC-combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0264-Retevmo-MTC-Stakeholder-Feedback.pdf']",Thyroid cancer,Reimburse with clinical criteria and/or conditions,Complete,29-Oct-21,26-Sep-22,PC0264-000
semaglutideOpens in new tab,Wegovy,semaglutide,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0725%20Wegovy%20-%20CADTH%20Final%20Recommendation-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0725-Wegovy_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0725%20Wegovy%20-%20Stakeholder%20Feedback%20October%202022.pdf']",Weight management,Do not reimburse,Complete,10-Mar-22,16-Sep-22,SR0725-000
ruxolitinibOpens in new tab,Jakavi,ruxolitinib,"['https://cadth.ca/sites/default/files/DRR/2022/SR0688%20Jakavi%20(acute)%20-%20CADTH%20Final%20Recommendation-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0688%20Jakavi%20(acute).pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0688%20Jakavi(acute)%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Graft versus host disease,Reimburse with clinical criteria and/or conditions,Complete,10-Aug-21,15-Sep-22,SR0688-000
pembrolizumab and lenvatinibOpens in new tab,Keytruda and Lenvima,pembrolizumab and lenvatinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0288%20Keytruda%20and%20Lenvima%20-%20Final%20CADTH%20Recommendation.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0288-Keytruda-Lenvima.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0288%20Keytruda%20and%20Lenvima%20-%20Stakeholder%20Feedback%20Sep%201%2C%202022.pdf']",Advanced endometrial cancer,Reimburse with clinical criteria and/or conditions,Complete,07-Mar-22,09-Sep-22,PC0288-000
Renal Cell Carcinoma (RCC)Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0013%20RCC_final.pdf'],Renal Cell Carcinoma (RCC),,Complete,,06-Sep-22,PH0013-000
atezolizumabOpens in new tab,Tecentriq,atezolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0277%20Tecentriq%20SCLC%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0277-Tecentriq-SCLC_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0277%20Tecentriq%20SCLC%20-%20Stakeholder%20Feedback.pdf']",Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,24-Jan-22,01-Sep-22,PC0277-000
atezolizumabOpens in new tab,Tecentriq,atezolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0269%20Tecentriq%20for%20NSCLC%20-%20CADTH%20Final%20Recommendation-Final-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0269-Tecentriq%20NSCLC_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0269%20Tecentriq%20NSCLC%20-%20Stakeholder%20Feedback.pdf']",Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,24-Feb-22,01-Sep-22,PC0269-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0279%20Keytruda%20TNBC%20-%20Final%20CADTH%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0279-Keytruda%20TNBC.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0279%20Keytruda%20TNBC%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20August%2031%2C%202022.pdf']",Triple-negative breast cancer,Reimburse with clinical criteria and/or conditions,Complete,17-Feb-22,31-Aug-22,PC0279-000
tepotinibOpens in new tab,Tepmetko,tepotinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0255%20Tepmetko%20-%20CADTH%20Final%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0255-Tepmetko_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0255%20Tepmetko%20-%20Stakeholder%20Feedback.pdf']",Locally advanced or metastatic non-small cell lung cancer,Do not reimburse,Complete,30-Aug-21,24-Aug-22,PC0255-000
dostarlimabOpens in new tab,Jemperli,dostarlimab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0263%20Jemperli%20-%20CADTH%20Final%20Recommendation_JH_SC-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0263-Jemperli-combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/Jemperli%20-%20Stakeholder%20Feedback.pdf']",Endometrial cancer,Do not reimburse,Complete,07-Oct-21,24-Aug-22,PC0263-000
abrocitinibOpens in new tab,Cibinqo,abrocitinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0686REC-Cibinqo_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/SR0686-Cibinqo.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0686%20Cibingo%20-%20Stakeholder%20Feedback%20August%2019%2C%202022%20for%20posting.pdf']","Atopic dermatitis, moderate to severe",Reimburse with clinical criteria and/or conditions,Complete,26-Apr-21,19-Aug-22,SR0686-000
faricimabOpens in new tab,Vabysmo,faricimab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0719REC-Vabysmo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0719-Vabysmo_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0719-Vabysmo-Stakeholder-Feedback.pdf']","Macular degeneration, age-related",Reimburse with clinical criteria and/or conditions,Complete,31-Jan-22,12-Aug-22,SR0719-000
mogamulizumabOpens in new tab,Poteligeo,mogamulizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0244REC-Poteligeo.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0244-Poteligeo_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0244%20Poteligeo%20-%20Stakeholder%20Feedback.pdf']","mycosis fungoides (MF), Sézary syndrome (SS)",Reimburse with clinical criteria and/or conditions,Complete,13-Sep-21,12-Aug-22,PC0244-000
nusinersenOpens in new tab,Spinraza,nusinersen,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0713-Spinraza-Reassessment.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0713-Spinraza-Reassessment-combined-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0713-Spinraza-Reassessment-Stakeholder-Feedback.pdf']",Spinal Muscular Atrophy,Do not reimburse,Complete,02-Dec-21,11-Aug-22,SR0713-000
asciminibOpens in new tab,Scemblix,asciminib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0275%20Scemblix%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0275-Scemblix.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0275%20Scemblix%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20August%205%2C%202022.pdf']",Philadelphia chromosome-positive chronic myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,20-Jan-22,05-Aug-22,PC0275-000
NSCLC without actionable oncog...Opens in new tab,,,['https://cadth.ca/sites/default//files/pdf/PH0012-NSCLC-Rapid%20Algorithm-for-CAPCA-Review.pdf'],Unmutated Non-small cell lung cancer,,Complete,,05-Aug-22,PH0012-000
selinexorOpens in new tab,Xpovio,selinexor,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0276%20Xpovio%20-%20Final%20CADTH%20Recommendation_KT_KAS_KT_GP-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0276-Xpovio.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0276-Xpovio-Stakeholder-Feedback.pdf']",Multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,14-Jan-22,29-Jul-22,PC0276-000
zanubrutinibOpens in new tab,Brukinsa,zanubrutinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0267%20Brukinsa%20MCL%20-%20Final%20CADTH%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0267-Brukinsa.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0267-Brukinsa-MCL-Stakeholder-Feedback.pdf']",Mantle cell lymphoma (MCL),Do not reimburse,Complete,30-Sep-21,27-Jul-22,PC0267-000
sodium phenylbutyrate and urso...Opens in new tab,Albrioza,sodium phenylbutyrate and ursodoxicoltaurine,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0711REC-Albrioza.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0711-Albrioza.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0711-Albrioza-Stakeholder-Feedback-July21-2022.pdf']",Amyotrophic lateral sclerosis (ALS),Reimburse with clinical criteria and/or conditions,Complete,24-Nov-21,21-Jul-22,SR0711-000
ruxolitinibOpens in new tab,Jakavi,ruxolitinib,"['https://cadth.ca/sites/default/files/DRR/2022/SR0706REC-Jakavi-(Chronic).pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0706-Jakavi-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0706-Jakavi-(chronic)-Stakeholder-Feedback.pdf']",Graft versus host disease,Reimburse with clinical criteria and/or conditions,Complete,10-Aug-21,15-Jul-22,SR0706-000
avalglucosidase alfaOpens in new tab,Nexviazyme,avalglucosidase alfa,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0703%20Nexviazyme%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0703%20Nexviazyme%20combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0703%20Nexviazyme%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Pompe disease,Reimburse with clinical criteria and/or conditions,Complete,30-Sep-21,05-Jul-22,SR0703-000
lisocabtagene maraleucelOpens in new tab,Breyanzi,lisocabtagene maraleucel,"['https://www.cadth.ca/sites/default/files/DRR/2022/PG0258%20Breyanzi%20-%20Final%20CADTH%20Rec-Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PG0258-Breyanzi.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PG0258-Breyanzi-Stakeholder-Feedback.pdf']",Relapsed or refractory large B-cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,09-Aug-21,29-Jun-22,PG0258-000
selpercatinibOpens in new tab,Retevmo,selpercatinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0274%20Retevmo%20DTC%20-%20CADTH%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0274-Retevmo%20DTC.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0274%20Retevmo%20DTC%20-%20Consolidated%20Feedback%20June%2029%2C%202022.pdf']",Thyroid cancer,Reimburse with clinical criteria and/or conditions,Complete,29-Oct-21,29-Jun-22,PC0274-000
lenvatinib and pembrolizumabOpens in new tab,Lenvima and Keytruda,lenvatinib and pembrolizumab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0268%20Lenvima%20and%20Keytruda%20-%20Final%20CADTH%20Rec_KT-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0268-Lenvima-Keytruda.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0268-Lenvima-Keytruda-Stakeholder-Feedback-on-Draft-Rec.pdf']",advanced or metastatic renal cell carcinoma,Reimburse with clinical criteria and/or conditions,Complete,15-Nov-21,23-Jun-22,PC0268-000
cenegerminOpens in new tab,Oxervate,cenegermin,"['https://cadth.ca/sites/default/files/DRR/2022/SR0704%20Oxervate%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0704-Oxervate%20combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0704%20Oxervate%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20June%2023%2C%202022.pdf']",Neurotrophic keratitis,Reimburse with clinical criteria and/or conditions,Complete,29-Oct-21,23-Jun-22,SR0704-000
Human Epidermal Growth Factor ...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0010-EC%20GEJC%20GC-Final-Report.pdf'],Esophageal or Gastroesophageal Junction Cancer,,Complete,,21-Jun-22,PH0010-000
tafamidisOpens in new tab,Vyndaqel,tafamidis,"['https://www.cadth.ca/sites/default/files/DRR/2022/SF0722%20Vyndaqel%20RfA%20-%20Final%20CADTH%20Rec-revised.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SF0722CL-Vyndaqel.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SF0722-Vyndaqel-RfA-Stakeholders-Feedback.pdf']",Transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,14-Dec-21,17-Jun-22,SF0722-000
elexacaftor/tezacaftor/ivacaft...Opens in new tab,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0710%20Trikafta%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0710-Trikafta_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0710-Trikafta-Stakeholder-Feedback.pdf']","Cystic fibrosis, F508del CFTR mutation, 6 years and older",Reimburse with clinical criteria and/or conditions,Complete,05-Nov-21,17-Jun-22,SR0710-000
amifampridine phosphateOpens in new tab,Firdapse,amifampridine phosphate,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0664%20Firdapse%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)%20KH_LdL-Clean-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0664-Firdapse.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0664-Firdapse-Stakeholder-Feedback-Draft-Rec.pdf']","Lambert-Eaton Myasthenic Syndrome, adults",Reimburse with clinical criteria and/or conditions,Complete,15-Nov-21,16-Jun-22,SR0664-000
immune globulin human and reco...Opens in new tab,HyQvia,immune globulin human and recombinant human hyaluronidase,"['https://www.cadth.ca/sites/default/files/DRR/2022/ST0695%20HyQvia%20-%20Final%20CADTH%20Recommendation%20July%204_KT_BF_KT_KT-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/ST0695-HyQvia-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/ST0695%20immune%20globulin%20human%20and%20recombinant%20human%20hyaluronidase%20-%20Patient%20Group%20Input%20_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/ST0695-HyQvia-Stakeholder-Feedback.pdf']",Humoral immunodeficiency,Reimburse with clinical criteria and/or conditions,Complete,24-Jun-21,15-Jun-22,ST0695-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0685REC-Rinvoq%20AD-KH_BF-KH-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0685-Rinvoq-AD.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0685-Rinvoq-AD-Stakeholder-Feedback.pdf']",atopic dermatitis,Reimburse with clinical criteria and/or conditions,Complete,13-Apr-21,08-Jun-22,SR0685-000
cemiplimabOpens in new tab,Libtayo,cemiplimab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0262%20Libtayo%20NSCLC%20%20%E2%80%93%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0262-Libtayo-combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0262%20Libtayo%20NSCLC%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20May%2019%2C%202022.pdf']",Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,13-Oct-21,02-Jun-22,PC0262-000
Multiple myelomaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0011-MM-Implementation-Advice-Report.pdf'],Multiple myeloma,,Complete,,25-May-22,PH0011-000
Anaplastic Lymphoma Kinase Pos...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0009-ALK%2BNSCLC-Algorithm.pdf'],ALK-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer,,Complete,,24-May-22,PH0009-000
ospemifeneOpens in new tab,Osphena,ospemifene,"['https://cadth.ca/sites/default/files/DRR/2022/SR0709%20Osphena%20-%20Final%20CADTH%20Rec%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0709-Osphena-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0709-Osphena-Stakeholder-Feedback.pdf']","Dyspareunia, vaginal dryness",Reimburse with clinical criteria and/or conditions,Complete,26-Oct-21,13-May-22,SR0709-000
selpercatinibOpens in new tab,Retevmo,selpercatinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0261%20Retevmo%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0261-Retevmo_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0261-Retevmo-Stakeholder-Feedback.pdf']",RET fusion-positive non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,17-Aug-21,28-Apr-22,PC0261-000
ripretinibOpens in new tab,Qinlock,ripretinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0265%20Qinlock%20-%20Confidential%20Final%20CADTH%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0265-Qinlock.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0265-Qinlock-Stakeholder-Feedback-Draft-Rec.pdf']",Gastrointestinal stromal tumours,Reimburse with clinical criteria and/or conditions,Complete,15-Oct-21,28-Apr-22,PC0265-000
prasteroneOpens in new tab,Intrarosa,prasterone,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0707%20Intrarosa%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0707-Intrarosa.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0707-Intrarosa-Stakeholder-Feedback.pdf']",Postmenopausal vulvovaginal atrophy,Reimburse with clinical criteria and/or conditions,Complete,01-Oct-21,14-Apr-22,SR0707-000
Alpha1-proteinase inhibitor (H...Opens in new tab,Zemaira,Alpha1-proteinase inhibitor (Human),"['https://www.cadth.ca/sites/default/files/DRR/2022/ST0702%20Zemaira%20-%20CADTH%20Final%20Rec%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/ST0702-ZemairaCombined.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/ST0702-Zemaira-Stakeholder-Feedback.pdf']",Severe Alpha1-proteinase inhibitor deficiency,Reimburse with clinical criteria and/or conditions,Complete,01-Oct-21,13-Apr-22,ST0702-000
HER2-Positive Metastatic Breas...Opens in new tab,,,['https://cadth.ca/sites/default/files/pdf/PH0006-HER2MBC-Algorithm%20Panel%20Scope.pdf'],HER2-Positive Metastatic Breast Cancer,,Complete,,12-Apr-22,PH0006-000
fostamatinibOpens in new tab,Tavalisse,fostamatinib,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0701%20Tavalisse%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0701-Tavalisse-combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0701%20Tavalisse%20-%20Patient%20Group%20Input_Redacted.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0701%20Tavalisse%20-%20Stakeholder%20Feedback%20January%2027%2C%202022.pdf']",Chronic immune thrombocytopenia,Do not reimburse,Complete,22-Jul-21,05-Apr-22,SR0701-000
bimekizumabOpens in new tab,Bimzelx,bimekizumab,"['https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0698%20Bimzelx%20-%20CADTH%20Final%20Rec%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0698-Bimzelx.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0698-Bimzelx-Stakeholder-Feedback.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,17-Aug-21,30-Mar-22,SR0698-000
Metastatic Urothelial Carcinom...Opens in new tab,,,['https://cadth.ca/sites/default/files/pdf/PH0008%20mUC%20Algorithm%20Report-Final.pdf'],Metastatic Urothelial Carcinoma,,Complete,,28-Mar-22,PH0008-000
pemigatinibOpens in new tab,Pemazyre,pemigatinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0252%20Pemazyre%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0252-Pemazyre.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0252%20pemigatinib%20-%20Patient%20Group%20Input_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0252-Pemazyre-Stakeholder-Feedback.pdf']",Cholangiocarcinoma,Do not reimburse,Complete,23-Jun-21,23-Mar-22,PC0252-000
lorlatinibOpens in new tab,Lorbrena,lorlatinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0249%20Lorbrena%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0249-Lorbrena.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0249%20Lorbrena%20-%20Patient%20Group%20Input_For%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0249-Lorbrena-Stakeholder-Feedback.pdf']",ALK-positive locally advanced or metastatic non-small cell lung,Reimburse with clinical criteria and/or conditions,Complete,18-Jun-21,17-Mar-22,PC0249-000
colchicineOpens in new tab,Myinfla,colchicine,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0691%20Myinfla%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0691-Myinfla-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0691%20Myinfla%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20posting.pdf']",Atherothrombotic events in coronary artery disease,Do not reimburse,Complete,28-May-21,08-Mar-22,SR0691-000
somatrogonOpens in new tab,Ngenla,somatrogon,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0683%20Ngenla%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0683-Ngenla-CombinedReport.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0683-Ngenla-Stakeholder-Feedback.pdf']",Growth hormone deficiency,Reimburse with clinical criteria and/or conditions,Complete,03-Jun-21,08-Mar-22,SR0683-000
tralokinumabOpens in new tab,Adtralza,tralokinumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0689%20Adtralza%20-%20Confidential%20Final%20CADTH%20Rec-Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0689-Adtralza_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0689%20tralokinumab%20(TBC)%20-%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0689%20Adtralza%20-%20Stakeholder%20Feedback%20March%207%2C%202022.pdf']",atopic dermatitis,Do not reimburse,Complete,27-Apr-21,07-Mar-22,SR0689-000
nivolumabOpens in new tab,Opdivo,nivolumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0259%20Opdivo%20-%20Final%20CADTH%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0259-Opdivo-combinedReport.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0259-Opdivo-Stakeholder-Feedback-Draft-Rec.pdf']","Gastric, gastroesophageal junction, or esophageal adenocarcinoma",Reimburse with clinical criteria and/or conditions,Complete,18-Aug-21,04-Mar-22,PC0259-000
cemiplimabOpens in new tab,Libtayo,cemiplimab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0260REC-Libtayo_Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0260-Libtayo-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0260-Libtayo-Stakeholder-Feedback.pdf']",Basal cell carcinoma,Reimburse with clinical criteria and/or conditions,Complete,19-Aug-21,04-Mar-22,PC0260-000
ravulizumabOpens in new tab,Ultomiris,ravulizumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0700%20Ultomiris%20-%20Final%20CADTH%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0700CL-Ultomiri_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0700%20Ultomiris%20-%20Patient%20Group%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0700%20Ultomiris-Stakeholder-Feedback-on-Draft-Recommendation.pdf']",Paroxysmal nocturnal hemoglobinuria,Reimburse with clinical criteria and/or conditions,Complete,22-Jul-21,11-Feb-22,SR0700-000
estradiol and progesteroneOpens in new tab,Bijuva,estradiol and progesterone,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0697%20Bijuva%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0697-BijuvaCombined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0697-Bijuva-Stakeholder-Feedback.pdf']",Vasomotor symptoms associated with menopause,Reimburse with clinical criteria and/or conditions,Complete,30-Jun-21,10-Feb-22,SR0697-000
trientine hydrochlorideOpens in new tab,Waymade-Trientine,trientine hydrochloride,"['https://cadth.ca/sites/default/files/DRR/2022/SR0696%20Waymade-Trientine%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0696-Waymade-Trientine-combinedReport.pdf', 'https://www.cadth.ca/sites/default/files/attachments/2021-07/SR0696%20Waymade-Trientine%20Patient%20Input%20for%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0696%20Waymade-Trientine%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20February%208%2C%202022.pdf']",Wilson's Disease,Reimburse with clinical criteria and/or conditions,Complete,21-Jul-21,08-Feb-22,SR0696-000
inclisiranOpens in new tab,Leqvio,inclisiran,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0681-Response-to-Procedural-Review-Panel-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0681_Memorandum%2C%20Panel%20Report%20%E2%80%93%20Inclisiran_Leqvio%E2%84%A2%20-%20Procedural%20Review.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Confidential%20Final%20CADTH%20Rec%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0681-Leqvio.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0681%20inclisiran%20-%20Patient%20Input%20for%20Posting%20April%2022%2C%202021.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Consolidated%20Clinician%20Input%20for%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Stakeholder%20Feedback%20Februray%207%2C%202022.pdf']",Primary hypercholesterolemia,Do not reimburse,Complete,17-Mar-21,07-Feb-22,SR0681-000
Adult Classical Hodgkin Lympho...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/PH0007-cHL-Algorithm-Report-Final.pdf'],Adult Classical Hodgkin Lymphoma,,Complete,,02-Feb-22,PH0007-000
isatuximabOpens in new tab,Sarclisa,isatuximab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0256%20Sarclisa%20-%20CADTH%20Final%20Rec%20revised.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0256-Sarclisa-CombinedReport.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0256%20Sarclisa%20-%20Patient%20Group%20Input_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0256-Sarclisa-Stakeholder-Feedback.pdf']",Multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,15-Jul-21,28-Jan-22,PC0256-000
daratumumabOpens in new tab,Darzalex,daratumumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0257%20Darzalex%20-%20CADTH%20Final%20Rec%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0257-Darzalex-combinedReport.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0257 Darzalex - Consolidated Patient Input for Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0257%20Darzalex%20-%20Consolidated%20Clinician%20Group%20Input%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0257-Darzalex-Stakeholder%20Feedback%20January%2028%2C%202022.pdf']",Light chain (AL) amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,15-Jul-21,28-Jan-22,PC0257-000
sacituzumab govitecanOpens in new tab,Trodelvy,sacituzumab govitecan,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0254%20Trodelvy%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0254-Trodelvy-CombinedReport.pdf', 'https://www.cadth.ca/sites/default/files/attachments/2021-08/Sacituzumab%20govitecan%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf']",Locally advanced or metastatic triple-negative breast cancer,Reimburse with clinical criteria and/or conditions,Complete,30-Jun-21,27-Jan-22,PC0254-000
nivolumabOpens in new tab,Opdivo,nivolumab,"['https://cadth.ca/sites/default/files/DRR/2022/PC0253%20Opdivo%20-%20CADTH%20Final%20Rec%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0253-Opdivo_combined.pdf']",Esophageal or gastroesophageal junction cancer,Reimburse with clinical criteria and/or conditions,Complete,07-Jul-21,26-Jan-22,PC0253-000
alpelisibOpens in new tab,Piqray,alpelisib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0247%20Piqray%20-%20Final%20CADTH%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0247-Piqray.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0247%20Piqray%20-%20Patient%20Group%20Input_for%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0247%20Piqray%20-%20Clinician%20Input%20for%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0247%20Piqray%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20January%2026%2C%202022.pdf']",Advanced or Metastatic Breast Cancer,Do not reimburse,Complete,21-Apr-21,26-Jan-22,PC0247-000
pertuzumabOpens in new tab,Perjeta,pertuzumab,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0241%20Perjeta%20-%20Final%20CADTH%20Rec_Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0241-Perjeta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0241%20Perjeta%20PI%20for%20redactions_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0241%20Perjeta%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0241%20Perjeta%20-%20Stakeholder%20Feedback%20January%2025%2C%202022.pdf']",Early stage breast cancer,Do not reimburse,Complete,14-Apr-21,25-Jan-22,PC0241-000
mecaserminOpens in new tab,Increlex,mecasermin,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0692REC-Increlex_JH_BF-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0692-combined_Increlex.pdf', 'https://www.cadth.ca/sites/default/files/attachments/2021-07/SR0692%20Increlex%20Patient%20Group%20Input_For%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0692-Increlex-Stakeholder-Feedback-Jan21-2022.pdf']",Severe primary insulin-like growth factor-1 deficiency,Reimburse with clinical criteria and/or conditions,Complete,14-Jun-21,21-Jan-22,SR0692-000
triheptanoinOpens in new tab,Dojolvi,triheptanoin,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0684%20Dojolvi%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0684-Dojolvi-CombinedReport.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0684%20Dojolvi%20Patient%20Input%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0684-Dojolvi-Clinician-Input-Redacted.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0684-Dojolvi-Stakeholder-Feedback-Sep23-2021-Jan7-2022.pdf']",Long-chain fatty acid oxidation disorders,Reimburse with clinical criteria and/or conditions,Complete,31-Mar-21,21-Jan-22,SR0684-000
estradiolOpens in new tab,Imvexxy,estradiol,"['https://www.cadth.ca/sites/default/files/DRR/2022/SR0694%20Imvexxy%20-%20CADTH%20Final%20Rec%20KH.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0694%20Imvexxy%20-%20Clinical%20and%20Economic%20Review%20Report%20_Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0694%20Imvexxy%20-%20Stakeholder%20Feedback%20January%2020%2C%202022.pdf']",Dyspareunia,Reimburse with clinical criteria and/or conditions,Complete,23-Jun-21,20-Jan-22,SR0694-000
osimertinibOpens in new tab,Tagrisso,osimertinib,"['https://cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso-rec%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0246_Tagrisso_PI%20Submission_for%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso-Clincian-Input-April-2021.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0246%20Tagrisso%20-%20Draft%20Recommendation%20Stakeholder%20Feedback%20February%203%2C%202022.pdf']",Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,24-Mar-21,10-Jan-22,PC0246-000
enfortumab vedotinOpens in new tab,Padcev,enfortumab vedotin,"['https://www.cadth.ca/sites/default/files/DRR/2022/PC0251REC-Padcev%20Final-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0251-Padcev.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0251 Enfortumab vedotin - Patient Group Input - For posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0251-Padcev-Stakeholder-Feedback-on-Draft-Rec.pdf']",Locally advanced or metastatic urothelial carcinoma,Reimburse with clinical criteria and/or conditions,Complete,23-Jun-21,06-Jan-22,PC0251-000
zanubrutinibOpens in new tab,Brukinsa,zanubrutinib,"['https://www.cadth.ca/sites/default/files/DRR/2021/PC0248%20Brukinsa%20%E2%80%93%20CADTH%20Final%20Recommendation%20Final-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0248-Brukinsa.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0248%20Brukinsa%20-%20Patient%20Group%20Input_Redacted_0.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0248-Brukinsa-Clinician-Group-Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0248-Brukinsa-Stakeholder-Feedback.pdf']",Waldenström’s macroglobulinemia,Reimburse with clinical criteria and/or conditions,Complete,21-May-21,21-Dec-21,PC0248-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2021/PC0250%20Keytruda%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0250CL-Keytruda.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0250%20Keytruda%20EC%20GEJ%20Patient%20Input_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso-Clincian-Input-April-2021.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0250-Keytruda-Final-Stakeholder-Feedback-Jan5-2022.pdf']","Esophageal carcinoma, gastroesophageal junction adenocarcinoma",Reimburse with clinical criteria and/or conditions,Complete,26-May-21,20-Dec-21,PC0250-000
galcanezumabOpens in new tab,Emgality,galcanezumab,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0693%20Emgality%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0693-Emgality.pdf', 'https://www.cadth.ca/sites/default/files/attachments/2021-07/SR0693%20Emgality%20-%20Patient%20Group%20Input%20-%20Migraine%20Canada%20and%20Migraine%20Quebec_For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0693-Emgality-Stakeholder-Feedback-on-Draft-Rec-jan18-2022.pdf']",Prevention of migraine,Reimburse with clinical criteria and/or conditions,Complete,03-Jun-21,15-Dec-21,SR0693-000
macitentan and tadalafilOpens in new tab,Opsynvi,macitentan and tadalafil,"['https://cadth.ca/sites/default/files/DRR/2021/SR0690%20Opsynvi-Rec%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0690-Opsynvi_combined.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0690-Opsynvi-Stakeholder-Feedback-on-Draft-Rec.pdf']",Pulmonary arterial hypertension,Reimburse with clinical criteria and/or conditions,Complete,20-May-21,14-Dec-21,SR0690-000
luspaterceptOpens in new tab,Reblozyl,luspatercept,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0670%20Reblozyl%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0670-Reblozyl-combinedReport.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0670%20Reblozyl%20-%20Patient%20Input%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0670-Reblozyl-Clinician-Input-for-Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0670-Reblozyl-Stakeholder-Feedback-Dec7-2021.pdf']",Myelodysplastic syndromes-associated anemia,Reimburse with clinical criteria and/or conditions,Complete,28-Jan-21,07-Dec-21,SR0670-000
chlormethine hydrochlorideOpens in new tab,Ledaga,chlormethine hydrochloride,"['https://www.cadth.ca/sites/default/files/DRR/2021/PC0242%20Ledaga%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0242-Ledaga-report.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/Ledaga%20-%20Patient%20Group%20Input%20-%20For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0242-Ledaga-clinician-group-input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PC0242-Ledaga-stakeholder-feedback-on-draft-rec.pdf']",T-cell lymphoma,Do not reimburse,Complete,21-Dec-20,24-Nov-21,PC0242-000
tucatinibOpens in new tab,Tukysa,tucatinib,"['https://cadth.ca/sites/default/files/DRR/2021/PC0243%20Tukysa%20-%20CADTH%20Final%20Rec_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0243-Tukysa-combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0243%20Tukysa%20-%20Patient%20Group%20Input_redacted.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0243%20Tukysa%20-%20Clinician%20Group%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0243%20Tukysa%20-%20Stakeholder%20Feedback.pdf']",Advanced or Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,26-Mar-21,17-Nov-21,PC0243-000
idecabtagene vicleucelOpens in new tab,Abecma,idecabtagene vicleucel,"['https://www.cadth.ca/sites/default/files/DRR/2021/PG0240%20Abecma%20-%20CADTH%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/Idecabtagene%20vicleucel%20-%20Consolidated%20Patient%20Group%20for%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma-Clinician-Input-Dec1-2021.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma-Stakeholder-Feedback-(with%20redactions)-Nov22-2021.pdf']",Multiple myeloma,Do not reimburse,Complete,16-Dec-20,12-Nov-21,PG0240-000
Colorectal CancerOpens in new tab,,,['https://www.cadth.ca/sites/default/files/attachments/2021-11/PH0005-000_CRC-FINAL-report-Nov11_0.pdf'],Colorectal Cancer,,Complete,,12-Nov-21,PH0005-000
Trientine HydrochlorideOpens in new tab,MAR-Trientine,Trientine Hydrochloride,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0680%20MAR-Trientine%20-%20CADTH%20Final%20Rec-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0680-MAR-Trientine.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2022/SR0680-MAR-Trientine-Stakeholder-Feedback-on-Draft-Recommendation-for-posting.pdf']",Wilson's Disease,Reimburse with clinical criteria and/or conditions,Complete,19-Apr-21,11-Nov-21,SR0680-000
romosozumabOpens in new tab,Evenity,romosozumab,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0676%20Evenity%20-%20CADTH%20Final%20Rec_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0676-Evenity-combined-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0676%20Evenity%20-%20Patient%20Group%20Input_For%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/SR0676%20Evenity-Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']","Osteoporosis, postmenopausal women",Reimburse with clinical criteria and/or conditions,Complete,01-Feb-21,11-Nov-21,SR0676-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20CADTH%20Final%20Rec%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda-combined-report.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/Keytruda%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20Stakeholder%20Feedback.pdf']",Classical Hodgkin lymphoma,Reimburse with clinical criteria and/or conditions,Complete,29-Jan-21,01-Nov-21,PC0236-000
azacitidineOpens in new tab,Onureg,azacitidine,"['https://cadth.ca/sites/default/files/DRR/2021/PC0245%20Onureg%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0245-Onureg-combined-Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0245-Onureg%20-%20Consolidated%20PI%20for%20Posting%20April%2022%2C%202021_Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0245-Onureg-Clinician-Group-Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2022/PC0245%20Onureg-Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Acute myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,01-Mar-21,20-Oct-21,PC0245-000
Decitabine-Cedazuridine (Inqov...Opens in new tab,Inqovi,Decitabine-Cedazuridine,"['https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_FnRec_REDACT_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_fnEGR_REDACT-ABBREV_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_fnCGR_REDACT_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_inRec_REDACT_Post02Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_PAG_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_Sponsor Feedback_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_Patient Feedback_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_Clinician Feedback_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_PatientCOI_Post22Sep2021_final.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_ClinicianCOI_Post22Sep2021_final_Redacted.pdf']",Myelodysplastic Syndromes (MDS),Reimburse with clinical criteria and/or conditions,Complete,09-Oct-20,22-Sep-21,PC0228-000
elexacaftor / tezacaftor / iva...Opens in new tab,Trikafta,elexacaftor / tezacaftor / ivacaftor and ivacaftor,"['https://cadth.ca/sites/default/files/DRR/2021/SR0673%20Trikafta%20-%20CADTH%20Final%20Rec%20Revised.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0673-combined-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/elexacaftor%20tezacaftor%20ivacaftor%20and%20ivacaftor%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0673-Trikafta%20-%20Clinician%20Group%20Input%20-%20Consolidated_For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0673-Trikafta%20-%20Stakeholder%20Feedback%20-%20For%20posting.pdf']","Cystic fibrosis, F508del CFTR mutation",Reimburse with clinical criteria and/or conditions,Complete,22-Jan-21,16-Sep-21,SR0673-000
budesonide/ glycopyrronium /fo...Opens in new tab,Breztri Aerosphere,budesonide/ glycopyrronium /formoterol fumarate,"['https://cadth.ca/sites/default/files/DRR/2021/SR0675%20Breztri%20Aerosphere%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0675-combined-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0675_budesonide-glycopyrronium-formoterol%20fumarate_PI%20Submission.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0675-Breztri%20Aerosphere%20-%20Clinician%20Group%20Input%20September%202021.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0675-Breztri%20Aerosphere%20-%20Stakeholder%20Feedback%20Septebmer%202021.pdf']",chronic obstructive pulmonary disease (COPD),Reimburse with clinical criteria and/or conditions,Complete,28-Jan-21,14-Sep-21,SR0675-000
larotrectinibOpens in new tab,Vitrakvi,larotrectinib,"['https://www.cadth.ca/sites/default/files/DRR/2021/PC0221%20Vitrakvi%20-%20CADTH%20Final%20Rec%20KG_NA_Corrected-meta.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0221-Vitrakvi-combined-report-meta.pdf', 'https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/Vitrakvi%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0221-Vitrakvi%20-%20Clinician%20Group%20Input%20-%20Consolidated_For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0221-Vitrakvi%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20Consolidated_For%20posting.pdf']",Solid tumours with NTRK gene fusion,Reimburse with clinical criteria and/or conditions,Complete,16-Nov-20,13-Sep-21,PC0221-000
incobotulinumtoxinAOpens in new tab,Xeomin,incobotulinumtoxinA,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0678%20Xeomin%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0678-combined-report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0678_Xeomin_PI Submission_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0678%20Xeomin%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Chronic sialorrhea associated with neurological disorders,Reimburse with clinical criteria and/or conditions,Complete,26-Feb-21,09-Sep-21,SR0678-000
risperidoneOpens in new tab,Perseris,risperidone,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0671%20Perseris%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0671-Perseris-Combine.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0671%20Perseris%20-%20Patient%20Group%20Input%20Submission_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0671-Perseris%20-%20Stakeholder%20Feedback.pdf']","Schizophrenia, adults",Reimburse with clinical criteria and/or conditions,Complete,29-Jan-21,08-Sep-21,SR0671-000
givosiranOpens in new tab,Givlaari,givosiran,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0679%20Givlaari%20-%20CADTH%20Final%20Rec-pw.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0679-Givlaari%20combined-meta.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0679%20Givlaari%20-%20Patient%20Input%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0679%20Givlaari%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Acute hepatic porphyria (AHP) in adults,Reimburse with clinical criteria and/or conditions,Complete,23-Feb-21,08-Sep-21,SR0679-000
liraglutideOpens in new tab,Saxenda,liraglutide,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0668 Saxenda - CADTH Final Rec KT_BF_KT-pw.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0668%20Saxenda-combined-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0668%20Saxenda%20-%20PI%20Submission.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0668%20Saxenda-stakeholder-feedback.pdf']",Chronic weight management in adults,Do not reimburse,Complete,23-Dec-20,01-Sep-21,SR0668-000
risdiplamOpens in new tab,Evrysdi,risdiplam,"['https://cadth.ca/sites/default/files/DRR/2021/SR0661%20Evrysdi%20Recommendation%20Final.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0661-combined-report-final.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/risdiplam%20-%20Consolidated%20Patient%20Input%20for%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0661%20Evrysdi%20-%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0661%20Evrysdi%20-%20Stakeholder%20Feedback%20August%205%2C%202021.pdf']",Spinal muscular atrophy,Reimburse with clinical criteria and/or conditions,Complete,19-Nov-20,26-Aug-21,SR0661-000
brexucabtagene autoleucelOpens in new tab,Tecartus,brexucabtagene autoleucel,"['https://cadth.ca/sites/default/files/DRR/2021/PG0219%20Tecartus%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PG0219-tecartus-combined-report-meta.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PG0219%20brexucabtagene%20autoleucel%20-%20Patient%20Group%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PG0219%20Tecartus%20-%20Clinician%20Group%20Input_For%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PG0219%20Tecartus%20-%20Stakeholder%20Feedback_For%20Posting.pdf']",Mantle cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,18-Dec-20,24-Aug-21,PG0219-000
daunorubicin and cytarabineOpens in new tab,Vyxeos,daunorubicin and cytarabine,"['https://cadth.ca/sites/default/files/DRR/2021/PC0237%20Vyxeos%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0237-combined-report-final.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0237%20Vyxeos%20-%20Patient%20Group%20Input_For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/pdf/htis/2021/PC0237%20Vyxeos%20-%20Clinician%20Input_For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/pdf/htis/2021/PC0237%20Vyxeos%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf']",Acute myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,22-Jan-21,24-Aug-21,PC0237-000
venetoclaxOpens in new tab,Venclexta,venetoclax,"['https://www.cadth.ca/sites/default/files/DRR/2021/PC0239 Venclexta  - CADTH Final Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0239-combined-report.pdf', 'https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0239%20Venclexta%20%28LDAC%29%20%E2%80%93%20Patient%20Group%20Input%20Submission_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0239%20Venclexta%20(LDAC)%20-%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0239%20Venclexta%20(LDAC)%20-%20Stakeholder%20Feedback.pdf']",Acute myeloid leukemia,Do not reimburse,Complete,22-Jan-21,23-Aug-21,PC0239-000
human insulinOpens in new tab,Entuzity KwikPen,human insulin,"['https://cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20CADTH%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0672-Entuzity-KwikPen%20Final.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20Patient%20Group%20Input_for%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20Feedback%20on%20Draft%20Recommendation%20-%20For%20posting.pdf']",Diabetes mellitus,Reimburse with clinical criteria and/or conditions,Complete,27-Jan-21,23-Aug-21,SR0672-000
budesonideOpens in new tab,Jorveza,budesonide,"['https://www.cadth.ca/sites/default/files/DRR/2021/SR0666 Jorveza - CADTH Final Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0666-combined-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0666%20Jorveza%20-%20Patient%20Input%20Submission.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0666-Jorveza-Stakeholder-Feedback-on-Draft-Recommendation.pdf']",Maintenance of Eosinophilic esophagitis in adults,Reimburse with clinical criteria and/or conditions,Complete,05-Nov-20,23-Aug-21,SR0666-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,"['https://cadth.ca/sites/default/files/DRR/2021/SR0658%20Rinvoq%20-%20Final%20CADTH%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0658-combined-report.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0658%20Rinvoq%20-%20Patient%20Input%20for%20Posting%20Consolidated.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SR0658%20Rinvoq%20-%20Stakeholder%20Feedback%20for%20Posting.pdf']","Psoriatic Arthritis, adults",Reimburse with clinical criteria and/or conditions,Complete,04-Jan-21,20-Aug-21,SR0658-000
venetoclaxOpens in new tab,Venclexta,venetoclax,"['https://cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20(AZA)%20-%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0238-combined-report-FINAL.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20-%20Consolidated%20PI%20for%20Posting%20February%2023%2C%202021%20(1).pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20(AZA)%20-%20Clinician%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20(AZA)%20-%20Stakeholder%20Feedback.pdf']",Acute myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,08-Jan-21,20-Aug-21,PC0238-000
nivolumab-ipilimumabOpens in new tab,Opdivo-Yervoy,nivolumab-ipilimumab,"['https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0229%20Opdivo-Yervoy%20%20Final%20Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0229-Opdivo-Yervoy-combined.pdf', 'https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/Opdivo-Yervoy%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0229%20Opdivo-Yervoy%20-%20Clinician%20Group%20Input_For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/PC0229%20Opdivo-Yervoy%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation_For%20Posting.pdf']",Malignant Pleural Mesothelioma (MPM),Reimburse with clinical criteria and/or conditions,Complete,09-Oct-20,04-Aug-21,PC0229-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://cadth.ca/sites/default/files/attachments/2021-07/PC0235%20Keytruda%20-%20CADTH%20Final%20Rec%20revised_1.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0235-Keytruda-Combined.pdf', 'https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/PC0235%20Keytruda%20-%20Patient%20Input_For%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0235%20Keytruda%20-%20Clinician%20Group%20Input_For%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0235%20Keytruda%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation_For%20Posting.pdf']",Colorectal cancer,Reimburse with clinical criteria and/or conditions,Complete,30-Nov-20,27-Jul-21,PC0235-000
durvalumabOpens in new tab,Imfinzi,durvalumab,"['https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0234-combined-final.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20posting.pdf']",Extensive-stage small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,01-Dec-20,27-Jul-21,PC0234-000
encorafenibOpens in new tab,Braftovi,encorafenib,"['https://cadth.ca/sites/default/files/DRR/2021/PC0233%20Braftovi%20-%20CADTH%20Final%20Rec.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0233-braftovi-combined-revised.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0233%20Braftovi%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0233 Braftovi - Clinician Input Group_For Posting.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0233 Braftovi - Stakeholder Feedback on Draft Recommendation_For Posting.pdf']",Metastatic colorectal cancer,Reimburse with clinical criteria and/or conditions,Complete,16-Dec-20,26-Jul-21,PC0233-000
encorafenib and binimetinibOpens in new tab,Braftovi and Mektovi,encorafenib and binimetinib,"['https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0232%20Braftovi%20and%20Mektovi%20Final.pdf', 'http://cadth.ca/sites/default/files/DRR/2021/PC0232-combined.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/PC0232%20Braftovi%20and%20Mektovi%20-%20Patient%20Group%20Input%20Submission_Redacted%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0232%20Braftovi%20and%20Mektovi%20-%20Clinician%20Input.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/PC0232%20Braftovi%20and%20Mektovi%20-%20Stakeholder%20Feedback.pdf']",Advanced Melanoma,Reimburse with clinical criteria and/or conditions,Complete,16-Dec-20,26-Jul-21,PC0232-000
dinutuximabOpens in new tab,Unituxin,dinutuximab,"['https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unituxin%20-%20CADTH%20Final%20Rec%20v4.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222-combined%20report%20for%20posting.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unituxin%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unituxin%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf', 'https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unitxuin%20-%20Stakeholder%20Feedback%20-%20For%20posting.pdf']",Neuroblastoma,Reimburse with clinical criteria and/or conditions,Complete,23-Nov-20,23-Jul-21,PC0222-000
ozanimodOpens in new tab,Zeposia,ozanimod,"['/sites/default/files/attachments/2021-06/SR0652%20Zeposia%20-%20CDEC%20Final%20Recommendation%20June%2029%2C%202021_for%20posting.pdf', 'https://cadth.ca/sites/default/files/cdr/clinical/SR0652%20Zeposia%20-%20Final%20Clinical%20Review%20Report%20(with%20redactions).pdf', 'https://cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0652%20Zeposia%20-%20Final%20Pharmacoeconomic%20Review%20Report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0652_ozanimod_PI%20Submission.pdf']","Multiple Sclerosis, relapsing - remitting",Do not reimburse,Complete,25-Aug-20,23-Jun-21,SR0652-000
tildrakizumabOpens in new tab,Ilumya,tildrakizumab,"['https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf', 'https://cadth.ca/sites/default/files/cdr/complete/SR0624%20Ilumya%20-%20CDEC%20Final%20Recommendation%20June%2023%2C%202021_for%20posting%20(1).pdf', 'https://cadth.ca/sites/default/files/cdr/clinical/sr0624-ilumya-clinical-review-report.pdf', 'https://cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0624-ilumya-pharmacoeconomic-review-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0624_Ilumya_PI%20Submission.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,15-Jul-19,21-Jun-21,SR0624-000
fedratinibOpens in new tab,Inrebic,fedratinib,"['https://www.cadth.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_fedratinib_%28inrebic%29_comp.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0205-combined.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/Inrebic%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0205-Inrebic%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0205-Inrebic%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf']",Myelofibrosis,Reimburse with clinical criteria and/or conditions,Complete,05-Nov-20,21-Jun-21,PC0205-000
semaglutideOpens in new tab,Rybelsus,semaglutide,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://cadth.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_semaglutide_%28rybelsus%29.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0637-combined.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0637%20Rybelsus%20-%20Patient%20Group%20Input%20Submission_redacted%20for%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/SR0637%20Rybelsus%20-%20Stakeholder%20Feedback.pdf']","diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,26-Nov-20,08-Jun-21,SR0637-000
luspaterceptOpens in new tab,Reblozyl,luspatercept,"['/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_luspatercept_%28reblozyl%29.pdf', '/sites/default/files/cdr/relatedinfo/Reblozyl%20-%20Patient%20Group%20Input%20for%20Posting.pdf', 'https://cadth.ca/sites/default/files/cdr/complete/SR0669%20Reblozyl%20-%20Steakholder%20Feedback%20July%202021.pdf', 'https://cadth.ca/sites/default/files/cdr/complete/SR0669%20Reblozyl-combined-final.pdf']",beta-thalassemia associated anemia,Reimburse with clinical criteria and/or conditions,Complete,26-Nov-20,08-Jun-21,SR0669-000
dupilumabOpens in new tab,Dupixent,dupilumab,"['/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_dupilumab_%28dupixent%29_1.pdf', '/sites/default/files/cdr/relatedinfo/SR0667%20Dupixent%20-%20Patient%20Input%20Submission_For%20Posting.pdf', 'https://cadth.ca/sites/default/files/cdr/complete/SR0667-combined%20clinical%20and%20PE%20report.pdf', 'https://cadth.ca/sites/default/files/cdr/complete/SR0667%20Dupixent%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20Posting.pdf', 'https://cadth.ca/sites/default/files/cdr/complete/SR0667%20Dupixent%20-%20Clinician%20Group%20Input_for%20posting.pdf']",Asthma,Reimburse with clinical criteria and/or conditions,Complete,26-Nov-20,08-Jun-21,SR0667-000
patiromerOpens in new tab,Veltassa,patiromer,"['/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_patiromer_%28veltassa%29.pdf', '/sites/default/files/cdr/relatedinfo/SR0665%20Veltassa%20-%20Patient%20Input%20Submission.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0665-combined.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0665%20Veltassa%20-%20Clinician%20Input.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0665%20Veltassa%20-%20Stakeholder%20Feedback.pdf']","Hyperkalemia, adults (chronic kidney disease)",Reimburse with clinical criteria and/or conditions,Complete,30-Oct-20,08-Jun-21,SR0665-000
Dabrafenib and Trametinib for ...Opens in new tab,Tafinlar and Mekinist,Dabrafenib and Trametinib,"['/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_inRec_pERC%20Chair%20Approved_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_FnRec_pERC%20Chair%20Approved_Post28May2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_fnEGR_REDACT-ABBREV_Post28May2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_fnCGR_REDACT_Post28May2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_PAG%20Feedback_Post28May2021_Final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_SponsorFeedback_Post28May2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_PatientFeedback_LCC_Post28May2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_ClinicianFeedback_Combined_Post28May2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_PatientCOI_LCC_Post19Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_Combined%20ClinicianCOI_Post28Mar2021_final.pdf']",NSCLC BRAF V600,Reimburse with clinical criteria and/or conditions,Complete,01-Oct-20,28-May-21,PC0226-000
ranolazineOpens in new tab,Corzyna,ranolazine,"['/sites/default/files/attachments/2021-08/sr0655CL-corzyna.pdf', '/sites/default/files/attachments/2021-08/sr0655PE-corzyna.pdf', '/sites/default/files/cdr/complete/SR0655%20Corzyna%20-%20CDEC%20Final%20Recommendation%20May%2031%2C%202021_For%20Posting.pdf']","Stable angina pectoris, adults",Do not reimburse,Complete,17-Aug-20,27-May-21,SR0655-000
Chronic Lymphocytic LeukemiaOpens in new tab,,,['https://www.cadth.ca/sites/default/files/attachments/2021-06/PH0004-CLL-Provisional-Algorithm-final-may18-rev.pdf'],B-Cell Precursor Acute Lymphoblastic Leukemia,,Completed,,18-May-21,PH0004-000
Sonidegib (Odomzo) for Basal C...Opens in new tab,Odomzo,Sonidegib,"['/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_fnRec_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_fnEGR_NOREDACT-ABBREV_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_fnCGR_NOREDACT_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_inRec_Post04Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_PAGFeedbackSummary_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_SponsorFeedback_Post29Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_PatientFeedback_Combined_Post29Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_ClinicianFeedback_CCO_Post29Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_PatientCOI_Combined_Post29Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_ClinicianInput_Combined_COIs%20Post29Apr2021_final_Redacted.pdf']",Basal Cell Carcinoma,Do not reimburse,Complete,19-Jun-20,29-Apr-21,PC0215-000
Niraparib (Zejula) for first l...Opens in new tab,Zejula,Niraparib,"['/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_fnRec_pERC%20Chair%20Approved_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_fnEGR_REDACT-ABBREV_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_fnCGR_NOREDACT_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_inRec_pERC%20Chair%20Approved_Post04Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_PAGFeedbackSummary_Post29Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_SponsorFeedback_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_PatientFeedback_OCC_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_ClinicianFeedback_CCO_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_Patient%20COI_OCC_Post29Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_Combined%20Clinician%20COIs_Post29Apr2021_final.pdf']",First Line OC,Reimburse with clinical criteria and/or conditions,Complete,21-Sep-20,29-Apr-21,PC0224-000
infliximabOpens in new tab,Remsima,infliximab,"['https://cadth.ca/sites/default/files/cdr/complete/SR0659%20Remsima%20SC%20-%20CDEC%20Final%20Recommendation%20April%2026%2C%202021_for%20posting.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/sr0659-remsima-sc-clinical-and-economic-review-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0659%20infliximab%20-%20Patient%20Input%20Submission.pdf']",Rheumatoid arthritis,Reimburse with clinical criteria and/or conditions,Complete,24-Sep-20,22-Apr-21,SR0659-000
Polatuzumab Vedotin (Polivy) f...Opens in new tab,Polivy,Polatuzumab Vedotin,"['/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_fnRec_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_fnCGR_NOREDACT_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_inRec_pERC%20Chair%20Approved_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_PAG%20Feedback_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_SponsorFeedback_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_PatientFeedback_LC_Final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_ClinicianFeedback_CCO_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_Patient%20COI_LC_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_Combined%20Clinician%20COIs%20EC21Apr2021_final_Redacted.pdf']",Diffuse large B-cell lymphoma (DLBCL),Reimburse with clinical criteria and/or conditions,Complete,29-Sep-20,21-Apr-21,PC0227-000
Brigatinib (Alunbrig) for Anap...Opens in new tab,Alunbrig,Brigatinib,"['/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_fnRec_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_fnCGR_NOREDACT_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_inRec_approvedbyChair_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_PAGFeedback_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_SponsorFeedback_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_PatientFeedback_LCC_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_Combined%20ClinicianFeedback_EC21Apr2021.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_Patient%20COI_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_Combined_COIs%20EC21Apr2021_final.pdf']",(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,30-Sep-20,21-Apr-21,PC0230-000
Olaparib (Lynparza) for metast...Opens in new tab,Lynparza,Olaparib,"['/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_fnRec_REDACT_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_fnCGR_REDACT_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_inRec_approvedbyChair_REDACT_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_PAGFeedback_EC21Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_SponsorFeedback_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_ClinicianFeedback_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_Patient%20COI_CCSN_EC21Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_Combined%20Clinician%20COI_EC21Apr2021_final_Redacted.pdf']",metastatic castration-resistant prostate cancer (mCRPC),Reimburse with clinical criteria and/or conditions,Complete,22-Sep-20,21-Apr-21,PC0223-000
Unresectable Hepatocellular Ca...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/ph0003-000_hcc-report-final.pdf'],Unresectable Hepatocellular Carcinoma,,Complete,,21-Apr-21,PH0003-000
satralizumabOpens in new tab,Enspryng,satralizumab,"['/sites/default/files/cdr/complete/SR0663%20Enspryng%20-%20CDEC%20Final%20Recommendation%20April%2023%2C%202021_for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/SR0663%20Enspryng%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0663-enspryng-clinical-review-report.pdf']",Neuromyelitis optica spectrum disorder,Reimburse with clinical criteria and/or conditions,Complete,22-Oct-20,21-Apr-21,SR0663-000
amifampridineOpens in new tab,Ruzurgi,amifampridine,"['/sites/default/files/cdr/complete/SR0660%20Ruzurgi%20-%20CDEC%20Final%20Recommendation%20April%2023%2C%202021_For%20posting.pdf', '/sites/default/files/attachments/2021-07/sr0660-ruzurgi-clinical-review-report.pdf', '/sites/default/files/attachments/2021-07/sr0660-ruzurgi-pharmacoeconomic-review-report.pdf']",Lambert-Eaton myasthenic syndrome,Reimburse with clinical criteria and/or conditions,Complete,05-Oct-20,20-Apr-21,SR0660-000
Isatuximab (Sarclisa) for Mult...Opens in new tab,Sarclisa,Isatuximab,"['/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_fnRec_pERC%20Chair%20Approved_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_fnEGR_NOREDACT-ABBREV_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_fnCGR_NOREDACT_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_inRec_pERC%20Chair%20Approved_Post4Feb2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_PAGFeedbackSummary_Post01Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_SponsorFeedback_Post01Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_PatientFeedback_MC_Post01Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_ClinicianFeedback_CCO_Post01Apr2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_Patient_COI_MyelomaCanada_Post01Apr2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_Clinician_Combined_COIs_Post_final_Redacted.pdf']",Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,17-Aug-20,01-Apr-21,PC0220-000
sacubitril/valsartanOpens in new tab,Entresto,sacubitril/valsartan,"['/sites/default/files/cdr/complete/SR0644%20Entresto%20-%20%20CDEC%20Final%20Recommendation%20March%2026%2C%202021%20%28Redacted%29_for%20Posting.pdf', '/sites/default/files/cdr/relatedinfo/SR0644_Entresto%20Resubmission_PI%20Submission.pdf']","Heart failure, NYHA Class II or III",Reimburse with clinical criteria and/or conditions,Complete,22-May-20,24-Mar-21,SR0644-000
fremanezumabOpens in new tab,Ajovy,fremanezumab,"['https://cadth.ca/sites/default/files/cdr/complete/SR0641%20Ajovy%20-%20CDEC%20Final%20Recommendation%20April%201%2C%202021_For%20Posting.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/sr0641-ajovy-clinical-review-report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/sr0641-ajovy-pharmacoeconomic-review-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0641%20Ajovy%20-%20Patient%20Input.pdf']",migraine,Reimburse with clinical criteria and/or conditions,Complete,03-Jun-20,24-Mar-21,SR0641-000
onasemnogene abeparvovecOpens in new tab,Zolgensma,onasemnogene abeparvovec,"['https://cadth.ca/sites/default/files/cdr/complete/SG0649%20Zolgensma%20-%20CDEC%20Final%20Recommendation%20March%2026%2C%202021%20for%20posting.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/sg0649-zolgensma-clinical-review-report.pdf', 'https://cadth.ca/sites/default/files/DRR/2021/sg0649-zolgensma-pharmacoeconomic-review-report.pdf', 'https://cadth.ca/sites/default/files/cdr/relatedinfo/SG0649_Zolgensma_PI%20Submission.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2021/SI0005%20Zolgensma%20-%20CADTH%20Drug%20Implementation%20Advice_KT-pw.pdf']","Spinal muscular atrophy (SMA), pediatrics",Reimburse with clinical criteria and/or conditions,Complete,25-Jun-20,24-Mar-21,SG0649-000
Avelumab (Bavencio) for Urothe...Opens in new tab,Bavencio,Avelumab,"['/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_FnRec_REDACT_EC23Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_fnEGR_REDACT-ABBREV_EC23Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_fnCGR_REDACT_EC23Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_inRec_redacted_Post04Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_PAGFeedbackSummary_EC23Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_SponsorFeedback_EC23Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_PatientFeedback_BCC_EC23Mar2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_CinicianFeedback_CCO_EC23Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_COI_BCC__Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_COI_CCO_EC23Mar2021_final.pdf']",Urothelial Carcinoma (UC),Reimburse with clinical criteria and/or conditions,Complete,18-Sep-20,23-Mar-21,PC0225-000
von Willebrand Factor [recombi...Opens in new tab,Vonvendi,von Willebrand Factor [recombinant],"['/sites/default/files/cdr/complete/ST0639%20Vonvendi%20-%20Final%20CPEC%20Recommendation%20March%2022%2C%202021%20for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/ST0639_Vonvendi_PI%20Submission.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/st0639-vonvendi-clinical-review-report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/st0639-vonvendi-pharmacoeconomic-review-report.pdf']","von Willebrand disease, adults, treatment and perioperative management",Reimburse with clinical criteria and/or conditions,Complete,29-Apr-20,17-Mar-21,ST0639-000
Nivolumab-Ipilimumab for Non-S...Opens in new tab,Opdivo in combination with Yervoy,Nivolumab in combination with Ipilimumab,"['/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_FnRec_pERC%20Chair%20Approved_redact%20Post04Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_fnEGR_NOREDACT-ABBREV_Post04Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_fnCGR_REDACT_Post04Mar2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10218Nivolumab-IpilimumabNSCLC_InRec_pERC%20Chair%20Approved_REDACT_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_PAG%20Feedback_Post04Mar2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_SponsorFeedback_Post04Mar2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_PatientFeedback_LCC__Post04Mar2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_Combined_ClinicianFeedback_Post04Mar2021_final-Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_Patient%20Combined%20COI_Post04Mar2021_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_Combined_COIs_Post04Mar2021_final_Redacted.pdf']",NSCLC,Reimburse with clinical criteria and/or conditions,Complete,23-Jun-20,04-Mar-21,PC0218-000
ofatumumabOpens in new tab,Kesimpta,ofatumumab,"['/sites/default/files/cdr/complete/SR0657%20Kesimpta%20-%20CDEC%20Final%20Recommendation%20March%201%2C%202021_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0657-kesimpta-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0657-kesimpta-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0657%20ofatumumab%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf']","Multiple Sclerosis, relapsing",Reimburse with clinical criteria and/or conditions,Complete,25-Aug-20,25-Feb-21,SR0657-000
Adult B-Cell Precursor Acute L...Opens in new tab,,,['https://www.cadth.ca/sites/default/files/pdf/ph0002-000-bcp-all-algorithm-report-v3.5.pdf'],B-Cell Precursor Acute Lymphoblastic Leukemia,,Complete,,24-Feb-21,PH0002-000
apomorphine hydrochlorideOpens in new tab,Kynmobi,apomorphine hydrochloride,"['/sites/default/files/cdr/complete/SR0650%20Kynmobi%20-%20CDEC%20Final%20Recommendation%20February%2026%2C%202021_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0650-kynmobi-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0650-kynmobi-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/Kynmobi%20-%20Patient%20Group%20Input_For%20Posting.pdf']",Parkinson’s disease,Reimburse with clinical criteria and/or conditions,Complete,25-Jun-20,24-Feb-21,SR0650-000
nintedanibOpens in new tab,Ofev,nintedanib,"['/sites/default/files/attachments/2021-07/SR0654%20Ofev%20-%20Final%20CDEC%20Recommendation%20February%2026%2C%202021_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0654-ofev-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0654-ofev-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0654%20Ofev%20-%20Consolidated%20Patient%20Input%20for%20Posting.pdf']",chronic fibrosing interstitial lung diseases,Reimburse with clinical criteria and/or conditions,Complete,24-Jul-20,24-Feb-21,SR0654-000
LevetiracetamOpens in new tab,pdp-levETIRAcetam,Levetiracetam,"['/sites/default/files/cdr/complete/SR0653%20pdp-levETIRAcetam%20-%20CDEC%20Final%20Recommendation%20February%208%2C%202021_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0653-pdp-levETIRAcetam-clinical-and-economic-review-report.pdf']",Epilepsy,Reimburse with clinical criteria and/or conditions,Complete,17-Jul-20,03-Feb-21,SR0653-000
Entrectinib (Rozlytrek) for RO...Opens in new tab,Rozlytrek,Entrectinib,"['/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_FnRec_EarlyConv_ApprovedbyChair_EC27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_fnEGR_NOREDACT-ABBREV_EC27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_fnCGR_REDACT_EC27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10206EntrectinibROS1NSCLC_InRec_approvedbyChair_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_PAG%20Feedback_EC27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_SponsorFeedback_27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_PatientFeedback_LCC_Post27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_Combined_ClinicianFeedback_EC27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_Patient_COI_LCC_EC27Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_Clinician_COI_Redacted.pdf']",ROS1-positive NSCLC,Reimburse with clinical criteria and/or conditions,Complete,08-Jan-20,27-Jan-21,PC0206-000
vedolizumabOpens in new tab,Entyvio,vedolizumab,"['/sites/default/files/cdr/complete/SR0647%20Entyvio%20-%20CDEC%20Final%20Recommendation%20January%2022%2C%202021_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0647-entyvio-clinical-economic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0647_Entyvio_PI%20Submission.pdf']",Crohn’s disease,Reimburse with clinical criteria and/or conditions,Complete,23-Jul-20,21-Jan-21,SR0647-000
Acalabrutinib (Calquence) for ...Opens in new tab,Calquence,Acalabrutinib,"['/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_FnRec_pERC%20Chair%20Approved_REDACT_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_fnEGR_REDACTABBREV_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_fnCGR_REDACT_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_inRec_pERC%20Chair%20Approved_REDACT_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_PAGFeedbackSummary_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_SponsorFeedback_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_PatientFeedback_CLLPAG_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_ClinicianFeedback_CCO_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_COIs_LC_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_Combined%20COIs_Post08Jan2021_final_Redacted.pdf']",Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL),Reimburse with clinical criteria and/or conditions,Complete,07-Apr-20,08-Jan-21,PC0210-000
Glasdegib (Daurismo) for acute...Opens in new tab,Daurismo,Glasdegib,"['/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_FnRec_approvedbyChair_REDACT_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_fnEGR_NOREDACT-ABBREV_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_fnCGR_REDACT_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_inRec_approvedbyChair.REDACT_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_PAGFeedbackSummary_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_SponsorFeedback_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_PatientFeedback_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_Combined_ClinicianFeedback_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_COI_LLSC_Post08Jan2021_final.pdf', '/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_ClinicianInput_Combined_COIs_Post08Jan2021_final.pdf']",Acute Myeloid Leukemia (AML),Do not reimburse,Complete,06-May-20,08-Jan-21,PC0207-000
dapagliflozinOpens in new tab,Forxiga,dapagliflozin,"['/sites/default/files/cdr/complete/SR0642%20Forxiga%20-%20CDEC%20Final%20Recommendation%20January%2021%2C%202021_revised_redacted_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0642-forxiga-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0642-forxiga-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0642_Forxiga_PI%20Submission.pdf']",Heart failure with reduced ejection fraction,Reimburse with clinical criteria and/or conditions,Complete,31-Mar-20,23-Dec-20,SR0642-000
Pembrolizumab (Keytruda) for H...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_FnRec_EC22Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_fnEGR_REDACTABBREV_EC22Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_fnCGR_REDACT_EC22Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_InRec_approvedbyChair_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_PAGFeedbackSummary_EC22Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_SponsorFeedback_EC22Dec2020_final.pdf', '', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_ClinicianFeedback_CCO_EC22Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_Patient_COI_LSTN_22EC22Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_Combined_Clinician%20COIs_EC22Dec2020_final.pdf']",head and neck squamous cell carcinoma (HNSCC),Reimburse with clinical criteria and/or conditions,Complete,01-May-20,22-Dec-20,PC0216-000
emicizumabOpens in new tab,Hemlibra,emicizumab,"['/sites/default/files/cdr/complete/ST0651%20Hemlibra%20-%20CPEC%20Final%20Recommendation%20December%2023%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/st0651-hemlibra-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/st0651-hemlibra-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/Hemlibra%20-%20Patient%20Group%20Input_For%20Posting.pdf']","Bleeding prevention, hemophilia A",Reimburse with clinical criteria and/or conditions,Complete,30-Jun-20,21-Dec-20,ST0651-000
esketamine hydrochlorideOpens in new tab,Spravato,esketamine hydrochloride,"['/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0621-spravato-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0621-spravato-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0621_Esketamine_PI%20Submission.pdf']","Major depressive disorder (MDD), adults",Do not reimburse,Complete,24-Jun-19,16-Dec-20,SR0621-000
Brentuximab Vedotin (Adcetris)...Opens in new tab,Adcetris,Brentuximab Vedotin,"['/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_fnRec_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_fnEGR_NOREDACTABBREV_03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_fnCGR_NOREDACT_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_inRec_01Oct2020_Post_final.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_PAGFeedbackSummary_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_SponsorFeedback_Post03Dec2020_final.pdf', '', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_ClinicianFeedback_CCO_Post03Dec2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_PatientCOIs_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_Clinician%20COI_Post03Dec2020_final.pdf']",Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF),Reimburse with clinical criteria and/or conditions,Complete,30-Mar-20,03-Dec-20,PC0213-000
Brentuximab Vedotin (Adcetris)...Opens in new tab,Adcetris,Brentuximab Vedotin,"['/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_FnRec_approvedbyChair_REDACT_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_fnEGR_NOREDACT-ABBREV_03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_fnCGR_REDACT_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_inRec_Post15Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_PAGFeedbackSummary_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_SponsorFeedback_Post03Dec2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_ClinicianFeedback_CCO_Post03Dec2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_Patient%20COIs_Post03Dec2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_Combined_Clinician%20COIs_Post03Dec2020_final.pdf']","Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)",Reimburse with clinical criteria and/or conditions,Complete,02-Apr-20,03-Dec-20,PC0214-000
indacaterol /mometasone furoat...Opens in new tab,Atectura Breezhaler,indacaterol /mometasone furoate,"['/sites/default/files/cdr/complete/SR0646%20Atectura%20Breezhaler%20-%20CDEC%20Final%20CDEC%20Recommendation%20November%2026%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0646-atectura-breezhaler-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0646-atectura-breezhaler-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0646%20Atectura%20Breezhaler%20-%20Patient%20Group%20Input_for%20posting.pdf']","Asthma maintenance (adults, children 12 or older)",Reimburse with clinical criteria and/or conditions,Complete,19-May-20,24-Nov-20,SR0646-000
Indacaterol  glycopyrronium  m...Opens in new tab,Enerzair Breezhaler,indacaterol  glycopyrronium  mometasone furoate,"['/sites/default/files/cdr/complete/SR0645%20Enerzair%20Breezhaler%20-%20CDEC%20Final%20Recommendation%20November%2026%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0645-enerzair-breezhaler-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0645-enerzair-breezhaler-pharmaceconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/Indacaterol%20glycopyrronium%20mometasone%20furoate%20-%20Patient%20Group%20Input%20June%204%2C%202020.pdf']","Asthma maintenance, adults",Reimburse with clinical criteria and/or conditions,Complete,19-May-20,24-Nov-20,SR0645-000
Tecentriq &amp; Avastin for He...Opens in new tab,Tecentriq & Avastin,Atezolizumab & Bevacizumab,"['/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_fnRec_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_fnCGR_REDACT_PostEC17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_inRec_ApprovedByChair_REDACT_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_PAGFeedbackSummary_EC_Post17Nov2020_finalRedacted.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_SponsorFeedback_EC_Post17Nov2020_final.pdf', '', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_Combined%20ClinicianFeedback_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_PatientCOIs_Combined_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_Clinician%20COIs_Combined_EC_Post17Nov2020_final_Redacted.pdf']",Hepatocellular Carcinoma (HCC),Reimburse with clinical criteria and/or conditions,Complete,21-May-20,17-Nov-20,PC0217-000
Venetoclax (Venclexta) in comb...Opens in new tab,Venclexta,Venetoclax Obinutuzumab,"['/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_fnRec_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_fnEGR_NOREDACTABBREV_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_fnCGR_REDACT_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_inRec_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_PAGFeedbackSummary_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_SponsorFeedback_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_PatientFeedback_CLLPAG_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_ClinicianFeedback_CCO_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_Patient%20COIs_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_Clinician%20Combined_COIs%20EC_Post17Nov2020_final_Redacted.pdf']",Obinutuzumab for CLL,Reimburse with clinical criteria and/or conditions,Complete,17-Apr-20,17-Nov-20,PC0212-000
Acalabrutinib (Calquence) for ...Opens in new tab,Calquence,Acalabrutinib,"['/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_fnRec_REDACT_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_fnCGR_REDACT_EC_Post17Nov2020_final_v2.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_inRec_pERC%20Chair%20Approved_REDACT_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_PAGFeedbackSummary_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_SponsorFeedback_EC_Post_17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_PatientFeedback_CLLPAG_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_ClinicianFeedback_CCO_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_COIs_EC_Post17Nov2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_Combined%20Clinician%20COIs_EC_Post17Nov2020_final_Redacted.pdf']",Chronic Lymphocytic Leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,07-Apr-20,17-Nov-20,PC0211-000
voretigene neparvovecOpens in new tab,Luxturna,voretigene neparvovec,"['/sites/default/files/cdr/complete/SG0643%20Luxturna%20-%20CDEC%20Final%20Recommendation%20November%2016%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sg0643-luxturna-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sg0643-luxturna-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sg0643-luxturna-ethics-review-report.pdf', '/sites/default/files/cdr/relatedinfo/Luxturna%20-%20Patient%20Group%20Input_For%20Posting.pdf']","Vision loss, inherited retinal dystrophy",Reimburse with clinical criteria and/or conditions,Complete,23-Apr-20,12-Nov-20,SG0643-000
Blincyto for MRD-positive B-ce...Opens in new tab,Blincyto,Blinatumomab,"['/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_fnREC_approvedbyChair_REDACT_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_fnEGR_NOREDACTABBREV_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_fnCGR_REDACT_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_inREC_ApprovedbyChair_REDACT_Post_03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_PAGFeedbackSummary_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_SponsorFeedback_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_PatientGroupFeedback_Ac2orn_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_ClinicianFeedback_Combined_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_PtGrp%20Combined%20COIs_Post29Oct2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_Combined%20COIs_Post29Oct2020_Redacted.pdf']",MRD+ ALL Resubmission,Reimburse with clinical criteria and/or conditions,Complete,20-Jan-20,29-Oct-20,PC0204-000
budesonideOpens in new tab,Jorveza,budesonide,"['/sites/default/files/cdr/complete/SR0634%20Jorveza%20-%20CDEC%20Final%20Recommendation%20October%2030%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0634-jorveza-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0634-jorveza-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0634_Jorveza_PI_Submission.pdf']","Eosinophilic esophagitis, adults",Reimburse with clinical criteria and/or conditions,Complete,08-Nov-19,28-Oct-20,SR0634-000
Halobetasol propionate and taz...Opens in new tab,Duobrii,Halobetasol propionate and tazarotene,"['/sites/default/files/cdr/complete/SR0638%20Duobrii%20-%20CDEC%20Final%20Recommendation%20October%2030%2C%202020_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0638-duobrii-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0638-duobrii-parmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0638%20Duobrii%20-%20Patient%20Input_For%20posting.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,24-Jan-20,28-Oct-20,SR0638-000
etonogestrelOpens in new tab,Nexplanon,etonogestrel,"['/sites/default/files/cdr/complete/SR0648%20Nexplanon%20-%20CDEC%20Final%20Recommendation%20October%2022%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0648-nexplanon-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0648-nexplanon-pharmacoeconomic-review-report.pdf']",Prevention of pregnancy,Reimburse with clinical criteria and/or conditions,Complete,03-Jun-20,20-Oct-20,SR0648-000
eculizumabOpens in new tab,Soliris,eculizumab,"['/sites/default/files/cdr/complete/SR0605%20Soliris%20MG%20-%20CDEC%20Final%20Recommendation%20October%2021%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0605-soliris-mg-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0605-soliris-mg-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0605_Soliris%20MG_PI%20Submission.pdf']","Myasthenia Gravis (gMG), adults",Reimburse with clinical criteria and/or conditions,Complete,01-Apr-20,19-Oct-20,SR0605-000
Enzalutamide (Xtandi) for Meta...Opens in new tab,Xtandi,Enzalutamide,"['/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_fnRec_EarlyConv_REDACT_ApprovedbyChair_Post23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_fnEGR_REDACT-ABBREV_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_fnCGR_REDACT_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_inRec_approvedbyChair_REDACT_Post_03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_PAGFeedbackSummary_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_SponsorFeedback_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_ClinicianFeedback_CCO_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_COI_CCS_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_PAGFeedbackSummary_Post_23Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_ClinicianCOI_Post23Sep2020_final_Redacted.pdf']",mHSPC,Reimburse with clinical criteria and/or conditions,Complete,24-Feb-20,23-Sep-20,PC0209-000
Niraparib (Zejula) for Ovarian...Opens in new tab,Zejula,Niraparib,"['/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_fnRec_pERC%20Chair%20Approved_Post_03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_fnEGR_REDACTABBREV_Post03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_fnCGR_REDACT_Post_03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_InitialRec_Approved_03Jul2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_PAGFeedbackSummary_Post03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_SponsorFeedback_2020-17-07_Post03Sep2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_PatientFeedback_OCC_2020-14-07_Post03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_ClinicianFeedback_CCO_2020-17-07_Post03Sep2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_PatientInput_OCC_2020-02-24_revised_Post03Sep2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_CombinedClinician%20COIs_Post03Sep2020_final_Redacted.pdf']",Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,07-Feb-20,03-Sep-20,PC0203-000
caplacizumabOpens in new tab,Cablivi,caplacizumab,"['/sites/default/files/cdr/complete/SR0633%20Cablivi%20-%20CDEC%20Final%20Recommendation%20September%201%2C%202020%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0633-cablivi-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0633-cablivi-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/Cablivi%20-%20Patient%20Group%20Input%20for%20posting.pdf']",Acquired thrombotic thrombocytopenic purpura (aTTP),Do not reimburse,Complete,13-Sep-19,26-Aug-20,SR0633-000
eculizumabOpens in new tab,Soliris,eculizumab,"['/sites/default/files/cdr/complete/SR0640%20Soliris%20-%20CDEC%20Final%20Recommendation%20August%2024%2C%202020%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0640-soliris-nmosd-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0640-soliris-nmosd-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0640_Soliris%20NMOSD_PI%20Submission.pdf']",Neuromyelitis optica spectrum disorder,Reimburse with clinical criteria and/or conditions,Complete,25-Feb-20,19-Aug-20,SR0640-000
erenumabOpens in new tab,Aimovig,erenumab,"['/sites/default/files/cdr/complete/SR0578%20Aimovig%20-%20CDEC%20Final%20Recommendation%20July%2024%2C%202020%20%28redacted%29_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0578-aimovig-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0578-aimovig-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0578-Aimovig-patient-input.pdf']",Migraine,Reimburse with clinical criteria and/or conditions,Complete,02-May-19,22-Jul-20,SR0578-000
cabotegravir/rilpivirineOpens in new tab,Vocabria and Cabenuva,cabotegravir sodium cabotegravir-rilpivirine,"['/sites/default/files/cdr/complete/SR0628%20Vocabria%20%2B%20Cabenuva%20-%20Final%20CDEC%20Recommendation%20September%209%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/SR0628%20cabotegravir%20%2B%20rilpivirne%20-%20Group%20Patient%20Input_October%2021%2C%202019.pdf', '/sites/default/files/attachments/2025-03/sr0628-vocabria%2Bcabenuva-clinical-review-report-QC_redacted-gg_0.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0628-vocabria%2Bcabenuva-pharmacoeconomic-review-report.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,19-Aug-19,22-Jul-20,SR0628-000
siponimodOpens in new tab,Mayzent,siponimod,"['/sites/default/files/cdr/relatedinfo/SR0631_Mayzent_PI%20Submission.pdf', '/sites/default/files/cdr/complete/SR0631%20Mayzent%20-%20CDEC%20Final%20Recommendation%20July%2023%2C%202020%20%28redacted%29_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0631-mayzent-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0631-mayzent-pharmacoeconomic-review-report.pdf']",Secondary progressive multiple sclerosis,Reimburse with clinical criteria and/or conditions,Complete,26-Sep-19,21-Jul-20,SR0631-000
icosapent ethylOpens in new tab,Vascepa,icosapent ethyl,"['/sites/default/files/cdr/complete/SR0619%20Vascepa%20-%20CDEC%20Final%20Recommendation%20July%2020%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0619-vascepa-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0619-vascepa-pharmacoeconomic-review-report.pdf']",Ischemic events in statin-treated patients,Reimburse with clinical criteria and/or conditions,Complete,17-Jun-19,16-Jul-20,SR0619-000
ustekinumabOpens in new tab,Stelara/Stelara I.V,ustekinumab,"['/sites/default/files/cdr/relatedinfo/SR0627_Stelara%20UC_PI%20Submission.pdf', '/sites/default/files/cdr/complete/SR0627%20Stelara%20-%20CDEC%20Final%20Recommendation%20July%2020%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0627-stelara-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0627-stelara-pharmacoeconomic-review-report.pdf']",Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,12-Aug-19,16-Jul-20,SR0627-000
Tecentriq &amp; Avastin Non-Sq...Opens in new tab,Tecentriq & Avastin,Atezolizumab & Bevacizumab,"['/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_FinalRec_Post03July2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_fnEGR_REDACT-ABBREV_Post03Jul2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_fnCGR_REDACT_Post03Jul2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_inRec_REDACT_pERC%20Chair%20Approved_Post30Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_PAGFeedbackSummary_Post03Jul2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_SponsorFeedback_Post03Jul2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_PatientFeedback_Post03Jul2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_Combined%20ClinicianFeedback_Post03Jul2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_COI_LCC_Post03Jul2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_Combined%20COIs_Post03Jul2020_final_Redacted.pdf']",NSQ-NSCLC,Do not reimburse,Complete,18-Nov-19,03-Jul-20,PC0155-000
glycopyrrolateOpens in new tab,Cuvposa,glycopyrrolate,"['/sites/default/files/cdr/complete/SR0613%20Cuvposa%20-%20CDEC%20Final%20Recommendation%20June%2026%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0613-cuvposa-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/clinical/sr0613-cuvposa-clinical-review-report.pdf']","chronic severe drooling, neurologic (pediatric)",Do not reimburse,Complete,31-May-19,24-Jun-20,SR0613-000
Kisqali for Advanced or Metast...Opens in new tab,Kisqali,Ribociclib,"['/sites/default/files/pcodr/RibociclibKisqali_MBC10194ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_FnRec_Chair%20Approved_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_fnCGR_NOREDACT_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_inRec_pERC%20Chair%20Approved_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_PAGFeedbackSummary_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_SponsorFeedback_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_Combined_PatientFeedback_Post04Jun2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_ClinicianFeedback_CCO_Post04Jun2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_Combined%20COI_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_Clinician%20Combined%20COI_Redacted.pdf']","HR+, HER2- advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,26-Aug-19,04-Jun-20,PC0194-000
Brentuximab Vedotin (Adcetris)...Opens in new tab,Adcetris,Brentuximab Vedotin,"['/sites/default/files/pcodr/BrentuximabVedotinAdcetris_PTCL10199ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_FnRec_approved_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_fnCGR_NOREDACT_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_inRec_approvedbyChair_NOREDACT_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_PAGFeedbackSummary_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_SponsorFeedback_Post04Jun2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_PatientFeedback_LC_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_ClinicianFeedback_CCO_Post02Jun2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_Patient_COI_LC_Post04Jun2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_Combined_Clinician_COIs_Post04Jun2020_final_Redacted.pdf']",peripheral T-cell lymphoma (PTCL),Reimburse,Complete,08-Oct-19,04-Jun-20,PC0199-000
naltrexone hydrochloride and b...Opens in new tab,Contrave,naltrexone hydrochloride and bupropion hydrochloride,"['/sites/default/files/cdr/complete/SR0610%20Contrave%20-%20CDEC%20Final%20Recommendation%20June%205%2C%202020%20Final_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0610-contrave-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0610-contrave-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0610%20Contrave%20-%20Patient%20Group%20Input%20June%2017%2C%202019.pdf']",Chronic weight management in adults,Do not reimburse,Complete,01-May-19,27-May-20,SR0610-000
burosumabOpens in new tab,Crysvita,burosumab,"['/sites/default/files/cdr/complete/SR0602%20Crysvita%20-%20CDEC%20Final%20Recommendation%20May%2029%2C%202020_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0602-crysvita-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0602-crysvita-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/Crysvita%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf']",Treatment of X-Linked Hypophosphatemia,Reimburse with clinical criteria and/or conditions,Complete,23-Jul-19,27-May-20,SR0602-000
brolucizumabOpens in new tab,Beovu,brolucizumab,"['/sites/default/files/cdr/complete/SR0632%20Beovu%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2025%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0632-beovu-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0632-beovu-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0632_Brolucizumab_PI%20Submission.pdf']","Macular degeneration, age-related",Reimburse with clinical criteria and/or conditions,Complete,26-Sep-19,21-May-20,SR0632-000
Gilteritinib (Xospata) for Acu...Opens in new tab,Xospata,Gilteritinib,"['/sites/default/files/pcodr/GilteritinibXospata__AML10102_ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_FnRec_REDACT_EarlyConv_20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_fnCGR_REDACT_EarlyConv_20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_fnEGR_REDACT-ABBREV_EarlyConv20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_inRec_REDACT_ApprovedbyChair_Post30Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_PAGFeedbackSummary_Post20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_SponsorFeedback_Post20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_PatientFeedback_LLSC_Post20May2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_ClinicianFeedback_CCODAC_Post20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_COI-LLSC_Post20May2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_Combined_ClincianInput_Post20May2020_final_Redacted.pdf']",,Reimburse with clinical criteria and/or conditions,Complete,28-Oct-19,20-May-20,PC0202 -000
vedolizumabOpens in new tab,Entyvio,vedolizumab,"['/sites/default/files/cdr/complete/SR0635%20Entyvio%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2021%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0635-entyvio-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0635-entyvio-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0635_Entyvio_PI%20Submission.pdf']",Ulcerative Colitis,Reimburse with clinical criteria and/or conditions,Complete,21-Nov-19,19-May-20,SR0635-000
belimumabOpens in new tab,Benlysta,Belimumab,"['/sites/default/files/cdr/complete/SR0616%20Benlysta%20-%20CDEC%20Final%20Recommendation%20April%2024%2C%202020_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0616-benlysta-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0616-benlysta-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0616_Benlysta_PI%20Submission1.pdf']",systemic lupus erythematosus,Do not reimburse,Complete,29-May-19,22-Apr-20,SR0616-000
Kisqali (with Fulvestrant) for...Opens in new tab,Kisqali,Ribociclib with Fulvestrant,"['/sites/default/files/pcodr/RibociclibKisqali%2BFulvestrant_MBC10195ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_fnRec_pERC%20Chair%20Approved_22April2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_fnCGR_NOREDACT_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_inRec_pERC%20Chair%20Approved_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_PAGFeedbackSummary__EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_SponsorFeedback_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_Combined_PatientFeedback.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_Combined%20COIs_EC_22Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_Combined%20Clinician%20COI_EC_22Apr2020_final_Redacted.pdf']","+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,26-Aug-19,22-Apr-20,PC0195-000
Darolutamide (Nubeqa) for Non-...Opens in new tab,Nubeqa,Darolutamide,"['/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_fnRec_REDACT_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_fnCGR_REDACT_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_inRec_approvedbyChair_REDACT_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_SponsorFeedback_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_COI_CCSN__EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_Combined%20COI_EC_22Apr2020_final_Redacted.pdf']",non-metastatic castration resistant prostate cancer (nmCRPC),Reimburse with clinical criteria and/or conditions,Complete,27-Aug-19,22-Apr-20,PC0196-000
Apalutamide (Erleada) for Meta...Opens in new tab,Erleada,Apalutamide,"['/sites/default/files/pcodr/ApalutamideErleada_mCSPC10200ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_fnRec_ChairApproved_EarlyConv_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_fnCGR_REDACT__EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_inRec_ApprovedbyChair_Post02Apr2020_final-updated.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_SponsorFeedback_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC%20COICCSN_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_COI_Combined_Clinician%20Redacted.pdf']",metastatic castration-sensitive prostate cancer (mCSPC),Reimburse with clinical criteria and/or conditions,Complete,15-Oct-19,22-Apr-20,PC0200-000
Cabozantinib (Cabometyx) for H...Opens in new tab,Cabometyx,Cabozantinib,"['/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_FnRec_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_inCGR_NOREDACT_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_inRec_2020-04-01_ApprovedbyChair_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_PAGFeedbackSummary_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_SponsorFeedback_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_Combined%20ClinicianFeedback_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_COI%20CLF_EC_22Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_Combined%20COI_EC_22Apr2020_final_Redacted.pdf']",HCC,Reimburse with clinical criteria and/or conditions,Complete,16-Oct-19,22-Apr-20,PC0186-000
dupilumabOpens in new tab,Dupixent,dupilumab,"['/sites/default/files/cdr/complete/SR0636%20Dupixent%20-%20CDEC%20Final%20%20Recommendation%20April%2024%2C%202020%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0636-dupixent-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0636-dupixent-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0636%20Dupixent%20-%20Patient%20Input%20Summary%20December%202019.pdf']",atopic dermatitis,Reimburse with clinical criteria and/or conditions,Complete,22-Oct-19,22-Apr-20,SR0636-000
Pembrolizumab (Keytruda) for R...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_fnRec_2020-03-31_ApprovedpERCChair_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_fnCGR_REDACT_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_PAGFeedbackSummary_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_SponsorFeedback_Post24Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_ClinicianFeedback_CCOGUDAC_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_PatientInput_KCC_COI_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_Combined%20COIs_Post02Apr2020_final_Redacted.pdf', 'https://www.cadth.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_inRec_2020-01-30_ApprovedbyChair_Post_30Jan2020_final.pdf']",Renal Cell Carcinoma (RCC),Reimburse with clinical criteria and/or conditions,Complete,02-Aug-19,02-Apr-20,PC0185-000
Gemtuzumab Ozogamicin (Mylotar...Opens in new tab,Mylotarg,Gemtuzumab Ozogamicin,"['/sites/default/files/pcodr/GemtuzumabOzogamicinMylotarg_AML10190ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamacinAML_FnRec_2020-04-01_approvedbyChair_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_fnCGR_NOREDACT_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamacinAML_inRec_ApprovedbyChair_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_PAGFeedbackSummary_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_SponsorFeedback_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_ClinicianFeedback_CCO_2020-02-13_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_Patient_COI_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_Combined_COI_Post02Apr2020_final_Redacted.pdf']",Acute Myeloid Leukemia (AML),Reimburse,Complete,09-Aug-19,02-Apr-20,PC0190-000
Midostaurin (Rydapt) for Syste...Opens in new tab,Rydapt,Midostaurin,"['/sites/default/files/pcodr/MidostaurinRydapt_Systemic%20Mastocytosis10193_ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_fnRec_approvedbyChair_REDACT_Post02Apr2020_draft.revised.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_fnCGR_REDACT_Post_02Apr2020_final.revised.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSystemicMastocytosis_InRec_approvedbyChair_Post_30Jan2020_REDACT_draft.revised.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_PAGFeedbackSummary_Post02Apr2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_SponsorFeedback_2020-02-13_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_PatientFeedback_CORD_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_ClinicianFeedback_CCO_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_PatientCOI_CORD_Post02Apr2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_COI_Post02Apr2020_final%20Redacted.pdf']",Systemic Mastocytosis,Do not reimburse,Complete,13-Aug-19,02-Apr-20,PC0193-000
Iron (III) Isomaltoside 1000Opens in new tab,Monoferric,Iron (III) Isomaltoside 1000,"['/sites/default/files/cdr/complete/SR0622%20Monoferric%20-%20CDEC%20Final%20%20Recommendation%20March%2027%2C%202020%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0622-monoferric-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0622-monoferric-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0622-Monoferric-Patient%20Input%20for%20Posting.pdf']",iron deficiency anemia,Reimburse with clinical criteria and/or conditions,Complete,26-Jun-19,25-Mar-20,SR0622-000
sodium zirconium cyclosilicateOpens in new tab,Lokelma,sodium zirconium cyclosilicate,"['/sites/default/files/cdr/complete/SR0612%20Lokelma%20-%20CDEC%20Final%20Recommendation%20March%2027%2C%202020%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0612-lokelma-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0612-lokelma-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0612-Sodium%20zirconium%20cyclosilicate-patient-input.pdf']","Hyperkalemia, adults",Do not reimburse,Complete,17-May-19,25-Mar-20,SR0612-000
safinamideOpens in new tab,Onstryv,safinamide,"['/sites/default/files/cdr/complete/SR0617%20Onstryv%20-%20CDEC%20Final%20Recommendation%20March%2027_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0617-onstryv-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0617-onstryv-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0617_Onstryv_PI%20Submission.pdf']",Parkinson's disease,Do not reimburse,Complete,29-May-19,25-Mar-20,SR0617-000
ixekizumabOpens in new tab,Taltz,ixekizumab,"['/sites/default/files/cdr/complete/SR0630%20Taltz%20-%20CDEC%20Final%20Recommendation%20March%2027%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0630-taltz-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0630-taltz-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0630_Taltz_PI%20Submission.pdf']",Ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,20-Sep-19,24-Mar-20,SR0630-000
Trifluridine-Tipiracil (Lonsur...Opens in new tab,Lonsurf,Trifluridine-Tipiracil,"['/sites/default/files/pcodr/Trifluridine-TipiracilLonsurf_GastricCancer10197ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_fnRec_EarlyConv_ApprovedbypERCChair_Post024Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_inEGR_NOREDACT-ABBREV_EC24Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_fnCGR_NOREDACT_EC24Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_inRec_2020-03-03_ApprovedbyChair_Post_05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_PAGFeedbackSummary_EC24Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_SponsorFeedback_EC24Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_ClinicianFeedback_EC24Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_MGF_COI_EC24Mar2020final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_Combined_COIs_EC24Mar2020_Redacted.pdf']",Gastric Cancer,Reimburse with clinical criteria and/or conditions,Complete,03-Sep-19,24-Mar-20,PC0197-000
Daratumumab (Darzalex) for Mul...Opens in new tab,Darzalex,Daratumumab,"['/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_fnRec_2020-03-03_ApprovedbyChair_Post_05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_fnEGR_NOREDACTABBREV_Post05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_fnCGR_Post05Mar2020_REDACT_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10189DaratumumabNDMM_inRec_2020_01-03_ApprovedbyChair_Post_03Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_PAGFeedbackSummary_Post05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_SponsorFeedback_Post_05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_ClinicianFeedback_CCO_Post05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_PatientCOI_Post05Mar2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_Combined_COI_Post_05Mar2020_final_Redacted.pdf']",Rd for MM,Reimburse with clinical criteria and/or conditions,Complete,17-Jul-19,05-Mar-20,PC0189-000
tafamidisOpens in new tab,Vyndaqel,tafamidis,"['/sites/default/files/cdr/complete/SR0625%20Vyndaqel%20-%20CDEC%20Final%20%20Recommendation%20February%2020%2C%202020%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0625-vyndaqel-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0625-vyndaqel-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0625_Tafamidis_PI%20Submission.pdf']",transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,04-Jul-19,19-Feb-20,SR0625-000
vortioxetine hydrobromideOpens in new tab,Trintellix,vortioxetine hydrobromide,"['/sites/default/files/cdr/complete/SR0611%20Trintellix%20-%20Final%20CDEC%20Recommendation%20February%2014%2C%202020_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0611-trintellix-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0611-trintellix-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0611-trintellix-pi-submission-redacted.pdf']","Major depressive disorder (MDD), adults.",Reimburse with clinical criteria and/or conditions,Complete,01-May-19,12-Feb-20,SR0611-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,"['/sites/default/files/cdr/complete/SR0614%20Rinvoq%20-%20CDEC%20Final%20Recommendation%20February%206%2C%202020_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0614-rinvoq-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0614-rinvoq-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0614%20Upadacitinib%20-%20Group%20Patient%20Input%20September%2012%2C%202019.pdf']","Arthritis, Rheumatoid",Reimburse with clinical criteria and/or conditions,Complete,04-Jul-19,04-Feb-20,SR0614-000
Lorlatinib (Lorbrena) for Non-...Opens in new tab,Lorbrena,Lorlatinib,"['/sites/default/files/pcodr/LorlatinibLorbrena_ALK%2BNSCLC10183ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_FnRec_ApprovedbyChair_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_fnCGR_NOREDACT_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10183LorlatinibNSCLC_ApprovedbyChair_2019-12-03_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_PAGFeedbackSummary_2019-12-13FINAL_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_SponsorFeedback_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined_PatientFeedback_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined_ClinicianFeedback_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined_Patient_COI_Post_30Jan2020.pdf', '/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined%20Clinician_COIs_Post_30Jan2020_Redacted.pdf']",Non-Small Cell Lung Cancer (NSCLC),Do not reimburse,Complete,11-Jun-19,30-Jan-20,PC0183-000
Tecentriq for Small Cell Lung ...Opens in new tab,Tecentriq,Atezolizumab,"['/sites/default/files/pcodr/Reviews2020/10156AtezolizumabSCLC_FnRec_ProceduralReview_approvedbyChair_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10156AtezolizumabSCLC_fnEGR_NOREDACT-ABBREV_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10156AtezolizumabSCLC_fnCGR_REDACT_Post_30Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_InRec_approvedbyChair_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_PAGFeedbackSummary_2019-10-11_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_SponsorFeedback_2019-10-18_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_PatientFeedback_Combined_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_ClinicianFeedback_Combined_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_Combined_Patient_COI_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_Combined%20COIs_Post_05Dec2019_final_Redacted.pdf']",Small Cell Lung Cancer (SCLC),Do not reimburse,Complete,04-Mar-19,30-Jan-20,PC0156-000
Trastuzumab Emtansine (Kadcyla...Opens in new tab,Kadcyla,Trastuzumab Emtansine,"['/sites/default/files/pcodr/TrastuzumabEmtansine%20Kadcyla_EBC10182_ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_fnRec_ChairApproved_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_fnEGR_NOREDACT-ABBREV_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_fnCGR_REDACT_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10182TrastuzumabEmtansineEBC_inRec_2020-01-02_ChairApproved_NOREDACT_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_PAGFeedbackSummary_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_SponsorFeedback_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_ClinicianFeedback_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_Combined%20COIs_EarlyConv_22Jan2020_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_Combined%20COIs_EarlyConv_22Jan2020_Redacted.pdf']",Early Breast Cancer (EBC),Reimburse,Complete,02-Jul-19,22-Jan-20,PC0182-000
Cemiplimab (Libtayo) for Cutan...Opens in new tab,Libtayo,Cemiplimab,"['/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_fnRec_REDACT_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_fnEGR_REDACT-ABBREV_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_fnCGR_REDACT_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10187CemiplimabCSCC_inRec__REDACT_approvedbyChair_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_PAGFeedbackSummary_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_SponsorFeedback_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_Combined%20PatientFeedback_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_ClinicianFeedback_CCOSkinDAC_EarlyConv_22Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_Combined_COI_EarlyConv_22Jan2020.pdf', '/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_Clinician%20Combined%20COIs_EarlyConv_22Jan2020_Redacted.pdf']",Advanced Cutaneous Squamous Cell Carcinoma (CSCC),Reimburse with clinical criteria and/or conditions,Complete,09-Jul-19,22-Jan-20,PC0187-000
glucagonOpens in new tab,Baqsimi,glucagon,"['/sites/default/files/cdr/complete/SR0626%20Baqsimi%20-%20CDEC%20Final%20Recommendation%20for%20Posting%20January%2024%2C%202020.pdf', '/sites/default/files/cdr/clinical/sr0626-baqsimi-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0626-baqsimi-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0626_glucagon_PI%20Submission.pdf']",Severe hypoglycemic reactions,Reimburse with clinical criteria and/or conditions,Complete,24-Jul-19,22-Jan-20,SR0626-000
Keytruda for Squamous NSCLC – ...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/PembrolizumabKeytruda_SquamousNSCLC10176_ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_fnRec_NOREDACT_ApprovedbyChair_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_fnCGR_REDACT_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_inRec_ApprovedbyChair_REDACT_Post_31Oct2019_final.pdf', '', '', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_PAGFeedbackSummary_2019-11-11FINAL_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_SponsorFeedback_2019-11-14_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_Combined_PatientFeedback_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_Combined_ClinicianFeedback_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_Patient_Combined_COIs_Post_03Jan2020_final.pdf', '/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_combined_Clinician%20COI_Post_03Jan2020_finalpdf_Redacted.pdf']",Squamous NSCLC,Reimburse with clinical criteria and/or conditions,Complete,08-Feb-19,03-Jan-20,PC0176-000
inotersenOpens in new tab,Tegsedi,inotersen,"['/sites/default/files/cdr/monograph/Tegsedi-product-monograph.pdf', '/sites/default/files/cdr/complete/SR0603%20Tegsedi%20-%20Final%20CDEC%20Recommendation%20December%2020%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0603-tegsedi-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0603-tegsedi-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0603_Tegsedi_Consolidated%20Patient%20Input_March%2019%2C%202019_Redacted.pdf']",hereditary transthyretin amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,22-Feb-19,18-Dec-19,SR0603-000
Lynparza for Newly Diagnosed O...Opens in new tab,Lynparza,Olaparib,"['/sites/default/files/pcodr/OlaparibLynparza_NewlyDiagnosedOC10174ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_fnRec_2019-12-04_ChairApproved_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_fnEGR_NOREDACT-ABBREV_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_fnCGR_NOREDACT_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_inRec_2019-10-03_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_PAGFeedbackSummary_2019-10-11_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_SponsorFeedback_2019-10-18_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_PatientFeedback_OCC_2019-10-16_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_ClinicianFeedback_CCO_2019-10-18_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_PatientInput_COI_2019-05-03_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_Combined%20COIs_Post_05Dec2019_final_Redacted.pdf']",Newly Diagnosed OC,Reimburse with clinical criteria and/or conditions,Complete,18-Apr-19,05-Dec-19,PC0174-000
Nerlynx for Hormone Receptor-P...Opens in new tab,Nerlynx,Neratinib,"['/sites/default/files/pcodr/NeratinibNerlynx_BreastCancer10172ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_fnRec_Chair%20Approved_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_inEGR_NOREDACT-ABBREV_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_fnCGR_NOREDACT_Post_05Dec2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_inRec_1%20Oct%202019_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_PAGFeedbackSummary_2019-10-11_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_SponsorFeedback_2019-10-18_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_PatientFeedback_Combined_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_ClinicianFeedback_CCO_2019-10-18_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_Combined%20Patient_COI_Post_05Dec2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_Combined_Clinician%20COIs_Post_05Dec2019_final_Redacted.pdf']",ERBB2-positive breast cancer,Do not reimburse,Complete,18-Apr-19,05-Dec-19,PC0172-000
certolizumab pegolOpens in new tab,Cimzia,certolizumab pegol,"['https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0587%20Cimzia%20-%20CDEC%20Final%20Recommendation%20November%2022%2C%202019_for%20posting.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/sr0587-cimzia-clinical-review-report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0587-cimzia-pharmacoeconomic-review-report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0587%20Cimzia%20-%20Group%20Patient%20Input%20-%20June%2028%2C%202019.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,13-May-19,20-Nov-19,SR0587-000
lanadelumabOpens in new tab,Takhzyro,lanadelumab,"['/sites/default/files/cdr/complete/SR0618%20Takhzyro%20-%20CDEC%20Final%20Recommendation%20November%2022%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0618-takhzyro-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0618-takhzyro-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0618%20Takhzyro%20-%20Patient%20Input%20for%20Posting.pdf']","Hereditary angioedema, prevention",Reimburse with clinical criteria and/or conditions,Complete,29-May-19,19-Nov-19,SR0618-000
teduglutideOpens in new tab,Revestive,teduglutide,"['/sites/default/files/cdr/complete/SR0606%20Revestive%20-%20CDEC%20Final%20Recommendation%20November%2021%2C%202019_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0606-revestive-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0606-revestive-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0606_Revestive_PI%20Submission.pdf']","Short Bowel Syndrome (SBS), pediatrics",Reimburse with clinical criteria and/or conditions,Complete,29-May-19,19-Nov-19,SR0606-000
cyclosporineOpens in new tab,Verkazia,cyclosporine,"['/sites/default/files/cdr/complete/SR0615%20Verkazia%20-%20CDEC%20Final%20Recommendation%20December%206%2C%202019_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0615-verkazia-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0615-verkazia-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0615_Verkazia_PI%20Submission1.pdf']","Severe vernal keratoconjunctivitis, pediatric (≥4 years)",Reimburse with clinical criteria and/or conditions,Complete,22-May-19,18-Nov-19,SR0615-000
Idhifa for Acute Myeloid Leuke...Opens in new tab,Idhifa,Enasidenib,"['/sites/default/files/pcodr/EnasidenibIdhifa_AML10144ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_fnRec_ApprovedbyChair_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_fnCGR_NOREDACT_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_inRec_approvedbyChair_NOREDACT_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_PAGFeedbackSummary_FINAL_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_SponsorFeedback_2019-09-19_revised_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_PatientFeedback_LLSC_2019-09-26_FINAL_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_ClinicianFeedback_CCO_2019-09-11_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_PatientInput_LLSC_COI_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_Clinician_Combined_COI_Post_31Oct2019_final_Redacted.pdf']",Acute myeloid leukemia (AML),Do not reimburse,Complete,05-Apr-19,31-Oct-19,PC0144-000
Larotrectinib for Neurotrophic...Opens in new tab,Vitrakvi,Larotrectinib,"['/sites/default/files/pcodr/LarotrectinibVitrakvi_NTRKLocallyAdvancedorMetastaticSolidTumours10159ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnRec_REDACT_31Oct201_ChairApproved_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnCGR_REDACT_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_inRec_2019-08-27_ChairApproval_REDACT_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_PAGFeedbackSummary_FINAL_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_SponsorFeedback_2019-09-19_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_PtFeedback_Combined_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_Combined_ClinicianF-B_Post_31Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_Combined_COI_Post_31Oct2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_Clombined%20COI_Post_31Oct2019_final_Redacted.pdf']",NTRKplus solid tumours,Do not reimburse,Complete,25-Feb-19,31-Oct-19,PC0159-000
insulin degludec + liraglutideOpens in new tab,Xultophy,insulin degludec + liraglutide,"['/sites/default/files/cdr/complete/SR0599%20Xultophy%20-%20CDEC%20Final%20Recommendation%20October%2028%2C%202019_redacted_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0599-xultophy-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0599-xultophy-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0599-Xultopy-Patient-Input.pdf']","Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,30-Jan-19,24-Oct-19,SR0599-000
onabotulinumtoxinAOpens in new tab,Botox,onabotulinumtoxinA,"['/sites/default/files/cdr/complete/SR0584%20Botox%20Resubmission%20-%20CDEC%20Final%20Recommendation%20October%2022%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0584-botox-clinical-review-report-resubmission.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0584-botox-pharmacoeconomic-review-report-resubmission.pdf', '/sites/default/files/cdr/relatedinfo/SR0584%20Botox%20Resubmission%20-%20Consolidated%20Patient%20Input_Dec%202018_Redacted.pdf']","Migraine, chronic",Reimburse with clinical criteria and/or conditions,Complete,02-Nov-18,17-Oct-19,SR0584-000
Keytruda Metastatic Urothelial...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/PembrolizumabKeytruda_MUCfirstline10177ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_FnRec_REDACT_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_fnEGR_NOREDACT-ABBREV_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_fnCGR_REDACT_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMM%28first%20line%29_InRec_REDACT_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_PAGFeedbackSummary_FINAL_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_SubmitterFeedback_2019-08-16_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_PatientFeedback_BCC_2019-08-16__Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_ClinicianFeedback_CCO_2019-08-16_Post_03Oct2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_PtGrp_COI_Post_03Oct2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_Combined%20ClinicianCOIs_Post_03Oct2019_final.pdf']",MUC First line,Do not reimburse,Complete,20-Feb-19,03-Oct-19,PC0177-000
dolutegravir / lamivudineOpens in new tab,Dovato,dolutegravir / lamivudine,"['/sites/default/files/cdr/complete/SR0601%20Dovato%20-%20CDEC%20Final%20Recommendation%20October%202%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0601-dovato-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0601-dovato-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0601-dovato-patient-input.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,21-Feb-19,30-Sep-19,SR0601-000
fluocinolone acetonide intravi...Opens in new tab,Iluvien,fluocinolone acetonide intravitreal implant,"['/sites/default/files/cdr/complete/SR0608%20Iluvien%20-%20CDEC%20Final%20Recommendation%20September%2030%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/sr0608-iIluvien-clinical-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0608-iIluvien-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0608-Iluvien-patient-input.pdf']",diabetic macular edema,Do not reimburse,Complete,03-Apr-19,26-Sep-19,SR0608-000
Pomalyst in combination with d...Opens in new tab,Pomalyst,Pomalidomide,"['/sites/default/files/pcodr/PomalidomidePomalystDex%26Bortez_MM2ndline10165_ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_fnRec_EarlyConv_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_fnEGR_NOREDACT-ABBREV_EarlyConv_Post_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_fnCGR_REDACT_EarlyConv_Post_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_InRec_approvedbyChair_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_PAGFeedbackSummary_FINAL_Post_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_SubmitterFeedback_2019-09-13_Post_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_ClinicianFeedback_CCO_2019-09-09_Post_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_COI_Post_18Sep2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_Combined%20Clinician_COI_Post_18Sep2019_final.pdf']",Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,15-Mar-19,18-Sep-19,PC0165-000
Trifluridine and Tipiracil (Lo...Opens in new tab,Lonsurf,Trifluridine and Tipiracil,"['/sites/default/files/pcodr/pcodr_provfund-10173-trifluridine-tipiracil_lonsurf_mcrc.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_fnrec_Chair%20Approved_Post_29Aug2019_revised_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_fnCGR_NOREDACT_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_inRec_Chair%20approved_NOREDACT_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_PAGFeedbackSummary_FINAL_2019-07-15_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_PatientFeedback_CCC_2019-07-19_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_ClinicianFeedback_Ko_2019-07-19_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_Patient%20COIs_Post_29Aug2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_Clinicians%20COIs_Post_29Aug2019_final_Redacted.pdf']",mCRC Resubmission,Do not reimburse,Complete,21-Jan-19,29-Aug-19,PC0173-000
Darzalex in combo with Bortezo...Opens in new tab,Darzalex,Daratumumab,"['/sites/default/files/pcodr/DaratumumabDarzalex_NewlyDiagnosedMM10148_ProvFunding.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_fnRec_REDACT_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_fnCGR_REDACT_Post_29Aug2910_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_inRec_ApprovedbyChair_REDACT_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_PAGFeedbackSummary_FINAL_2019-07-16_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_PatientFeedback_MC_2019-07-08_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_ClinicianFeedback_CCO_2019-07-15_Post_29Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_PatientI_COI_Post_29Aug2019.pdf', '/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_Combined%20Clinician%20COIs_Post_28Aug2019_Redacted.pdf']",BMP for Multiple Myeloma (newly diagnosed),Reimburse with clinical criteria and/or conditions,Complete,04-Jan-19,29-Aug-19,PC0148-000
baricitinibOpens in new tab,Olumiant,baricitinib,"['/sites/default/files/cdr/relatedinfo/SR0597%20Olumiant%20-%20Patient%20Group%20Input_February%207%2C%202019.pdf', '/sites/default/files/cdr/clinical/sr0597-olumiant-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0597-olumiant-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/complete/SR0597%20Olumiant%20-%20CDEC%20Final%20Recommendation_for%20posting.pdf']","Arthritis, Rheumatoid",Reimburse with clinical criteria and/or conditions,Complete,20-Dec-18,02-Aug-19,SR0597-000
Lutathera for Gastroenteropanc...Opens in new tab,Lutathera,Lutetium Lu 177 dotatate,"['/sites/default/files/pcodr/pcodr-provfund-10142-LutetiumLutathera_GEP_NETs.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_fnRec_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_fnCGR_NOREDACT_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_PAGFeedbackSummary_FINAL_Post_01Aug2019_draft.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_PatientFeedback_CNETS_2019-06-28_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_COI_Post_01Aug2019_final.pdf']",Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs),Reimburse with clinical criteria and/or conditions,Complete,30-Jul-18,01-Aug-19,PC0142-000
Brigatinib (Alunbrig) for Non-...Opens in new tab,Alunbrig,Brigatinib,"['/sites/default/files/pcodr/pcodr_provfund-10167-BrigatinibAlunbrig_NSCLC.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_FnRec_approvedbyChair_NOREDACT_Post_01AUG2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_fnEGR_NOREDACT-ABBREV_01AUG2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_fnCGR_NOREDACT_POST01AUG2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_PatientFeedback_LCC_2019-06-14_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_Combined_ClinicianFeedback_2019-06-14_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_Combined_PtGrp_COIs_Post_01Aug2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_Combined_Clinician_COIs_01Aug2019_final_Redacted.pdf']",NSCLC,Do not reimburse,Complete,05-Dec-18,01-Aug-19,PC0167-000
Keytruda for Melanoma Adjuvant...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/pcodr_provfund-10168-PembrolizumabKeytruda_MAT.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_FnRec_31%20July%202019__Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_fnCGR_REDACT_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembolizumabMAT_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_SubmitterFeedback_2019-06-12_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_ClinicianFeedback_CCO_2019-06-14_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_Combined_Patient_COIs_Post_01Aug2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_Combined_Clinician_COIs_Post_01Aug2019_final.pdf']",Melanoma Adjuvant Treatment,Reimburse with clinical criteria and/or conditions,Complete,13-Dec-18,01-Aug-19,PC0168-000
patisiranOpens in new tab,Onpattro,patisiran,"['/sites/default/files/cdr/relatedinfo/SR0598_Onpattro-patient-input.pdf', '/sites/default/files/cdr/complete/SR0598%20Onpattro%20-%20CDEC%20Final%20Recommendation%20July%2029%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0598-onpattro-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0598-onpattro-pharmacoeconomic-review-report.pdf']",Polyneuropathy in hereditary transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,25-Jan-19,25-Jul-19,SR0598-000
ulipristal acetateOpens in new tab,Fibristal,ulipristal acetate,"['/sites/default/files/cdr/relatedinfo/SF0609%20Fibristal%20-%20Group%20Patient%20Input%20June%2028%2C%202019.pdf', '/sites/default/files/cdr/complete/SF0609%20Fibristal%20RfA%20-%20CDEC%20Final%20Recommendation%20July%2030%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/advice/sf0609-fibristal-request-for-advice-clinical-review-report.pdf']",Uterine fibroids (signs and symptoms),Reimburse with clinical criteria and/or conditions,Complete,28-Mar-19,24-Jul-19,SF0609-000
Latanoprostene bunodOpens in new tab,Vyzulta,latanoprostene bunod,"['/sites/default/files/cdr/clinical/sr0590-vyzulta-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0590-vyzulta-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0590-vyzulta-patient-input.pdf', '/sites/default/files/cdr/complete/SR0590%20Vyzulta%20-%20CDEC%20Final%20Recommendation%20July%2026%2C%202019%20_for%20posting.pdf']",Open-angle glaucoma or ocular hypertension,Reimburse with clinical criteria and/or conditions,Complete,23-Nov-18,24-Jul-19,SR0590-000
Lenvima for Hepatocellular Car...Opens in new tab,Lenvima,Lenvatinib,"['/sites/default/files/pcodr/pcodr-profund-10175-LenvatinibLenvima_HCC.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_fnRec_2019-07-23_ApprovedByChair_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inEGR_NOREDACT-ABBREV_EarlyCon_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inCGR_NOREDACT_EarlyConv_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inRec_ApprovedByChair_NOREDACT_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_PAGFeedbackSummary_FINAL_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_SubmitterFeedback_2019-07-19_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_Canadian%20Liver%20Foundation%20v2%202019-07-22_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_ClinicianFeedback_BCCancer_2019-07-18_Post_24Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_CombinedPat_Post_24Jul2019_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_Combined%20Clinician%20COIs_Post_24Jul2019_final.pdf']",Hepatocellular Carcinoma (HCC),Reimburse with clinical criteria and/or conditions,Complete,08-Feb-19,24-Jul-19,PC0175-000
Ninlaro for Multiple Myeloma (...Opens in new tab,Ninlaro,Ixazomib,"['/sites/default/files/pcodr/pcodr-provfund-10164-ixazomib-ninlaro_mm2nd-beyond.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_fnRec_2019-07-05_ChairApproved_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_fnCGR_REDACT_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_inRec_2019-05-03_Approved_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_PAGFeedbackSummary_FINAL_Post_5Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_PatientFeedback_MC_2019-05-15_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_Patient_COI_MC_2018-12-13_Post_05Jul2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_Combined%20COIs_Post_05Jul2019_final%20Redacted.pdf']",Multiple Myeloma (2nd-beyond),Do not reimburse,Complete,30-Nov-18,05-Jul-19,PC0164-000
Abemaciclib for advanced or me...Opens in new tab,Verzenio,Abemaciclib,"['/sites/default/files/pcodr/pcodr-provfund-10161-AbemaciclibVerzenio_ABC.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_fnRec_ApprovedbyChair_v01_2019-07-04_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_fnCGR_NOREDACT_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_inRec_ApprovedbyChair_v01_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_PAGFeedbackSummary_FINAL_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_Combined%20PatientFeedback_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_Combined%20Patient%20COIs_%20Post_05Jul2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_Combined%20COIs_Post_05Jul2019_final.pdf']",Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,03-Dec-18,05-Jul-19,PC0161-000
telotristatOpens in new tab,Xermelo,telotristat,"['/sites/default/files/cdr/relatedinfo/SR0580_telotristat_PI%20Submission.pdf', '/sites/default/files/cdr/complete/SR0580%20Xermelo%20-%20CDEC%20Final%20Recommendation%20July%203%2C%202019_For%20Posting.pdf', '/sites/default/files/cdr/clinical/sr0580-xermelo-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0580-xermelo-pharmacoeconomic-review-report.pdf']",carcinoid syndrome,Do not reimburse,Complete,27-Sep-18,26-Jun-19,SR0580-000
buprenorphineOpens in new tab,Sublocade,buprenorphine,"['/sites/default/files/cdr/complete/SR0579%20Sublocade%20-%20CDEC%20Final%20Recommendation%20June%2021%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0579-sublocade-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0579-sublocade-pharmacoeconomic-review-report.pdf']","Opioid use disorder, treatment",Reimburse with clinical criteria and/or conditions,Complete,20-Dec-18,19-Jun-19,SR0579-000
Revlimid (in combo) bortezomib...Opens in new tab,Revlimid,Lenalidomide,"['/sites/default/files/pcodr/pcodr-provfund-10141-LenalidomideRevlimid_MM.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnRec_2019-06-19_ApprovedbyChair_EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnEGR_NOREDACT-ABBREV_EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnCGR_REDACT_EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_PAGFeedbackSummary_FINAL__EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_SubmitterFeedback_2019-06-14_EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_ClinicianFeedback_CCO_2019-06-14__EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_PatientCOI_MC_2019-01-11_EC-Post_19Jun2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_Clinician_Combined_COIs_Post_19Jun2019_final_Redacted.pdf']",Multiple Myeloma (+bortezomib+dex),Reimburse with clinical criteria and/or conditions,Complete,21-Dec-18,19-Jun-19,PC0141-000
cysteamineOpens in new tab,Cystadrops,cysteamine,"['/sites/default/files/cdr/complete/SR0595%20Cystadrops%20-%20CDEC%20Final%20Recommendation%20June%2020%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0595-cystadrops-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0595-cystadrops-pharmacoeconomic-review-report.pdf']",Corneal cystine crystal deposits,Reimburse with clinical criteria and/or conditions,Complete,10-Dec-18,18-Jun-19,SR0595-000
Keytruda for Non-Squamous NSCL...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/pcodr-provfund-10153-pembrolizumab-keytruda-non-squamous_nsclc.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_fnCGR_REDACT_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_InRec_POST04Apr2019_NOREDACT_corrected.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_Patient_Combined%20COIs_ForPosting_31May2019.pdf', '/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_Clinician_Combined%20COIs_Post_31May2019_final.pdf']",Nonsquamous NSCLC,Reimburse with clinical criteria and/or conditions,Complete,14-Sep-18,31-May-19,PC0153-000
Venclexta in combo Rituximab f...Opens in new tab,Venclexta in combo Rituximab,Venetoclax,"['/sites/default/files/pcodr/pcodr_provfund_10162_venetoclax_venclexta_and_rituximab.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_FnRec_approvedbyChair_REDACT_Post_31May2019-final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_fnEGR_NOREDACT-ABBREV_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_fnCGR_REDACT_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_InRec_POST04Apr2019_REDACT_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_PatientFeedback_LC_CLLPAG_2019-04-17_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_Patient_Combined_COIs_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_Clinician_Combined_COIs_Post_31May2019_final.pdf']",Chronic Lymphocytic Leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,24-Oct-18,31-May-19,PC0162-000
Vizimpro for Non-Small Cell Lu...Opens in new tab,Vizimpro,Dacomitinib,"['/sites/default/files/pcodr/pcodr-provfund-10129-dacomitinib-vizimpro.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_fnCGR_NOREDACT_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_InRec_POST04Apr2019_NOREDACT_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_Patient_Combined_COIs_ForPosting_31May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_Clinician_Combined_COIs_Post_31May2019_final.pdf']",Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,19-Sep-18,31-May-19,PC0129-000
risankizumabOpens in new tab,Skyrizi,risankizumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/complete/SR0583%20Skyrizi%20-%20CDEC%20Final%20Recommendation%20May%2028%2C%202019_For%20posting.pdf', '/sites/default/files/cdr/clinical/sr0583-skyrizi-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0583-skyrizi-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0583-risankizumab-patient-input.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,22-Oct-18,28-May-19,SR0583-000
cerliponase alfaOpens in new tab,Brineura,cerliponase alfa,"['/sites/default/files/cdr/complete/SR0574%20Brineura%20-%20Final%20CDEC%20Recommendation%20May%2027%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0574-brineura-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0574-brineura-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0574-brineura-patient-input.pdf']",Neuronal Ceroid Lipofuscinosis Type 2,Reimburse with clinical criteria and/or conditions,Complete,31-Jul-18,23-May-19,SR0574-000
efinaconazoleOpens in new tab,Jublia,efinaconazole,"['/sites/default/files/cdr/complete/SR0577%20Jublia%20-%20%20CDEC%20Final%20Recommendation%20May%2027%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0577-jublia-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0577-jublia-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0577-jublia_patient-input.pdf']",Onychomycosis,Do not reimburse,Complete,02-Aug-18,23-May-19,SR0577-000
Xalkori for ROS1-positive adva...Opens in new tab,Xalkori,Crizotinib,"['/sites/default/files/pcodr/pcodr-provfund-10151-crizotinib-xalkori-ROS-positive.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_fnRec_EC_approvedbyChair_Post_23May2019_final_cleaned.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_fnEGR_EC_NOREDACT-ABBREV_Post_23May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_fnCGR_EC_NOREDACT_Post_23May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_inRec_03May2019_approvedbyChair_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_PAGFeedbackSummary_Post_23May2019_final_cleaned.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_SubmitterFeedback_2019-05-17_Post_23May2019_final_cleaned.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_PatientFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_ClinicianFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_Combined_COIs_Post_23May2019.pdf', '/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_Combined_COI_Post_23May2019_final_Redacted.pdf']",ROS1-positive advanced non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,30-Oct-18,23-May-19,PC0151-000
semaglutideOpens in new tab,Ozempic,semaglutide,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0594%20Ozempic%20-%20CDEC%20Final%20Recommendation%20May%2017%2C%202019%20%28redacted%29_For%20posting.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/sr0594-ozempic-clinical-review-report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0594-ozempic-pharmacoeconomic-review-report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/sr0594-ozempic-patient-input.pdf']","Diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,23-Nov-18,15-May-19,SR0594-000
isavuconazoleOpens in new tab,Cresemba,isavuconazole,"['/sites/default/files/cdr/complete/SR0586%20Cresemba%20-%20CDEC%20Final%20Recommendation%20May%2017%2C%202019_for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0586-cresemba-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0586-cresemba-pharmacoeconomic-review-report.pdf']",Treatment of invasive aspergillosis and mucormycosis,Reimburse with clinical criteria and/or conditions,Complete,02-Nov-18,15-May-19,SR0586-000
doravirine lamuvidine tenofovi...Opens in new tab,Delstrigo,doravirine lamuvidine tenofovir disoproxil fumarate,"['/sites/default/files/cdr/complete/SR0581%20Delstrigo%20-%20CDEC%20Final%20Recommendation%20May%2016%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/SR0581%20Delstrigo%20-%20Patient%20Input%20for%20Posting.pdf', '/sites/default/files/cdr/relatedinfo/sr0581-delstrigo-cdr-new-combination-report.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,16-Nov-18,14-May-19,SR0581-000
doravirineOpens in new tab,Pifeltro,doravirine,"['/sites/default/files/cdr/complete/SR0582%20Pifeltro%20-%20CDEC%20Final%20Recommendation%20May%2016%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0582-pifeltro-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0582-pifeltro-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0582-pifeltro-patient-input.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,16-Nov-18,14-May-19,SR0582-000
Tafinlar &amp; Mekinist in com...Opens in new tab,Tafinlar & Mekinist in combo,Dabrafenib & Trametinib in combo,"['/sites/default/files/pcodr/pcodr-provfund_10152_dabrafenib_trametinib_and_tafinlar_mekinist.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_Final%20Recc_Approved%20by%20Chair_2May2019_REDACT_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_fnCGR_REDACT_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152%20Dabrafenib-Trametinib%20MAT_inRec_Approved%20by%20Chair_REDACT_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_SubmitterFeedback_2019-03-12_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_ClinicianFeedback_CCO_2019-03-14_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_PatientCOI_Combined_Post_03May2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_ClinicianCOI_Combined_Post_03May2019_final_Redacted.pdf']",Melanoma Adjuvant Therapy,Reimburse with clinical criteria and/or conditions,Complete,21-Sep-18,03-May-19,PC0152-000
Imfinzi for Non-Small Cell Lun...Opens in new tab,Imfinzi,Durvalumab,"['/sites/default/files/pcodr/pcodr_profund_durvalumabImfinzi_nsclc.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_fnRec_02May2019_approvedbyChair_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_fnCGR_NOREDACT_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_inRec_approvedbyChair_06Mar2019_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_ClinicianFeedback_CCO_2019-03-21_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_Combined_PatientCOI_2018-10-05_Post_03May2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_Combined_ClinicianCOI_Post_03May2019_final_Redacted.pdf']",Unresectable Non-Small Cell Lung Cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,21-Sep-18,03-May-19,PC0131-000
Ibrance (with Faslodex) for Ad...Opens in new tab,Ibrance (with Faslodex),Palbociclib (with Fulvestrant),"['/sites/default/files/pcodr/pcodr_provfund-10150-ibrance-faslodex-mbc.pdf', '/sites/default/files/pcodr/Reviews2019/10150%20PalbociclibFulvestrantMBC_fnRec_2019-05-03_Approved_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_fnCGR_NOREDACT_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_inRec_2019-03-06_ChairApproved_NOREDACT_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_ClinicianFeedback_CCO_2019-03-22_Post_03May2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_Combined_PatientCOI_RBC_Posting_03May2019_Redacted_final.pdf', '/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_Combined_ClinicianICOI_Post_03May2019_final_Redacted.pdf']","Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,28-Sep-18,03-May-19,PC0150-000
Blincyto for Philadelphia Chro...Opens in new tab,Blincyto,Blinatumomab,"['/sites/default/files/pcodr/pcodr_profung_10146_blinatumomab_blincyto-all.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_FnCGR_04April2019_REDACT_POST_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_FnRec_04Apr2019_REDACT_post_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146_BlinatumomabPh%2BALL_InRec_AprovedbyChair_REDACT_31Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146Blinatumomab_Ph%2BALL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_SubmitterFeedback_2019-02-19_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_PatientGroupCOI_LLSC_2018-09-14_final.pdf', '/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_ClinicianInputCOI_Combined_04Apr2019_post_final.pdf']",Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,31-Aug-18,04-Apr-19,PC0146-000
Folotyn for Peripheral T-Cell ...Opens in new tab,Folotyn,Pralatrexate,"['/sites/default/files/pcodr/pcodr_provfund_10138_pralatrexate_folotyn.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_fnRec__04Apr2019_NOREDACT_post_final2.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_fnCGR_NOREDACT_POST04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_InRec_31Jan2019_approvedbyChair_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138Pralatrexate_PTCL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_SubmitterFeedback_2019-02-14_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_PatientFeedback_LC_2019-02-14_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_PatientCOI_LC_2018-06-15_Post_04Apr2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_ClinicianCOI_Combined_Post_final.pdf']",Peripheral T-Cell Lymphoma (PTCL),Reimburse with clinical criteria and/or conditions,Complete,01-Jun-18,04-Apr-19,PC0138-000
reslizumabOpens in new tab,Cinqair,reslizumab,"['/sites/default/files/cdr/advice/sf0591-cinqair-request-for-advice.pdf', '/sites/default/files/cdr/relatedinfo/sf0591-cinqair-patient-input.pdf', '/sites/default/files/cdr/complete/sf0591-cinqair-cdec-rec-march-29-19.pdf']","Asthma, eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,24-Oct-18,27-Mar-19,SF0591-000
benralizumabOpens in new tab,Fasenra,benralizumab,"['/sites/default/files/cdr/advice/sf0592-fasenra-request-for-advice.pdf', '/sites/default/files/cdr/relatedinfo/sf0592-fasenra-patient-input.pdf', '/sites/default/files/cdr/complete/sf0592-fasenra-cdec-rec-march-29-19.pdf']","Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,24-Oct-18,27-Mar-19,SF0592-000
mepolizumabOpens in new tab,Nucala,mepolizumab,"['/sites/default/files/cdr/advice/sf0593-nucala-request-for-advice.pdf', '/sites/default/files/cdr/relatedinfo/sf0593-nucala-patient-input.pdf', '/sites/default/files/cdr/complete/sf0593-nucala-cdec-rec-march-29-19.pdf']","Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,24-Oct-18,27-Mar-19,SF0593-000
crisaboroleOpens in new tab,Eucrisa,crisaborole,"['/sites/default/files/cdr/complete/SR0570-Eucrisa-cdec-rec-april-2-2019.pdf', '/sites/default/files/cdr/clinical/sr0570-eucrisa-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0570-eucrisa-pharmacoeconomic-report.pdf', '/sites/default/files/cdr/relatedinfo/SR0570-eucrisa-patient-input.pdf']",atopic dermatitis,Do not reimburse,Complete,25-May-18,27-Mar-19,SR0570-000
edaravoneOpens in new tab,Radicava,edaravone,"['/sites/default/files/cdr/clinical/sr0573-radicava-clinical-review-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0573-radicava-pharmacoeconomic-review-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0573_radicava-patient-input.pdf', '/sites/default/files/cdr/complete/sr0573-radicava-cdec-rec-march-29-2019.pdf']",amyotrophic lateral sclerosis,Reimburse with clinical criteria and/or conditions,Complete,05-Jul-18,27-Mar-19,SR0573-000
Xtandi for non-metastatic Cast...Opens in new tab,Xtandi,Enzalutamide,"['/sites/default/files/pcodr/pcodr_profund_enzalutamide_xtandi_non-mcrpc_10149.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_FnRec_EarlyConv_2019-03-26-v4_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_fnCGR_EC_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_fnEGR_EC_NOREDACT-ABBREV_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_InRec_approvedbyChair_NOREDACT_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamide_nmCRPC_PAGFeedbackSummary_FINAL_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_SubmitterFeedback_2019-03-21_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_ClinicianFeedback_CCO_2019-03-21_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10149Enzalutamide-CRPC_COI_CCSN_Post_26Mar2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10149EnzalutamidenmCRPC_Combined_Clinician_COI_Post_26Mar2019_final.pdf']",Non-metastatic castration-resistant prostate cancer (nm-CRPC),Reimburse with clinical criteria and/or conditions,Complete,24-Sep-18,26-Mar-19,PC0149-000
Unituxin for Neuroblastoma – D...Opens in new tab,Unituxin,Dinutuximab,"['/sites/default/files/pcodr/pcodr-provfund-10154-dinutuximab-unituxin-neuroblastoma.pdf', '/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnRec_EC_ApprovedbyChair_2019-03-26_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnCGR_ECPost_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_inRec_approvedbyChair_05Mar2019_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10154Dinutuximab_Neuroblastoma_PAGFeedback_FINAL_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_ClinicianFeedback_POGO_2019-03-21_Post_26Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10154Dinutuximab_Neuroblastoma_COI_Ac2orn_2018-10-15_Post_26Mar2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10154Dinutuximab_NeuroblastomaCombined_Clinician%20COI_Post_26Mar2019_final.pdf']",Neuroblastoma,Reimburse with clinical criteria and/or conditions,Complete,01-Oct-18,26-Mar-19,PC0154-000
Opdivo for Melanoma Adjuvant T...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr_provfund_10147_nivolumab_opdivo.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMelanoma%28Adjuvant%29_FnRec_ChairApproved_Post_07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMelanoma%28Adjuvant%29_fnCGR_NOREDACT_POST07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_FnEGR_NOREDACT-ABBREV_POST07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMelanoma%28Adjuvant%29_inRec_2019-01-03_ChairApproved_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10147_Nivolumab_MAT_PAGFeedbackSummary_FINAL_Post_07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_SubmitterFeedback_2019-01-16_Post_07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_PatientFeedback_MNC_2019-01-17_Post_07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_ClinicianFeedback_CCO_2019-01-16_Post_07Mar2019_Final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_Patient_Combined_COIs_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_Clinician_Combined_COI_Post_07Mar2019_final.pdf']",Melanoma Adjuvant Therapy,Reimburse with clinical criteria and/or conditions,Complete,27-Aug-18,07-Mar-19,PC0147-000
Adcetris for Hodgkin Lymphoma ...Opens in new tab,Adcetris (Resubmission),Brentuximab Vedotin,"['/sites/default/files/pcodr/pcodr_profund_10145_brentuximab_adcetris_hl_resub.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_FnRec_approvedbyChair_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_fnCGR_NOREDACT_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_FnEGR_NOREDACT-ABBREV_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_InRec_approvedbyChair_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHLResubmission_PAGFeedbackSummary_FINAL_post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_SubmitterFeedback_2019-01-18_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_PatientGroupFeedback_LC_2019-01-18_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_Combined-ClinicianFeedback_Post_07Mar2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_PatientInputCOI_LC_REVISED2018102_Post_07Mar2019_REDACTED_final.pdf', '/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_ClinicianInputCOI_Combined_2018-09-10_ForPosting_REDACTED_final.pdf']",Hodgkin lymphoma (HL),Do not reimburse,Complete,27-Aug-18,07-Mar-19,PC0145-000
tofacitinibOpens in new tab,Xeljanz,tofacitinib,"['/sites/default/files/cdr/complete/SR0572-Xeljanz_UC-Mar-1-19.pdf', '/sites/default/files/cdr/clinical/sr0572-xeljanz-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0572-xeljanz-pharmacoeconomic-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0572-xeljanz-patient-input.pdf']",Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,27-Jun-18,27-Feb-19,SR0572-000
NusinersenOpens in new tab,Spinraza,Nusinersen,"['/sites/default/files/cdr/clinical/sr0576-spinraza-resubmission-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0576-spinraza-resubmission-pharmacoeconomic-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0576-spinraza-patient-input.pdf', '/sites/default/files/cdr/complete/SR0576-Spinraza-Resubmission-Mar-1-19.pdf']",Spinal Muscular Atrophy,Reimburse with clinical criteria and/or conditions,Complete,24-Jul-18,27-Feb-19,SR0576-000
Cabometyx for Renal Cell Carci...Opens in new tab,Cabometyx,Cabozantinib,"['/sites/default/files/pcodr/pcodr_profund_10163_cabozantinib_cabometix.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_FnRec_2019-02-20_ApprovedByChair_Post_20Feb2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_fnCGR_EC_NOREDACT_Post_21Feb2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_fnEGR_EC_NOREDACT-ABBREV_Post_20Feb2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibResubmissionRCC_inRec_2019-01-30_v10_ChairApproved_Post_31Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_PAGFeedbackSummary_FINAL_2019-02-08_Post_20Feb2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_SubmitterFeedback_2019-02-14_Post_20Feb2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_ClinicianFeedback_CCO_2019-02-11_Post_20Feb2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_COI_KCC_2017-10-23_Post_20Feb2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_Clinician_Combined%20COI_Post_20Feb2019_final.pdf']",Renal Cell Carcinoma (RCC),Reimburse with clinical criteria and/or conditions,Complete,17-Sep-18,20-Feb-19,PC0163-000
ertugliflozinOpens in new tab,Steglatro,ertugliflozin,"['/sites/default/files/cdr/complete/SR0565%20Steglatro%20-%20CDEC%20Final%20Recommendation%20January%2025%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0565-steglatro-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0565-steglatro-pharmacoeconomic-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0565-steglatro-patient-input.pdf']","Diabetes mellitus, Type 2",Do not reimburse,Complete,30-Apr-18,23-Jan-19,SR0565-000
ertugliflozin and metforminOpens in new tab,Segluromet,ertugliflozin and metformin hydrochloride,"['/sites/default/files/cdr/complete/SR0566%20Segluromet%20-%20CDEC%20Final%20Recommendation%20January%2025%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/sr0566-segluromet-combined-report.pdf']","Diabetes mellitus, Type 2",Do not reimburse,Complete,30-Apr-18,23-Jan-19,SR0566-000
Lenvima for Renal Cell Carcino...Opens in new tab,Lenvima,Lenvatinib,"['/sites/default/files/pcodr/pcodr_profund_lenvatinib_lenvima_rcc_10140.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_FnRec_approvedbyChair_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_fnCGR_REDACT_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_rcc_in_rec.pdf', '/sites/default/files/pcodr/Reviews2019/10140_Lenvatinib_RCC_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_SubmitterFeedback_2018-11-29_updated_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_PatientGroupFeedback_KCC_2018-11-15_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_ClinicianFeedback_Combined_Post_04Jan2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_COI_KCC_2018-06-22_Post_04Jan2019_draft_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_Combined_Clinician%20COIs_Post_04Jan2019_final.pdf']",Renal Cell Carcinoma (RCC),Do not reimburse,Complete,08-Jun-18,04-Jan-19,PC0140 -000
Tagrisso for Non-Small Cell Lu...Opens in new tab,Tagrisso,Osimertinib,"['/sites/default/files/pcodr/pcodr_provfund_osimertinib_tagrisso_nsclc_1ln.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_FnRec_2019-01-02_ChairApproved_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_fnCGR_NOREDACT_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_1stln_in_rec.pdf', '/sites/default/files/pcodr/Reviews2019/10137_Osimertinib_NSCLC_1L_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC%28firstline%29_SubmitterFeedback_2018-11-15_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC%28firstline%29_PatientGroupFeedback_LCC_2018-11-15_Post_04Jan2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC%28firstline%29_ClinicianFeedback_Combined_Post_04Jan2019_Redacted_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_COI_LCC_2018-05-31_Post_04Jan2019_final_Redacted.pdf', '/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_COI%20Combined_Post_04Jan2019_final.pdf']",Non-Small Cell Lung Cancer (NSCLC) (first line),Reimburse with clinical criteria and/or conditions,Complete,16-May-18,04-Jan-19,PC0137-000
sucroferric oxyhydroxideOpens in new tab,Velphoro,sucroferric oxyhydroxide,"['/sites/default/files/cdr/complete/SR0571%20Velphoro%20-%20CDEC%20%20Final%20Recommendation%20January%204%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0571-velphoro-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0571-velphoro-pharmacoeconomic-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0571-velphoro-patient-input.pdf']","Hyperphosphatemia, end-stage renal disease",Reimburse with clinical criteria and/or conditions,Complete,12-Jun-18,02-Jan-19,SR0571-000
lixisenatide + insulin glargin...Opens in new tab,Soliqua,lixisenatide + insulin glargine,"['/sites/default/files/cdr/complete/SR0564%20Soliqua%20-%20CDEC%20Final%20%20Recommendation%20January%203%2C%202019%20for%20posting.pdf', '/sites/default/files/cdr/clinical/sr0564-soliqua-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0564-soliqua-pharmacoeconomic-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0564-soliqua-patient-input.pdf']","Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,18-May-18,24-Dec-18,SR0564-000
fluticasone propionateOpens in new tab,Aermony RespiClick,fluticasone propionate,"['/sites/default/files/cdr/complete/SR0539%20Aermony%20RespiClick%20-%20CDEC%20Final%20Recommendation%20for%20posting%20December%2021%2C%202018.pdf', '/sites/default/files/cdr/clinical/sr0539-aermony-respiclick-clinical-report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0539-aermony-respiclick-pe-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0539-aermony-respiclick-PI-submissions.pdf']",Asthma,Reimburse with clinical criteria and/or conditions,Complete,04-Oct-17,19-Dec-18,SR0539-000
fluticasone propionate / salme...Opens in new tab,Arbesda RespiClick,fluticasone propionate / salmeterol xinafoate,"['/sites/default/files/cdr/complete/SR0540%20Arbesda%20RespiClick%20-%20CDEC%20Final%20Recommendation%20for%20Posting%20December%2021%2C%202018.pdf', '/sites/default/files/cdr/complete/sr0540-arbesda-respiclick_combined-report.pdf', '/sites/default/files/cdr/relatedinfo/sr0540_arbesda-respiclick_PI_submissions.pdf']",Asthma,Reimburse with clinical criteria and/or conditions,Complete,04-Oct-17,19-Dec-18,SR0540-000
Opdivo for Hepatocellular Carc...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr_provfund_nivolumab_opdivo_hcc.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_bmsc.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_coi_cln.pdf']",Metastatic Hepatocellular Carcinoma (HCC),Do not reimburse,Complete,08-May-18,29-Nov-18,PC0134-000
Perjeta-Herceptin Combo Pack f...Opens in new tab,Perjeta-Herceptin Combo Pack,Pertuzumab-Trastuzumab Combo Pack,"['/sites/default/files/pcodr/pcodr_provfund_10127perjeta-herceptin-combo_ebc.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_hlr.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_cln.pdf']",Early Breast Cancer,Do not reimburse,Complete,09-Apr-18,29-Nov-18,PC0127-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,"['/sites/default/files/cdr/complete/SR0569%20Xarelto%20-%20Confidential%20Final%20CDEC%20Recommendation%20%28redacted%29_for%20posting.pdf', '/sites/default/files/cdr/clinical/SR0569_Xarelto_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0569_Xarelto_PE_Report.pdf']",Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.,Reimburse with clinical criteria and/or conditions,Complete,24-May-18,20-Nov-18,SR0569-000
Opdivo in combo with Yervoy fo...Opens in new tab,Opdivo in combination with Yervoy,Nivolumab in combination with Ipilimumab,"['/sites/default/files/pcodr/pcodr_profund_10132opdivo-yervoy_rcc.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fdk_bms.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_coi_cln.pdf']",Advanced or Metastatic Renal Cell Carcinoma (RCC).,Reimburse with clinical criteria and/or conditions,Complete,26-Apr-18,01-Nov-18,PC0132-000
Gazyva for  Follicular Lymphom...Opens in new tab,Gazyva,Obinutuzumab,"['/sites/default/files/pcodr/pcodr_provfund_10126obinutuzumab_gazyva_fl_preun.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_in_rec.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fdk_hlr.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_coi_cln.pdf']",Follicular Lymphoma (previously untreated),Do not reimburse,Complete,15-Mar-18,01-Nov-18,PC0126-000
Erleada for Castrate Resistant...Opens in new tab,Erleada,Apalutamide,"['/sites/default/files/pcodr/pcodr_provfund_apalutamide_erleada_nm-cprc.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_coi_cln.pdf']",non-metastatic castrate resistant prostate cancer (nm-CRPC),Reimburse with clinical criteria and/or conditions,Complete,16-Apr-18,01-Nov-18,PC0133-000
bictegravir/emtricitabine/teno...Opens in new tab,Biktarvy,bictegravir/emtricitabine/tenofovir alafenamide,"['/sites/default/files/cdr/complete/SR0567%20Biktarvy%20-%20CDEC%20Final%20Recommendation%20October%2029%2C%202018.pdf', '/sites/default/files/cdr/clinical/SR0567_Biktarvy_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0567_Biktarvy_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0567_Biktarvy_PI_Submissions.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,30-Apr-18,25-Oct-18,SR0567-000
cladribineOpens in new tab,Mavenclad,cladribine,"['/sites/default/files/attachments/2025-03/TS0004-Cladribine-Natalizumab_Updated_Recommendations.pdf', '/sites/default/files/cdr/complete/SR0546-Mavenclad_Oct-26-18.pdf', '/sites/default/files/cdr/clinical/SR0546_Mavenclad_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0546_Mavenclad_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0546_Mavenclad_PI_Submissions.pdf']","Multiple Sclerosis, relapsing-remitting",Reimburse with clinical criteria and/or conditions,Complete,01-Dec-17,24-Oct-18,SR0546-000
ozenoxacinOpens in new tab,Ozanex,ozenoxacin,"['/sites/default/files/cdr/complete/SR0553_Ozanex_Oct-26-18.pdf', '/sites/default/files/cdr/clinical/SR0553_Ozanex_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0553_Ozanex_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0553_Ozanex_PI_Submissions.pdf']",Impetigo,Do not reimburse,Complete,25-Jan-18,24-Oct-18,SR0553-000
dexamethasoneOpens in new tab,Ozurdex,dexamethasone,"['/sites/default/files/cdr/complete/SR0535_Ozurdex_Oct-26-18.pdf', '/sites/default/files/cdr/clinical/SR0535_Ozurdex%20_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0535_Ozurdex_PE_Report%20.pdf', '/sites/default/files/cdr/relatedinfo/SR0535_Ozurdex_PI_Submissions.pdf']",Diabetic macular edema,Do not reimburse,Complete,26-Sep-17,24-Oct-18,SR0535-000
Tapentadol HydrochlorideOpens in new tab,Nucynta,tapentadol hydrochloride,"['/sites/default/files/cdr/complete/SR0563_Nucynta%20-%20CDEC%20Final%20Recommendation%20October%2025%2C%202018.pdf', '/sites/default/files/cdr/clinical/SR0563_Nucynta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0563_Nucynta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0563_Nucynta_PI_Submissions.pdf']","pain, severe",Do not reimburse,Complete,17-Apr-18,23-Oct-18,SR0563-000
sebelipase alfaOpens in new tab,Kanuma,sebelipase alfa,"['/sites/default/files/cdr/complete/SR0544%20Kanuma%20-%20CDEC%20Final%20Recommendation%20September%2028%2C%202018.pdf', '/sites/default/files/cdr/clinical/SR0544_Kanuma_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0544_Kanuma_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0544_Kanuma_PI_Submissions.pdf', '/sites/default/files/cdr/relatedinfo/si0003-kanuma-cadth-drug-implementation-advice.pdf']",Lysosomal acid lipase deficiency,Reimburse with clinical criteria and/or conditions,Complete,02-Nov-17,26-Sep-18,SR0544-000
lumacaftor/ivacaftorOpens in new tab,Orkambi,lumacaftor/ivacaftor,"['/sites/default/files/cdr/complete/SR0559%20Orkambi%20-%20CDEC%20Final%20Recommendation%20October%204%2C%202018.pdf', '/sites/default/files/cdr/clinical/SR0559_Orkambi_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0559_Orkambi_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0559_Orkambi_PI_Submissions.pdf']","Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older",Do not reimburse,Complete,22-Feb-18,26-Sep-18,SR0559-000
eluxadolineOpens in new tab,Viberzi,eluxadoline,"['/sites/default/files/cdr/complete/SR0560_cdr_complete_Viberzi_Aug_29_18.pdf', '/sites/default/files/cdr/clinical/SR0560_Viberzi_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0560_Viberzi_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0560_Viberzi_PI_Submissions.pdf']",Irritable bowel syndrome with diarrhea,Do not reimburse,Complete,23-Feb-18,24-Aug-18,SR0560-000
abobotulinumtoxinAOpens in new tab,Dysport Therapeutic,abobotulinumtoxinA,"['/sites/default/files/cdr/complete/SR0556_Dysport_Therapeutic_Aug_23_18.pdf', '/sites/default/files/cdr/clinical/SR0556_Dysport_Therapeutic_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0556_Dysport_Therapeutic_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0556_Dysport_PI_Submissions.pdf']",lower limb spasticity,Reimburse with clinical criteria and/or conditions,Complete,07-Feb-18,23-Aug-18,SR0556-000
fluticasone furoate/umeclidini...Opens in new tab,Trelegy Ellipta,fluticasone furoate umeclidinium vilanterol,"['/sites/default/files/cdr/complete/SR0562_cdr_complete_Trelegy_Ellipta_Aug_27_18.pdf', '/sites/default/files/cdr/clinical/SR0562_TrelegyEllipta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0562_TrelegyEllipta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0562_TrelegyEllipta_PI_Submissions.pdf']",Chronic obstructive pulmonary disease (COPD),Reimburse with clinical criteria and/or conditions,Complete,01-Mar-18,23-Aug-18,SR0562-000
nitisinoneOpens in new tab,Nitisinone,nitisinone,"['/sites/default/files/cdr/complete/SR0554_Nitisinone_Aug_23_18.pdf', '/sites/default/files/cdr/clinical/SR0554_Nitisinone_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0554_Nitisinone_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0554_Nitisinone_PI_Submissions.pdf']",Hereditary tyrosinemia type 1,Reimburse with clinical criteria and/or conditions,Complete,25-Jan-18,23-Aug-18,SR0554-000
Buprenorphine hydrochlorideOpens in new tab,Probuphine,buprenorphine hydrochloride,"['/sites/default/files/cdr/complete/SR0550_Probuphine_Aug_24_18.pdf', '/sites/default/files/cdr/clinical/SR0550_Probuphine_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0550_Probuphine_PE_Report.pdf']","Opioid drug dependence, treatment",Reimburse with clinical criteria and/or conditions,Complete,21-Dec-17,22-Aug-18,SR0550-000
Levodopa / carbidopa (Drug Pla...Opens in new tab,Duodopa,Levodopa / carbidopa (Drug Plan Submission),"['/sites/default/files/cdr/complete/SR0557_Duodopa_Aug_24-18.pdf', '/sites/default/files/cdr/clinical/SR0557_DuodopaFWG_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0557_DuodopaFWG_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0557_Duodopa_PI_Submissions.pdf', '/sites/default/files/cdr/relatedinfo/si0001-duodopa-drug-implementation-advice.pdf']",Parkinson's disease,Reimburse with clinical criteria and/or conditions,Complete,08-Feb-18,22-Aug-18,SR0557-000
ixekizumabOpens in new tab,Taltz,ixekizumab,"['/sites/default/files/cdr/complete/SR0558_Taltz_PsA_Aug_23_18.pdf', '/sites/default/files/cdr/clinical/SR0558_TaltzPsA_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0558_TaltzPsA_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0558_TaltzPsA_PI_Submissions.pdf']","Arthritis, psoriatic",Reimburse with clinical criteria and/or conditions,Complete,20-Feb-18,21-Aug-18,SR0558-000
benralizumabOpens in new tab,Fasenra,benralizumab,"['/sites/default/files/cdr/complete/SR0561_Fasenra_Aug_23_18.pdf', '/sites/default/files/cdr/clinical/SR0561_Fasenra_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0561_Fasenra_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0561_Fasenra_PI_Submissions.pdf']","Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,23-Feb-18,21-Aug-18,SR0561-000
Darunavir/cobicistat/emtricita...Opens in new tab,Symtuza,Darunavir/cobicistat/emtricitabine/tenofovir alafenamide,"['/sites/default/files/cdr/complete/SR0552_cdr_complete_Symtuza_July_27_18.pdf', '/sites/default/files/cdr/complete/SR0552_Symtuza_Combined_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0552_Symtuza_PI_Submissions.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,22-Dec-17,25-Jul-18,SR0552-000
Alecensaro for Non-Small Cell ...Opens in new tab,Alecensaro,Alectinib,"['/sites/default/files/pcodr/pcodr_provfund_alectinib_alecensaro_nsclc_1ln.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_in_rec.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fdk_hlr.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_coi_cln.pdf']",Locally advanced or metastatic ALK+ NSCLC (first line),Reimburse with clinical criteria and/or conditions,Complete,15-Jan-18,25-Jul-18,PC0125-000
Lonsurf for Metastatic Colorec...Opens in new tab,Lonsurf,Trifluridine and Tipiracil,"['/sites/default/files/pcodr/pcodr_provfund_trifluridine_tipiracil_lonsurf_mcrc.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_trifluridine-tipiracil_Lonsurf_mCRC_in_rec.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fdk_taiho.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_cln.pdf']",Metastatic Colorectal Cancer,Do not reimburse,Complete,06-Nov-17,06-Jul-18,PC0122-000
Besponsa for Acute Lymphoblast...Opens in new tab,Besponsa,Inotuzumab Ozogamicin,"['/sites/default/files/pcodr/pcodr_provfund_inotuzumab-ozogamicin_besponsa_all.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_besponsa_ALL_in_rec.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fdk_pfizer.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_coi_cln.pdf']",Acute Lymphoblastic Leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,13-Nov-17,06-Jul-18,PC0121-000
dupilumabOpens in new tab,Dupixent,dupilumab,"['/sites/default/files/cdr/complete/SR0533_cdr_complete_Dupixent_July_9_2018.pdf', '/sites/default/files/cdr/clinical/SR0533_Dupixent_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0533_Dupixent_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0533_Duxipent_Patient_Submsissions.pdf']",atopic dermatitis,Do not reimburse,Complete,27-Oct-17,27-Jun-18,SR0533-000
netupitant / palonosetronOpens in new tab,Akynzeo,netupitant / palonosetron,"['/sites/default/files/cdr/complete/SR0548_cdr_complete_Akynzeo_June_22_18.pdf', '/sites/default/files/cdr/clinical/SR0548_Akynzeo_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0548_Akynzeo_PE_Report.pdf']",Nausea and vomiting (chemotherapy induced) prevention,Reimburse with clinical criteria and/or conditions,Complete,08-Dec-17,20-Jun-18,SR0548-000
Tecentriq for Non-Small Cell L...Opens in new tab,Tecentriq,Atezolizumab,"['/sites/default/files/pcodr/pcodr_profund_10115_atezolizumab_tecentriq_nsclc.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fdk_hlroche.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_coi_cln.pdf']",Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,15-Dec-17,20-Jun-18,PC0115-000
Dolutegravir / rilpivirineOpens in new tab,Juluca,Dolutegravir rilpivirine,"['/sites/default/files/cdr/complete/SR0551_cdr_complete_Juluca_June_22_18.pdf', '/sites/default/files/cdr/clinical/SR0551_Juluca_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0551_Juluca_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0551_Juluca_PI_Submissions.pdf']",HIV infection,Reimburse with clinical criteria and/or conditions,Complete,21-Dec-17,20-Jun-18,SR0551-000
letermovirOpens in new tab,Prevymis,letermovir,"['/sites/default/files/cdr/complete/SR0545_cdr_complete_Prevymis_June_22_2018.pdf', '/sites/default/files/cdr/clinical/SR0545_Prevymis_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0545_Prevymis_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0545_Prevymis_PI_Submissions.pdf']","Cytomegalovirus infection, prophylaxis",Reimburse with clinical criteria and/or conditions,Complete,07-Dec-17,20-Jun-18,SR0545-000
brodalumabOpens in new tab,Siliq,brodalumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/complete/SR0547_cdr_complete_Siliq_June_22_18.pdf', '/sites/default/files/cdr/clinical/SR0547_Siliq_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0547_Siliq_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0547_Brodalumab_PI_Submissions.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,14-Dec-17,20-Jun-18,SR0547-000
Opdivo for classical Hodgkin L...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr_profund_nivolumab_opdivo_chl_fail_asct.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_chl_in_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fdk_bms.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_coi_cln.pdf']",classical Hodgkin Lymphoma (cHL) after failure of ASCT,Reimburse with clinical criteria and/or conditions,Complete,29-Sep-17,03-May-18,PC0120-000
ocrelizumabOpens in new tab,Ocrevus,ocrelizumab,"['/sites/default/files/cdr/complete/SR0542_cdr_complete_Ocrevus_PPMS_Apr_30_18_e.pdf', '/sites/default/files/cdr/clinical/SR0542_Ocrevus_PPMS_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0542_Ocrevus_PPMS_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0542_Ocrevus_PPMS_PI_Submissions.pdf']",Primary progressive multiple sclerosis,Reimburse with clinical criteria and/or conditions,Complete,26-Oct-17,26-Apr-18,SR0542-000
nitisinoneOpens in new tab,MDK-Nitisinone,nitisinone,"['/sites/default/files/cdr/complete/SR0538_cdr_complete_MDK_Nitisinone_Apr_27_18_e.pdf', '/sites/default/files/cdr/clinical/SR0538_MDK_Nitisinone_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0538_MDK_Nitisinone_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0538_MDK_Nitisinone_PI_Submissions.pdf']",Hereditary tyrosinemia type 1,Reimburse with clinical criteria and/or conditions,Complete,29-Sep-17,25-Apr-18,SR0538-000
latanoprostOpens in new tab,Monoprost,latanoprost,"['/sites/default/files/cdr/complete/SR0541_cdr_complete_Monoprost_apr-26-18_e.pdf', '/sites/default/files/cdr/clinical/SR0541_Monoprost_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0541_Monoprost_PE_Report.pdf']",glaucoma and ocular hypertension,Reimburse with clinical criteria and/or conditions,Complete,25-Oct-17,24-Apr-18,SR0541-000
Lartruvo for Advanced Soft Tis...Opens in new tab,Lartruvo,Olaratumab,"['/sites/default/files/pcodr/pcodr_profund_olaratumab_lartruvo_sts.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_in_rec.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fdk_elc.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_coi_cln.pdf']",Advanced Soft Tissue Sarcoma,Reimburse with clinical criteria and/or conditions,Complete,26-Oct-17,18-Apr-18,PC0111-000
Stivarga for Unresectable Hepa...Opens in new tab,Stivarga,Regorafenib,"['/sites/default/files/pcodr/pcodr_provfund_10119_regorafenib_stivarga_unresectable_hcc.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fdk_bayer.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_coi_cln.pdf']",Unresectable Hepatocellular Carcinoma (HCC),Reimburse with clinical criteria and/or conditions,Complete,12-Oct-17,18-Apr-18,PC0119-000
Kisqali for Metastatic Breast ...Opens in new tab,Kisqali,Ribociclib,"['/sites/default/files/pcodr/pcodr_provfund_10112_ribocliclib_kisqali_mbc.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_coi_cln.pdf']",Advanced or Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,17-Oct-17,18-Apr-18,PC0112-000
Vectibix for Left Sided Metast...Opens in new tab,Vectibix,Panitumumab,"['/sites/default/files/pcodr/pcodr_profund_panitumumab_vectibix_ls_mcrc.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fn_egr%20.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fdk_amgen.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_coi_cln.pdf']",Left Sided Metastatic Colorectal Cancer (mCRC),Do not reimburse,Complete,08-Sep-17,29-Mar-18,PC0118-000
Alecensaro for Locally Advance...Opens in new tab,Alecensaro,Alectinib,"['/sites/default/files/pcodr/AlectinibAlecensaro_NSCLCsecondline10114ProvFunding.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fn_cgr%20.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_in_rec.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_coi_cln.pdf']","Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Reimburse with clinical criteria and/or conditions,Complete,18-Aug-17,29-Mar-18,PC0114-000
tocilizumabOpens in new tab,Actemra,tocilizumab,"['/sites/default/files/cdr/complete/SR0534_Actemra_GCA_complete_Mar-27-18.pdf', '/sites/default/files/cdr/clinical/SR0534_ActemraGCA_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0534_Actemra_GCA_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0534_Actemra_GCA_PI_Submissions.pdf']",Giant cell arteritis (GCA),Reimburse with clinical criteria and/or conditions,Complete,25-Sep-17,27-Mar-18,SR0534-000
tenofovir alafenamideOpens in new tab,Vemlidy,tenofovir alafenamide,"['/sites/default/files/cdr/complete/SR0537_Vemlidy_complete_Mar-28-18.pdf', '/sites/default/files/cdr/clinical/SR0537_Vemlidy_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0537_Vemlidy_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0537_Vemlidy_PI_Submissions.pdf']","Hepatitis B, chronic",Reimburse with clinical criteria and/or conditions,Complete,28-Sep-17,26-Mar-18,SR0537-000
Bavencio for metastatic Merkel...Opens in new tab,Bavencio,Avelumab,"['/sites/default/files/pcodr/AvelumabBavencio_metastaticMerkelcellcarcinoma10124_ProvFunding2019-11-19.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mmcc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_espa.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_coi_cln.pdf']",metastatic Merkel Cell Carcinoma (mMCC),Reimburse with clinical criteria and/or conditions,Complete,10-Oct-17,21-Mar-18,PC0124-000
Venclexta for Chronic Lymphocy...Opens in new tab,Venclexta,Venetoclax,"['/sites/default/files/pcodr/pcodr_profund_venetoclax_venclexta_cll.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_in_rec.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fdk_abbvie.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_coi_cln.pdf']",Chronic Lymphocytic Leukemia,Reimburse with clinical criteria and/or conditions,Complete,10-Jul-17,02-Mar-18,PC0105-000
Keytruda for Metastatic Urothe...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/pcodr_provfund_pembrolizumab_keytruda_MUC.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fdk_merck.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_coi_cln.pdf']",For locally advanced or metastatic urothelial carcinoma,Reimburse with clinical criteria and/or conditions,Complete,24-Jul-17,02-Mar-18,PC0117-000
guselkumabOpens in new tab,Tremfya,guselkumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/complete/SR0530_Tremfya_complete_Feb-23-18.pdf', '/sites/default/files/cdr/clinical/SR0530_Tremfya_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0530_Tremfya_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0530_Tremfya_PI_Submissions.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,25-Aug-17,21-Feb-18,SR0530-000
nitisinoneOpens in new tab,Orfadin,nitisinone,"['/sites/default/files/cdr/complete/SR0531_Orfadin_complete_Feb-23-18.pdf', '/sites/default/files/cdr/clinical/SR0531_Orfadin_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0531_Orfadin_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0531_Orfadin_PI.pdf']",Hereditary tyrosinemia type 1,Reimburse with clinical criteria and/or conditions,Complete,29-Aug-17,21-Feb-18,SR0531-000
Adcetris for Hodgkin’s Lymphom...Opens in new tab,Adcetris,Brentuximab Vedotin,"['/sites/default/files/pcodr/pcodr_profund_brentuximab_adcetris_hl_post-asct_resub.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_in_rec.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fdk_sgi.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_cln.pdf']",HL at high risk of relapse or progression post-ASCT,Reimburse with clinical criteria and/or conditions,Complete,10-Aug-17,21-Feb-18,PC0116-000
infliximabOpens in new tab,Renflexis,infliximab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/complete/SE0532%20Renflexis%20-%20CDEC%20Final%20Recommendation%20February%2020%2C%202018%28redacted%29_for%20posting.pdf', '/sites/default/files/cdr/relatedinfo/SE0532_Renflexis_Combined_Report.pdf', '/sites/default/files/cdr/relatedinfo/SE0532_Renflexis_PI.pdf']","rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis",Reimburse with clinical criteria and/or conditions,Complete,05-Sep-17,20-Feb-18,SE0532-000
Faslodex for Locally Advanced ...Opens in new tab,Faslodex,Fulvestrant,"['/sites/default/files/pcodr/pcodr_provfund_fulvestrant_faslodex_mbc.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fdk_asz.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_coi_cln.pdf']",Locally advanced or metastatic breast cancer,Reimburse with clinical criteria and/or conditions,Complete,17-Jul-17,01-Feb-18,PC0110-000
migalastatOpens in new tab,Galafold,migalastat,"['/sites/default/files/cdr/complete/SR0522_Galafold_complete_Jan-26-18.pdf', '/sites/default/files/cdr/clinical/SR0522_Galafold_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0522_Galafold_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0522_Galafold_Patient_Input.pdf']",Fabry Disease,Reimburse with clinical criteria and/or conditions,Complete,09-Jun-17,24-Jan-18,SR0522-000
cysteamine bitartrateOpens in new tab,Procysbi,cysteamine bitartrate,"['/sites/default/files/cdr/complete/SR0526_Procysbi_complete_Jan-26-18.pdf', '/sites/default/files/cdr/clinical/SR0526_Procysbi_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0526_Procysbi_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0526_Procysbi_Patient_Input.pdf', '/sites/default/files/cdr/relatedinfo/SI0002-procysbi-drug-implementation-advice.pdf']",Nephropathic cystinosis,Reimburse with clinical criteria and/or conditions,Complete,08-Aug-17,24-Jan-18,SR0526-000
glecaprevir pibrentasvirOpens in new tab,Maviret,glecaprevir pibrentasvir,"['/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf', '/sites/default/files/cdr/clinical/SR0523_Maviret_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0523_Maviret_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0523_Maviret_Patient_Input.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,09-Jun-17,23-Jan-18,SR0523-000
ApomorphineOpens in new tab,Movapo,apomorphine hydrochloride,"['/sites/default/files/cdr/complete/SR0527_Movapo_complete-Jan-25-18.pdf', '/sites/default/files/cdr/clinical/SR0527_Movapo_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0527_Movapo_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0527_Movapo_Patient_Input.pdf']",Parkinson's disease,Reimburse with clinical criteria and/or conditions,Complete,06-Jul-17,23-Jan-18,SR0527-000
sofosbuvir velpatasvir voxilap...Opens in new tab,Vosevi,sofosbuvir velpatasvir voxilaprevir,"['/sites/default/files/cdr/complete/SR0529_Vosevi_complete_Jan-25-18.pdf', '/sites/default/files/cdr/clinical/SR0529_Vosevi_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0529_Vosevi_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0529%20Vosevi_Patient_Input.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,28-Jul-17,23-Jan-18,SR0529-000
Onivyde for Metastatic Pancrea...Opens in new tab,Onivyde,Irinotecan Liposome,"['/sites/default/files/pcodr/pcodr_provfund_irinotecan_liposome_onivyde_mpc.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_coi_cln.pdf']",Metastatic Pancreatic Cancer,Reimburse with clinical criteria and/or conditions,Complete,27-Apr-17,05-Jan-18,PC0107-000
Pembrolizumab (Keytruda) class...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/pcodr_profund_pembrolizumab_keytruda_chl.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fdk_merck.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_coi_cln.pdf']",classical Hodgkin Lymphoma (cHL),Reimburse with clinical criteria and/or conditions,Complete,07-Jul-17,05-Jan-18,PC0109-000
nusinersenOpens in new tab,Spinraza,nusinersen,"['/sites/default/files/cdr/complete/SR0525_Spinraza_complete_Dec_22_17.pdf', '/sites/default/files/cdr/clinical/SR0525_Spinraza_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0525_Spinraza_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0525_Spinraza_Patient_Input.pdf']",Spinal Muscular Atrophy,Reimburse with clinical criteria and/or conditions,Complete,28-Jun-17,22-Dec-17,SR0525-000
Rydapt for Acute Myeloid Leuke...Opens in new tab,Rydapt,Midostaurin,"['/sites/default/files/pcodr/pcodr_profund_midostaurin_rydapt_aml.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_in_rec.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_coi_cln.pdf']",Acute Myeloid Leukemia,Reimburse,Complete,12-Jun-17,19-Dec-17,PC0108-000
Opdivo in combo with Yervoy fo...Opens in new tab,Opdivo & Yervoy in combo,Nivolumab & Ipilimumab in combo,"['/sites/default/files/pcodr/pcodr_profund_opdivo_yervoy_metmela.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_in_rec.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fdk_bms.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_ptfdk_mnc.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_ptfdk_sys.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_clfdk.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_coi_cl.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,30-Nov-16,30-Nov-17,PC0098-000
lixisenatideOpens in new tab,Adlyxine,lixisenatide,"['/sites/default/files/cdr/complete/SR0520_Adlyxine_complete_Nov-23-17.pdf', '/sites/default/files/cdr/clinical/SR0520_Adlyxine_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0520_Adlyxine_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0520_Adlyxine_PI_Submissions.pdf']","Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,29-May-17,23-Nov-17,SR0520-000
BrexpiprazoleOpens in new tab,Rexulti,Brexpiprazole,"['/sites/default/files/cdr/tracking/cdr_SR0514_TBC.pdf', '/sites/default/files/cdr/complete/SR0514_Rexulti_complete_Nov_24_17.pdf', '/sites/default/files/cdr/clinical/SR0514_Rexulti_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0514_Rexulti_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0514_Rexulti_PI_Submissions.pdf']",schizophrenia,Reimburse with clinical criteria and/or conditions,Complete,03-Feb-17,22-Nov-17,SR0514-000
EvolocumabOpens in new tab,Repatha,Evolocumab,"['/sites/default/files/cdr/tracking/cdr_SR0515_Repatha.pdf', '/sites/default/files/cdr/complete/SR0515_Repatha_Resubmission_complete_Nov_24_17.pdf', '/sites/default/files/cdr/clinical/SR0515_Repatha_Resubmission_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0515_Repatha_Resubmission_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0515_Repatha_PI_Submissions.pdf']",Primary hyperlipidemia and mixed dyslipidemia,Reimburse with clinical criteria and/or conditions,Complete,17-Feb-17,22-Nov-17,SR0515-000
ulipristal acetateOpens in new tab,Fibristal,ulipristal acetate,"['/sites/default/files/cdr/complete/SF0528_Fibristal_RFA_complete_Nov_22_17.pdf', '/sites/default/files/cdr/advice/SF0528_Fibristal_RFA_Report.pdf', '/sites/default/files/cdr/relatedinfo/SF0528_Fibristal_PI_Submissions.pdf']",Uterine fibroids (signs and symptoms),Reimburse with clinical criteria and/or conditions,Complete,21-Jun-17,22-Nov-17,SF0528-000
ocrelizumabOpens in new tab,Ocrevus,ocrelizumab,"['/sites/default/files/cdr/complete/SR0519_Ocrevus_RMS_complete_Nov-23-17.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0519_Ocrevus_RMS%20_PE_Report.pdf', '/sites/default/files/cdr/clinical/SR0519_Ocrevus_RMS_CL_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0519_Ocrevus_RMS_PI_Submissions.pdf']","multiple sclerosis, relapsing",Reimburse with clinical criteria and/or conditions,Complete,16-May-17,21-Nov-17,SR0519-000
insulin degludecOpens in new tab,Tresiba,insulin degludec,"['/sites/default/files/cdr/complete/SR0521_Tresiba_complete_Nov-22-17_e.pdf', '/sites/default/files/cdr/clinical/SR0521_Tresiba_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0521_Tresiba_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0521_Tresiba_PI_Submissions.pdf']","Diabetes mellitus, Type 1 & 2",Reimburse with clinical criteria and/or conditions,Complete,31-May-17,20-Nov-17,SR0521-000
Tafinlar &amp; Mekinist in com...Opens in new tab,Tafinlar & Mekinist in combo,Dabrafenib & Trametinib in combo,"['/sites/default/files/pcodr/pcodr_provfund_tafinlar_mekinist_nsclc.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_clfdk.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_coi-cl.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_coi-pt.pdf']",Non-Small Cell Lung Cancer,Do not reimburse,Complete,31-Mar-17,02-Nov-17,PC0106-000
travoprost ophthalmic solutionOpens in new tab,Izba,travoprost ophthalmic solution,"['/sites/default/files/cdr/tracking/cdr_SR0516_Izba.pdf', '/sites/default/files/cdr/complete/SR0516_Izba_complete_Oct-30-17.pdf', '/sites/default/files/cdr/clinical/SR0516_Izba_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0516_Izba_PE_Report.pdf']",Glaucoma and ocular hypertension,Reimburse with clinical criteria and/or conditions,Complete,01-Mar-17,25-Oct-17,SR0516-000
abobotulinumtoxinAOpens in new tab,Dysport Therapeutic,abobotulinumtoxinA,"['/sites/default/files/cdr/monograph/dysport-therapeutic-product-monograph.pdf', '/sites/default/files/cdr/complete/SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf', '/sites/default/files/cdr/clinical/SR0517_Dysport_Therapeutic_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0517_Dysport_Therapeutic_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf']",Upper limb spasticity,Reimburse with clinical criteria and/or conditions,Complete,24-Apr-17,24-Oct-17,SR0517-000
Darzalex for Multiple Myeloma ...Opens in new tab,Darzalex,Daratumumab,"['/sites/default/files/pcodr/pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf']",Multiple Myeloma (second-line),Reimburse with clinical criteria and/or conditions,Complete,03-Mar-17,05-Oct-17,PC0104-000
Lynparza for Ovarian Cancer (R...Opens in new tab,Lynparza (Resubmission),Olaparib,"['/sites/default/files/pcodr/pcodr_profund_olaparib_lynparza_resub.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_in_rec.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_clinfdk.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_coi_clin.pdf']",Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,17-Mar-17,20-Sep-17,PC0103-000
Blincyto for Acute Lymphoblast...Opens in new tab,Blincyto (Resubmission),Blinatumomab,"['/sites/default/files/pcodr/pcodr_profund_blinatumomab_blincyto_all_resub.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_in_rec.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fdk_amgen.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_coi_ptgrp.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_coi_clinician.pdf']",Acute Lymphoblastic Leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,24-Feb-17,31-Aug-17,PC0097-000
Rituxan for Acute Lymphoblasti...Opens in new tab,Rituxan,Rituximab,"['/sites/default/files/pcodr/pcodr_profund_rituximab_rituxan_all.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_in_rec.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fdk_hlroche.pdf', '/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_coi_clinician.pdf']",Acute Lymphoblastic Leukemia,Do not reimburse,Complete,13-Feb-17,31-Aug-17,PC0102-000
Opdivo for Squamous Cell Carci...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr_profund_nivolumab_opdivo_scchn.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_in_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fdk_bms.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_coi_ptgrp.pdf']",Squamous Cell Carcinoma of Head and Neck (SCCHN),Reimburse with clinical criteria and/or conditions,Complete,31-Jan-17,31-Aug-17,PC0095-000
Keytruda for Advanced Non-Smal...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/PembrolizumabKeytruda_AdvancedNSCLCfirstline10101_ProvFunding.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fdk_merck.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_ptgrp.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_clinician.pdf']",Advanced non-small cell lung carcinoma (first line),Reimburse with clinical criteria and/or conditions,Complete,12-Dec-16,23-Aug-17,PC0101-000
Blinatumomab (Blincyto) for Ac...Opens in new tab,Blincyto,Blinatumomab,"['/sites/default/files/pcodr/pcodr_profund_blinatumomab_blincyto_all_pediatric.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_in_rec.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fdk_amgen.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_coi_ptgrp.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_coi_clinician.pdf']",Acute Lymphoblastic Leukemia (pediatric),Reimburse with clinical criteria and/or conditions,Complete,24-Feb-17,23-Aug-17,PC0099 -000
EliglustatOpens in new tab,Cerdelga,Eliglustat,"['/sites/default/files/cdr/tracking/cdr_SR0511_Cerdelga.pdf', '/sites/default/files/cdr/complete/SR0511_complete_Cerdelga_Jul_28_17_e.pdf', '/sites/default/files/cdr/clinical/SR0511_Cerdelga_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0511_Cerdelga_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0511_Cerdelga_PI_Submissions.pdf']",Gaucher disease,Reimburse with clinical criteria and/or conditions,Complete,20-Jan-17,26-Jul-17,SR0511-000
abobotulinumtoxinAOpens in new tab,Dysport Therapeutic,abobotulinumtoxinA,"['/sites/default/files/cdr/tracking/cdr_SR0512_Dysport_Therapeutic.pdf', '/sites/default/files/cdr/complete/SR0512_complete_Dysport_Therapeutic_Jul_28_17_e.pdf', '/sites/default/files/cdr/clinical/SR0512_Dysport_Therapeutic_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0512_Dysport_Therapeutic_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0512_Dysport_Therapeutic_PI_Submissions.pdf']",Cervical dystonia,Reimburse with clinical criteria and/or conditions,Complete,31-Jan-17,26-Jul-17,SR0512-000
Glatiramer acetateOpens in new tab,Glatect,Glatiramer acetate,"['/sites/default/files/cdr/tracking/cdr_SE0510_Glatect.pdf', '/sites/default/files/cdr/complete/SE0510_complete_Glatect-Jul-27-e.pdf', '/sites/default/files/cdr/relatedinfo/SE0510_Glatect%20_PI_Submissions.pdf', '/sites/default/files/cdr/complete/SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf']",Relapsing Remitting Multiple Sclerosis (RRMS),Reimburse with clinical criteria and/or conditions,Complete,20-Jan-17,25-Jul-17,SE0510-000
EtanerceptOpens in new tab,Erelzi,Etanercept,"['/sites/default/files/cdr/tracking/cdr_SE0513_TBC.pdf', '/sites/default/files/cdr/complete/SE0513_complete_Erelzi_Jul_28_17_e.pdf', '/sites/default/files/cdr/seb/SE0513_Erelzi_SEB_Report.pdf', '/sites/default/files/cdr/relatedinfo/SE0513_Erelzi_PI_Submissions.pdf']","Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis",Reimburse with clinical criteria and/or conditions,Complete,02-Feb-17,25-Jul-17,SE0513-000
Obeticholic AcidOpens in new tab,Ocaliva,Obeticholic Acid,"['/sites/default/files/cdr/tracking/cdr_SR0509_TBC.pdf', '/sites/default/files/cdr/complete/SR0509_complete_Ocaliva_Jul_27_17_e.pdf', '/sites/default/files/cdr/clinical/SR0509_Ocaliva_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0509_Ocaliva_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0509%20Ocaliva_PI_Submissions.pdf']",Primary Biliary Cholangitis,Reimburse with clinical criteria and/or conditions,Complete,22-Dec-16,25-Jul-17,SR0509-000
Ninlaro for Multiple Myeloma –...Opens in new tab,Ninlaro,Ixazomib,"['/sites/default/files/pcodr/pcodr_provfund_ixazomib_ninlaro_mm.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fdk_takeda.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_coi_mmc.pdf', '/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_coi_cln.pdf']",Multiple Myeloma,Do not reimburse,Complete,16-Dec-16,29-Jun-17,PC0088-000
Daclizumab betaOpens in new tab,Zinbryta,Daclizumab beta,"['/sites/default/files/cdr/tracking/cdr_SR0508_Zinbryta.pdf', '/sites/default/files/cdr/complete/SR0508_compelte_Zinbryta_Jun-22-17_e.pdf', '/sites/default/files/cdr/clinical/SR0508_Zinbryta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0508_Zinbryta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0508_Zinbryta_PI_Submissions.pdf']","Multiple Sclerosis, relapsing-remitting",Reimburse with clinical criteria and/or conditions,Complete,20-Dec-16,20-Jun-17,SR0508-000
Gazyva for Follicular Lymphoma...Opens in new tab,Gazyva,Obinutuzumab,"['/sites/default/files/pcodr/pcodr_profund_obinutuzumab_gazyva_fl.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fn_rec.pdf', '', '', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_in_rec.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_coi_pt.pdf']",Follicular Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,04-Nov-16,02-Jun-17,PC0091-000
EdoxabanOpens in new tab,Lixiana VTE,Edoxaban,"['/sites/default/files/cdr/tracking/cdr_SR0499_Lixiana_VTE.pdf', '/sites/default/files/cdr/complete/SR0499_complete_Lixiana_VTE_May_29_17_e.pdf', '/sites/default/files/cdr/clinical/SR0499_Lixiana_VTE_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0499_Lixiana_VTE_PE_Report.pdf']","Venous thromboembolism, treatment and recurrence prevention.",Reimburse with clinical criteria and/or conditions,Complete,09-Sep-16,25-May-17,SR0499-000
emtricitabine/rilpivirine/ ten...Opens in new tab,Odefsey,emtricitabine/rilpivirine/ tenofovir alafenamide,"['/sites/default/files/cdr/tracking/cdr_SR0507_TBC.pdf', '/sites/default/files/cdr/complete/SR0507_complete_Odefsey-%20May-25-17_e.pdf', '/sites/default/files/cdr/complete/SR0507_Odefsey_Combined_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0507_Odefsey_PI_Submissions.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,24-Nov-16,25-May-17,SR0507-000
IvabradineOpens in new tab,Lancora,Ivabradine,"['/sites/default/files/cdr/tracking/cdr_SR0506_Lancora.pdf', '/sites/default/files/cdr/complete/SR0506_complete_Lancora-Jun15-17_e.pdf', '/sites/default/files/cdr/clinical/SR0506_%20Lancora_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0506_%20Lancora_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0506_Lancora_PI_Submissions.pdf']","Heart failure, NYHA class II or III",Reimburse with clinical criteria and/or conditions,Complete,08-Nov-16,24-May-17,SR0506-000
Tagrisso for Non-Small Cell Lu...Opens in new tab,Tagrisso,Osimertinib,"['/sites/default/files/pcodr/pcodr_provfund_10076_osimertinib_tagrisso_nsclc.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fdk_azc.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_coi_cln.pdf']",Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,01-Apr-16,04-May-17,PC0076-000
Alecensaro for Non-Small Cell ...Opens in new tab,Alecensaro,Alectinib,"['/sites/default/files/pcodr/pcodr_provfund_alectinib_alecensaro_nsclc.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_clnfdk.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_coi_pt.pdf', '/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_coi_cln.pdf']",Non-Small Cell Lung Cancer,Do not reimburse,Complete,03-Oct-16,04-May-17,PC0092-000
Propiverine hydrochlorideOpens in new tab,Mictoryl,Propiverine hydrochloride,"['/sites/default/files/cdr/tracking/cdr_SR0504_Mictoryl.pdf', '/sites/default/files/cdr/clinical/SR0504_Mictoryl_CL%20Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0504_Mictoryl_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0504_Mictoryl_PI_Submissions.pdf', '/sites/default/files/cdr/complete/SR0504_complete_Mictoryl_Apr-21-17-e.pdf']",Overactive bladder (OAB),Reimburse with clinical criteria and/or conditions,Complete,14-Oct-16,19-Apr-17,SR0504-000
SarilumabOpens in new tab,Kevzara,sarilumab,"['/sites/default/files/cdr/tracking/cdr_SR0503_TBC.pdf', '/sites/default/files/cdr/clinical/SR0503_Kevzara_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0503_Kevzara_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0503_Kevzara_PI_Submissions.pdf', '/sites/default/files/cdr/complete/SR0503_complete_Kevzara-Apr-20-17.pdf']","Arthritis, Rheumatoid",Reimburse with clinical criteria and/or conditions,Complete,12-Oct-16,18-Apr-17,SR0503-000
Mifepristone and misoprostolOpens in new tab,Mifegymiso,Mifepristone and misoprostol,"['/sites/default/files/cdr/tracking/cdr_SR0502_Mifegymiso.pdf', '/sites/default/files/cdr/complete/SR0502_complete_Mifegymiso-Apr-20-17-e.pdf', '/sites/default/files/cdr/clinical/SR0502_Mifegymiso_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0502_Mifegymiso_PE_Report.pdf']",Medical termination of pregnancy (gestational age up to 49 days),Reimburse,Complete,07-Oct-16,18-Apr-17,SR0502-000
Caprelsa for Medullary Thyroid...Opens in new tab,Caprelsa,Vandetanib,"['/sites/default/files/pcodr/pcodr_provfund_vandetanib_caprelsa_mtc.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fdk_sanofig.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_ptfdk_tcc.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_coi_tcc.pdf', '/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_coi_cln.pdf']",Medullary Thyroid Cancer,Reimburse with clinical criteria and/or conditions,Complete,15-Aug-16,30-Mar-17,PC0090-000
Kyprolis for Multiple Myeloma ...Opens in new tab,Kyprolis,Carfilzomib,"['/sites/default/files/pcodr/pcodr_profund_carfilzomib_kyprolis_mm_rel.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_in_rec.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fdk_amgen.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_ptfdk_mmc.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fdk_cln.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_coi_mmc.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_coi_cln.pdf']",Multiple Myeloma (relapsed),Reimburse with clinical criteria and/or conditions,Complete,09-Sep-16,30-Mar-17,PC0084-000
ReslizumabOpens in new tab,Cinqair,Reslizumab,"['/sites/default/files/cdr/tracking/cdr_SR0495_Cinqair.pdf', '/sites/default/files/cdr/complete/SR0495_complete_Cinqair-Mar-24-17.pdf', '/sites/default/files/cdr/clinical/SR0495_Cinqair_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0495_Cinqair_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0495_Cinqair_PI_Submissions.pdf']","Asthma, eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,04-Aug-16,22-Mar-17,SR0495-000
Fluorouracil and Salicylic Aci...Opens in new tab,Actikerall,Fluorouracil and Salicylic Acid,"['/sites/default/files/cdr/tracking/cdr_SR0498_Actikerall.pdf', '/sites/default/files/cdr/complete/SR0498_complete_Actikerall-Mar-24-17.pdf', '/sites/default/files/cdr/clinical/SR0498_Actikerall_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0498_Actikerall_PE_Report.pdf']",Hyperkeratotic actinic keratosis,Reimburse with clinical criteria and/or conditions,Complete,31-Aug-16,22-Mar-17,SR0498-000
BudesonideOpens in new tab,Cortiment,Budesonide,"['/sites/default/files/cdr/tracking/cdr_SR0491_TBC.pdf', '/sites/default/files/cdr/complete/SR0491_complete_Cortiment-Mar-24-17.pdf', '/sites/default/files/cdr/clinical/SR0491_Cortiment_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0491_Cortiment_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0491%20Cortiment_PI_Submissions.pdf']",Ulcerative Colitis,Do not reimburse,Complete,24-May-16,22-Mar-17,SR0491-000
EdoxabanOpens in new tab,Lixiana NVAF,Edoxaban,"['/sites/default/files/cdr/tracking/cdr_SR0500_Lixiana_NVAF.pdf', '/sites/default/files/cdr/complete/SR0500_complete_Lixiana-NVAF_Mar-23-17.pdf', '/sites/default/files/cdr/clinical/SR0500_Lixiana_NVAF_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0500_Lixiana_NVAF_PE_Report.pdf']","Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism.",Reimburse with clinical criteria and/or conditions,Complete,09-Sep-16,21-Mar-17,SR0500-000
glycerol phenylbutyrateOpens in new tab,Ravicti,glycerol phenylbutyrate,"['/sites/default/files/cdr/tracking/cdr_SR0497_Ravicti.pdf', '/sites/default/files/cdr/complete/SR0497_complete_Ravicti_Mar-23-17.pdf', '/sites/default/files/cdr/clinical/SR0497_Ravicti_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0497_Ravicti_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0497_Ravicti_PI_Submissions.pdf']",Urea cycle disorders,Reimburse with clinical criteria and/or conditions,Complete,30-Aug-16,21-Mar-17,SR0497-000
ustekinumabOpens in new tab,Stelara/Stelara I.V.,ustekinumab,"['/sites/default/files/cdr/tracking/cdr_SR0501_Stelara.pdf', '/sites/default/files/cdr/complete/SR0501_complete_Stelara_Mar-23-17.pdf', '/sites/default/files/cdr/clinical/SR0501_Stelara_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0501_Stelara_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0501_Stelara_PI_Submissions.pdf']",Crohn’s disease,Reimburse with clinical criteria and/or conditions,Complete,12-Sep-16,21-Mar-17,SR0501-000
Zykadia for Non-Small Cell Lun...Opens in new tab,Zykadia (Resubmission),Ceritinib,"['/sites/default/files/pcodr/pcodr_provfund_ceritinib_zykadia_nsclc_resub.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_clinfdk.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_coi_lcc.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_coi_clin.pdf']",metastatic non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,19-Oct-16,21-Mar-17,PC0094-000
Fentanyl buccalOpens in new tab,Fentora,Fentanyl buccal,"['/sites/default/files/cdr/tracking/cdr_SR0494_Fentora.pdf', '/sites/default/files/cdr/clinical/SR0494_Fentora_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0494_Fentora_PE_Report.pdf', '/sites/default/files/cdr/complete/SR0494_complete_Fentora_Feb-23-17.pdf']","Pain (breakthrough), cancer (adults)",Do not reimburse,Complete,12-Jul-16,21-Feb-17,SR0494-000
Propranolol oral solutionOpens in new tab,Hemangiol,Propranolol oral solution,"['/sites/default/files/cdr/tracking/cdr_SR0496_Hemangiol.pdf', '/sites/default/files/cdr/complete/SR0496_complete_Hemangiol-Feb-23_17.pdf', '/sites/default/files/cdr/clinical/SR0496_Hemangiol_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0496_Hemangiol_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0496_Hemangiol_PI_Submissions.pdf']",Infantile hemangioma,Reimburse with clinical criteria and/or conditions,Complete,25-Aug-16,21-Feb-17,SR0496-000
BrivaracetamOpens in new tab,Brivlera,Brivaracetam,"['/sites/default/files/cdr/tracking/cdr_SR0484_Brivlera.pdf', '/sites/default/files/cdr/clinical/SR0484_Brivlera_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0484_Brivlera_PE_Report.pdf', '/sites/default/files/cdr/complete/sr0484_complete_brivlera_jan-27-17.pdf']","Epilepsy, partial-onset seizures",Reimburse with clinical criteria and/or conditions,Complete,19-Apr-16,25-Jan-17,SR0484-000
Darzalex for Multiple Myeloma ...Opens in new tab,Darzalex,Daratumumab,"['/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_in_rec.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fdk_mc.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fdk_clinician.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_coi_mc.pdf', '/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_coi_clinician.pdf']",Multiple Myeloma,Do not reimburse,Complete,21-Apr-16,01-Dec-16,PC0079-000
Afinitor for Neuroendocrine tu...Opens in new tab,Afinitor,Everolimus,"['/sites/default/files/pcodr/pcodr_profund_everolimus_afinitor_net-gil.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_in_rec.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fdk_cnets.pdf', '/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_coi_cnets.pdf']",Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin,Reimburse with clinical criteria and/or conditions,Complete,30-May-16,01-Dec-16,PC0083-000
LevofloxacinOpens in new tab,Quinsair,Levofloxacin,"['/sites/default/files/cdr/tracking/cdr_SR0493_Quinsair.pdf', '/sites/default/files/cdr/complete/SR0493_complete_Quinsair_Nov-23-16.pdf', '/sites/default/files/cdr/clinical/SR0493_Quinsair_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0493_Quinsair_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0493_Quinsair_PI_Submissions.pdf']",Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections,Reimburse with clinical criteria and/or conditions,Complete,31-May-16,21-Nov-16,SR0493-000
Ibrance for Advanced Breast Ca...Opens in new tab,Ibrance Resubmission,Palbociclib,"['/sites/default/files/pcodr/pcodr_profund_10093_palbociclib_ibrance_abc_resub.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fdk_pfizer.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_ptfdk_rethink.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_ptfdk_cbcn.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_coi_cbcn-rethink.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_coi_clinician.pdf']",Advanced breast cancer,Reimburse with clinical criteria and/or conditions,Complete,10-Jun-16,21-Nov-16,PC0093-000
Keytruda for Non-Small Cell Lu...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/pcodr_provfund_pembrolizumab_keytruda_nsclc_2lnbeyond.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fdk_merck.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_coi_lcc.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fdk_clinician.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_coi_clinician.pdf']",Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,21-Apr-16,03-Nov-16,PC0077-000
Imbruvica for Chronic Lymphocy...Opens in new tab,Imbruvica,Ibrutinib,"['/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-cll-sll-preun.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_cllpag.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_coi_cllpag.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_lc.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_coi_lc.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_coi_clinician.pdf']",Chronic Lymphocytic Leukemia (previously untreated),Reimburse with clinical criteria and/or conditions,Complete,20-Apr-16,03-Nov-16,PC0085-000
Imbruvica for Waldenström’s Ma...Opens in new tab,Imbruvica,Ibrutinib,"['/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-wm.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_ptfdk_cord.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_ptfdk_lc.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_coi_lc_cord.pdf']",Waldenstrom's Macroglobulinemia,Do not reimburse,Complete,21-Apr-16,03-Nov-16,PC0082-000
VedolizumabOpens in new tab,Entyvio,Vedolizumab,"['/sites/default/files/cdr/tracking/cdr_SR0487_Entyvio.pdf', '/sites/default/files/cdr/complete/SR0487_complete_Entyvio-Oct-31-16.pdf', '/sites/default/files/cdr/clinical/SR0487_Entyvio_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0487_Entyvio_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0487_Entyvio_PI_Submissions.pdf']",Crohn's disease,Reimburse with clinical criteria and/or conditions,Complete,27-Apr-16,31-Oct-16,SR0487-000
SelexipagOpens in new tab,Uptravi,Selexipag,"['/sites/default/files/cdr/tracking/cdr_SR0482_Uptravi.pdf', '/sites/default/files/cdr/complete/SR0482_complete_Uptravi-Oct-28-16.pdf', '/sites/default/files/cdr/relatedinfo/SR0482_Uptravi_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0482_Uptravi_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0482_Uptravi_PE_Report.pdf']",Pulmonary arterial hypertension (WHO class II and III),Reimburse with clinical criteria and/or conditions,Complete,31-Mar-16,28-Oct-16,SR0482-000
Sofosbuvir/ velpatasvirOpens in new tab,Epclusa,Sofosbuvir/ velpatasvir,"['/sites/default/files/cdr/tracking/cdr_SR0486_TBC.pdf', '/sites/default/files/cdr/complete/SR0486_complete_Epclusa-Oct-28-16.pdf', '/sites/default/files/cdr/clinical/SR0486_Epclusa_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0486_Epclusa_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0486_Epclusa_PI_Submissions.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,22-Apr-16,26-Oct-16,SR0486-000
EmpagliflozinOpens in new tab,Jardiance,Empagliflozin,"['/sites/default/files/cdr/tracking/cdr_SR0488_Jardiance.pdf', '/sites/default/files/cdr/complete/SR0488_complete_Jardiance-Oct-28-16.pdf', '/sites/default/files/cdr/clinical/SR0488_Jardiance_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0488_Jardiance_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0488_Jardiance_PI_Submissions.pdf']","Diabetes mellitus, type 2 with high cardiovascular risk",Reimburse with clinical criteria and/or conditions,Complete,27-Apr-16,26-Oct-16,SR0488-000
ApremilastOpens in new tab,Otezla,Apremilast,"['/sites/default/files/cdr/tracking/cdr_SR0478_Otezla_Resub.pdf', '/sites/default/files/cdr/complete/SR0478_complete_Otezla-Oct-28-16.pdf', '/sites/default/files/cdr/relatedinfo/SR0478_Otezla_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0478_Otezla_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0478_Otezla_PE_Report_e.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,03-Mar-16,26-Oct-16,SR0478-000
perindopril arginine / amlodip...Opens in new tab,Viacoram,perindopril arginine / amlodipine,"['/sites/default/files/cdr/tracking/cdr_SR0490_Viacoram.pdf', '/sites/default/files/cdr/complete/SR0490_complete_Viacoram-Oct-28-16.pdf', '/sites/default/files/cdr/clinical/SR0490_Viacoram_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0490_Viacoram_PE_Report.pdf']","Hypertension, essential",Reimburse with clinical criteria and/or conditions,Complete,02-May-16,26-Oct-16,SR0490-000
Sapropterin dihydrochlorideOpens in new tab,Kuvan,Sapropterin dihydrochloride,"['/sites/default/files/cdr/tracking/cdr_SR0472_Kuvan.pdf', '/sites/default/files/cdr/complete/SR0472_complete_Kuvan-Oct-28-16.pdf', '/sites/default/files/cdr/relatedinfo/SR0472_Kuvan_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0472_Kuvan_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0472_Kuvan_PE_Report_e.pdf']",Phenylketonuria (PKU),Reimburse with clinical criteria and/or conditions,Complete,01-Feb-16,26-Oct-16,SR0472-000
lumacaftor/ivacaftorOpens in new tab,Orkambi,lumacaftor/ivacaftor,"['/sites/default/files/cdr/tracking/cdr_SR0471_Orkambi.pdf', '/sites/default/files/cdr/complete/SR0471_complete_Orkambi-Oct-28-16.pdf', '/sites/default/files/cdr/clinical/SR0471_Orkambi_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0471_Orkambi_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0471_Orkambi_PI_Submissions.pdf']","Cystic Fibrosis, F508del CFTR mutation",Do not reimburse,Complete,28-Jan-16,26-Oct-16,SR0471-000
InfliximabOpens in new tab,Inflectra (Subsequent Entry Biologic),Infliximab,"['/sites/default/files/cdr/tracking/cdr_SE0483_Inflectra.pdf', '/sites/default/files/cdr/complete/SE0483_IBD_Inflectra-Oct-28-16.pdf', '/sites/default/files/cdr/relatedinfo/SE0483_Inflectra_PI_Submission_Consolidated.pdf', '/sites/default/files/cdr/seb/SE0483_Inflectra_SEB_Report.pdf']",Crohn’s disease and Ulcerative Colitis,Reimburse with clinical criteria and/or conditions,Complete,12-Apr-16,25-Oct-16,SE0483-000
EtanerceptOpens in new tab,Brenzys,Etanercept,"['/sites/default/files/cdr/tracking/cdr_SE0485_TBC.pdf', '/sites/default/files/cdr/complete/SE0485_complete_Brenzys-Oct-27-16.pdf', '/sites/default/files/cdr/relatedinfo/se0485_brenzys_pi.pdf', '/sites/default/files/cdr/seb/se0485_brenzys_seb_report.pdf']","Rheumatoid arthritis, Ankylosing spondylitis",Reimburse with clinical criteria and/or conditions,Complete,20-Apr-16,25-Oct-16,SE0485-000
IxekizumabOpens in new tab,Taltz,Ixekizumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/tracking/cdr_SR0481_TBC.pdf', '/sites/default/files/cdr/complete/SR0481_complete_Taltz-oct-27-16.pdf', '/sites/default/files/cdr/relatedinfo/SR0481_Taltz_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0481_Taltz_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0481_Taltz_PE_Report_e.pdf']","Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,23-Mar-16,25-Oct-16,SR0481-000
Empagliflozin and metforminOpens in new tab,Synjardy,Empagliflozin and metformin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0489_Synjardy.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0489_complete_Synjardy-oct-27-16.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0489_Synjardy_PI_Submissions.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/SR0489_Synjardy_CL_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0489_Synjardy_PE_Report.pdf']",Diabetes mellitus (Type 2),Reimburse with clinical criteria and/or conditions,Complete,29-Apr-16,25-Oct-16,SR0489-000
Lynparza for Ovarian Cancer (2...Opens in new tab,Lynparza,Olaparib,"['/sites/default/files/pcodr/pcodr_provfund_olaparib_lynparza_oc.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fdk_azc.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_ptfdk.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_coi_occ.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fdk_clinician.pdf', '/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_coi_clinician.pdf']",Ovarian Cancer,Do not reimburse,Complete,01-Apr-16,29-Sep-16,PC0081-000
Zydelig for Follicular Lymphom...Opens in new tab,Zydelig,Idelalisib,"['/sites/default/files/pcodr/pcodr-provfund_idelalisib-zydelig-fl.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_in_rec.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fdk_gilead.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_ptfdk_lc.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_coi_lc.pdf']",Follicular Lymphoma,Do not reimburse,Complete,12-Apr-16,29-Sep-16,PC0075-000
Lenvima for Differentiated Thy...Opens in new tab,Lenvima,Lenvatinib,"['/sites/default/files/pcodr/pcodr-provfund_lenvatinib-lenvima-dtc.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fdk_eisailtd.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_coi_tcc.pdf', '/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_coi_clinicians.pdf']",Differentiated Thyroid Cancer,Reimburse with clinical criteria and/or conditions,Complete,18-Apr-16,20-Sep-16,PC0080-000
Opdivo for Metastatic Renal Ce...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr-provfund_nivolumab-opdivo-mrcc.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fdk_bms.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_ptfdk_kcc.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_coi_kcc.pdf']",Metastatic Renal Cell Carcinoma,Reimburse with clinical criteria and/or conditions,Complete,24-Feb-16,01-Sep-16,PC0074-000
Canagliflozin and metformin hy...Opens in new tab,Invokamet,Canagliflozin and metformin hydrochloride,"['/sites/default/files/cdr/tracking/cdr_SR0480_TBC.pdf', '/sites/default/files/cdr/complete/SR0480_complete_Invokamet-Aug-29-16.pdf', '/sites/default/files/cdr/complete/SR0480_Invokamet_Combination_Product_Subsmission_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0480_Invokamet_PI_Submissions.pdf']","diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,03-Mar-16,25-Aug-16,SR0480-000
ticagrelorOpens in new tab,Brilinta,ticagrelor,"['/sites/default/files/cdr/tracking/cdr_SR0474_Brilinta.pdf', '/sites/default/files/cdr/complete/SR0474_complete_Brilinta-Aug-29-16.pdf', '/sites/default/files/cdr/clinical/SR0474_Brilinta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0474_Brilinta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0474_Brilinta_PI_Submissions.pdf']",Prevention of atherothrombotic events with history of myocardial infarction,Reimburse with clinical criteria and/or conditions,Complete,18-Feb-16,25-Aug-16,SR0474-000
TesamorelinOpens in new tab,Egrifta,Tesamorelin,"['/sites/default/files/cdr/tracking/cdr_SR0477_Egrifta.pdf', '/sites/default/files/cdr/complete/SR0477_complete_Egrifta_Aug-26-16.pdf', '/sites/default/files/cdr/clinical/SR0477_Egrifta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0477_Egrifta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0477_Egrifta_PI_Submissions.pdf']","Lipodystrophy, HIV-infected patients",Do not reimburse,Complete,02-Mar-16,24-Aug-16,SR0477-000
Emtricitabine/tenofovir disopr...Opens in new tab,Truvada,Emtricitabine/tenofovir disoproxil fumarate,"['/sites/default/files/cdr/tracking/cdr_SR0479_Truvada.pdf', '/sites/default/files/cdr/complete/SR0479_complete_Truvada_Aug-26-16.pdf', '/sites/default/files/cdr/clinical/SR0479_Truvada_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0479_Truvada_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0479_Truvada_PI_Submissions.pdf']","HIV-1 infection, pre-exposure prophylaxis",Reimburse with clinical criteria and/or conditions,Complete,03-Mar-16,24-Aug-16,SR0479-000
Emtricitabine /tenofovir alafe...Opens in new tab,Descovy,Emtricitabine /tenofovir alafenamide,"['/sites/default/files/cdr/tracking/cdr_SR0470_TBC.pdf', '/sites/default/files/cdr/complete/SR0470_complete_Descovy-Aug-26-16.pdf', '/sites/default/files/cdr/clinical/SR0470_Descovy_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0470_Descovy_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0470_Descovy_PI_Submissions.pdf']",HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,29-Jan-16,24-Aug-16,SR0470-000
SecukinumabOpens in new tab,Cosentyx,Secukinumab,"['/sites/default/files/cdr/tracking/cdr_SR0475_Cosentyx_AS.pdf', '/sites/default/files/cdr/complete/SR0475_complete_Cosentyx_AS_Aug-25-16.pdf', '/sites/default/files/cdr/clinical/SR0475_CosentyxAS_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0475_CosentyxAS_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0475_CosentyxAS_PI_Submissions.pdf']",ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,19-Feb-16,23-Aug-16,SR0475-000
SecukinumabOpens in new tab,Cosentyx,Secukinumab,"['/sites/default/files/cdr/tracking/cdr_SR0476_Cosentyx_PsA.pdf', '/sites/default/files/cdr/complete/SR0476_complete_Cosentyx_PsA_Aug-25-16.pdf', '/sites/default/files/cdr/clinical/SR0476_CosentyxPsA_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0476_CosentyxPsA_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0476_CosentyxPsA_PI_Submissions.pdf']","Arthritis, psoriatic",Reimburse with clinical criteria and/or conditions,Complete,19-Feb-16,23-Aug-16,SR0476-000
Yondelis for Liposarcoma or Le...Opens in new tab,Yondelis,Trabectedin,"['/sites/default/files/pcodr/pcodr_provfund_trabectedin_yondelis_lipo-leio.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_in_rec.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_coi_scfc.pdf']",Metastatic Liposarcoma or Leiomyosarcoma,Do not reimburse,Complete,22-Dec-15,05-Aug-16,PC0071-000
AfliberceptOpens in new tab,Eylea,Aflibercept,"['/sites/default/files/cdr/tracking/SR0460%20Eylea.pdf', '/sites/default/files/cdr/complete/SR0460_Eylea%20BRVO_complete_Jul-29_16.pdf', '/sites/default/files/cdr/clinical/SR0460_Eylea_BRVO_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0460_Eylea_BRVO_PE_Report.pdf']","Macular edema, branch retinal vein occlusion",Reimburse with clinical criteria and/or conditions,Complete,14-Dec-15,27-Jul-16,SR0460-000
teduglutideOpens in new tab,Revestive,Teduglutide,"['/sites/default/files/cdr/tracking/cdr_SR0459_Revestive.pdf', '/sites/default/files/cdr/complete/SR0459_Revestive_complete_Jul-29_16.pdf', '/sites/default/files/cdr/clinical/SR0459_Revestive_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0459_Revestive_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0459_Revestive_PI_Submissions.pdf']",Short bowel syndrome,Reimburse with clinical criteria and/or conditions,Complete,26-Nov-15,27-Jul-16,SR0459-000
AsunaprevirOpens in new tab,Sunvepra,Asunaprevir,"['/sites/default/files/cdr/tracking/SR0418%20Sunvepra.pdf', '/sites/default/files/cdr/complete/SR0418_complete_Sunvepra_Jul-20_16.pdf', '/sites/default/files/cdr/clinical/SR0418_Sunvepra_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0418_Sunvepra_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0418_Sunvepra_PI_Submissions.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,13-Feb-15,20-Jul-16,SR0418-000
dapagliflozin/metformin hydroc...Opens in new tab,XigDuo,dapagliflozin/metformin hydrochloride,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0468_XigDuo.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0468_complete_Xigduo_Jul_20-16.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0468_XigDuo_PI_Submissions.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0468_XigDuo_FDC_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0468_XigDuo_Summary_f.pdf']","Diabetes Mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,07-Jan-16,20-Jul-16,SR0468-000
AlirocumabOpens in new tab,Praluent,Alirocumab,"['/sites/default/files/cdr/tracking/cdr_SR0469_Praluent.pdf', '/sites/default/files/cdr/complete/SR0469_complete_Praluent_Jul-20-16.pdf', '/sites/default/files/cdr/clinical/SR0469_Praluent_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0469_Praluent_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0469_Praluent_PI_Submissions.pdf']","Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia",Reimburse with clinical criteria and/or conditions,Complete,12-Jan-16,20-Jul-16,SR0469-000
Imbruvica for Mantle Cell Lymp...Opens in new tab,Imbruvica,Ibrutinib,"['/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica_mcl.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_ptfdk_lfc.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_ptfdk_llsc-ccsn.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_coi_lfc.pdf', '/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_coi_llsc-ccsn.pdf']",Mantle Cell Lymphoma (relapsed/refractory),Reimburse with clinical criteria and/or conditions,Complete,29-Jan-16,19-Jul-16,PC0073-000
Cotellic for Metastatic Melano...Opens in new tab,Cotellic,Cobimetinib,"['/sites/default/files/pcodr/pcodr_provfund_cobimetinib_cotellic_metmela.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_in_rec.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_ptgrpfdk.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_coi_mnc.pdf', '/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_coi_sysf.pdf']",Metastatic melanoma,Reimburse with clinical criteria and/or conditions,Complete,11-Dec-15,30-Jun-16,PC0070-000
Kyprolis (with lenalidomide) f...Opens in new tab,Kyprolis (with lenalidomide),Carfilzomib (with lenalidomide),"['/sites/default/files/pcodr/pcodr_profund_10067carfilzomib_kyprolis_lenalidomide_mm.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_in_rec.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fdk_amgen.pdf', '/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_coi_mc.pdf']",Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,11-Dec-15,21-Jun-16,PC0067-000
CanakinumabOpens in new tab,Ilaris,Canakinumab,"['/sites/default/files/cdr/tracking/cdr_SR0463_Ilaris.pdf', '/sites/default/files/cdr/clinical/SR0463_Ilaris_sJIA_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0463_Ilaris_sJIA_PE_Report.pdf', '/sites/default/files/cdr/complete/SR0463_complete_Ilaris_sJIA_June_21_16_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0463_Ilaris_SJIA_PI_Submissions.pdf']",Systemic Juvenile Idiopathic Arthritis,Reimburse with clinical criteria and/or conditions,Complete,23-Dec-15,17-Jun-16,SR0463-000
dulaglutideOpens in new tab,Trulicity,dulaglutide,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0462_Trulicity.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0462_complete_Trulicity_June_21_16_e.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/SR0462_Trulicity_CL_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0462_Trulicity_PE_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0462_Trulicity_PI_Submissions.pdf']","Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,22-Dec-15,16-Jun-16,SR0462-000
MepolizumabOpens in new tab,Nucala,Mepolizumab,"['/sites/default/files/cdr/tracking/cdr_SR0461_Nucala.pdf', '/sites/default/files/cdr/clinical/SR0461_Nucala_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0461_Nucala_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0461_complete_Nucala_June-20-16_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0461_Nucala_PI_Submissions.pdf']","Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,18-Dec-15,16-Jun-16,SR0461-000
Opdivo for Non-Small Cell Lung...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr_provfund_nivolumab_opdivo_nsclc.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_in_rec.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fdk_bms.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_nsclc_coi_lcc.pdf']",Metastatic non small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,29-Oct-15,03-Jun-16,PC0069-000
DenosumabOpens in new tab,Prolia,Denosumab,"['/sites/default/files/cdr/tracking/cdr_SF0453_Prolia.pdf', '/sites/default/files/cdr/complete/SF0453_complete_RFA-Prolia_May-25-16_e.pdf', '/sites/default/files/cdr/advice/SF0453_Prolia_RfA_Review_Report.pdf', '/sites/default/files/cdr/relatedinfo/SF0453%20Prolia_PI_Submissions.pdf']",Osteoporosis,Reimburse with clinical criteria and/or conditions,Complete,26-Oct-15,20-May-16,SF0453-000
Elosulfase alfaOpens in new tab,Vimizim,Elosulfase alfa,"['/sites/default/files/cdr/tracking/SR0456%20Vimizim%20Resubmission.pdf', '/sites/default/files/cdr/complete/SR0456_complete_Vimizim_May-26_16.pdf', '/sites/default/files/cdr/clinical/SR0456_Vimizim_Resubmission_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0456_Vimizim_Resubmission_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0456_Vimizim_Resubmission_PI_Submissions_Consolidated_validated.pdf']",Mucopolysaccharidosis IVA (Morquio A syndrome),Reimburse with clinical criteria and/or conditions,Complete,10-Nov-15,20-May-16,SR0456-000
Elbasvir/grazoprevirOpens in new tab,Zepatier,Elbasvir/grazoprevir,"['/sites/default/files/cdr/tracking/cdr_SR0454_grazoprevir_elbasvir.pdf', '/sites/default/files/cdr/complete/SR0454_complete_Zepatier_May_25-16.pdf', '/sites/default/files/cdr/clinical/SR0454_Zepatier_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0454_Zepatier_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0454_grazoprevir%2Belbasvir_PI_Submissions_Consolidated_validated.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,27-Oct-15,19-May-16,SR0454-000
ombitasvir/paritaprevir/ritona...Opens in new tab,Holkira Pak,ombitasvir/paritaprevir/ritonavir and dasabuvir,"['/sites/default/files/cdr/tracking/cdr_SF0466_Holkira_Pak.pdf', '/sites/default/files/cdr/complete/SF0466_complete_Holkira_Pak_May-25-16.pdf', '/sites/default/files/cdr/advice/SF0466_HolkiraPak_RfA_Review_Report.pdf', '/sites/default/files/cdr/relatedinfo/SF0466_HolkiraPak_RfA_PI_Submissions.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,06-Jan-16,19-May-16,SF0466-000
daclatasvirOpens in new tab,Daklinza,daclatasvir,"['/sites/default/files/cdr/tracking/cdr_SF0467_Daklinza.pdf', '/sites/default/files/cdr/complete/SF0467_complete_Daklinza_May_25-16.pdf', '/sites/default/files/cdr/advice/SF0467_Daklinza_RfA_Review_Report.pdf', '/sites/default/files/cdr/relatedinfo/SF0467_Daklinza_RfA_PI_Submissions.pdf']","Hepatitis C, Chronic",Reimburse with clinical criteria and/or conditions,Complete,06-Jan-16,19-May-16,SF0467-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/SR0455%20Humira%20HS.pdf', '/sites/default/files/cdr/complete/SR0455_complete_Humira-HS_May-24-16_e.pdf', '/sites/default/files/cdr/clinical/SR0455_HumiraHS_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0455_HumiraHS_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0455%20Humira%20HS%20-%20_PI_Submissions_Consolidated_validated.pdf']",Hidradenitis suppurativa,Reimburse with clinical criteria and/or conditions,Complete,03-Nov-15,19-May-16,SR0455-000
PerampanelOpens in new tab,Fycompa,Perampanel,"['/sites/default/files/cdr/tracking/SR0458%20Fycompa%20PGTCS%20.pdf', '/sites/default/files/cdr/complete/SR0458_complete_Fycompa_May-20-16_e.pdf', '/sites/default/files/cdr/clinical/SR0458_Fycompa_PGTCS_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0458_Fycompa_PE.pdf', '/sites/default/files/cdr/relatedinfo/SR0458_Fycompa_PI_Submissions_Consolidated_validated.pdf']","Epilepsy, primary generalized tonic-clonic seizures",Reimburse with clinical criteria and/or conditions,Complete,24-Nov-15,18-May-16,SR0458-000
"ledipasvir, sofosbuvirOpens in new tab",Harvoni,"ledipasvir, sofosbuvir","['/sites/default/files/cdr/relatedinfo/SF0465%20Harvoni.pdf', '/sites/default/files/cdr/complete/SF0465_complete_Harvoni%20RFA_May_19-16.pdf', '/sites/default/files/cdr/relatedinfo/SF0465_Harvoni_Hep_C_RfA_PI_Submissions.pdf', '/sites/default/files/cdr/relatedinfo/SF0465_Harvoni_RfA_Review_Report.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,06-Jan-16,18-May-16,SF0465-000
sofosbuvirOpens in new tab,Sovaldi,sofosbuvir,"['/sites/default/files/cdr/tracking/cdr_SF0464_Sovaldi.pdf', '/sites/default/files/cdr/complete/SF0464_complete_Sovaldi-May_19_16.pdf', '/sites/default/files/cdr/advice/SF0464_Sovaldi_RfA_Review_Report.pdf', '/sites/default/files/cdr/relatedinfo/SF0464_Sovaldi_RFA_PI_Submissions.pdf']","Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,06-Jan-16,18-May-16,SF0464-000
Omalizumab (Drug Plan Submissi...Opens in new tab,Xolair,Omalizumab (Drug Plan Submission),"['/sites/default/files/cdr/tracking/cdr_SR0457_Xolair_Resub.pdf', '/sites/default/files/cdr/complete/SR0457_complete_Xolair_Resub-May_19_16.pdf', '/sites/default/files/cdr/relatedinfo/SR0457_Xolair_Resub_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0457_Xolair_Resubmission_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0457_Xolair_Resubmission_PE_Report_e.pdf']","Asthma, severe persistent",Reimburse with clinical criteria and/or conditions,Complete,18-Nov-15,18-May-16,SR0457-000
Avastin for Platinum-Resistant...Opens in new tab,Avastin,Bevacizumab,"['/sites/default/files/pcodr/pcodr-provfund_bevacizumab_avastin_proc.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc-in_rec.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_ptfdk_occ.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_coi_occ.pdf']",Platinum Resistant Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,29-Oct-15,05-May-16,PC0066-000
DapagliflozinOpens in new tab,Forxiga,Dapagliflozin,"['/sites/default/files/cdr/tracking/cdr_SR0445_Forxiga.pdf', '/sites/default/files/cdr/complete/SR0445_complete_Forxiga-May_2_16-e.pdf', '/sites/default/files/cdr/clinical/SR0445_Forxiga_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0445_Forxiga_PE_Report.pdf']","Diabetes mellitus, type 2",Do not list,Complete,04-Sep-15,27-Apr-16,SR0445-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/cdr_SR0450_Humira.pdf', '/sites/default/files/cdr/complete/SR0450_complete_Humira-Apr-19-16_e.pdf', '/sites/default/files/cdr/clinical/SR0450_Humira_UC_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0450_Humira_UC_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0450_Humira_UC_PI_Submissions.pdf']",Ulcerative colitis,Do not list at the submitted price,Complete,25-Sep-15,15-Apr-16,SR0450-000
Sodium phenylbutyrateOpens in new tab,Pheburane,Sodium phenylbutyrate,"['/sites/default/files/cdr/tracking/SR0452%20Pheburane.pdf', '/sites/default/files/cdr/complete/SR0452_complete_Pheburane-Apr-25_16-e.pdf', '/sites/default/files/cdr/clinical/SR0452_Pheburane_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0452_Pheburane_PE_Report.pdf']",Urea cycle disorders,List,Complete,20-Oct-15,15-Apr-16,SR0452-000
Insulin glargineOpens in new tab,Basaglar,Insulin glargine,"['/sites/default/files/cdr/tracking/cdr_SE0451_Basaglar.pdf', '/sites/default/files/cdr/complete/SE0451_complete_Basaglar-Apr_19-16-e.pdf', '/sites/default/files/cdr/relatedinfo/SE0451_Basaglar_PI_Submissions.pdf', '/sites/default/files/cdr/seb/SE0451_Basaglar_SEB_Report.pdf']","Diabetes mellitus, type 1; diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,05-Oct-15,14-Apr-16,SE0451-000
Blinatumomab (Blincyto) for Ph...Opens in new tab,Blincyto,Blinatumomab,"['/sites/default/files/pcodr/pcodr_profund_blinatumomab_blincyto_all.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_fn_rec.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_fn_cgr.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_in_rec.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_pagfdk.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_fdk_amgen.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_ptfdk_ccsn.pdf', '/sites/default/files/pcodr/blinatumomab_blincyto_all_coi_ccsn.pdf']",Acute Lymphoblastic Leukemia,Reimburse with clinical criteria and/or conditions,Complete,24-Aug-15,01-Apr-16,PC0064-000
Opdivo for Metastatic Melanoma...Opens in new tab,Opdivo,Nivolumab,"['/sites/default/files/pcodr/pcodr_provfund_nivolumab_opdivo_metmela.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_fn_rec.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_fn_cgr.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_nivolumab_opdivo_metmela_in_rec.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_pagfdk.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_fdk_bms.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_ptfdk_mnc.pdf', '/sites/default/files/pcodr/nivolumab_opdivo_mm_coi_mnc.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,13-Aug-15,01-Apr-16,PC0063-000
Denosumab (Drug Plan Submissio...Opens in new tab,Xgeva,Denosumab (Drug Plan Submission),"['/sites/default/files/cdr/tracking/cdr_SR0433-001_Xgeva.pdf', '/sites/default/files/cdr/complete/SR0433-001_complete_Xgeva_OST-Mar-28_16-e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0433-001%20Xgeva_FWG_OST_PE_Report.pdf', '/sites/default/files/cdr/clinical/SR0433-001%20Xgeva_FWG_OST_CL_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0433-001_Xgeva_PI_Submissions.pdf']","Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer",List with clinical criteria and/or conditions,Complete,31-Jul-15,23-Mar-16,SR0433-001
Asfotase alfaOpens in new tab,Strensiq,Asfotase alfa,"['/sites/default/files/cdr/tracking/cdr_SR0443_Strensiq.pdf', '/sites/default/files/cdr/complete/SR0443_complete_Strensiq-Apr-4-16_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0443%20Strensiq%20_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0443_Strensiq_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0443_Strensiq_PE_Report.pdf']","Hypophosphatasia, pediatric-onset",List with criteria/condition,Complete,21-Aug-15,23-Mar-16,SR0443-000
FilgrastimOpens in new tab,Grastofil,Filgrastim,"['/sites/default/files/cdr/tracking/cdr_SE0446_Grastofil.pdf', '/sites/default/files/cdr/complete/SE0446_cdr_complete_Grastofil_March-22-16_e.pdf', '/sites/default/files/cdr/seb/SE0446_Grastofil_SEB_Report.pdf', '/sites/default/files/cdr/relatedinfo/SE0446_Grastofil_PI_Submissions.pdf']",Neutropenia,List with clinical criteria and/or conditions,Complete,11-Sep-15,18-Mar-16,SE0446-000
DeferiproneOpens in new tab,Ferriprox,Deferiprone,"['/sites/default/files/cdr/tracking/cdr_SR0448_Ferriprox.pdf', '/sites/default/files/cdr/complete/SR0448_cdr_complete_Ferriprox_March-23-16_e.pdf', '/sites/default/files/cdr/clinical/SR0448_Ferriprox_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0448_Ferriprox_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0448_Ferriprox_PI_Submissions.pdf']",Transfusional iron overload,List with clinical criteria and/or conditions,Complete,24-Sep-15,18-Mar-16,SR0448-000
Elvitegravir/cobicistat/emtric...Opens in new tab,Genvoya,Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide,"['/sites/default/files/cdr/tracking/cdr_SR0449_ECFTAF.pdf', '/sites/default/files/cdr/clinical/SR0449_Genvoya_CL_Report-e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0449_Genvoya_PE_Report-e.pdf', '/sites/default/files/cdr/complete/SR0449_complete_Genvoya-March_22-16_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0449%20Genvoya_PI_Submissions.pdf']",HIV infection,List,Complete,24-Sep-15,18-Mar-16,SR0449-000
Sacubitril/valsartanOpens in new tab,Entresto,Sacubitril/valsartan,"['/sites/default/files/cdr/tracking/cdr_SR0447_sacubitril_valsartan.pdf', '/sites/default/files/cdr/complete/SR0447_complete_Entresto-Mar-22_e.pdf', '/sites/default/files/cdr/clinical/SR0447_Entresto_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0447_Entresto_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0447%20Entresto%20Template_PI_Submissions_Consolidated_validated.pdf']","Heart failure, NYHA class II or III",List with clinical criteria and/or conditions,Complete,18-Sep-15,18-Mar-16,SR0447-000
Ombitasvir/ paritaprevir/ rito...Opens in new tab,Technivie,Ombitasvir/ paritaprevir/ ritonavir,"['/sites/default/files/cdr/tracking/cdr_SR0444_ombitasvir-paritaprevir-ritonavir.pdf', '/sites/default/files/cdr/complete/SR0444_cdr_complete_Technivie_March-23-16_e.pdf', '/sites/default/files/cdr/clinical/SR0444_Technivie_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0444_Technivie_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0444%20Technivie%20-%20PI_Submissions_Consolidated_validated.pdf']","Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,04-Sep-15,18-Mar-16,SR0444-000
Jakavi for Polycythemia Vera -...Opens in new tab,Jakavi,Ruxolitinib,"['/sites/default/files/pcodr/pcodr_profund_ruxolitinib_jakavi_pv.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_ptfdk_mpn.pdf', '/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_coi_mpn.pdf']",Polycythemia vera,Reimburse with clinical criteria and/or conditions,Complete,27-Aug-15,03-Mar-16,PC0065-000
Denosumab  (Drug Plan Submissi...Opens in new tab,Xgeva,Denosumab  (Drug Plan Submission),"['/sites/default/files/cdr/tracking/SR0433-000%20Xgeva.pdf', '/sites/default/files/cdr/complete/SR0433-000_complete_Xgeva_BC-Mar_1_16_e.pdf', '/sites/default/files/cdr/clinical/SR0433_000_XgevaBC_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0433_000_XgevaBC_PE_Report.pdf']",Prevention of skeletal-related events due to bone metastases from breast cancer,List with clinical criteria and/or conditions,Complete,31-Jul-15,25-Feb-16,SR0433-000
TolvaptanOpens in new tab,Jinarc,Tolvaptan,"['/sites/default/files/cdr/tracking/SR0435%20Jinarc.pdf', '/sites/default/files/cdr/complete/SR0435_complete_Jinarc-Feb_26_16_e.pdf', '/sites/default/files/cdr/clinical/SR0435_Jinarc_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0435_Jinarc_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0435%20Jinarc%20Template_PI_Submissions.pdf']",Autosomal dominant polycystic kidney disease,Do not list,Complete,29-May-15,24-Feb-16,SR0435-000
Galsulfase (Drug Plan Submissi...Opens in new tab,Naglazyme,Galsulfase (Drug Plan Submission),"['/sites/default/files/cdr/tracking/cdr_SR0434_Naglazyme.pdf', '/sites/default/files/cdr/complete/SR0434_complete_Naglazyme-Feb-23_16_e.pdf', '/sites/default/files/cdr/clinical/SR0434_Naglazyme_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0434_Naglazyme_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0434_Naglazyme_PI_Submissions.pdf']",Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),List with clinical criteria and/or conditions,Complete,20-Aug-15,19-Feb-16,SR0434-000
EvolocumabOpens in new tab,Repatha,Evolocumab,"['/sites/default/files/cdr/tracking/cdr_SR0441_Repatha.pdf', '/sites/default/files/cdr/complete/SR0441_complete_Rapatha-Feb-23_16_e.pdf', '/sites/default/files/cdr/clinical/SR0441_Repatha_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0441_Repatha_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0441_Repatha_PI_Submissions.pdf']",Primary hyperlipidemia; mixed dyslipidemia,List with clinical criteria and/or conditions,Complete,30-Jun-15,19-Feb-16,SR0441-000
Fluticasone Furoate and Vilant...Opens in new tab,Breo Ellipta,Fluticasone Furoate and Vilanterol (as trifenatate),"['/sites/default/files/cdr/tracking/cdr_SR0442_Breo-Ellipta.pdf', '/sites/default/files/cdr/complete/SR0442_complete_Breo%20Ellipta-Feb-22-16_e.pdf', '/sites/default/files/cdr/clinical/SR0442_BreoEllipta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0442_BreoEllipta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0442_BreoEllipta_PI_Submissions.pdf']",Asthma,List with clinical criteria and/or conditions,Complete,10-Aug-15,18-Feb-16,SR0442-000
ApremilastOpens in new tab,Otezla,Apremilast,"['/sites/default/files/cdr/tracking/cdr_SR0437_Otezla_PsA.pdf', '/sites/default/files/cdr/complete/SR0437_complete_Otezla_PsA-Dec-21-15_e.pdf', '/sites/default/files/cdr/clinical/SR0437_OtezlaPsA_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0437_OtezlaPsA_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0437_OtezlaPsA_PI_Submissions.pdf']","Arthritis, psoriatic",List with criteria/condition,Complete,08-Jun-15,17-Dec-15,SR0437-000
Fluticasone furoateOpens in new tab,Arnuity Ellipta,Fluticasone furoate,"['/sites/default/files/cdr/tracking/cdr_SR0439_fluticasone_furoate.pdf', '/sites/default/files/cdr/complete/SR0439_complete_Arnuity-Ellipta-Dec-21-15_e.pdf', '/sites/default/files/cdr/clinical/SR0439_Arnuity_Ellipta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0439_Arnuity_Ellipta_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0439_Arnuity_Ellipta_PI_Submissions.pdf']",Asthma,List with criteria/condition,Complete,26-Jun-15,17-Dec-15,SR0439-000
Tiotropium / olodaterolOpens in new tab,Inspiolto Respimat,Tiotropium / olodaterol,"['/sites/default/files/cdr/tracking/cdr_SR0436_Inspiolto_Respimat.pdf', '/sites/default/files/cdr/complete/SR0436_complete_Inspiolto-Respimat-Dec_21-15-e.pdf', '/sites/default/files/cdr/clinical/SR0436_Inspiolto_Respimat_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0436_Inspiolto_Respimat_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0436_Inspiolto_Respimat_PI_Submissions.pdf']",Chronic obstructive pulmonary disease,List with criteria/condition,Complete,04-Jun-15,17-Dec-15,SR0436-000
RiociguatOpens in new tab,Adempas,Riociguat,"['/sites/default/files/cdr/tracking/cdr_SR0438_Adempas-PAH.pdf', '/sites/default/files/cdr/complete/SR0438_complete_Adempas-Dec-21-15_e.pdf', '/sites/default/files/cdr/clinical/SR0438_Adempas_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0438_Adempas_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0438_Adempas_PI_Submissions.pdf']",Pulmonary arterial hypertension (WHO group 1),List with clinical criteria and/or conditions,Complete,25-Jun-15,17-Dec-15,SR0438-000
Peginterferon beta-1aOpens in new tab,Plegridy,Peginterferon beta-1a,"['/sites/default/files/cdr/tracking/SR0440%20Plegridy.pdf', '/sites/default/files/cdr/complete/SR0440_complete_Plegridy-Dec-21-15_e.pdf', '/sites/default/files/cdr/clinical/SR0440_Plegridy_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0440_Plegridy_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0440_Plegridy%20Patient%20Input%20Submission.pdf']","Multiple sclerosis, relapsing-remitting",List with criteria/condition,Complete,26-Jun-15,17-Dec-15,SR0440-000
Vectibix for mCRC – DetailsOpens in new tab,Vectibix,Panitumumab,"['/sites/default/files/pcodr/pcodr_provfund_panitumumab_vectibix_mcrc.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fdk_amgen.pdf', '/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_coi_ccac.pdf']",Metastatic Colorectal Cancer,Reimburse with clinical criteria and/or conditions,Complete,15-Apr-15,03-Dec-15,PC0060-000
Revlimid for Newly Diagnosed M...Opens in new tab,Revlimid,Lenalidomide,"['/sites/default/files/pcodr/pcodr_provfund_lenalidomide_revlimid_nd-mm.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_mm_in_rec.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fdk_celgene.pdf', '/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_coi_mc.pdf']","Multiple Myeloma, newly diagnosed",Reimburse with clinical criteria and/or conditions,Complete,04-May-15,03-Dec-15,PC0061-000
Zykadia for Metastatic Non-Sma...Opens in new tab,Zykadia,Ceritinib,"['/sites/default/files/pcodr/pcodr_provfund_ceritinib_zykadia_nsclc.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_ptfdk_lcc.pdf', '/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_coi_lcc.pdf']",Metastatic Non-Small Cell Lung Cancer,Do not reimburse,Complete,05-Jun-15,03-Dec-15,PC0062-000
DapagliflozinOpens in new tab,Forxiga,Dapagliflozin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0370_Invokana.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0428_complete_Forxiga_Nov-24-15_e.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/SR0428_Forxiga_CL_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0428_Forxiga_PE_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0428%20Forxiga_PI_Submissions_Consolidated_validated.pdf']","Diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,30-Apr-15,20-Nov-15,SR0428-000
IvermectinOpens in new tab,Rosiver,Ivermectin,"['/sites/default/files/cdr/tracking/SR0429%20Rosiver.pdf', '/sites/default/files/cdr/complete/SR0429_complete_Rosiver_Nov-23-15_e.pdf', '/sites/default/files/cdr/clinical/SR0429_Rosiver_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0429_Rosiver_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0429%20Rosiver_PI_Submissions_Consolidated_validated.pdf']",Rosacea,List with criteria/condition,Complete,30-Apr-15,19-Nov-15,SR0429-000
IvacaftorOpens in new tab,Kalydeco,Ivacaftor,"['/sites/default/files/cdr/tracking/cdr_SR0430_Kalydeco_R117H.pdf', '/sites/default/files/cdr/complete/SR0430_complete_Kalydeco_R117H_Nov-23-15_e.pdf', '/sites/default/files/cdr/clinical/SR0430_KalydecoR117H_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0430_KalydecoR117H_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0430_KalydecoR117H_PI_Submissions.pdf']","Cystic fibrosis, R117H CFTR gating mutation",List with criteria/condition,Complete,08-May-15,19-Nov-15,SR0430-000
RotigotineOpens in new tab,Neupro,Rotigotine,"['/sites/default/files/cdr/tracking/cdr_SR0432_Neupro_Resubmission.pdf', '/sites/default/files/cdr/complete/SR0432_complete_Neupro_Resb_Nov-24-15_e.pdf', '/sites/default/files/cdr/clinical/SR0432_Neupro_CL_Report_resub.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0432_Neupro_PE_Report_resub.pdf', '/sites/default/files/cdr/relatedinfo/SR0432_Neupro_PI_Submissions.pdf']",Parkinson’s disease,List with clinical criteria and/or conditions,Complete,21-May-15,19-Nov-15,SR0432-000
Keytruda for Metastatic Melano...Opens in new tab,Keytruda,Pembrolizumab,"['/sites/default/files/pcodr/pcodr_provfund_pembrolizumab_keytruda_mm.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fdk-merck.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_ptfdk_sysf.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_ptfdk_mnc.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_coi_sysf.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_coi_mnc.pdf', '/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_coi_cspa.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,16-Apr-15,16-Nov-15,PC0058-000
Cyramza for Advanced GC or GEJ...Opens in new tab,Cyramza,Ramucirumab,"['/sites/default/files/pcodr/pcodr_profund_ramucirumab_cyramza_gc.pdf', '/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc-pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc-fdk-elc.pdf']",Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,15-Apr-15,29-Oct-15,PC0059-000
SecukinumabOpens in new tab,Cosentyx,Secukinumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/tracking/cdr_SR0407_Cosentyx.pdf', '/sites/default/files/cdr/complete/SR0407_Cosentyx_Oct-30-15.pdf', '/sites/default/files/cdr/clinical/SR0407_Cosentyx_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0407_Cosentyx_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0407_Cosentyx_PI_Submissions.pdf']",Plaque psoriasis,List with criteria/condition,Complete,08-Dec-14,28-Oct-15,SR0407-000
VedolizumabOpens in new tab,Entyvio,Vedolizumab,"['/sites/default/files/cdr/tracking/cdr_SR0421_Entyvio.pdf', '/sites/default/files/cdr/complete/SR0421_cdr_complete_Entyvio_Nov-2-15_e.pdf', '/sites/default/files/cdr/clinical/SR0421_Entyvio_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0421_Entyvio_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0421_Entyvio_PI_Submissions.pdf']",Ulcerative colitis,List with clinical criteria and/or conditions,Complete,20-Feb-15,28-Oct-15,SR0421-000
Taliglucerase alfaOpens in new tab,Elelyso,Taliglucerase alfa,"['/sites/default/files/cdr/tracking/cdr_SR0390_Elelyso.pdf', '/sites/default/files/cdr/complete/SR0390_Elelyso_Oct-30-15.pdf', '/sites/default/files/cdr/clinical/SR0390_Elelyso_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0390_Elelyso_PE_Report.pdf']",Gaucher disease,Do not list,Complete,15-Aug-14,28-Oct-15,SR0390-000
NintedanibOpens in new tab,Ofev,Nintedanib,"['/sites/default/files/cdr/tracking/cdr_SR0426_Ofev.pdf', '/sites/default/files/cdr/complete/SR0426_Ofev_Oct-19-15.pdf', '/sites/default/files/cdr/clinical/SR0426_Ofev_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0426_Ofev_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0426_Ofev_PI_Submissions.pdf']",Idiopathic pulmonary fibrosis,List with clinical criteria and/or conditions,Complete,23-Apr-15,15-Oct-15,SR0426-000
EmpagliflozinOpens in new tab,Jardiance,Empagliflozin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0427%20Jardiance.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/sr0427_jardiance_oct-19-15.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/SR0427_Jardiance_CL_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0427_Jardiance_PE_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0427_Jardiance_PI_Submissions.pdf']","Diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,23-Apr-15,15-Oct-15,SR0427-000
Iclusig for Chronic Myeloid Le...Opens in new tab,Iclusig,Ponatinib,"['/sites/default/files/pcodr/pcodr_provfund_iclusig_cml-all.pdf', '/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml_all_in_rec.pdf', '/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fdk_ariad.pdf']",Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia,Reimburse with clinical criteria and/or conditions,Complete,13-Mar-15,01-Oct-15,PC0056 -000
LinaclotideOpens in new tab,Constella,Linaclotide,"['/sites/default/files/cdr/tracking/cdr_SR0409_Constella.pdf', '/sites/default/files/cdr/complete/SR0409_Constella_%20Sept_25-15.pdf', '/sites/default/files/cdr/clinical/SR0409_Constella_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0409_Constella_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0409_Constella_PI_Submissions.pdf']",Irritable bowel syndrome with constipation,Do not list,Complete,17-Dec-14,23-Sep-15,SR0409-000
DaclatasvirOpens in new tab,Daklinza,Daclatasvir,"['/sites/default/files/cdr/tracking/cdr_SR0417_Daklinza.pdf', '/sites/default/files/cdr/complete/SR0417_cdr_complete_Daklinza_Sept-23-15_e.pdf', '/sites/default/files/cdr/clinical/SR0417_Daklinza_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0417_Daklinza_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0417%20Daklinza_PI_Submissions.pdf']","Hepatitis C, Chronic",List with clinical criteria and/or conditions,Complete,13-Feb-15,21-Sep-15,SR0417-000
Denosumab (Drug Plan Submissio...Opens in new tab,Prolia,Denosumab (Drug Plan Submission),"['/sites/default/files/cdr/tracking/cdr_SR0414_Prolia-Men.pdf', '/sites/default/files/cdr/complete/SR0414_cdr_complete_Prolia-Men_Sept-21-15-e.pdf', '/sites/default/files/cdr/clinical/SR0414_ProliaMen_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0414_ProliaMen_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0414_ProliaMen_PI_Submissions.pdf']","Osteoporosis, men",List with clinical criteria and/or conditions,Complete,10-Mar-15,21-Sep-15,SR0414-000
UmeclidiniumOpens in new tab,Incruse Ellipta,Umeclidinium,"['/sites/default/files/cdr/tracking/cdr_SR0422_Incruse-Ellipta.pdf', '/sites/default/files/cdr/complete/SR0422_Incruse_Ellipta_Sept-22-15.pdf', '/sites/default/files/cdr/clinical/SR0422_Incruse_Ellipta_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0422_Incruse_Ellipta_PE_Report.pdf']",Chronic obstructive pulmonary disease,List with criteria/condition,Complete,04-Mar-15,18-Sep-15,SR0422-000
Aclidinium bromide/formoterol ...Opens in new tab,Duaklir Genuair,Aclidinium bromide/formoterol fumarate dihydrate,"['/sites/default/files/cdr/tracking/cdr_SR0423_Duaklir_Genuair.pdf', '/sites/default/files/cdr/complete/SR0423_Duaklir_Genuair_Sept-22-15-e.pdf', '/sites/default/files/cdr/relatedinfo/SR0423_DuaklirGenuair_PI.pdf', '/sites/default/files/cdr/relatedinfo/SR0423_DuaklirGenuair_FDC_Report.pdf']",Chronic obstructive pulmonary disease,List with clinical criteria and/or conditions,Complete,01-Apr-15,18-Sep-15,SR0423-000
Zydelig for Chronic Lymphocyti...Opens in new tab,Zydelig,Idelalisib,"['/sites/default/files/pcodr/pcodr-provfund_idelalisib-zydelig-cll.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_fn_egr.pdf', '/sites/default/files/pcodr/Idelalisib%20Initial%20Recommendation_%202015-07-30_AC_30July2015_FinalPost.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_API.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_ptfdk_lc.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_coi_lc.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_ptfdk_cllpag_llsc.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_coi_cllpag.pdf', '/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_coi_llsc.pdf']",Chronic lymphocytic leukemia,Reimburse with clinical criteria and/or conditions,Complete,07-Apr-15,18-Aug-15,PC0057-000
ApremilastOpens in new tab,Otezla,Apremilast,"['/sites/default/files/cdr/tracking/cdr_SR0400_Otezla.pdf', '/sites/default/files/cdr/complete/SR0400-Otezla-Aug-10-15-e.pdf', '/sites/default/files/cdr/clinical/SR0400_Otezla_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0400_Otezla_PE_Report.pdf']",Plaque psoriasis,Do not list,Complete,08-Oct-14,22-Jul-15,SR0400-000
Xalkori Resubmission for First...Opens in new tab,Xalkori,Crizotinib,"['/sites/default/files/pcodr/pcodr-provfund_xalkori_nsclc1stline.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fdk_pfizer.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_coi_ola.pdf', '/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_coi_lcc.pdf']",First Line ALK Positive Advanced NSCLC,Reimburse with clinical criteria and/or conditions,Complete,17-Feb-15,21-Jul-15,PC0054-000
Tafinlar &amp; Mekinist in com...Opens in new tab,Tafinlar & Mekinist in combo,Dabrafenib & Trametinib in combo,"['/sites/default/files/pcodr/pcodr-provfund_tafinlarmekinist_melanoma.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_in_rec.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fdk_gsm.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_ptfdk_mnc.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_ptfdk_sysf.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_coi_mnc.pdf', '/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_coi_sysf.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,13-Feb-15,21-Jul-15,PC0053-000
Avastin (with capecitabine) fo...Opens in new tab,Avastin (with capecitabine),Bevacizumab,"['/sites/default/files/pcodr/pcodr_provfund_avastin-capecitabine_mcrc.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_ptfdk_ccac.pdf', '/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_coi_ccac.pdf']",Metastatic Colorectal Cancer,Reimburse with clinical criteria and/or conditions,Complete,18-Feb-15,21-Jul-15,PC0055-000
Tiotropium bromideOpens in new tab,Spiriva Respimat,Tiotropium bromide,"['/sites/default/files/cdr/relatedinfo/SR0412%20Spiriva%20Respimat.pdf', '/sites/default/files/cdr/complete/SR0412-complete-Spiriva-Respimat-July-20-15-e.pdf', '/sites/default/files/cdr/clinical/SR0412_SpirivaRespimat_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0412_SpirivaRespimat_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0412_SpirivaRespimat_PI_Submissions.pdf']",Chronic obstructive pulmonary disease,List with clinical criteria and/or conditions,Complete,23-Dec-14,16-Jul-15,SR0412-000
Nexavar for Metastatic Progres...Opens in new tab,Nexavar,Sorafenib,"['/sites/default/files/pcodr/pcodr-provfund_sorafenib_nexavar_dtc.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fdk_bayer.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_ptfdk_tcc.pdf', '/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_coi_tcc.pdf']",Metastatic Progressive Differentiated Thyroid Carcinoma (DTC),Do not reimburse,Complete,19-Dec-14,16-Jul-15,PC0049-000
Perjeta or Perjeta-Herceptin C...Opens in new tab,Perjeta or Perjeta-Herceptin Combo Pack,Pertuzumab,"['/sites/default/files/pcodr/pcodr-provfund_pertuzumab_perjeta_nbc.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fdk_roche.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_ptfdk_cbcn.pdf', '/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_coi_cbcn.pdf']",Neoadjuvant Breast Cancer,Do not reimburse,Complete,19-Dec-14,16-Jul-15,PC0050-000
Stivarga Resubmission for mCRC...Opens in new tab,Stivarga Resubmission (CRC),Regorafenib,"['/sites/default/files/pcodr/pcodr-provfund_regorafenib_stivarga-resub_mcrc.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fdk_bayer.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_ptfdk_ccac.pdf', '/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_coi_ccac.pdf']",Metastatic Colorectal Cancer,Do not reimburse,Complete,19-Dec-14,16-Jul-15,PC0046-000
Xtandi First Line mCRPC - Deta...Opens in new tab,Xtandi,Enzalutamide,"['/sites/default/files/pcodr/pcodr-provfund_xtandi_mcrpc1stline.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_egr.pdf', '/sites/default/files/pcodr_enzalutamide_xtandi_1stln_mcrcp_in_rec.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fdbk_astellas.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_ptfdk_pcc.pdf', '/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_coi_pcc.pdf']",First Line Metastatic Castration-Resistant Prostate Cancer,Reimburse with clinical criteria and/or conditions,Complete,02-Oct-14,22-Jun-15,PC0044-000
Proleukin for In-transit Melan...Opens in new tab,Proleukin,Aldesleukin (IL-2),"['/sites/default/files/pcodr/pcodr-provfund_proleukin-melanoma.pdf', '/sites/default/files/pcodr/pcodr_aldesleukin_proleukin_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_fn_egr.pdf', '/sites/default/files/pcodr/pcodr-aldesleukin-proleukin-in-transit-melanoma-in-rec.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_pagfdk_0.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_fdk_novartis.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_ptfdk_mnc.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_coi_mnc.pdf', '/sites/default/files/pcodr/pcodr_adesleukin_proleukin_coi_sysf.pdf']",In-transit Melanoma,Reimburse,Complete,30-Jan-15,22-Jun-15,PC0051-000
Sylvant Multicentric Castleman...Opens in new tab,Sylvant,Siltuximab,"['/sites/default/files/pcodr/pcodr_provfund_sylvant_mcd.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_in_rec.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fdk_janssen.pdf', '/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_coi_cord.pdf']",Multicentric Castleman's disease (MCD),Reimburse with clinical criteria and/or conditions,Complete,30-Jan-15,22-Jun-15,PC0052-000
AlemtuzumabOpens in new tab,Lemtrada,Alemtuzumab,"['/sites/default/files/cdr/tracking/cdr_SR0405_Lemtrada.pdf', '/sites/default/files/cdr/complete/cdr-complete-SR0405-Lemtrada-June-22-2015.pdf', '/sites/default/files/cdr/clinical/SR0405_Lemtrada_RRMS_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0405_Lemtrada_RRMS_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0405%20Lemtrada_RRMS_PI_Submissions.pdf']","Multiple sclerosis, relapsing-remitting",List with criteria/condition,Complete,27-Nov-14,18-Jun-15,SR0405-000
Ombitasvir/paritaprevir/ritona...Opens in new tab,Holkira Pak,Ombitasvir/paritaprevir/ritonavir and dasabuvir,"['/sites/default/files/cdr/tracking/SR0406%20Holkira%20Pak.pdf', '/sites/default/files/cdr/complete/SR0406-Holkira-Pak-July-22-15-e.pdf', '/sites/default/files/cdr/clinical/SR0406_HolkiraPak_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0406_HolkiraPak_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0406_HolkiraPak_PI_Submissions.pdf']","Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,03-Dec-14,18-Jun-15,SR0406-000
Brinzolamide / brimonidineOpens in new tab,Simbrinza,Brinzolamide / brimonidine,"['/sites/default/files/cdr/tracking/cdr_SR0403_Simbrinza.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0403_Simbrinza_June-19_2015.pdf', '/sites/default/files/cdr/relatedinfo/SR0403_Simbrinza_PI_Submissions.pdf', '/sites/default/files/cdr/relatedinfo/SR0403_Simbrinza_FDC_Review_Report.pdf']",Glaucoma and ocular hypertension,List,Complete,03-Nov-14,17-Jun-15,SR0403-000
Azelastine  HCl and fluticason...Opens in new tab,Dymista,Azelastine  HCl and fluticasone propionate,"['/sites/default/files/cdr/tracking/cdr_SR0408_Dymista.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0408_Dymista_June-19-2015.pdf', '/sites/default/files/cdr/clinical/SR0408_Dymista_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0408_Dymista_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0408_Dymista_PI_Submissions.pdf']",Seasonal allergic rhinitis,Do not list,Complete,09-Dec-14,17-Jun-15,SR0408-000
Avastin for Ovarian Cancer - D...Opens in new tab,Avastin,Bevacizumab,"['/sites/default/files/pcodr/pcodr_provfund_avastin-oc.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc-fn_rec.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc-fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc-fn_egr.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_in_rec.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_fdk_hlroche.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_ptfdk_occ.pdf', '/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_coi_occ_0.pdf']",Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,28-Nov-14,04-Jun-15,PC0047-000
Istodax for Peripheral T-Cell ...Opens in new tab,Istodax,Romidepsin,"['/sites/default/files/pcodr/pcodr_provfund_istodax_ptcl.pdf', '/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_in_rec.pdf', '/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fdk_celgene.pdf']",Peripheral T-Cell Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,01-Dec-14,19-May-15,PC0048-000
AfliberceptOpens in new tab,Eylea,Aflibercept,"['/sites/default/files/cdr/tracking/cdr_SR0401_Eylea_CRVO.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0401_Eylea-CRVO_May-11-15.pdf', '/sites/default/files/cdr/clinical/SR0401_EyleaCRVO_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0401_EyleaCRVO_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0401_EyleaCRVO_PI_Submissions.pdf']","Macular edema, central retinal vein occlusion",List with clinical criteria and/or conditions,Complete,17-Oct-14,07-May-15,SR0401-000
ApixabanOpens in new tab,Eliquis,Apixaban,"['/sites/default/files/cdr/tracking/cdr_SR0397_Eliquis_VTE.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0397_Eliquis-VTE_May-11-15.pdf', '/sites/default/files/cdr/clinical/SR0397_EliquisVTE_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0397_EliquisVTE_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0397_Eliquis_VTE_PI_Submissions.pdf']","Venous thromboembolic events, treatment and prevention of recurrence",List with clinical criteria and/or conditions,Complete,18-Sep-14,07-May-15,SR0397-000
OmalizumabOpens in new tab,Xolair,Omalizumab,"['/sites/default/files/cdr/tracking/cdr_SR0398_Xolair_CIU.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0398_Xolair-CIU_May-11-15.pdf', '/sites/default/files/cdr/clinical/SR0398_XolairCIU_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0398_XolairCIU_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0398%20Xolair_Template_PI_Submissions.pdf']",Chronic idiopathic urticaria,List with clinical criteria and/or conditions,Complete,22-Sep-14,07-May-15,SR0398-000
AfliberceptOpens in new tab,Eylea,Aflibercept,"['/sites/default/files/cdr/tracking/cdr_SR0396_Eylea_DME.pdf', '/sites/default/files/cdr/clinical/SR0396_EyleaDME_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0396_EyleaDME_PE_Report.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0396_Eylea-DME_May-11-15.pdf', '/sites/default/files/cdr/relatedinfo/SR0396%20Eylea%20DME_PI_Submissions.pdf']","Macular edema, diabetic",List with clinical criteria and/or conditions,Complete,16-Sep-14,07-May-15,SR0396-000
Bosulif for Chronic Myeloid Le...Opens in new tab,Bosulif,Bosutinib,"['/sites/default/files/pcodr/pcodr_profund_boustinib_bosulif_cml.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_rec.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_cgr.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_egr.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_in_rec.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_pagfdk.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fdk_pfizer.pdf', '/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_coi_cmlsc.pdf']",Chronic Myeloid Leukemia,Reimburse with clinical criteria and/or conditions,Complete,30-May-14,21-Apr-15,PC0039-000
TofacitinibOpens in new tab,Xeljanz,Tofacitinib,"['/sites/default/files/cdr/tracking/cdr_SR0380_Xeljanz.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0380_Xeljanz_Apr-21-15.pdf', '/sites/default/files/cdr/clinical/SR0380_Xeljanz_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0380_Xeljanz_PE_Report.pdf']","Arthritis, rheumatoid",List with criteria/condition,Complete,05-May-14,17-Apr-15,SR0380-000
Certolizumab pegolOpens in new tab,Cimzia,Certolizumab pegol,"['/sites/default/files/cdr/tracking/cdr_SR0385_Cimzia.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0385_Cimzia-AS_Apr-21-15.pdf', '/sites/default/files/cdr/relatedinfo/SR0385_Cimzia_AS_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0385_CimziaAS_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0385_CimziaAS_PE_Report_e.pdf']",Ankylosing spondylitis,List with criteria/condition,Complete,23-Jun-14,17-Apr-15,SR0385-000
LomitapideOpens in new tab,Juxtapid,Lomitapide,"['/sites/default/files/cdr/tracking/cdr_SR0386_Juxtapid.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0386_Juxtapid-Apr-21_15.pdf', '/sites/default/files/cdr/clinical/SR0386_Juxtapid_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0386_Juxtapid_PE_Report_e.pdf', '']","Hypercholesterolemia, homozygous familial",Do not list,Complete,08-Jul-14,17-Apr-15,SR0386-000
Certolizumab pegolOpens in new tab,Cimzia,Certolizumab pegol,"['/sites/default/files/cdr/tracking/SR0394%20Cimzia%20PsA.PDF', '/sites/default/files/cdr/complete/cdr_complete_SR0394_Cimzia-PsA_Apr-21-15.pdf', '/sites/default/files/cdr/clinical/SR0394_CimziaPsA_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0394_CimziaPsA_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0394%20Cimzia%20PsA_PI_Submissions.pdf']","Arthritis, psoriatic",List with criteria/condition,Complete,02-Sep-14,17-Apr-15,SR0394-000
Dolutegravir / abacavir / lami...Opens in new tab,Triumeq,Dolutegravir / abacavir / lamivudine,"['/sites/default/files/cdr/tracking/cdr_SR0387_Triumeq.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0387_Triumeq_Apr-21-15.pdf', '/sites/default/files/cdr/relatedinfo/SR0387_Triumeq_FDC_Review_Report_e.pdf']",HIV Infection,List with criteria/condition,Complete,31-Jul-14,17-Apr-15,SR0387-000
RifaximinOpens in new tab,Zaxine,Rifaximin,"['/sites/default/files/cdr/tracking/cdr_SR0388_Zaxine.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0388_Zaxine-Apr-20-15.pdf', '/sites/default/files/cdr/clinical/SR0388_Zaxine_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0388_Zaxine_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0388%20Zaxine_PI_Submissions_e.pdf']",Hepatic encephalopathy,List with criteria/condition,Complete,05-Aug-14,16-Apr-15,SR0388-000
Eslicarbazepine acetateOpens in new tab,Aptiom,Eslicarbazepine acetate,"['/sites/default/files/cdr/tracking/cdr_SR0391_Aptiom.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0391_Aptiom_Apr-20-15.pdf', '/sites/default/files/cdr/clinical/SR0391_Aptiom_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0391_Aptiom_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0391%20Aptiom_PI_Submissions_e.pdf']","Epilepsy, partial-onset seizures",List with criteria/condition,Complete,15-Aug-14,16-Apr-15,SR0391-000
EverolimusOpens in new tab,Afinitor,Everolimus,"['/sites/default/files/cdr/tracking/cdr_SR0376_Afinitor_SEGA.pdf', '/sites/default/files/cdr/complete/cdr_compelte_SR0376_Afinitor_Apr-17-15.pdf', '/sites/default/files/cdr/relatedinfo/SR0376%20Afinitor%20SEGA_Template_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0376_AfinitorSEGA_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0376_AfinitorSEGA_PE_Report.pdf']",Subependymal giant cell astrocytoma associated with tuberous sclerosis complex,Do not list,Complete,19-Mar-14,15-Apr-15,SR0376-000
PirfenidoneOpens in new tab,Esbriet,Pirfenidone,"['/sites/default/files/cdr/tracking/cdr_SR0393_Esbriet.pdf', '/sites/default/files/cdr/complete/cdr_compelte_SR0393_Esbriet_Apr-17-15.pdf', '/sites/default/files/cdr/clinical/SR0393_Esbriet_CL_Report_resub.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0393_Esbriet_PE_Report_resub.pdf']",Idiopathic pulmonary fibrosis,List with criteria/condition,Complete,29-Aug-14,15-Apr-15,SR0393-000
Elosulfase alfaOpens in new tab,Vimizim,Elosulfase alfa,"['/sites/default/files/cdr/tracking/cdr_SR0389_Vimizim.pdf', '/sites/default/files/cdr/complete/SR0389_complete_Vimizim_Mar-27-15.pdf', '/sites/default/files/cdr/clinical/SR0389_Vimizim_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0389_Vimizim_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0389%20Vimizim_PI_Submissions_e.pdf']",Mucopolysaccharidosis IVA (Morquio A syndrome),Do not list,Complete,05-Aug-14,25-Mar-15,SR0389-000
Avastin for Cervical Cancer - ...Opens in new tab,Avastin,Bevacizumab,"['/sites/default/files/pcodr/pcodr_provfund_avastin-cc.pdf', '/sites/default/files/pcodr/pcodr-avastincc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-avastin-cc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-avastin-cc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-avastin-cc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-avastincc-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-avastincc-fdk-hlr.pdf', '/sites/default/files/pcodr/pcodr-avastincc-fdk-occ.pdf', '/sites/default/files/pcodr/pcodr-avastincc-coi-occ.pdf']",Cervical Cancer,Reimburse with clinical criteria and/or conditions,Complete,27-Oct-14,23-Mar-15,PC0045-000
EltrombopagOpens in new tab,Revolade,Eltrombopag,"['/sites/default/files/cdr/tracking/cdr_SR0377_Revolade.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0377_Revolade_Mar-23-2015_e.pdf', '/sites/default/files/cdr/clinical/SR0377_RevoladeTCP_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0377_RevoladeTCP_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0377%20Revolade%20TCP_PI_Submissions.pdf']",Thrombocytopenia associated with chronic hepatitis c infection,List with criteria/condition,Complete,31-Mar-14,18-Mar-15,SR0377-000
Darunavir/cobicistatOpens in new tab,Prezcobix,Darunavir/cobicistat,"['/sites/default/files/cdr/tracking/cdr_SR0381_Prezcobix.pdf', '/sites/default/files/cdr/complete/cdr_complete_%20SR0381_Prezcobix_Mar_20-15.pdf', '/sites/default/files/cdr/clinical/SR0381_Prezcobix_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0381_Prezcobix_PE_Report_e.pdf', '']",HIV Infection,List with criteria/condition,Complete,22-May-14,18-Mar-15,SR0381-000
Ledipasvir / SofosbuvirOpens in new tab,Harvoni,Ledipasvir / Sofosbuvir,"['/sites/default/files/cdr/tracking/cdr_SR0395_Harvoni.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0395_Harvoni_Mar_20-15.pdf', '/sites/default/files/cdr/clinical/SR0395_Harvoni_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0395_Harvoni_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0395%20Harvoni_PI_Submissions_e.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,15-Sep-14,18-Mar-15,SR0395-000
Imbruvica for Chronic Lymphocy...Opens in new tab,Imbruvica,Ibrutinib,"['/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-CLL.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-in-rec.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-fdk-janssen.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-fdk-llsccllpag.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-coi-llsc.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-coi-cllpag.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fdk-lc.pdf', '/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-coi-lc.pdf']",Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,15-Aug-14,05-Mar-15,PC0043-000
Pasireotide diaspartateOpens in new tab,Signifor,Pasireotide diaspartate,"['/sites/default/files/cdr/tracking/cdr_SR0372_Signifor.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0372_Signifor_Feb-26-15.pdf', '/sites/default/files/cdr/clinical/SR0372_Signifor_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0372_Signifor_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0372%20Signifor_PI_Submissions.pdf']",Cushing’s disease,Do not list,Complete,27-Feb-14,24-Feb-15,SR0372-000
RanibizumabOpens in new tab,Lucentis,Ranibizumab,"['/sites/default/files/cdr/tracking/cdr_SR0373_Lucentis.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0373_Lucentis_CNV_Feb-20-15.pdf', '/sites/default/files/cdr/clinical/SR0373_LucentisCNV_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0373_LucentisCNV_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0373_Lucentis_PI_Submissions_e.pdf']",Myopic choroidal neovascularisation,List with criteria/condition,Complete,28-Feb-14,19-Feb-15,SR0373-000
TocilizumabOpens in new tab,Actemra,Tocilizumab,"['/sites/default/files/cdr/tracking/cdr_SR0374_Actemra%20SC.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0374_Actemra_SC_Feb-23-15.pdf', '/sites/default/files/cdr/clinical/SR0374_ActemraSC_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0374_ActemraSC_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0374_Actemra%20SC_PI_Submissions.pdf']","Arthritis, rheumatoid",List with criteria/condition,Complete,03-Mar-14,19-Feb-15,SR0374-000
Arzerra for Chronic Lymphocyti...Opens in new tab,Arzerra,Ofatumumab,"['/sites/default/files/pcodr/pcodr_profund_ofatumumab_arzerra_cll.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-in-rec.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-fdk-gsk.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-coi-llsc.pdf', '/sites/default/files/pcodr/pcodr-arzerra-cll-coi-cllpag.pdf']",Chronic Lymphocytic Leukemia,Do not reimburse,Complete,14-Apr-14,29-Jan-15,PC0038-000
MacitentanOpens in new tab,Opsumit,Macitentan,"['/sites/default/files/cdr/tracking/cdr_SR0364_Opsumit.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0364_Opsumit_Jan-30-15.pdf', '/sites/default/files/cdr/clinical/SR0364_Opsumit_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0364_Opsumit_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0364_Opsumit_PI_e.pdf']",Pulmonary arterial hypertension,List with clinical criteria and/or conditions,Complete,18-Dec-13,28-Jan-15,SR0364-000
Gazyva for Chronic Lymphocytic...Opens in new tab,Gazyva,Obinutuzumab,"['/sites/default/files/pcodr/pcodr-provfund_gazyva-cll.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-in-rec.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-fdk-roche.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-fdk-lc.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-coi-lc.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-ptfdk.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-coi-llsc.pdf', '/sites/default/files/pcodr/pcodr-gazyva-cll-coi-cllpag.pdf']",Chronic Lymphocytic Leukemia,Reimburse,Complete,11-Aug-14,27-Jan-15,PC0041-000
AlogliptinOpens in new tab,Nesina,Alogliptin,"['/sites/default/files/cdr/tracking/cdr_SR0368_Nesina.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0368_Nesina_Jan-19-15.pdf', '/sites/default/files/cdr/clinical/SR0368_Nesina_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0368_Nesina_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0368_Nesina_PI_Submissions.pdf']","Diabetes mellitus, type 2",Do not list,Complete,30-Jan-14,15-Jan-15,SR0368-000
Alogliptin Plus MetforminOpens in new tab,Kazano,Alogliptin plus metformin,"['/sites/default/files/cdr/tracking/cdr_SR0367_Kazano.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0367_Kazano_Jan-19-15.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0367_Kazano_PE_Report.pdf', '/sites/default/files/cdr/clinical/SR0367_Kazano_CL_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0367_Kazano_PI_Submissions.pdf']","Diabetes mellitus, type 2",Do not list,Complete,30-Jan-14,15-Jan-15,SR0367-000
CanagliflozinOpens in new tab,Invokana,Canagliflozin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0370_Invokana.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0370_Invokana_Jan-19_15.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/SR0370_Invokana_CL_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0370_Invokana_PE_Report.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0370%20Invokana_PI_Submissions.pdf']","Diabetes mellitus, type 2",List with criteria/condition,Complete,24-Feb-14,15-Jan-15,SR0370-000
Umeclidinium/vilanterolOpens in new tab,Anoro Ellipta,Umeclidinium/vilanterol,"['/sites/default/files/cdr/tracking/cdr_SR0371_Anoro_Ellipta.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0371_Anoro_Ellipta_Jan-23-15.pdf', '/sites/default/files/cdr/relatedinfo/SR0371_Anoro_Ellipta_PI_Submissions.pdf', '/sites/default/files/cdr/clinical/SR0371_Anoro_Ellipta_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0371_Anoro_Ellipta_PE_Report_e.pdf']",Chronic obstructive pulmonary disease,List with criteria/condition,Complete,26-Feb-14,15-Jan-15,SR0371-000
Yervoy for First Line Advanced...Opens in new tab,Yervoy,Ipilimumab,"['/sites/default/files/pcodr/pcodr_profund_ipilimumab_yervoy_melanoma1stline.pdf', '/sites/default/files/pcodr/pcodr-yervoy1st-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-yervoy1stsub-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-yervoy1stsub-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-yervoy1stsub-in-rec.pdf', '/sites/default/files/pcodr/pcodr-yervoy1stsub-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-yervoy1stsub-bms.pdf', '/sites/default/files/pcodr/pcodr-yervoy1st-mncfdk.pdf', '/sites/default/files/pcodr/pcodr-yervoy1st-coi-mnc.pdf']",First Line Advanced Melanoma,Reimburse with clinical criteria and/or conditions,Complete,15-Aug-14,22-Dec-14,PC0042-000
AripiprazoleOpens in new tab,Abilify Maintena,Aripiprazole,"['/sites/default/files/cdr/tracking/cdr_SR0366_Abilify_Maintena.pdf', '/sites/default/files/cdr/clinical/SR0366_Abilify%20Maintena_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0366_Abilify%20Maintena_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0366_Abilify%20Maintena_PI_Submissions.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0366_Abilify-Maintena_Dec-23-14.pdf']",Schizophrenia,List with criteria/condition,Complete,06-Jan-14,19-Dec-14,SR0366-000
Indacaterol/glycopyrroniumOpens in new tab,Ultibro Breezhaler,Indacaterol/glycopyrronium,"['/sites/default/files/cdr/tracking/cdr_SR0369_Ultibro_Breezhaler.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0369_Ultibro%20Breezhaler_Jan30_2015.pdf', '/sites/default/files/cdr/relatedinfo/SR0369_Ultibro%20Breezhaler_PI.pdf', '/sites/default/files/cdr/clinical/SR0369_UltibroBreezhaler_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0369_UltibroBreezhaler_PE_Report.pdf']",Chronic obstructive pulmonary disease,List with criteria/condition,Complete,03-Feb-14,19-Dec-14,SR0369-000
IcatibantOpens in new tab,Firazyr,Icatibant,"['/sites/default/files/cdr/tracking/cdr_SR0375_Firazyr.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0375_Firazyr_Dec-23-14.pdf', '/sites/default/files/cdr/clinical/SR0375_Firazyr_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0375_Firazyr_PE_Report.pdf']",Hereditary angioedema,List with clinical criteria and/or conditions,Complete,04-Mar-14,19-Dec-14,SR0375-000
IvacaftorOpens in new tab,Kalydeco,Ivacaftor,"['/sites/default/files/cdr/tracking/cdr_SR0379_Kalydeco%20CF.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0379_Kalydeco_Dec-23-14.pdf', '/sites/default/files/cdr/clinical/SR0379_KalydecoCF_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0379_KalydecoCF_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0379_Kalydeco_PI_Submissions_e.pdf']","Cystic Fibrosis, CFTR gating mutations",List with criteria/condition,Complete,01-May-14,19-Dec-14,SR0379-000
InfliximabOpens in new tab,Inflectra,Infliximab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/tracking/cdr_SE0384_Inflectra.pdf', '/sites/default/files/cdr/complete/cdr_complete_SE0384_Inflectra_Dec-23-14.pdf', '/sites/default/files/cdr/seb/SE0384_Inflectra_SEB_Report.pdf', '/sites/default/files/cdr/relatedinfo/SE0384%20Inflectra_PI_Submissions.pdf']","Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis",List with criteria/condition,Complete,17-Jun-14,19-Dec-14,SE0384-000
OnabotulinumtoxinAOpens in new tab,Botox,OnabotulinumtoxinA,"['/sites/default/files/cdr/tracking/cdr_SR0362_Botox_OAB.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0362_Botox-OAB_nov14_2014.pdf', '/sites/default/files/cdr/clinical/SR0362_BotoxOAB_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0362_BotoxOAB_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0362_Botox%20OAB_PI_Submissions_e.pdf']",Urinary incontinence,List with criteria/condition,Complete,25-Nov-13,12-Nov-14,SR0362-000
MirabegronOpens in new tab,Myrbetriq,Mirabegron,"['/sites/default/files/cdr/tracking/cdr_SR0363_Myrbetriq.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0363_Myrbetriq_nov14_2014.pdf', '/sites/default/files/cdr/clinical/SR0363_Myrbetriq_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0363_Myrbetriq_PE_Report_e.pdf', '/sites/default/files/cdr/relatedinfo/SR0363_Myrbetriq_PI_Submissions_e.pdf']",Overactive bladder,List with criteria/condition,Complete,27-Nov-13,12-Nov-14,SR0363-000
AripiprazoleOpens in new tab,Abilify,Aripiprazole,"['/sites/default/files/cdr/tracking/cdr_SR0354_Abilify.pdf', '/sites/default/files/cdr/clinical/SR0354_AbilifyMDD_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0354_AbilifyMDD_PE_Report.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0354_Abilify-MDD_Oct-24_2014.pdf']","Depression, Major Depressive Disorder",Do not list,Complete,01-Oct-13,22-Oct-14,SR0354-000
UstekinumabOpens in new tab,Stelara,Ustekinumab,"['/sites/default/files/cdr/tracking/cdr_SR0359_Stelara.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0359_Stelara_Oct-22-14.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0359_Stelara_PE_Report.pdf', '/sites/default/files/cdr/clinical/SR0359_Stelara_CL_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0359_Stelara_PI_Submissions.pdf']","Arthritis, psoriatic",Do not list at the submitted price,Complete,30-Oct-13,20-Oct-14,SR0359-000
AfliberceptOpens in new tab,Eylea,Aflibercept,"['/sites/default/files/cdr/tracking/cdr_SR0361_Eylea.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0361-000_eylea_october_22_2014.pdf', '/sites/default/files/cdr/clinical/SR0361_Eylea_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0361_Eylea_PE_Report.pdf', '/sites/default/files/cdr/relatedinfo/SR0361_Eylea_PI_Submissions.pdf']","Macular degeneration, age-related",List with criteria/condition,Complete,18-Nov-13,20-Oct-14,SR0361-000
StiripentolOpens in new tab,Diacomit,Stiripentol,"['/sites/default/files/cdr/tracking/cdr_SR0360_Diacomit.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0360_Diacomit_October_20_2014.pdf', '/sites/default/files/cdr/clinical/sr0360_diacomit_cl_report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0360_diacomit_pe_report.pdf']",Dravet Syndrome,List with criteria/condition,Complete,30-Oct-13,16-Oct-14,SR0360-000
Guanfacine hydrochlorideOpens in new tab,Intuniv XR,Guanfacine hydrochloride,"['/sites/default/files/cdr/tracking/cdr_SR0349_Intuniv-XR.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0349_Intuniv-XR_sep-26_14.pdf', '/sites/default/files/cdr/clinical/SR0349_IntunivXR_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0349_IntunivXR_PE_Report_e.pdf']",Attention-deficit/hyperactivity disorder (ADHD),Do not list,Complete,27-Aug-13,24-Sep-14,SR0349-000
Phleum pratenseOpens in new tab,Grastek,Phleum pratense,"['/sites/default/files/cdr/tracking/cdr_SR0352_Grastek.pdf', '/sites/default/files/cdr/clinical/SR0352_Grastek_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0352_Grastek_PE_Report_e.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0352_Grastek_sep-26_14.pdf']",Allergic rhinitis,Do not list,Complete,30-Sep-13,24-Sep-14,SR0352-000
Abraxane for Metastatic Pancre...Opens in new tab,Abraxane,Nab-paclitaxel,"['/sites/default/files/pcodr/pcodr_profund_nabpaclitaxel_abraxane_pc.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-pag-fdk.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-fdk-celgene.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-coi-pcc.pdf', '/sites/default/files/pcodr/pcodr-abraxane-mpc-coi-cc.pdf']",Metastatic Pancreatic Cancer,Reimburse with clinical criteria and/or conditions,Complete,14-Feb-14,23-Sep-14,PC0037-000
Zaltrap for Metastatic Colorec...Opens in new tab,Zaltrap,Aflibercept,"['/sites/default/files/pcodr/pcodr-provfund_zaltrap-mcrc.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-pag-fdk.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fdk-sanofi.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fdk-ccac.pdf', '/sites/default/files/pcodr/pcodr-zaltrap-mcrc-coi-ccac.pdf']",Metastatic Colorectal Cancer,Do not reimburse,Complete,26-Nov-13,05-Sep-14,PC0035-000
DolutegravirOpens in new tab,Tivicay,Dolutegravir,"['/sites/default/files/cdr/tracking/cdr_SR0357_Tivicay.pdf', '/sites/default/files/cdr/complete/cdr_complete_tivicay_august_20_2014.pdf', '/sites/default/files/cdr/clinical/sr0357_tivicay_cl_report.pdf', '/sites/default/files/cdr/pharmacoeconomic/sr0357_tivicay_pe_report.pdf']",HIV infection,List,Complete,18-Oct-13,18-Aug-14,SR0357-000
Fluticasone furoate /vilantero...Opens in new tab,Breo Ellipta,Fluticasone furoate /vilanterol,"['/sites/default/files/cdr/tracking/cdr_SR0358_Breo_Ellipta.pdf', '/sites/default/files/cdr/complete/cdr_complete_breo_ellipta_august_20_2014.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0358_BreoEllipta_PE_Report.pdf', '/sites/default/files/cdr/clinical/SR0358_BreoEllipta_CL_Report.pdf']",Chronic Obstructive Pulmonary Disease (COPD),List with criteria/condition,Complete,29-Oct-13,18-Aug-14,SR0358-000
SofosbuvirOpens in new tab,Sovaldi,Sofosbuvir,"['/sites/default/files/cdr/tracking/cdr_SR0356_TBC_%28Sofosbuvir%29.pdf', '/sites/default/files/cdr/clinical/SR0356_Sovaldi_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0356_Sovaldi_PE_Report_e.pdf', '/sites/default/files/cdr/complete/cdr_complete_sovaldi_august_20_2014.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,01-Oct-13,18-Aug-14,SR0356-000
Pomalyst for Multiple Myeloma ...Opens in new tab,Pomalyst,Pomalidomide,"['/sites/default/files/pcodr/pcodr_profund_pomalidomide_pomalyst_mm.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-in-rec.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-pag-fdk.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-fdk-celgene.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-fdk-myelcan.pdf', '/sites/default/files/pcodr/pcodr-pomalyst-mm-coi-myelcan.pdf']",Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,13-Jan-14,31-Jul-14,PC0036-000
RiociguatOpens in new tab,Adempas,Riociguat,"['/sites/default/files/cdr/tracking/cdr_SR0353_Adempas.pdf', '/sites/default/files/cdr/complete/SR0353_complete_Adempas_Jul-21-14.pdf', '/sites/default/files/cdr/clinical/SR0353_Adempas_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0353_Adempas_PE_Report-e.pdf']",Chronic thromboembolic pulmonary hypertension,List with criteria/condition,Complete,30-Sep-13,17-Jul-14,SR0353-000
GolimumabOpens in new tab,Simponi I.V.,Golimumab,"['/sites/default/files/cdr/tracking/cdr_SR0351_Simponi-IV.pdf', '/sites/default/files/cdr/complete/SR0351_complete_Simponi_IV_Jul-21-14.pdf', '/sites/default/files/cdr/clinical/SR0351_SimponiIV_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0351_SimponiIV_PE_Report.pdf']","Arthritis, rheumatoid",List with criteria/condition,Complete,12-Sep-13,17-Jul-14,SR0351-000
Saxagliptin + MetforminOpens in new tab,Komboglyze,Saxagliptin + metformin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0348_Komboglyze-TL.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/SR0348_complete_Komboglyze-Jun-24-14.pdf', 'https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0348_Komboglyze_FDC_Report_e.pdf']","Diabetes Mellitus, type 2",List with criteria/condition,Complete,23-Aug-13,20-Jun-14,SR0348-000
SimeprevirOpens in new tab,Galexos,Simeprevir,"['/sites/default/files/cdr/tracking/cdr_SR0347_TBC.pdf', '/sites/default/files/cdr/complete/SR0347_complete_Galexos-Jun-20-14.pdf', '/sites/default/files/cdr/clinical/SR0347_Galexos_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0347_Galexos_PE_Report.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,22-Aug-13,18-Jun-14,SR0347-000
TeriflunomideOpens in new tab,Aubagio,Teriflunomide,"['/sites/default/files/cdr/tracking/cdr_SR0350_Aubagio.pdf', '/sites/default/files/cdr/clinical/SR0350_Aubagio_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0350_Aubagio_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0350_complete_Aubagio_Jun-19-14.pdf']","Multiple sclerosis, relapsing-remitting",Do not list at the submitted price,Complete,28-Aug-13,18-Jun-14,SR0350-000
OnabotulinumtoxinAOpens in new tab,Botox,OnabotulinumtoxinA,"['/sites/default/files/cdr/tracking/cdr_SR0345_Botox-Migraine.pdf', '/sites/default/files/cdr/complete/SR0345_complete_Botox-May-30-14.pdf', '/sites/default/files/cdr/clinical/SR0345_Botox_Migraine_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0345_Botox_Migraine_PE_Report_e.pdf']",Migraine,Do not list,Complete,15-Aug-13,28-May-14,SR0345-000
RotigotineOpens in new tab,Neupro,Rotigotine,"['/sites/default/files/cdr/tracking/cdr_SR0344_Neupro.pdf', '/sites/default/files/cdr/clinical/SR0344_Neupro_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0344_Neupro_PE_Report.pdf', '/sites/default/files/cdr/complete/SR0344_complete_Neupro_May-30-14.pdf']",Parkinson's disease,Do not list,Complete,31-Jul-13,28-May-14,SR0344-000
Giotrif for Advanced Non Small...Opens in new tab,Giotrif,Afatinib,"['/sites/default/files/pcodr/pcodr-provfund_giotrif-nsclc.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-infdk-bicl.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-ptfdbk-lcc.pdf', '/sites/default/files/pcodr/pcodr-giotrif-nsclc-coi-lcc.pdf']",Advanced or Metastatic Non-Small Cell Lung Cancer,Reimburse,Complete,07-Jun-13,02-May-14,PC0032-000
Stivarga for Gastrointestinal ...Opens in new tab,Stivarga (GIST),Regorafenib,"['/sites/default/files/pcodr/pcodr_profund_regorafenib_stivarga_gist.pdf', '/sites/default/files/pcodr/pcodr-stivarga-gist-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-stivarga-gist-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-stivarga-gist-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-stivarga-gist-in-rec.pdf', '/sites/default/files/pcodr/pcodr-stivargagist-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-stivargagist-fdk-bayer.pdf', '/sites/default/files/pcodr/pcodr-stivargagist-fdk-scfc.pdf', '/sites/default/files/pcodr/pcodr-stivargagist-coi-scfc.pdf']",Gastrointestinal Stromal Tumour,Reimburse with clinical criteria and/or conditions,Complete,11-Oct-13,02-May-14,PC0034-000
EplerenoneOpens in new tab,Inspra,Eplerenone,"['/sites/default/files/cdr/tracking/cdr_SR0342%20Inspra%20HF.pdf', '/sites/default/files/cdr/clinical/SR0342_InspraHF_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0342_Inspra%20HF_PE_Report_e.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0342_Inspra_Apr-28_14.pdf']","Heart failure, NYHA class II",Do not list at the submitted price,Complete,12-Jul-13,24-Apr-14,SR0342-000
Aclidinium bromideOpens in new tab,Tudorza Genuair,Aclidinium bromide,"['/sites/default/files/cdr/tracking/cdr_SR0346_Tudorza_Genuair.pdf', '/sites/default/files/cdr/clinical/SR0346_TudorzaGenuair_CL_Report.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0346_TudorzaGenuair_PE_Report.pdf', '/sites/default/files/cdr/complete/cdr_complete_SR0346_Tudorza%20Genuair_Ap_23_2014.pdf']",Chronic Obstructive Pulmonary Disease,List with criteria/condition,Complete,21-Aug-13,21-Apr-14,SR0346-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,"['/sites/default/files/cdr/tracking/cdr_SR0327_Xarelto_PEm.pdf', '/sites/default/files/cdr/complete/SR0327_complete_Xarelto%20PEm_Mar-28-14.pdf', '/sites/default/files/cdr/clinical/SR0327_Xarelto%20PEm_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0327_Xarelto%20PEm_PE_Report_e.pdf']","Venous thromboembolic events, pulmonary embolism",List with criteria/condition,Complete,06-May-13,26-Mar-14,SR0327-000
TocilizumabOpens in new tab,Actemra,Tocilizumab,"['/sites/default/files/cdr/tracking/cdr_SR0343_Actemra-pJIA.pdf', '/sites/default/files/cdr/clinical/SR0343_Actemra%20pJIA_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0343_Actemra%20pJIA_PE_Report_e.pdf', '/sites/default/files/cdr/complete/cdr_complete_Actemra_Mar_24_14_e.pdf']","Arthritis, polyarticular juvenile idiopathic",List with criteria/condition,Complete,29-Jul-13,19-Mar-14,SR0343-000
GolimumabOpens in new tab,Simponi,Golimumab,"['/sites/default/files/cdr/tracking/cdr_SR0341%20Simponi%20UC.pdf', '/sites/default/files/cdr/clinical/SR0341_Simponi_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0341_Simponi_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0341_complete_Simponi_Mar-28-14.pdf']",Ulcerative colitis,Do not list at the submitted price,Complete,12-Jul-13,19-Mar-14,SR0341-000
Trisenox for Acute Promyelocyt...Opens in new tab,Trisenox,Arsenic Trioxide,"['/sites/default/files/pcodr/pcodr-provfund_trisenox-apl.pdf', '/sites/default/files/pcodr/pcodr-trisenox-apl-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-trisenox-apl-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-trisenox-apl-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-trisenox-apl-in-rec.pdf', '/sites/default/files/pcodr/pcodr-trisenox-apl-pag-fdbdk.pdf', '/sites/default/files/pcodr/pcodr-trisenox-apl-coi-llsc.pdf']",Acute Promyelocytic Leukemia,Reimburse,Complete,30-Aug-13,18-Feb-14,PC0033-000
Ingenol mebutateOpens in new tab,Picato,Ingenol mebutate,"['/sites/default/files/cdr/tracking/cdr_SR0330_Picato.pdf', '/sites/default/files/cdr/clinical/SR0330_Picato_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0330_Picato_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0330_complete_Picato-30-Jan-14.pdf']",Actinic keratosis,Do not list,Complete,09-May-13,22-Jan-14,SR0330-000
Erbitux for Metastatic Colorec...Opens in new tab,Erbitux,Cetuximab,"['/sites/default/files/pcodr/pcodr-provfund_erbitux-mcrc.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-fdbk-ccac.pdf', '/sites/default/files/pcodr/pcodr-erbitux-mcrc-coi-ccac.pdf']",Metastatic Colorectal Cancer,Do not reimburse,Complete,10-Jun-13,10-Jan-14,PC0031-000
Vismodegib (Erivedge) for Adva...Opens in new tab,Erivedge,Vismodegib,"['/sites/default/files/pcodr/pcodr-provfund_erivedge-abcc.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-fdk-roche.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-fdk-sys.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-coi-sys.pdf', '/sites/default/files/pcodr/pcodr-erivedge-bcc-coi-mnc.pdf']",Basal Cell Carcinoma,Reimburse with clinical criteria and/or conditions,Complete,14-Jun-13,10-Jan-14,PC0015-000
Trastuzumab emtansine for Meta...Opens in new tab,Kadcyla,Trastuzumab emtansine,"['/sites/default/files/pcodr/pcodr-provfund_kadcyla-mbc.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-fdk-roche.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-coi-cbcn.pdf', '/sites/default/files/pcodr/pcodr-kadcyla-mbc-coi-rebc.pdf']",Advanced or Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,15-Mar-13,10-Jan-14,PC0024-000
LurasidoneOpens in new tab,Latuda,Lurasidone,"['/sites/default/files/cdr/tracking/cdr_SR0331_Latuda-Resub-1.pdf', '/sites/default/files/cdr/clinical/SR0331_Latuda_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0331_Latuda_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0331_complete_Latuda_Dec-24-13.pdf']",Schizophrenia,List with criteria/condition,Complete,09-May-13,20-Dec-13,SR0331-000
SomatropinOpens in new tab,Genotropin,Somatropin,"['/sites/default/files/cdr/tracking/cdr_SR0332_Genotropin_GHD-A.pdf', '/sites/default/files/cdr/clinical/SR0332_GenotropinGHD-A_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0332_GenotropinGHD-A_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0332_complete_Genotropin-GHD-Adults_Dec-23-13.pdf']","Growth hormone deficiency, adult",List with criteria/condition,Complete,27-May-13,20-Dec-13,SR0332-000
SomatropinOpens in new tab,Genotropin,Somatropin,"['/sites/default/files/cdr/tracking/cdr_SR0333_Genotropin_GHD-P.pdf', '/sites/default/files/cdr/clinical/SR0333_GenotropinGHD-P_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0333_GenotropinGHD-P_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0333_complete_Genotropin-GHD-P_Dec-23-13.pdf']","Growth hormone deficiency, children",List with criteria/condition,Complete,27-May-13,20-Dec-13,SR0333-000
SomatropinOpens in new tab,Genotropin,Somatropin,"['/sites/default/files/cdr/tracking/cdr_SR0334_Genotropin_TS.pdf', '/sites/default/files/cdr/clinical/SR0334_GenotropinTS_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0334_GenotropinTS_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0334_complete_Genotropin-TS_Dec-23-13.pdf']",Turner Syndrome,List with criteria/condition,Complete,27-May-13,20-Dec-13,SR0334-000
OcriplasminOpens in new tab,Jetrea,Ocriplasmin,"['/sites/default/files/cdr/tracking/cdr_SR0337_Jetrea.pdf', '/sites/default/files/cdr/clinical/SR0337_Jetrea_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0337_Jetrea_PE_Report_e.pdf', '/sites/default/files/cdr/complete/SR0337_complete_Jetrea_Dec-23-13.pdf']",Vitreomacular adhesion,List with criteria/condition,Complete,06-Jun-13,20-Dec-13,SR0337-000
Adcetris for systemic Anaplast...Opens in new tab,Adcetris,Brentuximab vedotin,"['/sites/default/files/pcodr/pcodr-provfund_adcetris-salcl.pdf', '/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-adcetris-salcl-in-rec.pdf', '/sites/default/files/pcodr/pcodr-adcetris-salcl-pagfdk.pdf', '/sites/default/files/pcodr/pcodr-adcetris-salcl-coi-lfc.pdf']",Systemic Anaplastic Large Cell Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,15-Mar-13,05-Dec-13,PC0021-000
Tafinlar for Metastatic Melano...Opens in new tab,Tafinlar,Dabrafenib,"['/sites/default/files/pcodr/pcodr-provfund_tafinlar-metmel.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-metmla-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-metmla-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-metmla-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-metmla-in-rec.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-in-fdk-gsk.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-ptfdk-mnc.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-coi-mnc.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-ptfdk-sysf.pdf', '/sites/default/files/pcodr/pcodr-tafinlar-coi-sysf.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,18-Mar-13,05-Dec-13,PC0025-000
Pemetrexed Alimta for Advanced...Opens in new tab,Alimta,Pemetrexed,"['/sites/default/files/pcodr/pcodr_provfund_alimta-nsclc.pdf', '/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-alimta-pagfdk-inrec.pdf', '/sites/default/files/pcodr/pcodr-alimta-infdk-elilc.pdf', '/sites/default/files/pcodr/pcodr-alimta-coi-ccsn.pdf', '/sites/default/files/pcodr/pcodr-alimta-coi-lcc.pdf']",Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,31-May-13,19-Nov-13,PC0027-000
Ulipristal acetateOpens in new tab,Fibristal,Ulipristal acetate,"['/sites/default/files/cdr/tracking/cdr_SR0326_Fibristal.pdf', '/sites/default/files/cdr/clinical/SR0326_Fibristal_CL_Report_e.pdf', '/sites/default/files/cdr/pharmacoeconomic/SR0326_Fibristal_PE_Report_e.pdf', '/sites/default/files/cdr/complete/complete_SR0326_Fibristal_19-Nov-13_e.pdf']",Uterine fibroids,List with criteria/condition,Complete,17-Apr-13,15-Nov-13,SR0326-000
SaxagliptinOpens in new tab,Onglyza,Saxagliptin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0329_Onglyza-2.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/complete_SR0329_Onglyza-preNOC_19-Nov-13_e.pdf', 'https://www.cadth.ca/sites/default/files/cdr/clinical/SR0329_Onglyza_CL_Report_e.pdf', 'https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0329_Onglyza_PE_Report_e.pdf']","Diabetes mellitus, type 2",List with criteria/condition,Complete,09-May-13,15-Nov-13,SR0329-000
Stivarga for Metastatic Colore...Opens in new tab,Stivarga (CRC),Regorafenib,"['/sites/default/files/pcodr/pcodr_provfund_stivarga-mcrc.pdf', '/sites/default/files/pcodr/pcodr-stivargamcrc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-stivargamcrc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-stivargamcrc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-stivargamcrc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-stivarga-mcrc-pagfdk-inr.pdf', '/sites/default/files/pcodr/pcodr-stivarga-mcrc-fdk-bayer.pdf', '/sites/default/files/pcodr/pcodr-stivarga-mcrc-ptfdk-ccac.pdf', '/sites/default/files/pcodr/pcodr-stivarga-mcrc-coi-ccac.pdf']",Metastatic Colorectal Cancer,Do not reimburse,Complete,22-Mar-13,15-Nov-13,PC0026-000
Zytiga for Metastatic Castrati...Opens in new tab,Zytiga,Abiraterone acetate,"['/sites/default/files/pcodr/pcodr_profund_abiraterone_zytiga_mcrpc.pdf', '/sites/default/files/pcodr/pcodr-zytiga-mcrpc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-zytiga-mcrpc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-zytiga-mcrpc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-zytiga-mcrpc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-zytiga-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-zytiga-in-fdk-janssen.pdf', '/sites/default/files/pcodr/pcodr-zytiga-in-fdk-ccsn.pdf', '/sites/default/files/pcodr/pcodr-zytiga-coi-ccsn.pdf', '/sites/default/files/pcodr/pcodr-zytiga-in-fdk-pcc.pdf', '/sites/default/files/pcodr/pcodr-zytiga-coi-pcc.pdf']",Metastatic Castration Resistant Prostate Cancer,Reimburse with clinical criteria and/or conditions,Complete,28-Mar-13,22-Oct-13,PC0028-000
Mekinist for Metastatic Melano...Opens in new tab,Mekinist,Trametinib,"['/sites/default/files/pcodr/pcodr_provfund_mekinist-metmel.pdf', '/sites/default/files/pcodr/pcodr-mekinist-mm-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-mekinist-metmela-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-mekinist-metmela-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-mekinist-metmela-in-rec.pdf', '/sites/default/files/pcodr/pcodr-mekinist-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-mekinist-in-fdk-gsk.pdf', '/sites/default/files/pcodr/pcodr-mekinist-in-fdk-mnc.pdf', '/sites/default/files/pcodr/pcodr-mekinist-coi-mnc.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,06-May-13,22-Oct-13,PC0030-000
Revlimid for Multiple Myeloma ...Opens in new tab,Revlimid,Lenalidomide,"['/sites/default/files/pcodr/pcodr_provfund_revlimid-mm.pdf', '/sites/default/files/pcodr/pcodr-revlimid-mm-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-revlimid-mm-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-revlimid-mm-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-revlimid-mm-in-rec.pdf', '/sites/default/files/pcodr/pcodr-revlimid-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-revlimid-in-fdk-celgene.pdf', '/sites/default/files/pcodr/pcodr-revlimid-coi-mc.pdf']",Multiple Myeloma (as maintenance therapy),Reimburse with clinical criteria and/or conditions,Complete,05-Apr-13,22-Oct-13,PC0029-000
PerampanelOpens in new tab,Fycompa,Perampanel,"['/sites/default/files/cdr/tracking/cdr_SR0316_Fycompa.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fycompa_October-21-13_e.pdf']","Epilepsy, partial onset seizures",List with criteria/condition,Complete,08-Mar-13,17-Oct-13,SR0316-000
Azilsartan medoxomilOpens in new tab,Edarbi,Azilsartan medoxomil,"['/sites/default/files/cdr/tracking/cdr_SR0317_Edarbi.pdf', '/sites/default/files/cdr/complete/cdr_complete_Edarbi_October-21-13_e.pdf']",Hypertension,Do not list at the submitted price,Complete,08-Mar-13,17-Oct-13,SR0317-000
Azilsartan medoxomil + chlorth...Opens in new tab,Edarbyclor,Azilsartan medoxomil + chlorthalidone,"['/sites/default/files/cdr/tracking/cdr_SR0318_Edarbyclor.pdf', '/sites/default/files/cdr/complete/cdr_complete_Edarbyclor_October-21-13_e.pdf']",Hypertension,Do not list,Complete,08-Mar-13,17-Oct-13,SR0318-000
Linagliptin-metforminOpens in new tab,Jentadueto,Linagliptin-metformin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0306_Jentadeuto.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Jentadueto_October-21-13_e.pdf']","Diabetes mellitus, type 2",List with criteria/condition,Complete,08-Mar-13,17-Oct-13,SR0306-000
Zolpidem tartrateOpens in new tab,Sublinox,Zolpidem tartrate,"['/sites/default/files/cdr/tracking/cdr_SR0314_Sublinox.pdf', '/sites/default/files/cdr/complete/cdr_complete_Sublinox_September_27_13.pdf']",Insomnia,Do not list,Complete,07-Mar-13,25-Sep-13,SR0314-000
Dimethyl fumarateOpens in new tab,Tecfidera,Dimethyl fumarate,"['/sites/default/files/cdr/tracking/cdr_SR0309_Tecfidera.pdf', '/sites/default/files/cdr/complete/cdr_complete_Tecfidera_September_30-13.pdf']","Multiple sclerosis, relapsing-remitting",List with criteria/condition,Complete,04-Feb-13,25-Sep-13,SR0309-000
EverolimusOpens in new tab,Afinitor,Everolimus,"['/sites/default/files/cdr/tracking/cdr_SR0315_Afinitor.pdf', '/sites/default/files/cdr/complete/cdr_compete_Afinitor_September_27_13.pdf']",Renal angiomyolipoma associated with tuberous sclerosis complex (TSC),Do not list,Complete,08-Mar-13,25-Sep-13,SR0315-000
Votrient for metastatic renal ...Opens in new tab,Votrient,Pazopanib hydrochloride,"['/sites/default/files/pcodr/pcodr-provfund_votrientmrcc-re.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-in-rec.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-pag-fdbk.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-infdk-gsk.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-ptfdk-kcc.pdf', '/sites/default/files/pcodr/pcodr-votrientmrccre-coi-kcc.pdf']",Metastatic Renal Cell Carcinoma,Reimburse,Complete,20-Feb-13,29-Aug-13,PC0022-000
Adcetris for Hodgkin Lymphoma ...Opens in new tab,Adcetris,Brentuximab vedotin,"['/sites/default/files/pcodr/pcodr-provfund_adcetris-hl.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-in-rec.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-pag-fdk-inrec.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-in-fdk-sg.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-pt-fdk-lfc.pdf', '/sites/default/files/pcodr/pcodr-adcetrishl-coi-lfc.pdf']",Hodgkin Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,14-Mar-13,29-Aug-13,PC0020-000
Interferon beta-1aOpens in new tab,Rebif,Interferon beta-1a,"['/sites/default/files/cdr/tracking/cdr_SR0298_Rebif.pdf', '/sites/default/files/cdr/complete/cdr_complete_Rebif_Aug-19-13.pdf']",Clinically isolated syndrome,Do not list,Complete,08-Mar-13,15-Aug-13,SR0298-000
Perjeta for Metastatic Breast ...Opens in new tab,Perjeta Herceptin Combo Pack,Pertuzumab,"['/sites/default/files/pcodr/pcodr_profund_pertuzumab_perjeta_mbc.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-in-fdk-hlr.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-coi-cbcn.pdf', '/sites/default/files/pcodr/pcodr-perjetacp-mbc-coi-rethin.pdf']",Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,02-Nov-12,01-Aug-13,PC0018-000
Xtandi for metastatic Castrati...Opens in new tab,Xtandi,Enzalutamide,"['/sites/default/files/pcodr/pcodr_profund_enzalutamide_xtandi_mcrpc.pdf', '/sites/default/files/pcodr/pcodr-xtandi-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-xtandi-mcrpc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-xtandi-mcrpc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-xtandi-mcrpc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-xtandi-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-xtandi-in-fdk-astellas.pdf', '/sites/default/files/pcodr/pcodr-xtandi-coi-pcc.pdf', '/sites/default/files/pcodr/pcodr-xtandi-coi-ccsn.pdf']",Metastatic Castration Resistant Prostate Cancer,Reimburse with clinical criteria and/or conditions,Complete,04-Mar-13,23-Jul-13,PC0023-000
Dabigatran etexilateOpens in new tab,Pradaxa,Dabigatran etexilate,"['/sites/default/files/cdr/tracking/cdr_SF0320_Pradaxa_SPAF_RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Pradaxa-SPAF-RfA_July-22-13_e.pdf']",Atrial fibrillation prevention of stroke and systemic embolism,List with clinical criteria and/or conditions,Complete,18-Mar-13,18-Jul-13,SF0320-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,"['/sites/default/files/cdr/tracking/cdr_SF0321_Xarelto_SPAF_RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xarelto-SPAF-RfA_July-22-13_e.pdf']",,List with clinical criteria and/or conditions,Complete,18-Mar-13,18-Jul-13,SF0321-00
AbataceptOpens in new tab,Orencia,Abatacept,"['/sites/default/files/cdr/tracking/cdr_tracking_Orencia_RA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Orencia-RA_July-22-13_e.pdf']","Arthritis, rheumatoid",List with clinical criteria and/or conditions,Complete,29-Nov-12,18-Jul-13,SR0299-000
EculizumabOpens in new tab,Soliris,Eculizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Soliris.pdf', '/sites/default/files/cdr/complete/cdr_complete_Soliris-aHUS_July-23-13.pdf']","Hemolytic Uremic Syndrome, Atypical",Do not list,Complete,07-Jan-13,18-Jul-13,SR0304-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/cdr_SR0308_Humira-JIA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Humira-JIA_July-22-13_e.pdf']","Arthritis, juvenile idiopathic",List with clinical criteria and/or conditions,Complete,04-Feb-13,18-Jul-13,SR0308-000
NebivololOpens in new tab,Bystolic,Nebivolol,"['/sites/default/files/cdr/tracking/cdr_SR0307_Bystolic.pdf', '/sites/default/files/cdr/complete/CDR_complete_Bystolic_July-22-13_e.pdf']",Hypertension,Do not list at the submitted price,Complete,04-Feb-13,18-Jul-13,SR0307-000
Tykerb Letrozole for Metastati...Opens in new tab,Tykerb (in combination with Letrozole),Lapatinib,"['/sites/default/files/pcodr/pcodr-provfund_tykerb-mbc.pdf', '/sites/default/files/pcodr/pcodr-tykerb-mbc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-tykerb-mbc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-tykerb-mbc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-tykerb-mbc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-tykerbmbc-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-tykerbmbc-in-fdk-gsk.pdf']",Metastatic Breast Cancer,Do not reimburse,Complete,14-Dec-12,05-Jul-13,PC0019-000
TelaprevirOpens in new tab,Incivek,Telaprevir,"['/sites/default/files/cdr/tracking/cdr_SF0311_Incivek-HCV-HIV_RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Incivek%20RFA-SR0311-June-14-13.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,19-Feb-13,13-Jun-13,SF0311-000
BoceprevirOpens in new tab,Victrelis,Boceprevir,"['/sites/default/files/cdr/tracking/cdr_SF0312_Victrelis-HIV-HCV_RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_SF0312-Victrelis_RFA_June-14-13.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,19-Feb-13,13-Jun-13,SF0312-000
TelaprevirOpens in new tab,Incivek,Telaprevir,"['/sites/default/files/cdr/tracking/cdr_tracking_Incivek_RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Incivek%20RFA-SR0305-June-14-13.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,21-Dec-12,13-Jun-13,SF0305-000
BoceprevirOpens in new tab,Victrelis,Boceprevir,"['/sites/default/files/cdr/tracking/cdr_tracking_Victrelis_RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_SF0303-Victrelis-RFA_June-14-13.pdf']","Hepatitis C, chronic",List with criteria/condition,Complete,21-Dec-12,13-Jun-13,SF0303-000
Palonosetron hydrochlorideOpens in new tab,Aloxi (injection),Palonosetron hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Aloxi-IV.pdf', '/sites/default/files/cdr/complete/cdr_complete_Aloxi%20IV_may-17-13.pdf']",Chemotherapy-induced nausea and vomiting,Do not list at the submitted price,Complete,05-Oct-12,15-May-13,SR0293-000
Elvitegravir/  Cobicistat/  Em...Opens in new tab,Stribild,Elvitegravir/  Cobicistat/  Emtricitabine/  Tenofovir Disoproxil Fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Stribild.pdf', '/sites/default/files/cdr/complete/cdr_complete_Stribild_May-17-13.pdf']",HIV infection,List with criteria/condition,Complete,30-Nov-12,15-May-13,SR0301-000
Glycopyrronium bromideOpens in new tab,Seebri,Glycopyrronium bromide,"['/sites/default/files/cdr/tracking/cdr_tracking_Seebri.pdf', '/sites/default/files/cdr/complete/cdr_complete_Seebri-May-17-13.pdf']",Chronic obstructive pulmonary disease,List with criteria/condition,Complete,30-Nov-12,15-May-13,SR0300-000
Xalkori for Advanced NSCLC - R...Opens in new tab,Xalkori,Crizotinib,"['/sites/default/files/pcodr/pcodr-provfund_xalkorire-nsclc.pdf', '/sites/default/files/pcodr/pcodr-xalkoriresub-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-xalkoriresub-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-xalkoriresub-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-xalkoriresub-in-rec.pdf', '/sites/default/files/pcodr/pcodr-xalkorire-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-xalkoriresub-fdk-pfizer.pdf', '/sites/default/files/pcodr/pcodr-xalkorire-fdk-lcc.pdf', '/sites/default/files/pcodr/pcodr-xalkoriresub-coi-lcc.pdf']",Advanced or Metastatic Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,23-Oct-12,02-May-13,PC0017-000
Palonosetron hydrochlorideOpens in new tab,Aloxi (capsule),Palonosetron hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Aloxi-capsules.pdf', '/sites/default/files/cdr/complete/cdr_complete_Aloxi%20PO_April-25-13.pdf']",Chemotherapy-induced nausea and vomiting,Do not list,Complete,05-Oct-12,24-Apr-13,SR0294-000
PirfenidoneOpens in new tab,Esbriet,Pirfenidone,"['/sites/default/files/cdr/tracking/cdr_tracking_Esbriet.pdf', '/sites/default/files/cdr/complete/cdr_complete_Esbriet_April-24-13.pdf']",Idiopathic pulmonary fibrosis,Do not list,Complete,05-Oct-12,18-Apr-13,SR0292-000
Doxycycline monohydrateOpens in new tab,Apprilon,Doxycycline monohydrate,"['/sites/default/files/cdr/tracking/cdr_tracking_Apprilon.pdf', '/sites/default/files/cdr/complete/cdr_complete_Apprilon_April-1-13.pdf']",Rosacea,Do not list,Complete,27-Apr-12,27-Mar-13,SR0279-000
Collagenase clostridium histol...Opens in new tab,Xiaflex,Collagenase clostridium histolyticum,"['/sites/default/files/cdr/tracking/cdr_tracking_Xiaflex.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xiaflex_April-1-13.pdf']",Dupuytren’s contracture,List with criteria/condition,Complete,30-Aug-12,27-Mar-13,SR0287-000
Velcade for Multiple Myeloma -...Opens in new tab,Velcade,Bortezomib,"['/sites/default/files/pcodr/pcodr-provfund_velcade-mm.pdf', '/sites/default/files/pcodr/pcodr-velcademm-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-velcademm-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-velcademm-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-velcademm-in-rec.pdf', '/sites/default/files/pcodr/pcodr-velcademm-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-velcademm-in-fdk-janssen.pdf', '/sites/default/files/pcodr/pcodr-velcademm-in-fdk-ccohdsg.pdf', '/sites/default/files/pcodr/pcodr-velcademm-ptfdk-inrec-mc.pdf', '/sites/default/files/pcodr/pcodr-velcademm-coi-mc.pdf']",Multiple Myeloma,Reimburse,Complete,29-Oct-12,25-Mar-13,PC0016-000
Afinitor for Advanced Breast -...Opens in new tab,Afinitor,Everolimus,"['/sites/default/files/pcodr/pcodr-provfund_afinitor-ab.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-in-rec.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-pag-fdk-inrec.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-in-fdk-novart.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-coi-cbcn.pdf', '/sites/default/files/pcodr/pcodr-afinitorab-coi-rebc.pdf']",Advanced Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,05-Sep-12,25-Mar-13,PC0014-000
IvacaftorOpens in new tab,Kalydeco,Ivacaftor,"['/sites/default/files/cdr/tracking/cdr_tracking_Kalydeco.pdf', '/sites/default/files/cdr/complete/cdr_complete_Kalydeco_March-25-13_e.pdf']","Cystic fibrosis, G551D mutation",List with criteria/condition,Complete,27-Sep-12,22-Mar-13,SR0291-000
Grass Pollen Allergen ExtractOpens in new tab,Oralair,Grass Pollen Allergen Extract,"['/sites/default/files/cdr/tracking/cdr_tracking_Oralair.pdf', '/sites/default/files/cdr/complete/cdr_complete_Oralair_March-25-13_e.pdf']",Allergic rhinitis,List with criteria/condition,Complete,21-Sep-12,20-Mar-13,SR0290-000
ApixabanOpens in new tab,Eliquis,Apixaban,"['/sites/default/files/cdr/tracking/cdr_tracking_Eliquis-SPAF_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Eliquis_SPAF_Mar-22-13-e.pdf']","Thromboembolic events prevention, (atrial fibrillation)",List with clinical criteria and/or conditions,Complete,25-Sep-12,20-Mar-13,SR0288-000
Inlyta for metastatic renal ce...Opens in new tab,Inlyta,Axitinib,"['/sites/default/files/pcodr/pcodr-provfund_inlyta-mrcc.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-in-rec.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-pag-fdk-inrec.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-infdk-pfizer.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-infdk-kcc.pdf', '/sites/default/files/pcodr/pcodr-inlytamrcc-coi-kcc.pdf']",Metastatic Renal Cell Carcinoma,Reimburse,Complete,16-Aug-12,07-Mar-13,PC0013-000
Treanda for Chronic Lymphocyti...Opens in new tab,Treanda,Bendamustine hydrochloride,"['/sites/default/files/pcodr/pcodr_profund_treandacllrel.pdf', '/sites/default/files/pcodr/pcodr-treandacll1st-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-treandacll1st-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-treandacll1st-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-treandacll1st-in-rec.pdf', '/sites/default/files/pcodr/pcodr-cll1stline-pag-fdk-inrec.pdf', '/sites/default/files/pcodr/pcodr-cll1st-infdk-lundbeckcan.pdf', '/sites/default/files/pcodr/pcodr-cll1st-coi-cllpag.pdf', '/sites/default/files/pcodr/pcodr-cll1st-coi-llsc.pdf']",Chronic Lymphocytic Leukemia (first-line),Reimburse with clinical criteria and/or conditions,Complete,24-Apr-12,19-Feb-13,PC0011-000
TolvaptanOpens in new tab,Samsca,Tolvaptan,"['/sites/default/files/cdr/tracking/cdr_tracking_Samsca.pdf', '/sites/default/files/cdr/complete/cdr_complete_Samsca_Feb-12-13-e.pdf']","Hyponatremia, non-hypovolemic",Do not list,Complete,03-Jul-12,13-Feb-13,SR0283-000
LurasidoneOpens in new tab,Latuda,Lurasidone,"['/sites/default/files/cdr/tracking/cdr_tracking_Latuda.pdf', '/sites/default/files/cdr/complete/cdr_complete_Latuda_Jan-25-13_e.pdf']",Schizophrenia,Do not list,Complete,03-Jul-12,23-Jan-13,SR0284-000
Jakavi for myelofibrosisOpens in new tab,Jakavi,Ruxolitinib,"['/sites/default/files/pcodr/pcodr-provfund_jakavi_myelo.pdf', '/sites/default/files/pcodr/pcodr-jakavimyelofibro-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-jakavi-myelofibro-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-jakavi-myelofibro-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-jakavi-myelofibro-in-rec.pdf', '/sites/default/files/pcodr/pcodr-jakavi-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-jakavi-in-fdk-novartis.pdf', '/sites/default/files/pcodr/pcodr-jakavi-pt-fdk-in-rec-cml.pdf', '/sites/default/files/pcodr/pcodr-jakavi-coi-cml.pdf', '/sites/default/files/pcodr/pcodr-jakavi-pt-fdkinrec-cpmnn.pdf', '/sites/default/files/pcodr/pcodr-jakavi-coi-cpmnn.pdf']",Myelofibrosis,Reimburse with clinical criteria and/or conditions,Complete,25-Jun-12,14-Jan-13,PC0012-000
Colesevelam hydrochlorideOpens in new tab,Lodalis,Colesevelam hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_lodalis.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lodalis_Decembe_21_12.pdf']",Hypercholesterolemia,Do not list at the submitted price,Complete,27-Apr-12,19-Dec-12,SR0274-000
Mometasone/formoterolOpens in new tab,Zenhale,Mometasone/formoterol,"['/sites/default/files/cdr/tracking/cdrr_tracking_Zenhale-RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Zenhale%20RfA_December_21_12.pdf']",Asthma,List with clinical criteria and/or conditions,Complete,06-Jun-12,19-Dec-12,SF0281-000
FidaxomicinOpens in new tab,Dificid,Fidaxomicin,"['/sites/default/files/cdr/tracking/cdr_tracking_Dificid.pdf', '/sites/default/files/cdr/complete/cdr_complete_Dificid_December_21_12.pdf']",Clostridium difficile infection,Do not list at the submitted price,Complete,10-Jul-12,19-Dec-12,SR0285-000
Votrient for Soft Tissue Sarco...Opens in new tab,Votrient,Pazopanib Hydrochloride,"['/sites/default/files/pcodr/pcodr-provfund_votrient-sts.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-in-rec.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-pcodr9.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-pcodr10.pdf', '/sites/default/files/pcodr/pcodr-votrientsts-pcodr11.pdf']",Soft Tissue Sarcoma,Do not reimburse,Complete,04-Jun-12,29-Nov-12,PC0009-000
Treanda for Chronic Lymphocyti...Opens in new tab,Treanda,Bendamustine hydrochloride,"['/sites/default/files/pcodr/pcodr_provfund_treandacllrel.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-treandacll-in-rec.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr1.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr2.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr3.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr4.pdf', '/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr12.pdf']",Chronic Lymphocytic Leukemia (relapsed/refractory),Do not reimburse,Complete,24-Apr-12,29-Nov-12,PC0011-000
Treanda for indolent Non-Hodgk...Opens in new tab,Treanda,Bendamustine hydrochloride,"['/sites/default/files/pcodr/pcodr_provfund_treandanhl.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-in-rec.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-pcodr5.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-pcodr6.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-pcodr7.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-pcodr8.pdf', '/sites/default/files/pcodr/pcodr-treandanhl-pcodr13.pdf']",Non-Hodgkin Lymphoma  and Mantle Cell Lymphoma,Reimburse,Complete,24-Apr-12,29-Nov-12,PC0010-000
FampridineOpens in new tab,Fampyra,Fampridine,"['/sites/default/files/cdr/tracking/cdr_tracking_Fampyra.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fampyra_Nov-30-12.pdf']","Multiple sclerosis, improve walking disability",Do not list,Complete,16-Apr-12,28-Nov-12,SR0275-000
Ranibizumab injectionOpens in new tab,Lucentis,Ranibizumab injection,"['/sites/default/files/cdr/tracking/cdr_tracking_Lucentis-RVO-2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lucentis%20RVO_Oct-22-12_e.pdf']","Macular edema, secondary to retinal vein occlusion",List with clinical criteria and/or conditions,Complete,25-Apr-12,18-Oct-12,SR0276-000
Fesoterodine fumarateOpens in new tab,Toviaz,Fesoterodine fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Toviaz.pdf', '/sites/default/files/cdr/complete/cdr_complete_Toviaz_Oct-22-12_e.pdf']",Overactive bladder,List in a similar manner,Complete,27-Apr-12,18-Oct-12,SR0277-000
Xalkori for Advanced Non-Small...Opens in new tab,Xalkori,Crizotinib,"['/sites/default/files/pcodr/pcodr-xalkorinsclc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-xalkorinsclc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-xalkorinsclc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-xalkori-in-rec.pdf', '/sites/default/files/pcodr/pcodr-xalkori-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-xalkori-in-fdk-pfizer.pdf', '/sites/default/files/pcodr/pcodr_xalkorinsclc_lcc_in_fdk.pdf', '/sites/default/files/pcodr/pcodr-xalkori-coi-lcc.pdf']",Advanced Non-Small Cell Lung Cancer,Do not reimburse,Complete,26-Mar-12,04-Oct-12,PC0008-000
PlerixaforOpens in new tab,Mozobil,Plerixafor,"['/sites/default/files/cdr/tracking/cdr_tracking_Mozobil.pdf', '/sites/default/files/cdr/complete/cdr_complete_Mozobil_Sept-28-12_e.pdf']",Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma,Do not list,Complete,24-Jan-12,26-Sep-12,SR0265-000
Afinitor for pancreatic neuroe...Opens in new tab,Afinitor,Everolimus,"['/sites/default/files/pcodr/pcodr-provfund_afinitor-pnet.pdf', '/sites/default/files/pcodr/pcodr-afinitor-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-afinitor-pnets-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-afinitor-pnets-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-afinitor-pnets-in-rec.pdf', '/sites/default/files/pcodr/pcodr-afinitor-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-afinitor-in-fdk-novartis.pdf', '/sites/default/files/pcodr/pcodr-afinitor-coi-cnets.pdf']",Pancreatic Neuroendocrine Tumour,Reimburse with clinical criteria and/or conditions,Complete,27-Feb-12,30-Aug-12,PC0007-000
IndacaterolOpens in new tab,Onbrez,Indacaterol,"['/sites/default/files/cdr/tracking/cdr_tracking_Onbrez.pdf', '/sites/default/files/cdr/complete/cdr_complete_Onbrez_Aug-20-12_e.pdf']",Chronic obstructive pulmonary disease,List in a similar manner,Complete,29-Feb-12,16-Aug-12,SR0273-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,"['/sites/default/files/cdr/tracking/cdr_tracking_Xarelto_DVT.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xarelto%20DVT_Aug-20-12_e.pdf']",Deep-vein thrombosis without symptomatic pulmonary embolism,List with clinical criteria and/or conditions,Complete,27-Feb-12,16-Aug-12,SR0271-000
RituximabOpens in new tab,Rituxan,Rituximab,"['/sites/default/files/cdr/tracking/cdr_tracking_Rituxan-2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Rituxan-Aug_16-12_e.pdf']",Granulomatosis with polyangiitis and microscopic polyangiitis,List with clinical criteria and/or conditions,Complete,24-Feb-12,16-Aug-12,SR0270-000
Halaven for Metastatic Breast ...Opens in new tab,Halaven,Eribulin Mesylate,"['/sites/default/files/pcodr/pcodr-provfund_halaven-mbc.pdf', '/sites/default/files/pcodr/pcodr-halavenmb-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-halavenmb-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-halavenmb-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-halaven-metbreast-in-rec.pdf', '/sites/default/files/pcodr/pcodr-halaven-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-halaven-in-fdk-eisai.pdf', '/sites/default/files/pcodr/pcodr-halavenmb-coi-cbcn.pdf', '/sites/default/files/pcodr/pcodr-halavenmb-coi-ccsn.pdf']",Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,09-Feb-12,02-Aug-12,PC0005-000
ExenatideOpens in new tab,Byetta,Exenatide,"['/sites/default/files/cdr/tracking/cdr_tracking_Byetta.pdf', '/sites/default/files/cdr/complete/cdr_complete_Byetta_July-23-12.pdf']","Diabetes mellitus, type 2",Do not list,Complete,23-Aug-11,19-Jul-12,SR0246-000
PrucaloprideOpens in new tab,Resotran,Prucalopride,"['/sites/default/files/cdr/tracking/cdr_tracking_Resotran.pdf', '/sites/default/files/cdr/complete/cdr_complete_Resotran_July-23-12.pdf']","Constipation, chronic",Do not list,Complete,30-Jan-12,19-Jul-12,SR0266-000
OnabotulinumtoxinAOpens in new tab,Botox,OnabotulinumtoxinA,"['/sites/default/files/cdr/tracking/cdr_tracking_Botox.pdf', '/sites/default/files/cdr/complete/cdr_complete_Botox_July-23-12.pdf']",Neurogenic detrusor overactivity,List with clinical criteria and/or conditions,Complete,31-Jan-12,19-Jul-12,SR0268-000
TocilizumabOpens in new tab,Actemra,Tocilizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Actemra-2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Actemra-sJIA_July-23-12_e.pdf']","Arthritis, juvenile idiopathic",List with clinical criteria and/or conditions,Complete,30-Jan-12,19-Jul-12,SR0267-000
AsenapineOpens in new tab,Saphris,Asenapine,"['/sites/default/files/cdr/tracking/cdr_tracking_Saphris.pdf', '/sites/default/files/cdr/complete/cdr_complete_Saphris-000-June%2018_2012.pdf']",Schizophrenia,Do not list,Complete,12-Dec-11,14-Jun-12,SR0262-000
PrasugrelOpens in new tab,Effient,Prasugrel,"['/sites/default/files/cdr/tracking/cdr_tracking_Effient_Resub-1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Effient-Resubmission_June-18-12.pdf']",Acute coronary syndrome,Do not list,Complete,12-Dec-11,14-Jun-12,SR0263-000
ApixabanOpens in new tab,Eliquis,Apixaban,"['/sites/default/files/cdr/tracking/cdr_tracking_Eliquis.pdf', '/sites/default/files/cdr/complete/cdr_complete_Eliquis_June-18-12_e.pdf']","Venous thromboembolic events, prevention",List with clinical criteria and/or conditions,Complete,20-Dec-11,14-Jun-12,SR0264-000
AsenapineOpens in new tab,Saphris,Asenapine,"['/sites/default/files/cdr/tracking/cdr_tracking_Saphris.pdf', '/sites/default/files/cdr/complete/cdr_complete_Saphris-001-June%2018_2012.pdf']",Bipolar I disorder,List with clinical criteria and/or conditions,Complete,12-Dec-11,14-Jun-12,SR0262-001
Zelboraf for Advanced Melanoma...Opens in new tab,Zelboraf,Vemurafenib,"['/sites/default/files/pcodr/pcodr_provfund_vemurafenib_zelboraf-advmel.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-adv-mel-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-unredact-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-adv-mel-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-in-rec.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-pag-fdk-in-rec.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-in-fdk-roche.pdf', '/sites/default/files/pcodr/pcodr-zelborafadmel-in-fdk-mnc.pdf', '/sites/default/files/pcodr/pcodr-zelboraf-adv-mel-coi-mnc.pdf']",Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,06-Dec-11,01-Jun-12,PC0006-000
Oxybutynin Chloride GelOpens in new tab,Gelnique,Oxybutynin Chloride Gel,"['/sites/default/files/cdr/tracking/cdr_tracking_Gelnique.pdf', '/sites/default/files/cdr/complete/cdr_complete_Gelnique_May%2028-2012.pdf']",Overactive bladder,Do not list,Complete,25-Oct-11,24-May-12,SR0260-000
Mometasone furoateOpens in new tab,ASMANEX,Mometasone furoate,"['/sites/default/files/cdr/tracking/cdr_tracking_Asmanex.pdf', '/sites/default/files/cdr/complete/cdr_complete_Asmanex_%20May-16-12.pdf']",Asthma,List,Complete,10-Nov-11,16-May-12,SR0258-000
Sutent for pancreatic neuroend...Opens in new tab,Sutent,Sunitinib malate,"['/sites/default/files/pcodr/pcodr-provfund_sutent-pnets.pdf', '/sites/default/files/pcodr/pcodr-sutent-pnet-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-sutent-pnet-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-sutent-pnet-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-sutent-in-rec.pdf', '/sites/default/files/pcodr/pcodr-sutent-pnet-pag-fd-irec.pdf', '/sites/default/files/pcodr/pcodr-sutentpnet-in-fdk-pzr.pdf', '/sites/default/files/pcodr/pcodr-sutent-pnet-coi-cnets.pdf']",Pancreatic Neuroendocrine Tumour,Reimburse with clinical criteria and/or conditions,Complete,07-Nov-11,03-May-12,PC0004-000
Dexamethasone intravitreal imp...Opens in new tab,Ozurdex,Dexamethasone intravitreal implant,"['/sites/default/files/cdr/tracking/cdr_tracking_Ozurdex.pdf', '/sites/default/files/cdr/complete/cdr_complete_Ozurdex_April-27-1_e.pdf']","Macular edema, central retinal vein occlusion",Do not list,Complete,01-Sep-11,25-Apr-12,SR0247-000
BelimumabOpens in new tab,Benlysta,Belimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Benlysta.pdf', '/sites/default/files/cdr/complete/cdr_complete_Benlysta_April-27-12_e.pdf']",Systemic lupus erythematosus,Do not list,Complete,19-Sep-11,25-Apr-12,SR0251-000
SilodosinOpens in new tab,RAPAFLO,Silodosin,"['/sites/default/files/cdr/tracking/cdr_tracking_Rapaflo.pdf', '/sites/default/files/cdr/complete/cdr_complete_Rapaflo_April-20-12.pdf']",Benign prostatic hyperplasia,Do not list,Complete,25-Oct-11,19-Apr-12,SR0261-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,"['/sites/default/files/cdr/tracking/cdr_tracking_Xarelto-SPAF_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xarelto-SPAF_April-20-12.pdf']","Atrial fibrillation, stroke prevention",List with clinical criteria and/or conditions,Complete,21-Oct-11,19-Apr-12,SR0257-000
DienogestOpens in new tab,Visanne,Dienogest,"['/sites/default/files/cdr/tracking/cdr_tracking_Visanne.pdf', '/sites/default/files/cdr/complete/cdr_complete_Visanne_April-20-12.pdf']","Pain, pelvic pain associated with endometriosis",List with clinical criteria and/or conditions,Complete,18-Oct-11,19-Apr-12,SR0255-000
Emtricitabine/ rilpivirine/ te...Opens in new tab,COMPLERA,Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Complera.pdf', '/sites/default/files/cdr/complete/cdr_complete_Complera_April-20-12.pdf']",HIV infection,List,Complete,19-Oct-11,19-Apr-12,SR0256-000
Yervoy for advanced melanoma -...Opens in new tab,Yervoy,Ipilimumab,"['/sites/default/files/pcodr/pcodr-provfund_yervoy-advmel.pdf', '/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-yervoy-in-rec.pdf', '/sites/default/files/pcodr/pcodr-yervoyadvmel-pag-fd-irec.pdf', '/sites/default/files/pcodr/pcodr-yervoyadvmel-in-fdk-bms.pdf', '/sites/default/files/pcodr/pcodr-yervoyadvmel-in-fdk-mnc.pdf', '/sites/default/files/pcodr/pcodr-yervoy-adv-mel-coi-mnc.pdf', '/sites/default/files/pcodr/pcodr-yervoy-adv-mel-coi-sys.pdf']",Advanced Melanoma,Reimburse with clinical criteria and/or conditions,Complete,01-Dec-11,18-Apr-12,PC0003-000
RanibizumabOpens in new tab,Lucentis,Ranibizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Lucentis.pdf', '/sites/default/files/cdr/complete/cdr-complete_Lucentis_DME_March-21-12.pdf']","Macular edema, diabetic",List with clinical criteria and/or conditions,Complete,14-Sep-11,19-Mar-12,SR0253-000
RufinamideOpens in new tab,Banzel,Rufinamide,"['/sites/default/files/cdr/tracking/cdr_tracking_Banzel.pdf', '/sites/default/files/cdr/complete/cdr_complete_Banzel_March-19-12_e.pdf']",Lennox-Gastaut syndrome,List with clinical criteria and/or conditions,Complete,20-Sep-11,15-Mar-12,SR0252-000
RilpivirineOpens in new tab,Edurant,Rilpivirine,"['/sites/default/files/cdr/tracking/cdr_tracking_edurant.pdf', '/sites/default/files/cdr/complete/cdr_complete_Edurant_Feb-17-12_e.pdf']",HIV infection,List,Complete,29-Jul-11,15-Feb-12,SR0243-000
LinagliptinOpens in new tab,Trajenta,Linagliptin,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_tracking_Trajenta.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Trajenta_February_18_2012.pdf']","Diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,23-Aug-11,15-Feb-12,SR0244-000
TelaprevirOpens in new tab,Incivek,Telaprevir,"['/sites/default/files/cdr/tracking/cdr_tracking_Incivek.pdf', '/sites/default/files/cdr/complete/cdr_complete_Incivek_Feb-17-12_e.pdf']","Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,23-Aug-11,15-Feb-12,SR0249-000
Fentanyl CitrateOpens in new tab,Onsolis,Fentanyl Citrate,"['/sites/default/files/cdr/tracking/cdr_tracking_Onsolis_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Onsolis_Feb-17-12_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_onsolis-resub_plr_aug-13-12_e.pdf']","Pain, breakthrough cancer pain",Do not list,Complete,22-Aug-11,15-Feb-12,SR0248-000
Oxycodone HCI / naloxone HCIOpens in new tab,Targin,Oxycodone HCI / naloxone HCI,"['/sites/default/files/cdr/tracking/cdr_tracking_targin_Resub1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Targin_2_Jan-27-12_e.pdf']","Pain, moderate to severe and relief of opioid-induced constipation",Do not list,Complete,05-Jul-11,25-Jan-12,SR0241-000
Votrient for metastatic renal ...Opens in new tab,Votrient,Pazopanib hydrochloride,"['/sites/default/files/pcodr/pcodr-provfund_votrient-mrcc.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-fn-rec.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-fn-cgr.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-fn-egr.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-initial-rec.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-pag-fd-irec.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-in-fdk-gsk.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-in-fdk-kcc.pdf', '/sites/default/files/pcodr/pcodr-votrientmrcc-kcc-coi.pdf']",Metastatic Renal Cell Carcinoma,Reimburse,Complete,14-Jul-11,05-Jan-12,PC0000-000
TicagrelorOpens in new tab,Brilinta,Ticagrelor,"['/sites/default/files/cdr/tracking/cdr_tracking_brilinta.pdf', '/sites/default/files/cdr/complete/cdr_complete_Brilinta_Dec-20-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Brilinta_plr_Aug-13-12_e.pdf']",Acute coronary syndromes,Do not list,Complete,01-Jun-11,16-Dec-11,SR0234-000
Fentanyl CitrateOpens in new tab,Abstral,Fentanyl citrate,"['/sites/default/files/cdr/tracking/cdr_tracking_abstral.pdf', '/sites/default/files/cdr/complete/cdr_complete_Abstral_Dec-20-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Abstral_PLR_July-3-12.pdf']","Pain, breakthrough cancer pain",Do not list,Complete,30-Jun-11,16-Dec-11,SR0240-000
Telmisartan/ AmlodipineOpens in new tab,Twynsta,Telmisartan/ Amlodipine,"['/sites/default/files/cdr/tracking/cdr_tracking_Twynsta_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Twynsta_Dec-20-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Twynsta_plr_June-15-12.pdf']",Hypertension,List,Complete,23-Aug-11,16-Dec-11,SR0245-000
FingolimodOpens in new tab,Gilenya,Fingolimod,"['/sites/default/files/cdr/tracking/cdr_tracking_gilenya.pdf', '/sites/default/files/cdr/complete/cdr_complete_Gilenya_Nov-18-11_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Gilenya_plr_Mar-1-12.pdf']","Multiple Sclerosis, relapsing-remitting",List with clinical criteria and/or conditions,Complete,10-May-11,16-Nov-11,SR0228-000
DenosumabOpens in new tab,XGEVA,Denosumab,"['/sites/default/files/cdr/tracking/cdr_tracking_XGEVA-Pilot.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xgeva_Nov-18-11_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Xgeva_plr_Mar-8-12.pdf']",Prevention of skeletal-related events due to bone metastases from solid tumours,List with clinical criteria and/or conditions,Complete,06-Jun-11,16-Nov-11,SR0235-000
Zoledronic acidOpens in new tab,Aclasta,Zoledronic acid,"['/sites/default/files/cdr/tracking/cdr_tracking_aclasta_request-advice.pdf', '/sites/default/files/cdr/complete/cdr_complete_Aclasta-RFA_Nov-18-11_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Aclasta_RfA_PLR_April%204-2012.pdf']",Osteoporosis,List with clinical criteria and/or conditions,Complete,20-Jul-11,16-Nov-11,SF0242-000
BoceprevirOpens in new tab,Victrelis,Boceprevir,"['/sites/default/files/cdr/tracking/cdr_tracking_Victrelis_Pre-NOC.pdf', '/sites/default/files/cdr/complete/cdr_complete_Victrelis_Oct-26-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Victrelis_plain-lang-rec_Jan-6-12%20.pdf']","Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,03-May-11,24-Oct-11,SR0231-000
Eltrombopag olamineOpens in new tab,Revolade,Eltrombopag olamine,"['/sites/default/files/cdr/tracking/cdr_tracking_revolade.pdf', '/sites/default/files/cdr/complete/cdr_complete_Revolade_Oct-26-11_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Revolade_plain-lang-rec_Jan-6-12%20.pdf']",Chronic immune thrombocytopenic purpura,Do not list,Complete,26-Apr-11,24-Oct-11,SR0230-000
AlitretinoinOpens in new tab,Toctino,Alitretinoin,"['/sites/default/files/cdr/tracking/cdr_tracking_toctino.pdf', '/sites/default/files/cdr/complete/cdr_complete_Toctino_October_26_2011.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Toctino_plain-lang-rec__Jan-6-12%20.pdf']",Eczema,List with clinical criteria and/or conditions,Complete,06-May-11,24-Oct-11,SR0232-000
TapentadolOpens in new tab,Nucynta CR,Tapentadol,"['/sites/default/files/cdr/tracking/cdr_tracking_Nucynta.pdf', '/sites/default/files/cdr/complete/cdr_complete_Nucynta_March-25-2014.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Nucynta_CR_PL_Nov-24-11.pdf']","Pain, moderate to moderately severe",Do not list,Complete,01-Feb-11,28-Sep-11,SR0224-000
Mometasone furoate and formote...Opens in new tab,Zenhale (inhalation aerosol),Mometasone furoate and formoterol,"['/sites/default/files/cdr/tracking/cdr_tracking_Zenhale.pdf', '/sites/default/files/cdr/complete/cdr_complete_zenhale_Oct-3-11_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Zenhale_plr_Dec-6-11.pdf']",Asthma,Do not list,Complete,16-Feb-11,28-Sep-11,SR0225-000
Buprenorphine transdermal patc...Opens in new tab,BuTrans,Buprenorphine transdermal patch,"['/sites/default/files/cdr/tracking/cdr_tracking_BuTrans_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Butrans-September-30-2011.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Butrans_PL_Nov-24-11.pdf']","Pain, moderate intensity persistent pain",Do not list,Complete,09-May-11,28-Sep-11,SR0233-000
LiraglutideOpens in new tab,Victoza,Liraglutide,"['/sites/default/files/cdr/tracking/cdr_tracking_victoza.pdf', '/sites/default/files/cdr/complete/cdr_complete-Victoza-September-30-2011.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Victoza_plr_Dec_6-11.pdf']","Diabetes mellitus, Type 2",Do not list,Complete,29-Nov-10,28-Sep-11,SR0217-000
RoflumilastOpens in new tab,Daxas,Roflumilast,"['/sites/default/files/cdr/tracking/cdr_tracking_Daxas.pdf', '/sites/default/files/cdr/complete/cdr_complete_Daxas_August-3-2011_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Daxas_pl-Rec_Sept-16-11_e.pdf']",Chronic obstructive pulmonary disease,Do not list,Complete,30-Nov-10,27-Jul-11,SR0218-000
CyclosporineOpens in new tab,Restasis ophthalmic emulsion,Cyclosporine,"['/sites/default/files/cdr/tracking/cdr_tracking_Restasis.pdf', '/sites/default/files/cdr/complete/cdr_complete_Restatis_Final_July-20-2011_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Restasis_plr_Sept-2-11_e.pdf']",Dry eye disease,Do not list,Complete,17-Dec-10,18-Jul-11,SR0222-000
MaravirocOpens in new tab,Celsentri,Maraviroc,"['/sites/default/files/cdr/tracking/cdr_tracking_Celsentri_TNaive.pdf', '/sites/default/files/cdr/complete/cdr_complete_Celsentri_Final_July-20-2011_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Celsentri_pl-rec_Sept-13-11.pdf']",HIV infection,Do not list,Complete,08-Dec-10,18-Jul-11,SR0221-000
AripiprazoleOpens in new tab,Abilify,Aripiprazole,"['/sites/default/files/cdr/tracking/cdr_tracking_Abilify_request-advice.pdf', '/sites/default/files/cdr/complete/cdr_complete_Abilify_July-20-2011_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Abilify_plr_Sept-2-11_e.pdf']",Schizophrenia and related psychotic disorders,List with clinical criteria and/or conditions,Complete,29-Mar-11,18-Jul-11,SF0226-000
Aztreonam for inhalation solut...Opens in new tab,Cayston,Aztreonam for inhalation solution,"['/sites/default/files/cdr/tracking/cdr_tracking_Cayston.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cayston_July-20-2011_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Cayston_plr_Sept-2-11_e.pdf']","Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections",List with clinical criteria and/or conditions,Complete,02-Dec-10,18-Jul-11,SR0220-000
Dabigatran etexilateOpens in new tab,Pradaxa,Dabigatran etexilate,"['/sites/default/files/cdr/tracking/cdr_tracking_Pradax_AF2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Pradax_June-27-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Pradax_Plain_Lang_Rec_August-19-11_e.pdf']",Atrial fibrillation prevention of stroke and systemic embolism,List with clinical criteria and/or conditions,Complete,28-Oct-10,22-Jun-11,SR0214-000
Paliperidone palmitateOpens in new tab,Invega Sustenna,Paliperidone palmitate,"['/sites/default/files/cdr/tracking/cdr_tracking_Invega%20Sustenna.pdf', '/sites/default/files/cdr/complete/cdr_complete_Invega-Sustenna_April-29-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Invega-Sustenna_pl-recSept-13-11.pdf']",Schizophrenia,Do not list,Complete,09-Jul-10,25-Apr-11,SR0206-000
FebuxostatOpens in new tab,Uloric,Febuxostat,"['/sites/default/files/cdr/tracking/cdr_tracking_Uloric.pdf', '/sites/default/files/cdr/complete/cdr_complete_Uloric_April-29-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Uloric_plr_June-10-11.pdf']",Gout,List with clinical criteria and/or conditions,Complete,27-Oct-10,25-Apr-11,SR0213-000
LacosamideOpens in new tab,Vimpat,Lacosamide,"['/sites/default/files/cdr/tracking/cdr_tracking_Vimpat.pdf', '/sites/default/files/cdr/complete/cdr_complete_Vimpat_April-29-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Vimpat_plr_June-10-11.pdf']","Epilepsy, partial onset seizures",List with clinical criteria and/or conditions,Complete,25-Oct-10,25-Apr-11,SR0212-000
Velaglucerase alfaOpens in new tab,VPRIV,Velaglucerase alfa,"['/sites/default/files/cdr/tracking/cdr_tracking_Vpriv.pdf', '/sites/default/files/cdr/complete/cdr_complete_Vpriv_April-29-11.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_VPRIV_plain-l-r_July-12-011_e.pdf']",Gaucher Disease,List with clinical criteria and/or conditions,Complete,28-Oct-10,25-Apr-11,SR0215-000
DenosumabOpens in new tab,Prolia,Denosumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Prolia.pdf', '/sites/default/files/cdr/complete/cdr_complete_Prolia_April-1-11.pdf', '/sites/default/files/cdr/relatedinfo/Prolia_Plain_Language_May-17-11_e.pdf']","Osteoporosis, postmenopausal women",List with clinical criteria and/or conditions,Complete,26-Aug-10,30-Mar-11,SR0208-000
Prasugrel hydrochlorideOpens in new tab,Effient,Prasugrel hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Effient.pdf', '/sites/default/files/cdr/complete/cdr_complete_Effient-Feb-18-2011.pdf']",Acute Coronary Syndrome,Do not list,Complete,05-May-10,16-Feb-11,SR0200-000
Azelaic acidOpens in new tab,Finacea,Azelaic acid,"['/sites/default/files/cdr/tracking/cdr_tracking_Finacea.pdf', '/sites/default/files/cdr/complete/cdr_complete_Finacea_Feb-18-2011.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_finacea_plain-language_rec_april_5%2C_2011_e.pdf']",Rosacea,List,Complete,31-Aug-10,16-Feb-11,SR0209-000
CanakinumabOpens in new tab,Ilaris,Canakinumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Ilaris.pdf', '/sites/default/files/cdr/complete/cdr_complete_Ilaris_Jan-28-2011.pdf', '/sites/default/files/cdr/relatedinfo/ilaris_plain_language_rec_march-15-2011_e.pdf']",Cryopyrin-Associated Periodic Syndrome,Do not list,Complete,07-Jul-10,26-Jan-11,SR0204-000
Sapropterin dihydrochlorideOpens in new tab,Kuvan,Sapropterin dihydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Kuvan.pdf', '/sites/default/files/cdr/complete/cdr_complete_Kuvan_Jan-28-2011.pdf', '/sites/default/files/cdr/relatedinfo/kuvan_plain-language_rec_march-15-2011_e.pdf']",Phenylketonuria (PKU),Do not list,Complete,08-Jul-10,26-Jan-11,SR0205-000
TocilizumabOpens in new tab,Actemra,Tocilizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Actemra.pdf', '/sites/default/files/cdr/complete/cdr_complete_Actemra-Nov-19-2010.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_actemra_plainl-r-r_jan11_2011_e.pdf']","Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,27-May-10,17-Nov-10,SR0201-000
CalcitriolOpens in new tab,Silkis,Calcitriol,"['/sites/default/files/cdr/tracking/cdr_tracking_Silkis.pdf', '/sites/default/files/cdr/complete/cdr_complete_Silkis_recommendation_Sept_23_2010.pdf']","Psoriasis, mild to moderate plaque",Do not list,Complete,15-Mar-10,22-Sep-10,SR0199-000
TadalafilOpens in new tab,Adcirca,Tadalafil,"['/sites/default/files/cdr/tracking/cdr_tracking_Adcirca.pdf', '/sites/default/files/cdr/complete/cdr_complete_Adcirca_July-19-2010.pdf']",Pulmonary arterial hypertension,List with clinical criteria and/or conditions,Complete,05-Feb-10,15-Jul-10,SR0197-000
Sitagliptin phosphateOpens in new tab,Januvia,Sitagliptin phosphate,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_tracking_Januvia_Resubmission-1.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Januvia%20Resubmission_June-29-2010.pdf']",Diabetes mellitus (Type 2),List with clinical criteria and/or conditions,Complete,29-Oct-09,23-Jun-10,SR0181-000
Sitagliptin phosphate monohydr...Opens in new tab,Janumet,Sitagliptin phosphate monohydrate / metformin hydrochloride,"['https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_tracking_Janumet.pdf', 'https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Janumet_June-29-2010.pdf']",Diabetes mellitus (Type 2),List with clinical criteria and/or conditions,Complete,04-Nov-09,23-Jun-10,SR0182-000
RaltegravirOpens in new tab,Isentress,Raltegravir,"['/sites/default/files/cdr/tracking/cdr_tracking_Isentress_New-Indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Isentress-HIV_June-29-2010.pdf']",HIV (treatment naïve),Do not list,Complete,04-Dec-09,23-Jun-10,SR0191-000
SaxagliptinOpens in new tab,Onglyza,Saxagliptin,"['/sites/default/files/cdr/tracking/cdr_tracking_Onglyza.pdf', '/sites/default/files/cdr/complete/cdr_complete_Onglyza_June-18-2010.pdf']",Diabetes mellitus (Type 2),Do not list,Complete,09-Nov-09,17-Jun-10,SR0185-000
AbataceptOpens in new tab,Orencia,Abatacept,"['/sites/default/files/cdr/tracking/cdr_tracking_Orencia_Resubmission-1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Orencia-Resubmission_June-17-2010.pdf']","Arthritis, Rheumatoid",List in a similar manner,Complete,02-Dec-09,17-Jun-10,SR0187-000
DarunavirOpens in new tab,Prezista,Darunavir,"['/sites/default/files/cdr/tracking/cdr_tracking_Prezista_New_Indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Prezista_Pediatric_HIV_June-17-2010.pdf']",HIV infection (Pediatric),List with clinical criteria and/or conditions,Complete,22-Dec-09,17-Jun-10,SR0194-000
Certolizumab pegolOpens in new tab,Cimzia,Certolizumab pegol,"['/sites/default/files/cdr/tracking/cdr_tracking_Cimzia.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cimzia_May-28-2010.pdf']","Arthritis, rheumatoid",Do not list,Complete,03-Sep-09,27-May-10,SR0175-000
Dronedarone hydrochlorideOpens in new tab,Multaq,Dronedarone hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Multaq.pdf', '/sites/default/files/cdr/complete/cdr_complete_Multaq_May-31-2010.pdf']",Atrial fibrillation,Do not list,Complete,18-Sep-09,27-May-10,SR0177-000
RomiplostimOpens in new tab,Nplate,Romiplostim,"['/sites/default/files/cdr/tracking/cdr_tracking_Nplate.pdf', '/sites/default/files/cdr/complete/cdr_complete_Nplate_May-27-2010.pdf']",Chronic immune (idiopathic) thrombocytopenic purpura (ITP),Do not list,Complete,29-Sep-09,27-May-10,SR0179-000
Loteprednol etabonateOpens in new tab,Lotemax,Loteprednol etabonate,"['/sites/default/files/cdr/tracking/cdr_tracking_Lotemax.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lotemax_May-19-2010.pdf']",Post-operative inflammation following cataract surgery,Do not list,Complete,02-Dec-09,19-May-10,SR0186-000
Hydromorphone hydrochlorideOpens in new tab,Jurnista,Hydromorphone hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Jurnista.pdf', '/sites/default/files/cdr/complete/cdr_complete_Jurnista_May-19-2010.pdf']","Pain, Chronic (moderate to severe)",Do not list,Complete,04-Dec-09,19-May-10,SR0190-000
AripiprazoleOpens in new tab,Abilify,Aripiprazole,"['/sites/default/files/cdr/tracking/cdr_tracking_Abilify.pdf', '/sites/default/files/cdr/complete/cdr_complete_Abilify_April-30-2010_e.pdf']",Schizophrenia,Do not list,Complete,06-Nov-09,27-Apr-10,SR0183-000
GolimumabOpens in new tab,Simponi,Golimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Simponi_RA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Simponi-RA_March-17-2010_e.pdf']","Arthritis, Rheumatoid",List in a similar manner,Complete,03-Sep-09,17-Mar-10,SR0174-000
Teriparatide (rDNA origin) inj...Opens in new tab,Forteo,Teriparatide (rDNA origin) injection,"['/sites/default/files/cdr/tracking/cdr_tracking_Forteo_ACP_Submission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Forteo-ACP_March-17-2010.pdf']","Osteoporosis (in women), Severe",Do not list,Complete,23-Oct-09,17-Mar-10,SR0180-000
GolimumabOpens in new tab,Simponi,Golimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Simponi_PsA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Simponi-PsA_March-17-2010_e.pdf']","Arthritis, psoriatic",List in a similar manner,Complete,03-Sep-09,17-Mar-10,SR0195-000
GolimumabOpens in new tab,Simponi,Golimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Simponi_AS.pdf', '/sites/default/files/cdr/complete/cdr_complete_Simponi-AS_March-17-2010_e.pdf']",Ankylosing spondylitis,List in a similar manner,Complete,03-Sep-09,17-Mar-10,SR0196-000
Brinzolamide and timolol malea...Opens in new tab,Azarga,Brinzolamide and timolol maleate suspension,"['/sites/default/files/cdr/tracking/cdr_tracking_Azarga.pdf', '/sites/default/files/cdr/complete/cdr_complete_Azarga_February_18_2010.pdf']",Glaucoma and ocular hypertension,List in a similar manner to other drugs in class,Complete,28-Aug-09,18-Feb-10,SR0173-000
EculizumabOpens in new tab,Soliris,Eculizumab,"['/sites/default/files/cdr/tracking/cdr_SR0176_Soliris.pdf', '/sites/default/files/cdr/complete/cdr_complete_Soliris_February_18_2010.pdf']",Paroxysmal nocturnal hemoglobinuria (PNH),Do not list,Complete,18-Sep-09,18-Feb-10,SR0176-000
Lisdexamfetamine dimesylateOpens in new tab,Vyvanse,Lisdexamfetamine dimesylate,"['/sites/default/files/cdr/tracking/cdr_tracking_Vyvanse.pdf', '/sites/default/files/cdr/complete/cdr_complete_Vyvanse-December-18-2009.pdf']",Attention deficit hyperactivity disorder,Do not list,Complete,10-Jul-09,18-Dec-09,SR0171-000
Clostridium botulinum neurotox...Opens in new tab,Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins","['/sites/default/files/cdr/tracking/cdr_tracking_Xeomin_Blepharospasm.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xeomin_Blepharospasm-December-18-2009.pdf']",Blepharospasm,List in a similar manner,Complete,12-Jun-09,16-Dec-09,SR0168-000
Clostridium botulinum neurotox...Opens in new tab,Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins","['/sites/default/files/cdr/tracking/cdr_tracking_Xeomin_Cervical_Dystonia.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xeomin_Cervical_Dystonia-December-18-2009.pdf']",Cervical Dystonia,List in a similar manner,Complete,12-Jun-09,16-Dec-09,SR0192-000
Clostridium botulinum neurotox...Opens in new tab,Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins","['/sites/default/files/cdr/tracking/cdr_tracking_Xeomin_Post-Stroke_Spasticity.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xeomin_Post-Stroke_Spasticity-December-18-2009.pdf']","Spasticity, Post-stroke",Do not list,Complete,12-Jun-09,16-Dec-09,SR0193-000
Glatiramer acetateOpens in new tab,Copaxone,Glatiramer acetate,"['/sites/default/files/cdr/tracking/cdr_tracking_Copaxone.pdf', '/sites/default/files/cdr/complete/cdr_comoplete_Copaxone_November-27-2009%20.pdf']","Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis",Do not list,Complete,29-Apr-09,25-Nov-09,SR0164-000
EplerenoneOpens in new tab,Inspra,Eplerenone,"['/sites/default/files/cdr/tracking/cdr_tracking_Inspra.pdf', '/sites/default/files/cdr/complete/cdr_complete_Inspra_November-27-2009.pdf']",Post myocardial infarction,Do not list,Complete,06-May-09,25-Nov-09,SR0165-000
DarunavirOpens in new tab,Prezista,Darunavir,"['/sites/default/files/cdr/tracking/cdr_tracking_Prezista_New_Indication-naive.pdf', '/sites/default/files/cdr/complete/cdr_complete_Prezista_HIV_October-14-2009.pdf']",HIV (treatment naive),List with clinical criteria and/or conditions,Complete,27-Mar-09,14-Oct-09,SR0163-000
Desvenlafaxine succinateOpens in new tab,Pristiq,Desvenlafaxine succinate,"['/sites/default/files/cdr/tracking/cdr_tracking_Pristiq.pdf', '/sites/default/files/cdr/complete/cdr_complete_Pristiq_September-25-2009.pdf']","Depressive, Major Disorder (MDD)",Do not list,Complete,05-Mar-09,23-Sep-09,SR0159-000
PregabalinOpens in new tab,Lyrica,Pregabalin,"['/sites/default/files/cdr/tracking/cdr_tracking_Lyrica_Resubmission_1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lyrica%20Resubmission_September_25-2009.pdf']",diabetic peripheral neuropathy,Do not list,Complete,20-Mar-09,23-Sep-09,SR0162-000
Insulin detemirOpens in new tab,Levemir,Insulin detemir,"['/sites/default/files/cdr/tracking/cdr_tracking_Levemir_Resubmission_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Levemir_Resubmission_Adults_August_20-2009.pdf']",Diabetes mellitus,Do not list,Complete,10-Mar-09,20-Aug-09,SR0160-000
Insulin detemirOpens in new tab,Levemir,Insulin detemir,"['/sites/default/files/cdr/tracking/cdr_tracking_Levemir_new_indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Levemir_Pediatrics_August_20_2009.pdf']","Diabetes mellitus Type1, Pediatrics",Do not list,Complete,10-Mar-09,20-Aug-09,SR0172-000
Levodopa / carbidopaOpens in new tab,Duodopa,Levodopa / carbidopa,"['/sites/default/files/cdr/tracking/cdr_tracking_Duodopa.pdf', '/sites/default/files/cdr/complete/cdr_complete_Duodopa_July_24_2009.pdf']",Parkinson's disease,Do not list,Complete,19-Dec-08,22-Jul-09,SR0154-000
Teriparatide (rDNA origin) inj...Opens in new tab,Forteo,Teriparatide (rDNA origin) injection,"['/sites/default/files/cdr/tracking/cdr_Forteo_New-Indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Forteo_SIO_July%2023_2009.pdf']","Osteoporosis, glucocorticoid induced",Do not list,Complete,18-Dec-08,22-Jul-09,SR0152-000
Alendronate sodium / cholecalc...Opens in new tab,Fosavance 70/5600,Alendronate sodium / cholecalciferol,"['/sites/default/files/cdr/tracking/cdr_tracking_Fosavance-5600.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fosavance-70_5600_June-17-2009.pdf']",Osteoporosis,List in a similar manner to other drugs in class,Complete,18-Dec-08,17-Jun-09,SR0153-000
UstekinumabOpens in new tab,Stelara,Ustekinumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/tracking/cdr_tracking_Stelara.pdf', '/sites/default/files/cdr/complete/cdr_complete_Stelara_June-17-2009.pdf']",Psoriasis,List with clinical criteria and/or conditions,Complete,07-Jan-09,17-Jun-09,SR0156-000
Solifenacin succinateOpens in new tab,Vesicare,Solifenacin succinate,['/sites/default/files/cdr/complete/cdr_complete_Vesicare-Resubmisson_1_June-17-2009.pdf'],"Bladder, overactive",List with clinical criteria and/or conditions,Complete,05-Jan-09,17-Jun-09,SR0155-000
Olmesartan medoxomil + hydroch...Opens in new tab,Olmetec Plus,Olmesartan medoxomil + hydrochlorothiazide,"['/sites/default/files/cdr/tracking/cdr_tracking_Olmetec-Olmetec_Plus.pdf', '/sites/default/files/cdr/complete/cdr_complete_Olmetec-Plus_May-27-2009.pdf']",Hypertension,List in a similar manner to other drugs in class,Complete,28-Nov-08,27-May-09,SR0151-000
Olmesartan medoxomilOpens in new tab,Olmetec,Olmesartan medoxomil,"['/sites/default/files/cdr/tracking/cdr_tracking_Olmetec.pdf', '/sites/default/files/cdr/complete/cdr_complete_Olmetec_May-27-2009.pdf']",Hypertension,List in a similar manner to other drugs in class,Complete,28-Nov-08,27-May-09,SR0150-000
AbataceptOpens in new tab,Orencia,Abatacept,"['/sites/default/files/cdr/tracking/cdr_Orencia_New_Indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Orencia_Final_April%2024_2009.pdf']","Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid",List with clinical criteria and/or conditions,Complete,29-Aug-08,22-Apr-09,SR0145-000
InfliximabOpens in new tab,Remicade,Infliximab,"['/sites/default/files/cdr/tracking/cdr_tracking_Remicade.pdf', '/sites/default/files/cdr/complete/cdr_complete_Remicade_Final_April_24_2009.pdf']",Ulcerative Colitis,Do not list,Complete,29-Sep-08,22-Apr-09,SR0146-000
Darifenacin hydrobromideOpens in new tab,Enablex,Darifenacin hydrobromide,"['/sites/default/files/cdr/tracking/cdt_update_Enablex_Resubmission-1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Enablex%20Resubmission-1_April-17-2009.pdf']","Bladder, overactive",List with clinical criteria and/or conditions,Complete,01-Oct-08,16-Apr-09,SR0147-000
Tenofovir disoproxil fumarateOpens in new tab,Viread,Tenofovir disoproxil fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Viread-HBV.pdf', '/sites/default/files/cdr/complete/cdr_complete_Viread-HBV_March-18-2009.pdf']",Hepatitis B (chronic),List with clinical criteria and/or conditions,Complete,02-Oct-08,18-Mar-09,SR0148-000
NatalizumabOpens in new tab,Tysabri,Natalizumab,"['/sites/default/files/attachments/2025-03/TS0004-Cladribine-Natalizumab_Updated_Recommendations_1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Tysabri-Resubmission_February-25-2009.pdf', '/sites/default/files/cdr/tracking/cdr_tracking_Tysabri-Resubmission_1.pdf']","Multiple Sclerosis, relapsing-remitting",List with clinical criteria and/or conditions,Complete,06-May-08,25-Feb-09,SR0133-000
Insulin glulisineOpens in new tab,Apidra,Insulin glulisine,"['/sites/default/files/cdr/tracking/cdr_tracking_Apidra.pdf', '/sites/default/files/cdr/complete/cdr_complete_Apidra_February-19-2009.pdf']","Diabetes, Mellitus (Type 1 & 2)",List in a similar manner to other drugs in class,Complete,29-Aug-08,19-Feb-09,SR0144-000
Dabigatran etexilateOpens in new tab,Pradaxa,Dabigatran etexilate,"['/sites/default/files/cdr/tracking/cdr_tracking_Pradax.pdf', '/sites/default/files/cdr/complete/cdr_complete_Pradax_March-3-2009.pdf']","Thromboembolism (venous), prevention",Do not list,Complete,08-Jul-08,28-Jan-09,SR0140-000
Sodium oxybateOpens in new tab,Xyrem,Sodium oxybate,"['/sites/default/files/cdr/tracking/cdr_tracking_Xyrem_Resubmission_1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xyrem%20Resubmission_January-28-2009.pdf']",Narcolepsy,Do not list,Complete,09-Jul-08,28-Jan-09,SR0141-000
Sitaxsentan sodiumOpens in new tab,Thelin,Sitaxsentan sodium,"['/sites/default/files/cdr/tracking/CDR_tracking_Thelin-Resubmission_1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Thelin%20Resubmission_January-28-2009.pdf']",Pulmonary arterial hypertension (WHO class II and III),Do not list,Complete,05-May-08,28-Jan-09,SR0132-000
Methylnaltrexone bromideOpens in new tab,Relistor,Methylnaltrexone bromide,"['/sites/default/files/cdr/tracking/cdr_tracking_Relistor.pdf', '/sites/default/files/cdr/complete/cdr_complete_Relistor_January-30-2009.pdf']","Constipation, Opioid-induced",Do not list,Complete,07-May-08,28-Jan-09,SR0135-000
AmbrisentanOpens in new tab,Volibris,Ambrisentan,"['/sites/default/files/cdr/tracking/cdr_tracking_Volibris.pdf', '/sites/default/files/cdr/complete/cdr_volibris_complete-dec17-08.pdf']",Pulmonary arterial hypertension (WHO class II and III),List with clinical criteria and/or conditions,Complete,09-Jul-08,17-Dec-08,SR0142-000
Emtricitabine/tenofovir disopr...Opens in new tab,Truvada,Emtricitabine/tenofovir disoproxil fumarate,"['/sites/default/files/cdr/complete/cdr_truvada_rfa_complete-dec17-08.pdf', '/sites/default/files/cdr/tracking/cdr_request-advice_Truvada.pdf']",HIV infection,List with clinical criteria and/or conditions,Complete,07-Jul-08,17-Dec-08,SF0138-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,"['/sites/default/files/cdr/tracking/cdr_tracking_Xarelto.pdf', '/sites/default/files/cdr/complete/cdr_xarelto_complete-dec17-08.pdf']","Thromboembolism (venous), prevention",List with clinical criteria and/or conditions,Complete,07-May-08,17-Dec-08,SR0134-000
MaravirocOpens in new tab,Celsentri,Maraviroc,"['/sites/default/files/cdr/tracking/cdr_tracking_Celsentri-Resubmission_1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Celsentri_Final_Nov-12-08.pdf']",HIV,List with clinical criteria and/or conditions,Complete,07-May-08,12-Nov-08,SR0136-000
Ciclesonide nasal sprayOpens in new tab,Omnaris,Ciclesonide nasal spray,"['/sites/default/files/cdr/tracking/cdr_tracking_Omnaris.pdf', '/sites/default/files/cdr/complete/cdr_complete_Omnaris_Nov-12-08.pdf']",Allergic Rhinitis (seasonal and perennial),Do not list,Complete,07-May-08,12-Nov-08,SR0137-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf', '/sites/default/files/cdr/tracking/cdr_Humira_New_Indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Humira-Psoriasis_October_2008.pdf']",Psoriasis,List with clinical criteria and/or conditions,Complete,15-Apr-08,16-Oct-08,SR0130-000
"Carbidopa, levodopa and entaca...Opens in new tab",Stalevo,"Carbidopa, levodopa and entacapone","['/sites/default/files/cdr/tracking/cdr_tracking_Stalevo.pdf', '/sites/default/files/cdr/complete/cdr_complete_Stalevo_October-2008.pdf']",Parkinsons Disease,List in a similar manner,Complete,15-Apr-08,16-Oct-08,SR0131-000
DaptomycinOpens in new tab,Cubicin,Daptomycin,"['/sites/default/files/cdr/tracking/cdr_tracking_Cubicin.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cubicin_%20September-24-2008.pdf']",Skin and skin structure infections & bacteremia,Do not list,Complete,06-Mar-08,24-Sep-08,SR0127-000
Buprenorphine/naloxoneOpens in new tab,Suboxone,Buprenorphine/naloxone,"['/sites/default/files/cdr/tracking/cdr_tracking_Suboxone.pdf', '/sites/default/files/cdr/complete/cdr_complete_Suboxone_September-24-2008.pdf']",Opioid drug dependence (Substitution treatment),List with clinical criteria and/or conditions,Complete,06-Mar-08,24-Sep-08,SR0128-000
Ziprasidone hydrochlorideOpens in new tab,Zeldox,Ziprasidone hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Zeldox.pdf', '/sites/default/files/cdr/complete/cdr_complete_Zeldox_August-14-2008.pdf']",Schizophrenia and related psychotic disorders,List with clinical criteria and/or conditions,Complete,10-Jan-08,14-Aug-08,SR0124-000
Duloxetine hydrochlorideOpens in new tab,Cymbalta,Duloxetine hydrochloride,"['/sites/default/files/cdr/tracking/cdr_update_Cymbalta-DPN.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cymbalta-DPN_August-14-2008.pdf']","Pain, Neuropathic, Diabetic",List with clinical criteria and/or conditions,Complete,08-Feb-08,14-Aug-08,SR0126-000
Duloxetine hydrochlorideOpens in new tab,Cymbalta,Duloxetine hydrochloride,"['/sites/default/files/cdr/tracking/cdr_update_Cymbalta-MDD.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cymbalta-MDD_August-14-2008.pdf']","Depressive, Major Disorder (MDD)",Do not list,Complete,08-Feb-08,14-Aug-08,SR0125-000
EtravirineOpens in new tab,Intelence,Etravirine,"['/sites/default/files/cdr/tracking/cdr_tracking_Intelence.pdf', '/sites/default/files/cdr/complete/cdr_complete_Intelence_August-14-2008.pdf']",HIV,List with clinical criteria and/or conditions,Complete,02-Apr-08,14-Aug-08,SR0129-000
RivastigmineOpens in new tab,Exelon Patch,Rivastigmine,"['/sites/default/files/cdr/tracking/cdr_tracking_Exelon.pdf', '/sites/default/files/cdr/complete/cdr_complete_Exelon-Patch_%20July-23-2008_e.pdf']",Dementia (Alzheimer's type),Do not list,Complete,21-Dec-07,23-Jul-08,SR0123-000
Tramadol hydrochlorideOpens in new tab,Ralivia,Tramadol hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Ralivia.pdf', '/sites/default/files/cdr/complete/cdr_complete_Ralivia_June_25_2008.pdf']",Pain,Do not list,Complete,29-Oct-07,25-Jun-08,SR0110-000
Zoledronic acidOpens in new tab,Aclasta,Zoledronic acid,"['/sites/default/files/cdr/tracking/cdr_tracking_Aclasta.pdf', '/sites/default/files/cdr/complete/cdr_complete_Aclasta_FINAL_Nov-16-11_e.pdf']","Osteoporosis, postmenopausal women",Do not list,Complete,29-Nov-07,25-Jun-08,SR0114-000
Mixed amphetamine saltsOpens in new tab,Adderall XR,Mixed amphetamine salts,"['/sites/default/files/cdr/tracking/cdr_tracking_Adderall-XR_new-indication.pdf', '/sites/default/files/cdr/complete/cdr_complete_Adderall_June-25-2008.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Adderall%20XR_Resub2_SOD_Aug-12-09.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Adderall%20XR_Resub2_OVW_Aug-12-09.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Adderall%20XR_Resub2_PLR_Aug-12-09.pdf']","Attention deficit hyperactivity disorder, Adult",Do not list,Complete,29-Nov-07,25-Jun-08,SR0116-000
AliskirenOpens in new tab,Rasilez,Aliskiren,"['/sites/default/files/cdr/tracking/cdr_tracking_Rasilez.pdf', '/sites/default/files/cdr/complete/cdr_complete_Rasilez_June-25-2008_e.pdf']",Hypertension,Do not list,Complete,30-Nov-07,25-Jun-08,SR0118-000
Sitagliptin phosphateOpens in new tab,Januvia,Sitagliptin phosphate,"['/sites/default/files/cdr/tracking/cdr_update_Januvia.pdf', '/sites/default/files/cdr/complete/cdr_complete_Januvia_June-18-2008_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_januvia_cedac-discuss_Sep-16-08_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_januvia_overview_Sep-16-08_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_januvia_plain-lang_Sep-16-08_e.pdf']",Diabetes mellitus (Type 2),Do not list,Complete,20-Dec-07,18-Jun-08,SR0122-000
PaliperidoneOpens in new tab,Invega,Paliperidone,"['/sites/default/files/cdr/tracking/cdr_tracking_Invega.pdf', '/sites/default/files/cdr/complete/cdr_complete_Invega_May_05_28.pdf']",Schizophrenia,Do not list,Complete,01-Nov-07,28-May-08,SR0112-000
RaltegravirOpens in new tab,Isentress,Raltegravir,"['/sites/default/files/cdr/tracking/cdr_tracking_Isentress.pdf', '/sites/default/files/cdr/complete/cdr_complete_Isentress_May-14-2008.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Isentress_discussion_Jul-10-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Isentress_overview_Jul-10-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Isentress_plainl-r-r_Posting_Jul-10-08.pdf']",HIV,List with clinical criteria and/or conditions,Complete,29-Nov-07,14-May-08,SR0115-000
"Efavirenz, emtricitabine, teno...Opens in new tab",Atripla,"Efavirenz, emtricitabine, tenofovir disoproxil fumarate","['/sites/default/files/cdr/tracking/cdr_tracking_Atripla.pdf', '/sites/default/files/cdr/complete/cdr_complete_Atripla_April-17-2008.pdf']",HIV,List with clinical criteria and/or conditions,Complete,30-Oct-07,17-Apr-08,SR0111-000
Tramadol hydrochlorideOpens in new tab,Tridural,Tramadol hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Tridural.pdf', '/sites/default/files/cdr/complete/cdr_complete_Tridural_April-17-2008.pdf']",Pain,Do not list,Complete,29-Nov-07,17-Apr-08,SR0117-000
RanibizumabOpens in new tab,Lucentis,Ranibizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Lucentis1.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lucentis_March-27-2008.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Lucentis_summary_Oct%2006-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Lucentis_overview_Jul-30-08_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_Lucentis_plain-language_Jul-30-08_e.pdf']","Macular degeneration, age-related",List with clinical criteria and/or conditions,Complete,12-Jul-07,27-Mar-08,SR0098-000
Acamprosate calciumOpens in new tab,Campral,Acamprosate calcium,"['/sites/default/files/cdr/tracking/cdr_tracking_Campral.pdf', '/sites/default/files/cdr/complete/cdr_complete_Campral_March-2008.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_campral_discussion_Jul-29-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_campral_overview_Jul-29-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_campral_plainl-r-r_Jul-29-08.pdf']",Alcohol Abstinence,List with clinical criteria and/or conditions,Complete,29-Aug-07,27-Mar-08,SR0108-000
Delta-9-tetrahydrocannabinol/c...Opens in new tab,Sativex,Delta-9-tetrahydrocannabinol/cannabidiol,"['/sites/default/files/cdr/tracking/cdr_tracking_Sativex_resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Sativex-Resubmission_February-20-2008.pdf']","Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids)",Do not list,Complete,07-Aug-07,20-Feb-08,SR0106-000
AprepitantOpens in new tab,Emend,Aprepitant,"['/sites/default/files/cdr/tracking/cdr_tracking_Emend.pdf', '/sites/default/files/cdr/complete/cdr_complete_Emend_February-20-2008.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_emend_cedac-discussion_May_28-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_emend_overview_May-28-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_emend_plainl-r-r_May-28-08.pdf']","Nausea and Vomiting, Chemotherapy induced",List with clinical criteria and/or conditions,Complete,29-Aug-07,20-Feb-08,SR0109-000
PosaconazoleOpens in new tab,Spriafil,Posaconazole,"['/sites/default/files/cdr/tracking/cdr_tracking_Spriafil.pdf', '/sites/default/files/cdr/complete/cdr_complete_Spriafil_January-30-2008.pdf']",Aspergillus and Candida infections,Do not list,Complete,24-May-07,30-Jan-08,SR0097-000
Sitaxsentan sodiumOpens in new tab,Thelin,Sitaxsentan sodium,"['/sites/default/files/cdr/tracking/cdr_tracking_Thelin.pdf', '/sites/default/files/cdr/complete/cdr_complete_Thelin_January-30-2008.pdf']",Pulmonary arterial hypertension (WHO class II and III),Do not list,Complete,22-Jun-07,30-Jan-08,SR0099-000
Lanthanum carbonate hydrateOpens in new tab,Fosrenol,Lanthanum carbonate hydrate,"['/sites/default/files/cdr/tracking/cdr_tracking_Fosrenol.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fosrenol_February-29-2008.pdf']","Hyperphosphatemia, end-stage renal disease",Do not list,Complete,28-Jun-07,30-Jan-08,SR0100-000
IdursulfaseOpens in new tab,Elaprase,Idursulfase,"['/sites/default/files/cdr/tracking/cdr_tracking_Elaprase.pdf', '/sites/default/files/cdr/complete/cdr_complete_Elaprase_Dec-19-2007.pdf']","Mucopolysarccharidosis II (MPS II), Hunter Syndrome",Do not list,Complete,13-Jul-07,19-Dec-07,SR0104-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Humira_Resubmission_3.pdf', '/sites/default/files/cdr/complete/cdr_complete_Humira-Resubmission-Crohns_Dec-19-2007.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_humira-resub3-crohns_cedac-discussion-Mar-26-08.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_humira-resub3-crohns_overview_Mar-07-08_e.pdf', '/sites/default/files/cdr/relatedinfo/cdr_trans_humira-resub3-crohns_%20plainl-r-r_Mar-05-08_e.pdf']",Crohn's disease,List with clinical criteria and/or conditions,Complete,12-Jul-07,19-Dec-07,SR0105-000
EntecavirOpens in new tab,Baraclude,Entecavir,"['/sites/default/files/cdr/tracking/cdr_tracking_Baraclude.pdf', '/sites/default/files/cdr/complete/cdr_complete_Baracude_November-28-2007.pdf']",Hepatitis B (chronic),List with clinical criteria and/or conditions,Complete,12-Dec-06,28-Nov-07,SR0089-000
Ciprofloxacin hydrochloride &a...Opens in new tab,Ciprodex,Ciprofloxacin hydrochloride & dexamethasone otic suspension,"['/sites/default/files/cdr/tracking/cdr_tracking_Ciprodex-Request-advice.pdf', '/sites/default/files/cdr/complete/cdr_complete_Ciprodex_October-18-2007.pdf']","Otitis media with otorrhea & otitis externa, acute",List with clinical criteria and/or conditions,Complete,15-Jun-07,18-Oct-07,SF0101-000
Adefovir dipivoxilOpens in new tab,Hepsera,Adefovir dipivoxil,"['/sites/default/files/cdr/tracking/cdr_request_advice_Hepsera.pdf', '/sites/default/files/cdr/complete/cdr_complete_Hepsera_October-18-2007.pdf']",Hepatitis B,List with clinical criteria and/or conditions,Complete,29-Jun-07,18-Oct-07,SF0103-000
TelbivudineOpens in new tab,Sebivo,Telbivudine,"['/sites/default/files/cdr/tracking/cdr_tracking_Sebivo.pdf', '/sites/default/files/cdr/complete/cdr_complete_Sebivo_September-26-2007.pdf']",Hepatitis B (chronic),Do not list,Complete,04-Dec-06,26-Sep-07,SR0088-000
Delta-9-tetrahydrocannabinol/c...Opens in new tab,Sativex,Delta-9-tetrahydrocannabinol/cannabidiol,"['/sites/default/files/cdr/tracking/cdr_tracking_Sativex.pdf', '/sites/default/files/cdr/complete/cdr_complete_Sativex_September-26-2007.pdf']","Pain, Neuropathic (adjunctive) in MS.",Do not list,Complete,27-Feb-07,26-Sep-07,SR0092-000
Tramadol hydrochlorideOpens in new tab,Zytram XL,Tramadol hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Zytram_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_ZytramXL_September-26-2007.pdf']","Pain, acute",Do not list,Complete,15-Mar-07,26-Sep-07,SR0093-000
Varenicline tartrateOpens in new tab,Champix,Varenicline tartrate,"['/sites/default/files/cdr/tracking/cdr_tracking_Champix.pdf', '/sites/default/files/cdr/complete/cdr_complete_Champix_August-16-07.pdf']",Smoking-cessation,List with clinical criteria and/or conditions,Complete,21-Mar-07,16-Aug-07,SR0094-000
LumiracoxibOpens in new tab,Prexige,Lumiracoxib,"['/sites/default/files/cdr/tracking/cdr_tracking_Prexige.pdf', '/sites/default/files/cdr/complete/cdr_complete_Prexige_July25-2007.pdf']",Osteoarthritis (Knee),Do not list,Complete,15-Dec-06,25-Jul-07,SR0090-000
Lanreotide acetateOpens in new tab,Somatuline Autogel,Lanreotide acetate,"['/sites/default/files/cdr/tracking/cdr_tracking_Somatuline.pdf', '/sites/default/files/cdr/complete/cdr_complete_Somatuline-Autogel_July-19_2007.pdf']",Acromegaly,List in a similar manner to other drugs in class,Complete,20-Feb-07,19-Jul-07,SR0091-000
AbataceptOpens in new tab,Orencia,Abatacept,"['/sites/default/files/cdr/tracking/cdr_tracking_Orencia.pdf', '/sites/default/files/cdr/complete/cdr_complete_Orencia_June-27-2007.pdf']","Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,26-Oct-06,27-Jun-07,SR0084-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Humira%20Resubmission_02.pdf', '/sites/default/files/cdr/complete/cdr_complete_Humira_Resubmission_June-27-2007.pdf']",Ankylosing spondylitis (AS),List with clinical criteria and/or conditions,Complete,17-Nov-06,27-Jun-07,SR0087-000
AlglucosidaseOpens in new tab,Myozyme,Alglucosidase,"['/sites/default/files/cdr/tracking/cdr_tracking_Myozyme.pdf', '/sites/default/files/cdr/complete/cdr_complete_Myozyme_June-14-2007_e.pdf']",Pompe's disease,List with clinical criteria and/or conditions,Complete,10-Oct-06,14-Jun-07,SR0080-000
Ramipril/hydrochlorothiazideOpens in new tab,Altace HCT,Ramipril/hydrochlorothiazide,"['/sites/default/files/cdr/tracking/cdr_tracking_Altace-HCR_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Altace-HCT_June-14-2007_e.pdf']",Hypertension,List,Complete,26-Mar-07,14-Jun-07,SR0095-000
Tramadol hydrochloride /acetam...Opens in new tab,Tramacet,Tramadol hydrochloride /acetaminophen,"['/sites/default/files/cdr/tracking/cdr_tracking_Tramacet.pdf', '/sites/default/files/cdr/complete/cdr_complete_Tramacet_May17-07.pdf']",Acute pain,Do not list,Complete,02-Oct-06,17-May-07,SR0079-000
PenciclovirOpens in new tab,Denavir,Penciclovir,"['/sites/default/files/cdr/tracking/cdr_tracking_Denavir.pdf', '/sites/default/files/cdr/complete/cdr_complete_Denavir_e_April-26-2007.pdf']",Herpes labialis (cold sores),Do not list,Complete,20-Sep-06,26-Apr-07,SR0075-000
Sunitinib malateOpens in new tab,Sutent,Sunitinib malate,"['/sites/default/files/cdr/tracking/cdr_tracking_Sutent_resubmission_01.pdf', '/sites/default/files/cdr/complete/cdr_complete_Sutent_e_April-26-2007%20.pdf']","Cancer, Metastatic renal cell carcinoma",Do not list,Complete,20-Sep-06,26-Apr-07,SR0077-000
Histrelin acetateOpens in new tab,Vantas,Histrelin acetate,"['/sites/default/files/cdr/tracking/cdr_tracking_Vantas.pdf', '/sites/default/files/cdr/complete/cdr_complete_Vantas_e_April-26-2007%20.pdf']","Cancer, prostate",Do not list,Complete,20-Sep-06,26-Apr-07,SR0078-000
NatalizumabOpens in new tab,Tysabri,Natalizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Tysabri.pdf', '/sites/default/files/cdr/complete/cdr_complete_Tysabri_e_April-26-2007.pdf']","Multiple Sclerosis, relapsing-remitting",Do not list,Complete,26-Oct-06,26-Apr-07,SR0082-000
DeferasiroxOpens in new tab,Exjade,Deferasirox,"['/sites/default/files/cdr/tracking/cdr_tracking_Exjade.pdf', '/sites/default/files/cdr/complete/cdr_complete_Exjade_2007April19.pdf']",Iron overload,List with clinical criteria and/or conditions,Complete,26-Oct-06,19-Apr-07,SR0081-000
SunitinibOpens in new tab,Sutent,Sunitinib,"['/sites/default/files/cdr/tracking/cdr_tracking_Sutent.pdf', '/sites/default/files/cdr/complete/cdr_complete_Sutent_March-28-07.pdf']",Gastrointestinal stromal tumour (GIST),List with clinical criteria and/or conditions,Complete,20-Jul-06,28-Mar-07,SR0069-000
Rasagiline mesylateOpens in new tab,Azilect,Rasagiline mesylate,"['/sites/default/files/cdr/tracking/cdr_tracking_Azilect.pdf', '/sites/default/files/cdr/complete/cdr_complete_Azilect_March-28-07.pdf']",Parkinson's disease,Do not list,Complete,01-Sep-06,28-Mar-07,SR0073-000
Sorafenib tabletsOpens in new tab,Nexavar,Sorafenib tablets,"['/sites/default/files/cdr/tracking/cdr_tracking_Nexavar.pdf', '/sites/default/files/cdr/complete/cdr_complete_Nexavar_Fe-28-07.pdf']","Cancer, Renal cell carcinoma",Do not list,Complete,31-Jul-06,28-Feb-07,SR0071-000
RituximabOpens in new tab,Rituxan,Rituximab,"['/sites/default/files/cdr/tracking/cdr_tracking_Rituxan.pdf', '/sites/default/files/cdr/complete/cdr_complete_Rituxan_Feb14-2007.pdf']","Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,26-Jun-06,14-Feb-07,SR0068-000
DarunavirOpens in new tab,Prezista,Darunavir,"['/sites/default/files/cdr/tracking/cdr_tracking_Prezista.pdf', '/sites/default/files/cdr/complete/cdr_complete_Prezista_Feb14-2007.pdf']",HIV infection,List with clinical criteria and/or conditions,Complete,29-Aug-06,14-Feb-07,SR0072-000
Sildenafil citrateOpens in new tab,Revatio,Sildenafil citrate,"['/sites/default/files/cdr/tracking/cdr_tracking_Revatio.pdf', '/sites/default/files/cdr/complete/cdr_complete_Revatio_Feb14-2007.pdf']",Pulmonary arterial hypertension (WHO class II and III),List in a similar manner,Complete,20-Sep-06,14-Feb-07,SR0076-000
Escitalopram oxalateOpens in new tab,Cipralex,Escitalopram oxalate,"['/sites/default/files/cdr/tracking/cdr_tracking_Cipralex_resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cipralex_Resubmission_Jan-24-2007.pdf']","Depression, Major Depressive Disorder (MDD)",Do not list,Complete,08-Jun-06,24-Jan-07,SR0064-000
Solifenacin succinateOpens in new tab,Vesicare,Solifenacin succinate,"['/sites/default/files/cdr/tracking/cdr_tracking_Vesicare.pdf', '/sites/default/files/cdr/complete/cdr_complete_Vesicare_Jan-24-2007.pdf']","Bladder, overactive",Do not list,Complete,24-Jul-06,24-Jan-07,SR0070-000
CiclesonideOpens in new tab,Alvesco,Ciclesonide,"['/sites/default/files/cdr/tracking/cdr_tracking_Alvesco.pdf', '/sites/default/files/cdr/complete/cdr_complete_Alvesco_Dec-20-06.pdf']",asthma,List,Complete,24-Jul-06,20-Dec-06,SR0074-000
Adefovir dipivoxilOpens in new tab,Hepsera,Adefovir dipivoxil,"['/sites/default/files/cdr/tracking/cdr_tracking_Hepsera.pdf', '/sites/default/files/cdr/complete/cdr_complete_Hepsera_Nov29-06.pdf']",Hepatitis B,Do not list,Complete,24-Apr-06,29-Nov-06,SR0060-000
Etonogestrel/ethinyl estradiolOpens in new tab,NuvaRing,Etonogestrel/ethinyl estradiol,"['/sites/default/files/cdr/tracking/cdr_tracking_NuvaRing.pdf', '/sites/default/files/cdr/complete/cdr_complete_NuvaRing_Nov29-06.pdf']","Contraceptive, ring",List with clinical criteria and/or conditions,Complete,05-May-06,29-Nov-06,SR0062-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Humira_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Humira_Resubmission_Nov29-06.pdf']","Arthritis, Psoriatic",List with clinical criteria and/or conditions,Complete,21-Jun-06,29-Nov-06,SR0066-000
Ramipril/felodipine extended r...Opens in new tab,Altace Plus Felodipine,Ramipril/felodipine extended release,"['/sites/default/files/cdr/tracking/cdr_tracking_Altace_Plus_Felodipine.pdf', '/sites/default/files/cdr/complete/cdr_complete_AltacePlus_Felodipine_Nov_15-06.pdf']",Hypertension,Do not list,Complete,22-Jun-06,15-Nov-06,SR0067-000
Insulin glargine (rDNA origin)Opens in new tab,Lantus,Insulin glargine (rDNA origin),"['/sites/default/files/cdr/tracking/cdr_tracking_Lantus%20Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lantus_Oct25-06.pdf']","Diabetes mellitus, Type 1 & 2",Do not list,Complete,27-Mar-06,25-Oct-06,SR0058-000
VoriconazoleOpens in new tab,VFEND,Voriconazole,"['/sites/default/files/cdr/tracking/cdr_tracking_Vfend_Resubmission_2.pdf', '/sites/default/files/cdr/complete/cdr_complete_Vfend_Resubmission_oct25-06.pdf']",Candidemia,List with clinical criteria and/or conditions,Complete,24-Mar-06,25-Oct-06,SR0056-000
Emtricitabine/tenofovir disopr...Opens in new tab,Truvada,Emtricitabine/tenofovir disoproxil fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Truvada.pdf', '/sites/default/files/cdr/complete/cdr_complete_Truvada_oct25-06.pdf', '/sites/default/files/cdr/complete/cdr_truvada_rfa_complete-dec17-08.pdf']",HIV infection,List with clinical criteria and/or conditions,Complete,29-May-06,25-Oct-06,SR0063-000
Darifenacin hydrobromideOpens in new tab,Enablex,Darifenacin hydrobromide,"['/sites/default/files/cdr/tracking/cdr_tracking_Enablex.pdf', '/sites/default/files/cdr/complete/cdr_complete_Enablex_Oct-19-06.pdf']","Bladder, overactive",Do not list,Complete,26-Apr-06,19-Oct-06,SR0061-000
AlefaceptOpens in new tab,Amevive,Alefacept,"['/sites/default/files/cdr/tracking/cdr_tracking_Amevive_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Amevive_Resubmission_Sept-27-06.pdf']","Psoriasis, moderate to severe chronic plaque",Do not list,Complete,28-Feb-06,27-Sep-06,SR0053-000
Alendronate sodium/cholecalcif...Opens in new tab,Fosavance,Alendronate sodium/cholecalciferol,"['/sites/default/files/cdr/tracking/cdr_tracking_Fosavance.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fosavance_Sept-27-06.pdf']",Osteoporosis,Do not list,Complete,27-Mar-06,27-Sep-06,SR0059-000
EfalizumabOpens in new tab,Raptiva,Efalizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Raptiva.pdf', '/sites/default/files/cdr/complete/cdr_complete_Raptiva_August24-06.pdf']","Psoriasis, moderate to severe chronic plaque",List with clinical criteria and/or conditions,Complete,25-Oct-05,24-Aug-06,SR0043-000
Travoprost and timolol maleateOpens in new tab,DuoTrav,Travoprost and timolol maleate,"['/sites/default/files/cdr/tracking/cdr_tracking_DuoTrav.pdf', '/sites/default/files/cdr/complete/cdr_complete_DuoTrav_August24-06.pdf']",Glaucoma,List with clinical criteria and/or conditions,Complete,24-Mar-06,24-Aug-06,SR0057-000
Trospium chlorideOpens in new tab,Trosec,Trospium chloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Trosec.pdf', '/sites/default/files/cdr/complete/cdr_complete_Trosec_August24-06.pdf']","Bladder, overactive",List with clinical criteria and/or conditions,Complete,24-Mar-06,24-Aug-06,SR0055-000
Insulin detemirOpens in new tab,Levemir,Insulin detemir,"['/sites/default/files/cdr/tracking/cdr_tracking_Levemir.pdf', '/sites/default/files/cdr/complete/cdr_complete_Levemir_August2_2006.pdf']",Diabetes mellitus,Do not list,Complete,19-Dec-05,02-Aug-06,SR0049-000
PegvisomantOpens in new tab,Somavert,Pegvisomant,"['/sites/default/files/cdr/tracking/cdr_tracking_Somavert.pdf', '/sites/default/files/cdr/complete/cdr_complete_Somavert_%20August2_2006.pdf']",acromegaly,Do not list,Complete,25-Jan-06,02-Aug-06,SR0050-000
Pantoprazole magnesiumOpens in new tab,Pantoloc M,Pantoprazole magnesium,"['/sites/default/files/cdr/tracking/cdr_tracking_PantolocM.pdf', '/sites/default/files/cdr/complete/cdr_complete_Pantoloc%20M_July20_2006.pdf']","Gastric acid secretion, reduction of",List in a similar manner to other drugs in class,Complete,17-Mar-06,20-Jul-06,SR0054-000
Triptorelin pamoateOpens in new tab,Trelstar,Triptorelin pamoate,"['/sites/default/files/cdr/tracking/cdr_tracking_Trelstar.pdf', '/sites/default/files/cdr/complete/cdr_complete_Trelstar_July20_2006.pdf']","Cancer, prostate",List in a similar manner to other drugs in class,Complete,27-Feb-06,20-Jul-06,SR0051-000
Treprostinil sodiumOpens in new tab,Remodulin,Treprostinil sodium,"['/sites/default/files/cdr/tracking/cdr_tracking_Remodulin_Resubmission_July21_2006.pdf', '/sites/default/files/cdr/complete/cdr_complete_Remodulin_July20_2006.pdf']",Pulmonary arterial hypertension (NYHA Class III and IV patients),List with clinical criteria and/or conditions,Complete,24-Feb-06,20-Jul-06,SR0052-000
Pegaptanib sodiumOpens in new tab,Macugen,Pegaptanib sodium,"['/sites/default/files/cdr/tracking/cdr_tracking_Macugen.pdf', '/sites/default/files/cdr/complete/cdr_complete_Macugen_May25-06.pdf']","Macular degeneration, age-related",Do not list,Complete,20-Oct-05,25-May-06,SR0044-000
Quinagolide hydrochlorideOpens in new tab,Norprolac,Quinagolide hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Norprolac%20Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Norprolac_Resubmission_May-17-06.pdf']",Hyperprolactinemia,List with clinical criteria and/or conditions,Complete,23-Nov-05,17-May-06,SR0046-000
TipranavirOpens in new tab,Aptivus,Tipranavir,"['/sites/default/files/cdr/tracking/cdr_tracking_Aptivus.pdf', '/sites/default/files/cdr/complete/cdr_complete_Aptivus_May-17-06.pdf']",HIV infection,List with clinical criteria and/or conditions,Complete,15-Dec-05,17-May-06,SR0047-000
Amlodipine besylate/ atorvasta...Opens in new tab,Caduet,Amlodipine besylate/ atorvastatin calcium,"['/sites/default/files/cdr/tracking/cdr_tracking_Caduet.pdf', '/sites/default/files/cdr/complete/cdr_complete_Caduet_May17-06.pdf']",Hypertension/ Dyslipidemia,List with clinical criteria and/or conditions,Complete,15-Dec-05,17-May-06,SR0048-000
Insulin aspart/insulin aspart ...Opens in new tab,NovoMix 30,Insulin aspart/insulin aspart protamine,['/sites/default/files/cdr/complete/cdr_complete_NovoMix30_April-26-06.pdf'],Diabetes mellitus,Do not list,Complete,13-Oct-05,26-Apr-06,SR0041-000
Niacin/lovastatinOpens in new tab,Advicor,Niacin/lovastatin,"['/sites/default/files/cdr/tracking/cdr_tracking_Advicor.pdf', '/sites/default/files/cdr/complete/cdr_complete_Advicor_April-26-06.pdf']",Hypercholesterolemia and mixed dyslipidemia,List,Complete,18-Oct-05,26-Apr-06,SR0042-000
Tenofovir disoproxil fumarateOpens in new tab,Viread,Tenofovir disoproxil fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Viread_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Viread_Resubmission_march2006.pdf']",HIV infection,List with clinical criteria and/or conditions,Complete,11-Aug-05,15-Mar-06,SR0040-000
OmalizumabOpens in new tab,Xolair,Omalizumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Xolair_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Xolair_March7-06.pdf']","Asthma, severe persistent",Do not list,Complete,13-Oct-05,07-Mar-06,SR0045-000
PregabalinOpens in new tab,Lyrica,Pregabalin,"['/sites/default/files/cdr/tracking/cdr_tracking_Lyrica.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lyrica_Jan26-06.pdf']","Pain, Neuropathic",Do not list,Complete,27-Jun-05,25-Jan-06,SR0036-000
ErlotinibOpens in new tab,Tarceva,Erlotinib,"['/sites/default/files/cdr/tracking/cdr_tracking_Tarceva.pdf', '/sites/default/files/cdr/complete/cdr_complete_Tarceva_Dec605.pdf']","Cancer, Lung , non-small cell",List with clinical criteria and/or conditions,Complete,19-Jul-05,07-Dec-05,SR0037-000
Abacavir/lamivudineOpens in new tab,Kivexa,Abacavir/lamivudine,"['/sites/default/files/cdr/tracking/cdr_tracking_Kivexa.pdf', '/sites/default/files/cdr/complete/cdr_complete_Kivexa_Dec605.pdf']",HIV infection,List in a similar manner to other drugs in class,Complete,26-Jul-05,07-Dec-05,SR0038-000
Memantine hydrochlorideOpens in new tab,Ebixa,Memantine hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Ebixa.pdf', '/sites/default/files/cdr/complete/cdr_complete_Ebixa_2005nov23.pdf']","Dementia (Alzheimer type), moderate to severe",Do not list,Complete,21-Dec-04,23-Nov-05,SR0025-000
Quinagolide hydrochlorideOpens in new tab,Norprolac,Quinagolide hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Norprolac.pdf', '/sites/default/files/cdr/complete/cdr_complete_Norprolac_2005Sept28.pdf']",Hyperprolactinemia,Do not list,Complete,16-Dec-04,28-Sep-05,SR0026-000
Atomoxetine hydrochlorideOpens in new tab,Strattera,Atomoxetine hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Strattera.pdf', '/sites/default/files/cdr/complete/cdr_complete_Strattera_2005Sept28.pdf']",Attention deficit hyperactivity disorder,Do not list,Complete,25-Jan-05,28-Sep-05,SR0031-000
Insulin glargine (rDNA origin)Opens in new tab,Lantus,Insulin glargine (rDNA origin),"['/sites/default/files/cdr/tracking/cdr_tracking_Lantus.pdf', '/sites/default/files/cdr/complete/cdr_complete_Lantus_2005Sept28.pdf']","Diabetes mellitus, Type 1 & 2",Do not list,Complete,11-Feb-05,28-Sep-05,SR0033-000
LaronidaseOpens in new tab,Aldurazyme,Laronidase,"['/sites/default/files/cdr/tracking/cdr_tracking_Aldurazyme.pdf', '/sites/default/files/cdr/complete/cdr_complete_Aldurazyme_2005July14.pdf']","Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie",Do not list,Complete,03-Feb-05,14-Jul-05,SR0032-000
Mycophenolate sodiumOpens in new tab,Myfortic,Mycophenolate sodium,"['/sites/default/files/cdr/tracking/cdr_tracking_Myfortic.pdf', '/sites/default/files/cdr/complete/cdr_complete_Myfortic_2005July8.pdf']","Organ rejection in allogeneic renal transplants, Prophylaxis",List in a similar manner to other drugs in class,Complete,03-Mar-05,08-Jul-05,SR0034-000
Drospirenone /ethinyl estradio...Opens in new tab,Yasmin,Drospirenone /ethinyl estradiol,['/sites/default/files/cdr/complete/cdr_complete_Yasmin_June162005.pdf'],"Contraceptive, oral",List,Complete,20-Jan-05,16-Jun-05,SR0029-000
Fosamprenavir calciumOpens in new tab,Telzir,Fosamprenavir calcium,"['/sites/default/files/cdr/tracking/cdr_tracking_Telzir.pdf', '/sites/default/files/cdr/complete/cdr_complete_Telzir_June162005.pdf']",HIV infection,List in a similar manner to other drugs in class,Complete,24-Jan-05,16-Jun-05,SR0030-000
AlefaceptOpens in new tab,Amevive,Alefacept,"['/sites/default/files/cdr/tracking/cdr_tracking_Amevive.pdf', '/sites/default/files/cdr/complete/cdr_complete_Amevive_2005May26.pdf']","Psoriasis, moderate to severe chronic plaque",Do not list,Complete,16-Nov-04,26-May-05,SR0024-000
Agalsidase betaOpens in new tab,Fabrazyme,Agalsidase beta,"['/sites/default/files/cdr/tracking/cdr_tracking_Fabrazyme_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fabrazyme_Resubmission_may2005.pdf']",Fabry Disease,Do not list,Complete,10-Dec-04,18-May-05,SR0028-000
VoriconazoleOpens in new tab,VFEND,Voriconazole,"['/sites/default/files/cdr/tracking/cdr_tracking_Vfend_Resubmission.pdf', '/sites/default/files/cdr/complete/cdr_complete_Voriconazole%28Vfend%29_April%2014-05.pdf']","Aspergillosis, Invasive",List with clinical criteria and/or conditions,Complete,25-Oct-04,14-Apr-05,SR0023-000
Cinacalcet hydrochlorideOpens in new tab,Sensipar,Cinacalcet hydrochloride,"['/sites/default/files/cdr/tracking/cdr_tracking_Sensipar.pdf', '/sites/default/files/cdr/complete/cdr_complete_Cinacalcet%28Sensipar%29_mar23-05.pdf']",Secondary hyper-parathyroidism in chronic kidney disease,Do not list,Complete,20-Aug-04,23-Mar-05,SR0018-000
Eletriptan hydrobromideOpens in new tab,Relpax,Eletriptan hydrobromide,['/sites/default/files/cdr/tracking/cdr_tracking_Relpax.pdf'],Migraine,Do not list,Complete,21-Sep-04,23-Mar-05,SR0021-000
AdalimumabOpens in new tab,Humira,Adalimumab,"['/sites/default/files/cdr/tracking/cdr_tracking_Humira.pdf', '/sites/default/files/cdr/complete/cdr_complete_Humira%28adalimumab%29Feb11-05.pdf']","Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,24-Sep-04,11-Feb-05,SR0022-000
Ciprofloxacin hydrochloride an...Opens in new tab,Ciprodex,Ciprofloxacin hydrochloride and dexamethasone otic suspension,"['/sites/default/files/cdr/tracking/cdr_tracking_Ciprodex.pdf', '/sites/default/files/cdr/complete/cdr_complete_Ciprodex_feb24-06.pdf']","Otitis media with otorrhea & otitis externa, acute",Do not list,Complete,11-Jun-04,26-Jan-05,SR0014-000
Butoconazole nitrateOpens in new tab,Gynazole.1,Butoconazole nitrate,['/sites/default/files/cdr/tracking/cdr_tracking_Gynazole.1.pdf'],Vaginal infection,Do not list,Complete,30-Jun-04,26-Jan-05,SR0017-000
DutasterideOpens in new tab,Avodart,Dutasteride,"['/sites/default/files/cdr/tracking/cdr_tracking_Avodart.pdf', '/sites/default/files/cdr/complete/cdr_complete_Avodart_2005Jan24.pdf']","Prostatic hyperplasia, benign",List in a similar manner to other drugs in class,Complete,24-Aug-04,20-Jan-05,SR0019-000
Teriparatide (rDNA origin) inj...Opens in new tab,Forteo,Teriparatide (rDNA origin) injection,"['/sites/default/files/cdr/tracking/cdr_tracking_Forteo.pdf', '/sites/default/files/cdr/complete/cdr_complete_Forteo_2004Dec22.pdf']",Osteoporosis,Do not list,Complete,08-Jun-04,22-Dec-04,SR0015-000
Eprosartan mesylate/ hydrochlo...Opens in new tab,Teveten Plus,Eprosartan mesylate/ hydrochlorothiazide,[],"Hypertension, Essential",List in a similar manner to other drugs in class,Complete,08-Jul-04,15-Dec-04,SR0016-000
Agalsidase alfaOpens in new tab,Replagal,Agalsidase alfa,"['/sites/default/files/cdr/tracking/cdr_tracking_replagal.pdf', '/sites/default/files/cdr/complete/cdr_complete_Replagal_2004Nov24.pdf']",Fabry Disease,Do not list,Complete,19-Feb-04,24-Nov-04,SR0006-000
Agalsidase betaOpens in new tab,Fabrazyme,Agalsidase beta,"['/sites/default/files/cdr/tracking/cdr_tracking_Fabrazyme.pdf', '/sites/default/files/cdr/complete/cdr_complete_Fabrazyme_2004Nov24.pdf']",Fabry Disease,Do not list,Complete,24-Feb-04,24-Nov-04,SR0007-000
Mixed amphetamine saltsOpens in new tab,Adderall XR,Mixed amphetamine salts,"['/sites/default/files/cdr/tracking/cdr_tracking_Adderall.pdf', '/sites/default/files/cdr/complete/cdr_complete_AdderallXR_2004Nov24.pdf']",Attention deficit hyperactivity disorder,Do not list,Complete,13-Apr-04,24-Nov-04,SR0010-000
MiglustatOpens in new tab,Zavesca,Miglustat,"['/sites/default/files/cdr/tracking/cdr_tracking_Zavesca.pdf', '/sites/default/files/cdr/complete/cdr_complete_Zavesca_2004Nov24.pdf']",Gaucher disease,Do not list,Complete,13-May-04,24-Nov-04,SR0012-000
Treprostinil sodiumOpens in new tab,Remodulin,Treprostinil sodium,"['/sites/default/files/cdr/tracking/cdr_tracking_Remodulin.pdf', '/sites/default/files/cdr/complete/cdr_complete_Remodulin%20%28treprostinil%29_Nov17_04.pdf']",Pulmonary arterial hypertension (NYHA Class III and IV patients),Do not list,Complete,14-Jul-04,17-Nov-04,SR0011-000
PegfilgrastimOpens in new tab,Neulasta,Pegfilgrastim,"['/sites/default/files/cdr/tracking/cdr_tracking_neulasta.pdf', '/sites/default/files/cdr/complete/cdr_complete_neulasta_10-27-04.pdf']",Neutropenia,List with clinical criteria and/or conditions,Complete,29-Mar-04,27-Oct-04,SR0009-000
Peginterferon alfa-2a and Riba...Opens in new tab,Pegasys RBV,Peginterferon alfa-2a and Ribavirin,['/sites/default/files/cdr/complete/cdr_complete_Pegasys_10_14_04.pdf'],"Hepatitis C, chronic",List in a similar manner to other drugs in class,Complete,14-May-04,14-Oct-04,SR0013-000
Tenofovir disoproxil fumarateOpens in new tab,Viread,Tenofovir disoproxil fumarate,"['/sites/default/files/cdr/tracking/cdr_tracking_Viread.pdf', '/sites/default/files/cdr/complete/cdr_complete_viread_08-25-04.pdf']",HIV infection,Do not list,Complete,23-Feb-04,25-Aug-04,SR0008-000
GefitinibOpens in new tab,Iressa,Gefitinib,"['/sites/default/files/cdr/tracking/cdr_tracking_Iressa.pdf', '/sites/default/files/cdr/complete/cdr_complete_iressa_06-23-04.pdf']","Cancer, Lung , non-small cell",Do not list,Complete,22-Dec-03,23-Jun-04,SR0003-000
Norgelestromin/ethinyl estradi...Opens in new tab,Evra,Norgelestromin/ethinyl estradiol,"['/sites/default/files/cdr/tracking/cdr_tracking_EVRA.pdf', '/sites/default/files/cdr/complete/cdr_complete_Evra_06-23-04.pdf']","Contraceptive, patch",Do not list,Complete,19-Dec-03,23-Jun-04,SR0004-000
Brimonidine tartrate/timolol m...Opens in new tab,Combigan Ophthalmic Solution,Brimonidine tartrate/timolol maleate,"['/sites/default/files/cdr/tracking/cdr_tracking_Combigan.pdf', '/sites/default/files/cdr/complete/cdr_complete_Combigan_05-27-04.pdf']",Glaucoma,List with clinical criteria and/or conditions,Complete,15-Dec-03,27-May-04,SR0001-000
AtazanavirOpens in new tab,Reyataz,Atazanavir,"['/sites/default/files/cdr/tracking/cdr_tracking_Reyataz.pdf', '/sites/default/files/cdr/complete/cdr_complete_Reyataz_05-27-04.pdf']",HIV infection,List in a similar manner to other drugs in class,Complete,16-Dec-03,27-May-04,SR0002-000
AlmotriptanOpens in new tab,Axert,Almotriptan,"['/sites/default/files/cdr/tracking/cdr_tracking_Axert.pdf', '/sites/default/files/cdr/complete/cdr_complete_Axert_05-27-04.pdf']",Migraine,List in a similar manner to other drugs in class,Complete,24-Dec-03,27-May-04,SR0005-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
osilodrostatOpens in new tab,Isturisa,osilodrostat,[],Endogenous Cushing’s syndrome,,Suspended,16-Oct-23,,SR0804-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
clascoteroneOpens in new tab,Winlevi,clascoterone,[],Acne vulgaris,,Withdrawn,04-Jul-23,,SR0786-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
fidaxomicinOpens in new tab,Dificid,fidaxomicin,[],Clostridium difficile infection,N/A,Withdrawn,29-Jan-24,,SF0847-000
Colorectal cancerOpens in new tab,,,[],Colorectal cancer,,Withdrawn,,,PH0043-000
nab-paclitaxelOpens in new tab,N/A,nab-paclitaxel,"['https://www.cda-amc.ca/sites/default/files/DRR/2024/PX0360-Nab-paclitaxel_FINAL.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0360-Nab-Paclitaxel-DPI-Table.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0360_Clinical_and_Pharmacoeconomic_Combined_Report.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0360_Stakeholder_Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0360_consolidated_FDR.pdf']",Gastrointestinal cancer,Reimburse with clinical criteria and/or conditions,Complete,12-Feb-24,,PX0360-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
Biologics in Plaque PsoriasisOpens in new tab,,,"['https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Streamlined-Rec.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-DPI-Table.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf', 'https://cadth.ca/sites/default/files/DRR/2023/TS0001-000-Biologics-In-Plaque-Psoriasis.pdf']",,,Complete,,,TS0001-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
AcalabrutinibOpens in new tab,Calquence,Acalabrutinib,[],Chronic Lymphocytic Leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,07-Apr-20,,PC0211-000
Nivolumab-IpilimumabOpens in new tab,Opdivo-Yervoy,Nivolumab-Ipilimumab,[],NSCLC,Reimburse with clinical criteria and/or conditions,Complete,23-Jun-20,,PC0218-000
guanfacine hydrochloride exten...Opens in new tab,N/A,guanfacine hydrochloride extended-release,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SX0755_guanfacine_hydrochloride_proposed_scope.pdf'],Attention Deficit Hyperactivity Disorder (ADHD),,Pending,06-Mar-25,,SX0755-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
inebilizumabOpens in new tab,Uplizna,inebilizumab,[],Immunoglobulin G4-related disease,,Pending,,,SR0889-000
teprotumumabOpens in new tab,TBC,teprotumumab,['https://cda-amc.ca/sites/default/files/DRR/2024/SR0853-teprotumumab_Patient_Clinician_Input.pdf'],"Thyroid Eye Disease (TED), chronic",,Withdrawn,25-Oct-24,,SR0853-001
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
amivantamabOpens in new tab,Rybrevant,amivantamab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0393_Rybrevant_Patient_Clinician_Input.pdf'],Locally advanced or metastatic non-small cell lung cancer (NSCLC),,Active,20-Feb-25,,PC0393-000
datopotamab deruxtecanOpens in new tab,TBC,datopotamab deruxtecan,[],advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC),,Cancelled,,,PC0384-000
FampridineOpens in new tab,Fampyra,Fampridine,['/sites/default/files/cdr/tracking/cdr_SR0404_Fampyra.pdf'],"Multiple sclerosis, improve walking disability",,Withdrawn,06-Nov-14,,SR0404-000
VortioxetineOpens in new tab,Trintellix,Vortioxetine,['/sites/default/files/cdr/tracking/cdr_SR0402_Trintellix.pdf'],"Depression, major depressive disorder",,Withdrawn,31-Oct-14,,SR0402-000
PropranololOpens in new tab,Hemangiol,Propranolol,['/sites/default/files/cdr/tracking/cdr_SR0411_Hemangiol.pdf'],Infantile hemangioma,,Withdrawn,23-Dec-14,,SR0411-000
Tedizolid phosphateOpens in new tab,Sivextro,Tedizolid phosphate,['/sites/default/files/cdr/tracking/cdr_SR0413_Sivextro.pdf'],Acute bacterial skin and skin structure infections,,Withdrawn,16-Jan-15,,SR0413-000
PalonosetronOpens in new tab,Aloxi (capsule),Palonosetron,['/sites/default/files/cdr/tracking/cdr_SR0415_Aloxi.pdf'],Chemotherapy-induced nausea and vomiting,,Withdrawn,06-Feb-15,,SR0415-000
EculizumabOpens in new tab,Soliris,Eculizumab,"['/sites/default/files/cdr/tracking/cdr_SF0416_Soliris.pdf', '/sites/default/files/cdr/advice/cdr-advice-Soliris-aHUS-June-2-2015.pdf', '/sites/default/files/cdr/advice/SF0416_Soliris_aHUS_RfA_Report.pdf']",Atypical hemolytic uremic syndrome,N/A,Complete,09-Feb-15,,SF0416-000
Solifenacin succinate / tamsul...Opens in new tab,VesiFlow,Solifenacin succinate / tamsulosin hydrochloride,['/sites/default/files/cdr/tracking/cdr_SR0424_VesiFlow.pdf'],Benign prostatic hyperplasia,,Withdrawn,06-Apr-15,,SR0424-000
bimekizumabOpens in new tab,Bimzelx,bimekizumab,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0856_Bimzelx_Patient_Clinician.pdf'],Hidradenitis suppurative,,Active,18-Oct-24,,SR0856-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
Breast CancerOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0083-Breast-Cancer_revised_scope.pdf'],Breast Cancer,,Active,,,PH0083-000
Non-small Cell Lung CancerOpens in new tab,,,[],Non-small Cell Lung Cancer,,Merged,,,PH0081-000
asciminibOpens in new tab,Scemblix,asciminib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0405_and_PC0418_Scemblix_Patient_Clinician_Input.pdf'],Philadelphia chromosome-positive chronic myeloid leukemia,,Active,10-Mar-25,,PC0405-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0410-Keytruda%20Patient_Clinician_Group_Input.pdf'],Head and neck squamous cell carcinoma,,Active,18-Mar-25,,PC0410-000
risperidoneOpens in new tab,Okedi,risperidone,['/sites/default/files/DRR/2025/SR0879-Okedi_Patient_Clinician_Group_Input.pdf'],"Schizophrenia, adults",,Active,21-Mar-25,,SR0879-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0411_Keytruda_Patient_Clinician_Input.pdf'],Cervical cancer,,Active,25-Mar-25,,PC0411-000
acalabrutinibOpens in new tab,Calquence,acalabrutinib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0413_Calquence_Patient_Clinician_Input.pdf'],Mantle cell lymphoma (MCL),,Active,26-Mar-25,,PC0413-000
nivolumab and ipilimumabOpens in new tab,Opdivo and Yervoy,nivolumab and ipilimumab,['http://www.cda-amc.ca/sites/default/files/DRR/2025/PC0396_Opdivo_Yervoy_Patient_Clinician_Input.pdf'],Unresectable or metastatic MSI-H or dMMR colorectal cancer,,Active,26-Mar-25,,PC0396-000
talazoparibOpens in new tab,Talzenna,talazoparib,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0417-Talzenna_Patient_Clinician_Grou_Input.pdf'],Metastatic castration-resistant prostate cancer,,Active,27-Mar-25,,PC0417-000
Sodium-Glucose Cotransporter 2...Opens in new tab,,Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus,"['https://cadth.ca/sites/default/files/DRR/2024/TS0002%20Streamlined%20Drug%20Class%20Review%20-%20Final%20Recommendation%20and%20Reasons.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/TS0002-SGLT2-Inhibitors-in-Type2-Diabetes-Report.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/TS0002-000-SGLT2-Inhibitors-in-Type2-Diabetes-Supplemental-Material.pdf']",,,Complete,,,TS0002-000
Adcetris for  Hodgkin Lymphoma...Opens in new tab,Adcetris,Brentuximab vedotin,[],,,Withdrawn,05-Apr-16,,PC0086-000
Cyramza for Non-Small Cell Lun...Opens in new tab,Cyramza,Ramucirumab,[],,,Cancelled,,,PC0078-000
Idarucizumab (Drug Plan Submis...Opens in new tab,Praxbind,Idarucizumab (Drug Plan Submission),['/sites/default/files/cdr/tracking/cdr_SR0492_Praxbind.pdf'],Reversal of dabigatran anticoagulant effects,,Withdrawn,30-May-16,,SR0492-000
Venclexta for Chronic Lymphocy...Opens in new tab,Venclexta,Venetoclax,"['/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_17pdel_in_cgr.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_17pdel_in_egr.pdf', '/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_17pdel_in_rec.pdf']",,,Withdrawn,08-Jul-16,,PC0087-000
LiraglutideOpens in new tab,Victoza,Liraglutide,['/sites/default/files/cdr/tracking/cdr_SR0505_Victoza_Resubmission.pdf'],"Diabetes Mellitus, Type 2",,Withdrawn,20-Oct-16,,SR0505-000
pasireotideOpens in new tab,Signifor LAR,pasireotide,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0859-Signifor-LAR_DRAFT_REC.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0859_Patient_and_Clinician_Group_Input.pdf']","​Acromegaly, adults",,Active,02-Oct-24,,SR0859-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
"durvalumab, olaparib, carbopla...Opens in new tab","Imfinzi, Lynparza","durvalumab, olaparib, carboplatin, paclitaxel",['https://cda-amc.ca/sites/default/files/DRR/2024/PC0366-001-Patient_Clinician_Group_Input.pdf'],Endometrial cancer that is mismatch repair proficient (pMMR),,Withdrawn,16-Oct-24,,PC0366-001
guselkumabOpens in new tab,Tremfya,guselkumab,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0874_Tremfya_Patient_and_Clinician_Group_Input.pdf'],Ulcerative colitis,,Active,21-Oct-24,,SR0874-000
Ibrance for Advanced Breast Ca...Opens in new tab,Ibrance,Palbociclib,"['/sites/default/files/pcodr/pcodr_palbociclib_ibrance_abc_rec.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_abc_cgr.pdf', '/sites/default/files/pcodr/pcodr_palbociclib_ibrance_abc_egr.pdf']",,,Withdrawn,11-Nov-15,,PC0068-000
Mifepristone and misoprostolOpens in new tab,Mifegymiso,Mifepristone and misoprostol,['/sites/default/files/cdr/tracking/cdr_SR0473_Mifegymiso.pdf'],Medical termination of pregnancy (gestational age up to 49 days),,Withdrawn,12-Feb-16,,SR0473 -000
ibrutinibOpens in new tab,Imbruvica,ibrutinib,[],Leukemia,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0004-000
durvalumabOpens in new tab,Imfinzi,durvalumab,['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0372_Patient_and_Clinician_Group_Input.pdf'],resectable non-small cell lung cancer (NSCLC),,Active,13-Aug-24,,PC0372-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
VoriconazoleOpens in new tab,VFEND,Voriconazole,['/sites/default/files/cdr/tracking/cdr_tracking_Vfend.pdf'],"Aspergillosis, Invasive",,Withdrawn,24-Aug-04,,SR0020-000
Mixed amphetamine saltsOpens in new tab,Adderall XR,Mixed amphetamine salts,['/sites/default/files/cdr/tracking/cdr_tracking_AdderallXR_Resubmission.pdf'],Attention deficit hyperactivity disorder,,Withdrawn,15-Dec-04,,SR0027-000
OmalizumabOpens in new tab,Xolair,Omalizumab,['/sites/default/files/cdr/tracking/cdr_tracking_Xolair.pdf'],"Asthma, severe persistent",,Cancelled,18-Apr-05,,SR0035-000
Escitalopram oxalateOpens in new tab,Cipralex,Escitalopram oxalate,['/sites/default/files/cdr/tracking/cdr_tracking_Cipralex.pdf'],"Depression, Major Depressive Disorder (MDD)",,Withdrawn,03-Aug-05,,SR0039-000
MirabegronOpens in new tab,Myrbetriq,Mirabegron,['/sites/default/files/cdr/tracking/cdr_SR0319_Myrbetriq.pdf'],Overactive bladder,,Withdrawn,08-Mar-13,,SR0319-000
CanagliflozinOpens in new tab,Invokana,Canagliflozin,['/sites/default/files/cdr/tracking/cdr_SR0335_Invokana.pdf'],"Diabetes Mellitus, Type 2",,Withdrawn,05-Jun-13,,SR0335-000
Saxagliptin + metforminOpens in new tab,Komboglyze,Saxagliptin + metformin,['/sites/default/files/cdr/tracking/cdr_SR0336_Komboglyze.pdf'],"Diabetes Mellitus, Type 2",,Withdrawn,06-Jun-13,,SR0336-000
AlemtuzumabOpens in new tab,Lemtrada,Alemtuzumab,['/sites/default/files/cdr/tracking/cdr_SR0355_Lemtrada.pdf'],"Multiple sclerosis, relapsing-remitting",,Withdrawn,01-Oct-13,,SR0355-000
AdalimumabOpens in new tab,Humira,Adalimumab,['/sites/default/files/cdr/tracking/cdr_SR0365_Humira.pdf'],ulcerative colitis,,Withdrawn,23-Dec-13,,SR0365-000
Darunavir / cobicistatOpens in new tab,TBC,Darunavir / cobicistat,['/sites/default/files/cdr/tracking/cdr_SR0378_Darunavir.pdf'],HIV infection,,Withdrawn,04-Apr-14,,SR0378-000
Ingenol mebutateOpens in new tab,Picato,Ingenol mebutate,"['/sites/default/files/cdr/tracking/cdr_SF0382_Picato%20RfA.pdf', '/sites/default/files/cdr/complete/cdr_complete_SF0382_Picato-RfA_Oct_29-14.pdf', '/sites/default/files/cdr/advice/SF0382_PicatoRfA_CDEC_Briefing_Doc.pdf']",Actinic keratosis,N/A,Complete,26-May-14,,SF0382-000
InfliximabOpens in new tab,Remsima,Infliximab,['/sites/default/files/cdr/tracking/cdr_SE0383_Remsima.pdf'],"Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis",,Withdrawn,30-May-14,,SE0383-000
Fentanyl CitrateOpens in new tab,Onsolis,Fentanyl Citrate,['/sites/default/files/cdr/tracking/cdr_tracking_Onsolis_1.pdf'],"Pain, breakthrough cancer pain",,Withdrawn,10-May-11,,SR0229-000
Sapropterin dihydrochlorideOpens in new tab,Kuvan,Sapropterin dihydrochloride,['/sites/default/files/cdr/tracking/cdr_tracking_Kuvan_request-advice.pdf'],Phenylketonuria,N/A,Complete,01-Jun-11,,SF0236-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,['/sites/default/files/cdr/tracking/cdr_tracking_xarelto_request-advice.pdf'],"Venous thromboembolism, prevention",N/A,Complete,24-Jun-11,,SF0239-000
SaxagliptinOpens in new tab,Onglyza,Saxagliptin,['/sites/default/files/cdr/tracking/cdr_tracking_Onglyza-Resub1.pdf'],"Diabetes mellitus, type 2",,Withdrawn,28-May-12,,SR0280-000
RivaroxabanOpens in new tab,Xarelto,Rivaroxaban,['/sites/default/files/cdr/tracking/cdr_tracking_Xarelto-DVT_request-advice.pdf'],Deep-vein thrombosis without symptomatic pulmonary embolism,,Complete,10-Oct-12,,SF0295-000
Acamprosate calciumOpens in new tab,Campral,Acamprosate calcium,['/sites/default/files/cdr/tracking/cdr_request-advice_Campral.pdf'],Alcohol Abstinence,N/A,Complete,22-Jul-08,,SF0143-000
Tenofovir disoproxil fumarateOpens in new tab,Viread,Tenofovir disoproxil fumarate,['/sites/default/files/cdr/tracking/cdr_request-advice_Viread.pdf'],HIV infection,N/A,Complete,07-Jul-08,,SF0139-000
Teriparatide (rDNA origin) inj...Opens in new tab,Forteo,Teriparatide (rDNA origin) injection,['/sites/default/files/cdr/tracking/cdr_tracking_Forteo_Resubmission_2.pdf'],Osteoporosis,,Withdrawn,18-Dec-08,,SR0157-000
Insulin detemirOpens in new tab,Levemir,Insulin detemir,['/sites/default/files/cdr/tracking/cdr_trackinig_Levemir_Resubmission-1.pdf'],Diabetes mellitus,,Withdrawn,02-Feb-09,,SR0158-000
Rasagiline mesylateOpens in new tab,Azilect,Rasagiline mesylate,['/sites/default/files/cdr/tracking/cdr_Azilect_Request_for_Advice.pdf'],Parkinson's disease,N/A,Complete,10-Mar-09,,SF0161-000
Insulin glargineOpens in new tab,Lantus,Insulin glargine (rDNA origin),['/sites/default/files/cdr/tracking/cdr_Lantus_Request_for_Advice.pdf'],"Diabetes mellitus, Type 1 & 2",N/A,Complete,09-Jun-09,,SF0166-000
Somatropin (rDNA origin)Opens in new tab,Omnitrope,Somatropin (rDNA origin),"['/sites/default/files/cdr/tracking/cdr_tracking_Omnitrope.pdf', '/sites/default/files/cdr/advice/cdr_advice_Omnitrope-December-18-2009.pdf']",Growth hormone deficiency in children and adults,N/A,Complete,12-Jun-09,,SR0167-000
Teriparatide (rDNA origin) inj...Opens in new tab,Forteo,Teriparatide (rDNA origin) injection,['/sites/default/files/cdr/tracking/cdr_tracking_Forteo_Resubmission_3.pdf'],Osteoporosis,,Withdrawn,12-Jun-09,,SR0169-000
Dabigatran etexilateOpens in new tab,Pradaxa,Dabigatran etexilate,['/sites/default/files/cdr/tracking/cdr_tracking_Pradax_pre-noc.pdf'],Atrial fibrillation prevention of stroke and systemic embolism,,Cancelled,31-May-10,,SR0202-000
TicagrelorOpens in new tab,Brilinta,Ticagrelor,['/sites/default/files/cdr/tracking/cdr_tracking_Brilinta_pre-noc.pdf'],Acute Coronary Syndromes,,Cancelled,08-Jun-10,,SR0203-000
Telmisartan / AmlodipineOpens in new tab,Twynsta,Telmisartan / Amlodipine,['/sites/default/files/cdr/tracking/cdr_trracking_Twynsta_PreNOC.pdf'],Hypertension,,Cancelled,09-Jul-10,,SR0207-000
Buprenorphine transdermal patc...Opens in new tab,BuTrans,Buprenorphine transdermal patch,['/sites/default/files/cdr/tracking/cdr_tracking_BuTrans.pdf'],"Pain, persistent (moderate intensity)",,Cancelled,15-Oct-10,,SR0211-000
Oxycodone / naloxoneOpens in new tab,Targin,Oxycodone / naloxone,['/sites/default/files/cdr/tracking/cdr_tracking_Targin.pdf'],"Pain, Moderate to severe and relief of opioid-induced constipation",,Cancelled,30-Nov-10,,SR0219-000
Teriparatide (rDNA origin) inj...Opens in new tab,Forteo,Teriparatide (rDNA origin) injection,['/sites/default/files/cdr/tracking/cdr_tracking_Forteo_resubmission.pdf'],Osteoporosis,,Withdrawn,29-May-06,,SR0065-000
Ramipril/hydrochlorothiazideOpens in new tab,Altace HCT,Ramipril/hydrochlorothiazide,['/sites/default/files/cdr/tracking/cdr_tracking_AltaceHCT.pdf'],Hypertension,,Cancelled,26-Oct-06,,SR0083-000
Tramadol hydrochlorideOpens in new tab,Zytram XL,Tramadol hydrochloride,['/sites/default/files/cdr/tracking/cdr_tracking_ZytramXL.pdf'],"Pain, acute",,Withdrawn,03-Nov-06,,SR0086-000
Atomoxetine hydrochlorideOpens in new tab,Strattera,Atomoxetine hydrochloride,['/sites/default/files/cdr/tracking/cdr_request_advice_Strattera_dec22-06.pdf'],Attention deficit hyperactivity disorder,N/A,Complete,25-Sep-06,,SF0085-000
EfalizumabOpens in new tab,Raptiva,Efalizumab,['/sites/default/files/cdr/tracking/cdr_request_advice_Raptiva.pdf'],"Psoriasis, moderate to severe chronic plaque",N/A,Complete,19-Jun-07,,SF0102-000
Sodium oxybateOpens in new tab,Xyrem,Sodium oxybate,['/sites/default/files/cdr/tracking/cdr_tracking_Xyrem.pdf'],Narcolepsy,,Withdrawn,29-Aug-07,,SR0107-000
MaravirocOpens in new tab,Celsentri,Maraviroc,['/sites/default/files/cdr/tracking/cdr_tracking_Celsentri.pdf'],HIV,,Withdrawn,02-Nov-07,,SR0113-000
empagliflozinOpens in new tab,Jardiance,empagliflozin,[],Chronic kidney disease,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0040-000
setmelanotideOpens in new tab,Imcivree,setmelanotide,[],"Weight management for pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0041-000
efgartigimod alfaOpens in new tab,Vyvgart,efgartigimod alfa,[],Chronic inflammatory demyelinating polyneuropathy,,Pending,,,SR0894-000
Treanda-Rituximab for Chronic ...Opens in new tab,Treanda (in combination with rituximab),Bendamustine hydrochloride,[],Chronic Lymphocytic Leukemia,,Withdrawn,27-Jun-14,,PC0040-000
dabrafenib trametinibOpens in new tab,Tafinlar-Mekinist,dabrafenib trametinib,[],Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation,,Cancelled,,,PC0337-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
pegcetacoplanOpens in new tab,TBC,pegcetacoplan,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0810-pegcetacoplan_Patient_Clinician_Group_Input.pdf'],Geographic atrophy secondary to age-related macular degeneration,,Withdrawn,23-Jul-24,,SR0810-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
lecanemabOpens in new tab,Leqembi,lecanemab,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0822_Patient_and_Clinician_Input.pdf'],Alzheimer’s disease,,Suspended,14-Jun-24,,SR0822-000
Onivyde for Metastatic Pancrea...Opens in new tab,Onivyde,Nanoliposomal Irinotecan,[],,,Cancelled,,,PC0096-000
Avastin for Malignant Pleural ...Opens in new tab,Avastin,Bevacizumab,[],,,Withdrawn,16-Dec-16,,PC0100-000
RFA: Inlyta for Metastatic Ren...Opens in new tab,Inlyta (RFA),Axitinib,"['/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_rfa_rec.pdf', '/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_rfa_cgr.pdf', '/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_fdk_pfizer.pdf', '/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_fdk_kcc.pdf']",Metastatic Renal Cell Carcinoma,N/A,Complete,18-Apr-17,,PA0001-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
fluticasone furoate/vilanterolOpens in new tab,Breo Ellipta,fluticasone furoate/vilanterol,[],Asthma,,Withdrawn,02-May-18,,SR0568-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,[],Gastrointestinal Cancer,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0012-000
Rituximab for Non-Hodgkin’s Ly...Opens in new tab,TBD,Rituximab,[''],,,Cancelled,,,PC0180-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
lurasidoneOpens in new tab,Latuda,lurasidone,[],Bipolar I disorder,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0010-000
tofacitinibOpens in new tab,Xeljanz,tofacitinib,[],,,Cancelled,,,SR0575-000
Beleodaq for Peripheral T-Cell...Opens in new tab,Beleodaq,Belinostat,[],,,Withdrawn,29-Jun-18,,PC0139-000
Blincyto for MRD-positive B-ce...Opens in new tab,Blincyto,Blinatumomab,[],,,Withdrawn,29-Jun-18,,PC0143-000
Nelarabine for Acute Lymphobla...Opens in new tab,Atriance,Nelarabine,[''],,,Cancelled,,,PC0170-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
ravulizumabOpens in new tab,TBC,ravulizumab,[],Paroxysmal nocturnal hemoglobinuria.,,Withdrawn,04-Jul-19,,SR0623-000
decitabineOpens in new tab,Demylocan,decitabine,[],Myelodysplastic Syndromes,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0001-000
Cabozantinib for Advanced Rena...Opens in new tab,TBD,Cabozantinib,[],,,Withdrawn,06-Oct-17,,PC0123-000
cyclosporineOpens in new tab,Ikervis,cyclosporine,[],"keratitis, severe",,Withdrawn,15-May-17,,SR0518-000
fluticasone furoate/vilanterolOpens in new tab,Breo Ellipta,fluticasone furoate/vilanterol,['/sites/default/files/cdr/monograph/Breo_Ellipta_Product_Monograph.pdf'],COPD,,Withdrawn,28-Jun-17,,SR0524-000
RFA: Bosulif for Chronic Myelo...Opens in new tab,Bosulif (RFA),Bosutinib,"['/sites/default/files/pcodr/pcodr-profund-rfa-0002-bosutinib.pdf', '/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_FnRec_2019-07-31_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_RFA-ClinicalReport_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_RFA_Post_01Aug2019_final.pdf', '/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_PatientInput_CML_2019-04-24_Post_01Aug2019_final.pdf']",Chronic Myeloid Leukemia,N/A,Complete,08-Apr-19,,PA0002-000
Trastuzumab for Breast and Gas...Opens in new tab,TBD,Trastuzumab,[],,,Cancelled,,,PC0160-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
Rituximab (Truxima) for Non-Ho...Opens in new tab,Truxima,Rituximab,[],,,Cancelled,,,PC0184-000
Bevacizumab (TBD) mCRC NSCLC B...Opens in new tab,TBD,Bevacizumab,[],,,Cancelled,14-Mar-19,,PC0178-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
atalurenOpens in new tab,Translarna,ataluren,[],,,Cancelled,,,SR0607-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
vilazodoneOpens in new tab,Viibryd,vilazodone,[],"Depression, Major depressive disorder",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0006-000
ibrutinibOpens in new tab,Imbruvica,ibrutinib,[],Chronic graft versus host disease,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0009-000
eltrombopagOpens in new tab,Revolade,eltrombopag,[],Severe aplastic anemia,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0007-000
tezacaftor/ivacaftorOpens in new tab,Symdeko,tezacaftor/ivacaftor,[],"Cystic fibrosis, F508del mutation(s)",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0008-000
Abiraterone (Zytiga) for Prost...Opens in new tab,Zytiga (Resubmission),Abiraterone,[],Prostate Cancer Resubmission,,Withdrawn,29-Jul-19,,PC0201-000
Entrectinib (TBD) for Neurotro...Opens in new tab,TBD,Entrectinib,[],,,Withdrawn,29-Jul-19,,PC0157-000
ibrutinibOpens in new tab,Imbruvica,ibrutinib,[],Leukemia,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0005-000
pegaspargaseOpens in new tab,Oncaspar,pegaspargase,[],Adult Acute Lymphocytic Leukemia (ALL),Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0002-000
ibritumomab tiuxetanOpens in new tab,Zevalin,iIbritumomab tiuxetan,[],Non-Hodgkin’s Lymphoma (NHL),Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0003-000
Atezolizumab (Tecentriq) for A...Opens in new tab,Tecentriq,Atezolizumab,[],,,Withdrawn,02-Oct-19,,PC0171-000
etonogestrelOpens in new tab,TBC,etonogestrel,[],Prevention of pregnancy,,Withdrawn,26-Sep-19,,SR0629-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
filgrastimOpens in new tab,TBC,filgrastim,[],Prevention or treatment of neutropenia in various indications,,Cancelled,01-Nov-18,,SE0585-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
pegfilgrastimOpens in new tab,Fulphila,pegfilgrastim,['/sites/default/files/cdr/relatedinfo/se0588-fulphila-biosimilar-dossier.pdf'],Febrile neutropenia in non-myeloid malignancies,N/A,Complete,14-Nov-18,,SE0588-000
insulin glargineOpens in new tab,Semglee,insulin glargine,[''],"Diabetes mellitus, Type 1 & 2",,Withdrawn,14-Nov-18,,SE0589-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
Ogivri for Early Breast Cancer...Opens in new tab,Ogivri,Trastuzumab,[],,,Withdrawn,18-Dec-18,,PC0169-000
Zytiga for Prostate Cancer – D...Opens in new tab,Zytiga,Abiraterone,[],,,Withdrawn,25-Feb-19,,PC0166-000
fluocinolone acetonideOpens in new tab,Iluvien,fluocinolone acetonide,[],Diabetic macular edema (DME),,Withdrawn,21-Dec-17,,SR0549-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
filgrastimOpens in new tab,TBC,filgrastim,[],,,Cancelled,,,SE0596-000
halobetasol propionate and taz...Opens in new tab,TBC,halobetasol propionate and tazarotene,[],"Psoriasis, moderate to severe plaque",,Withdrawn,04-Feb-19,,SR0600-000
Insulin lisproOpens in new tab,Admelog,Insulin lispro,[],,,Cancelled,,,SE0543-000
Erbitux for Left Sided Metasta...Opens in new tab,Erbitux,Cetuximab,[],,,Cancelled,,,PC0128-000
PegfilgrastimOpens in new tab,Lapelga,Pegfilgrastim,['/sites/default/files/cdr/relatedinfo/SE0555_lapelga_biosimilar_dossier.pdf'],Febrile neutropenia,N/A,Complete,23-Feb-18,,SE0555-000
anakinraOpens in new tab,Kineret,anakinra,['/sites/default/files/cdr/relatedinfo/SR0662_Kineret_PI%20Submission.pdf'],Still's disease,,Withdrawn,21-Dec-20,,SR0662-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
Orilissa (elagolix)Opens in new tab,Orilissa,elagolix,[],Moderate to severe pain associated with endometriosis,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0011-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
brentuximab vedotinOpens in new tab,Adcetris,brentuximab vedotin,[],Hodgkin lymphoma,,Withdrawn,,,PC0311-000
daprodustatOpens in new tab,TBC,daprodustat,[],Anemia due to chronic kidney disease,,Withdrawn,25-Oct-22,,SR0762-000
masitinib mesylateOpens in new tab,Alsitek,masitinib mesylate,[],Amyotrophic lateral sclerosis (ALS),,Suspended,28-Oct-22,,SR0766-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
talazoparibOpens in new tab,Talzenna,talazoparib,[],Metastatic castration-resistant prostate cancer (mCRPC),,Withdrawn,15-Aug-23,,PC0316-000
rimegepantOpens in new tab,Nurtec ODT,rimegepant,[],"Migraine, prevention",,Withdrawn,15-Aug-23,,SR0797-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
aducanumabOpens in new tab,Aduhelm,aducanumab,[],Alzheimer’s disease,,Withdrawn,26-Nov-21,,SR0705-000
pembrolizumab and lenvatinibOpens in new tab,Keytruda and Lenvima,pembrolizumab and lenvatinib,[],Advanced endometrial cancer,,Withdrawn,15-Dec-21,,PC0271-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
tirzepatideOpens in new tab,TBC,tirzepatide,[],"Diabetes mellitus, type 2",,Cancelled,12-Aug-22,,SR0751-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
abaloparatideOpens in new tab,TBC,abaloparatide,[],"Osteoporosis, postmenopausal women",,Withdrawn,02-Aug-22,,SR0744-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
RET fusion-positive non-small ...Opens in new tab,,,[],RET fusion-positive non-small cell lung cancer,,Withdrawn,,,PH0020-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
ferumoxytolOpens in new tab,TBC,ferumoxytol,[],Iron deficiency anemia,,Withdrawn,31-Aug-22,,SR0753-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
Mvasi for Metastatic Colorecta...Opens in new tab,Mvasi,Bevacizumab,"['/sites/default/files/pcodr/pcodr_provfund_10158_bevacizumab_mvasi_mcrc_nsclc.pdf', '/sites/default/files/pcodr/Reviews2019/10158MVASI_CADTHBiosimilarSummaryDossier_FINAL_14Jan2019.pdf']",mCRC NSCLC Biosimilar,N/A,Complete,03-Oct-18,,PC0158-000
natalizumabOpens in new tab,Tysabri,natalizumab,[],"Multiple Sclerosis, relapsing-remitting",,Withdrawn,21-Apr-21,,SR0687-000
apomorphine hydrochlorideOpens in new tab,Kynmobi,apomorphine hydrochloride,['/sites/default/files/cdr/relatedinfo/SR0604-Patient-Input-Kynmobi.pdf'],Parkinson’s Disease,,Withdrawn,25-Feb-19,,SR0604-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
filgotinibOpens in new tab,TBC,filgotinib,[],"Arthritis, Rheumatoid",,Withdrawn,04-Aug-20,,SR0656-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,Pending,,,
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
zanubrutinibOpens in new tab,Brukinsa,zanubrutinib,[],Relapsed or refractory follicular lymphoma,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0037-000
solriamfetolOpens in new tab,Sunosi,solriamfetol,[],Excessive daytime sleepiness (narcolepsy),Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0038-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,[],Primary mediastinal B-cell lymphoma,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0034-000
olaparibOpens in new tab,Lynparza,olaparib,[],Breast Cancer,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0013-000
icatibantOpens in new tab,Firazyr,icatibant,[],Acute attacks of hereditary angioedema,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0014-000
vorinostatOpens in new tab,Zolinza,vorinostat,[],Cutaneous T-cell lymphoma,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0015-000
baloxavir marboxilOpens in new tab,Xofluza,baloxavir marboxil,[],Influenza,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0016-000
talazoparibOpens in new tab,Talzenna,talazoparib,[],Breast Cancer,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0017-000
mepolizumabOpens in new tab,Nucala,mepolizumab,[],Eosinophilic granulomatosis with polyangiitis,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0018-000
galcanezumabOpens in new tab,Emgality,galcanezumab,[],Episodic cluster headache,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0019-000
clofarabineOpens in new tab,Clolar,clofarabine,[],Acute lymphoblastic leukemia,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0020-000
dapagliflozinOpens in new tab,Forxiga,dapagliflozin,[],Chronic kidney disease,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0021-000
Rivaroxaban (granules for oral...Opens in new tab,Xarelto,Rivaroxaban (granules for oral suspension),[],Venous Thromboembolic Events,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0022-000
glecaprevir / pibrentasvirOpens in new tab,Maviret,glecaprevir / pibrentasvir,[],"Hepatitis C, chronic",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0023-000
sofosbuvir / velpatasvirOpens in new tab,Epclusa,sofosbuvir / velpatasvir,[],"Hepatitis C, chronic",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0024-000
fluticasone furoate/umeclidini...Opens in new tab,Trelegy Ellipta,fluticasone furoate/umeclidinium bromide/vilanterol trifenatate,[],"Asthma, maintenance",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0025-000
omalizumabOpens in new tab,Xolair,omalizumab,[],Chronic rhinosinusitis with nasal polyps,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0026-000
mepolizumabOpens in new tab,Nucala,mepolizumab,[],"Asthma, severe eosinophilic (pediatric)",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0027-000
dabrafenib and trametinibOpens in new tab,Tafinlar and Mekinist,dabrafenib and trametinib,[],Pediatric high-grade glioma with BRAF V600E,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0028-000
dabrafenib and trametinibOpens in new tab,Tafinlar and Mekinist,dabrafenib and trametinib,[],Pediatric low-grade glioma with BRAF V600E,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0029-000
treosulfanOpens in new tab,Trecondyv,treosulfan,[],Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric),Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0030-000
daratumumabOpens in new tab,Darzalex,daratumumab,[],"Multiple myeloma, eligible for autologous stem cell transplant",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0031-000
liraglutideOpens in new tab,Victoza,liraglutide,[],"Diabetes Mellitus, Type 2 (pediatric)",Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0032-000
dexamethasone intravitreal imp...Opens in new tab,Ozurdex,dexamethasone intravitreal implant,[],Non-infectious uveitis,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0033-000
trastuzumab deruxtecanOpens in new tab,Enhertu,trastuzumab deruxtecan,[],Metastatic HER2-positive breast cancer,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0035-000
capmatinibOpens in new tab,Tabrecta,capmatinib,[],Metastatic non-small cell lung cancer (NSCLC),Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0036-000
solriamfetolOpens in new tab,Sunosi,solriamfetol,[],Excessive daytime sleepiness,Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.,Not filed,,,NS0039-000
"belantamab mafodotin, pomalido...Opens in new tab",TBC,"belantamab mafodotin, pomalidomide, dexamethasone",['https://cda-amc.ca/sites/default/files/DRR/2024/PC0380_Patient_Clinician_Group_Input.pdf'],Previously treated multiple myeloma,,Active,19-Dec-24,,PC0380-000
fidaxomicinOpens in new tab,N/A,fidaxomicin,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0754_fidaxomicin_Proposed_scope.pdf'],Clostridioides difficile infection,,Active,13-Nov-24,,SX0754-000
nivolumabOpens in new tab,N/A,nivolumab,['https://cda-amc.ca/sites/default/files/DRR/2024/PX0376_Proposed_Scoping.pdf'],Hodgkin lymphoma,,Active,12-Nov-24,,PX0376-000
naloxagolOpens in new tab,N/A,naloxagol,['https://cda-amc.ca/sites/default/files/DRR/2024/SX0753_Proposed_Scoping.pdf'],Management of opioid-induced constipation (OIC).,,Active,19-Nov-24,,SX0753-000
NSCLC without actionable oncog...Opens in new tab,,,[],Non-small Cell Lung Cancer,,Merged,,,PH0059-000
Multiple MyelomaOpens in new tab,,,[],Multiple Myeloma,,Merged,,,PH0060-000
Pharmaceutical Reviews Update ...Opens in new tab,,,[],,,,,,
Philadelphia negative acute ly...Opens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0067_Adult_%20B-cell_precursor_acute_lymphoblastic%20leukemia_proposed_scope.pdf'],Philadelphia negative acute lymphoblastic leukemia,,Active,,,PH0067-000
Non-small-cell lung cancerOpens in new tab,,,"['https://cda-amc.ca/sites/default/files/DRR/2024/PH0065_NSCLC_proposed_scope.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0059_NSCLC_proposed_scope.pdf']",Non-small-cell lung cancer,,Active,,,PH0065-000
Endometrial cancerOpens in new tab,,,[],Endometrial cancer,,Merged,,,PH0066-000
abemaciclibOpens in new tab,Verzenio,abemaciclib,['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0409_Verzenio_fulvestrant_Patient_Clinician_Group_Input.pdf'],"HR-positive, HER2-negative advanced or metastatic breast cancer",,Active,14-Feb-25,,PC0409-000
venetoclaxOpens in new tab,Venclexta,venetoclax,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0402-Venclexta-MCL_Patient_Clinician_Group_Input.pdf'],Mantle cell lymphoma (MCL),,Active,20-Feb-25,,PC0402-00
inavolisibOpens in new tab,Itovebi,inavolisib,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0382-Itovebi_Patient_Clinician_Group_Input.pdf'],Advanced or metastatic breast cancer,,Active,19-Feb-25,,PC0382-000
pertuzumabOpens in new tab,N/A,pertuzumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0379_Neoadjuvant_Proposed_Project_Scope.pdf'],HER2+ breast cancer,,Active,,,PX0379-000
cabozantinibOpens in new tab,N/A,cabozantinib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0378_Cabozantinib_Proposed_Project_Scope.pdf'],Neuroendocrine tumours,,Active,,,PX0378-000
trabectedinOpens in new tab,N/A,trabectedin,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0377_Trabectedin_Proposed_Project_Scope.pdf'],Soft tissue and uterine leiomyosarcoma,,Active,,,PX0377-000
tofersenOpens in new tab,Qalsody,tofersen,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0883-Qalsody_Patient_Clinician_Group_Input.pdf'],Amyotrophic  lateral sclerosis (ALS),,Active,27-Feb-25,,SR0883-000
MesotheliomaOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0077_Mesothelioma_proposed_scope.pdf'],Mesothelioma,,Active,,,PH0077-000
Endometrial cancerOpens in new tab,,,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0076_Endometrial_Cancer_proposed_scope.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0066_Endometrial_Cancer_proposed_scope.pdf']",Endometrial cancer,,Active,,,PH0076-000
leniolisibOpens in new tab,TBC,leniolisib,[],Activated phosphoinositide 3 kinase delta syndrome,,Suspended,19-Apr-24,,SR0792-000
imiquimodOpens in new tab,N/A,imiquimod,[],Gynecological cancers,,Withdrawn,06-Mar-24,,PX0364-000
CADTH Pharmaceutical Reviews U...Opens in new tab,,,[],,,,,,
Nab-paclitaxelOpens in new tab,N/A,Nab-paclitaxel,"['https://www.cadth.ca/sites/default/files/DRR/2024/PX0354-Nab-paclitaxel-FINAL_REC.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0354-Nab-Paclitaxel-DPI_Table.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0354-Nab-Paclitaxel-in-Combo-Gemcitabine_combined.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/PX0354-PX0354-Nab-Paclitaxel-in-Combo-Gemcitabine-Stakeholder-Feedback.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0354_consolidated_Feedback_DR.pdf']",Gastrointestinal cancer,Do not reimburse,Complete,21-Dec-23,,PX0354-000
bulevirtideOpens in new tab,Hepcludex,bulevirtide,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0881_Hepcludex_Patient_Clinician_Input.pdf'],chronic hepatitis delta virus (HDV) infection,,Active,09-Apr-25,,SR0881-000
odevixibatOpens in new tab,Bylvay,odevixibat,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0884-Bylvay_Patient_Clinician_Group_Input.pdf'],Alagille syndrome,,Active,28-Feb-25,,SR0884-000
mirvetuximab soravtansineOpens in new tab,TBC,mirvetuximab soravtansine,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0394-mirvetuximab-soravtansine_Patient_Clinician_Group_Input.pdf'],"Epithelial ovarian, fallopian tube, or primary peritoneal cancer",,Active,03-Mar-25,,PC0394-000
Gastric cancerOpens in new tab,,,[],Gastric cancer,,Merged,,,PH0080-000
abemaciclibOpens in new tab,Verzenio,abemaciclib,['https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0409_Verzenio_fulvestrant_Patient_Clinician_Group_Input.pdf'],"HR-positive, HER2-negative advanced or metastatic breast cancer",,Active,14-Feb-25,,PC0400-000
letermovirOpens in new tab,Prevymis,letermovir,[],"Cytomegalovirus infection (CMV), prophylaxis",,Withdrawn,30-Oct-23,,SR0824-000
AripiprazoleOpens in new tab,N/A,Aripiprazole,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SX0756_Aripiprazole_Proposed_Scope.pdf'],Depression,,Active,11-Mar-25,,SX0756-000
mirikizumabOpens in new tab,Omvoh,mirikizumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0880_Omvoh_Patient_Clinician_Input.pdf'],Crohn’s disease,,Active,04-Mar-25,,SR0880-000
risankizumabOpens in new tab,Skyrizi,risankizumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0890_Skyrizi_Patient_Clinician_Input.pdf'],Ulcerative colitis,,Active,31-Mar-25,,SR0890-000
pegunigalsidase alfaOpens in new tab,TBC,pegunigalsidase alfa,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0872-pegunigalsidase-alfa_Clinician_Patient_Group_Input.pdf'],Fabry disease,,Active,04-Apr-25,,SR0872-000
trofinetideOpens in new tab,Daybue,trofinetide,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0829_Daybue_DRAFT_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0829_Patient_Clinician_Group_Input.pdf']",Rett syndrome (RTT),,Active,29-Oct-24,,SR0829-000
ruxolitinibOpens in new tab,Opzelura,ruxolitinib,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0835_Opzelura_DRAFT_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0835_Opzelura_Patient_and_Clinician_Group_Input.pdf']",Nonsegmental vitiligo,,Active,17-Oct-24,,SR0835-000
asciminibOpens in new tab,Scemblix,asciminib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0405_and_PC0418_Scemblix_Patient_Clinician_Input.pdf'],Philadelphia chromosome-positive chronic myeloid leukemia,,Active,10-Mar-25,,PC0418-000
regorafenibOpens in new tab,N/A,regorafenib,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0374_Regorafenib_DRAFT_REC.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0374_Regorafenib_DPI.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0374-Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0374-Supplemental_Material.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0374-Regorafenib_Proposed_Project.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0374_consolidated_input.pdf']",Metastatic osteosarcoma,,Active,07-Oct-24,,PX0374-000
durvalumabOpens in new tab,Imfinzi,durvalumab,[],Muscle invasive bladder cancer,,Pending,,,PC0414-000
"belantamab mafodotin, bortezom...Opens in new tab",TBC,"belantamab mafodotin, bortezomib, dexamethasone",['https://cda-amc.ca/sites/default/files/DRR/2024/PC0379-Patient_Clinician_Group_Input.pdf'],Previously treated multiple myeloma,,Active,19-Dec-24,,PC0379-000
donanemabOpens in new tab,TBC,donanemab,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0857_Patient_and_Clinician_Group_Input.pdf'],Alzheimer's disease,,Suspended,28-Aug-24,,SR0857-000
crovalimabOpens in new tab,TBC,crovalimab,['https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0858_Consolidated_Patient_and_Clinician_Group_Input.pdf'],paroxysmal nocturnal  hemoglobinuria (PNH),,Active,01-Oct-24,,SR0858-000
Optimal Pharmacotherapy for Tr...Opens in new tab,,Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma,"['https://cadth.ca/sites/default/files/DRR/2024/TR0014%20Final%20Recommendation%20and%20Reasons.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/TR0014-Updated%20Reimbursement%20Recommendations.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/TR0014-MM-ESHPM-Combined-Report.pdf', 'https://www.cadth.ca/sites/default/files/DRR/2024/TR0014-Stakeholder-Feedback.pdf', 'https://www.cadth.ca/sites/default/files/ou-tr/Myeloma%20Canada_Combined%20document.pdf', 'https://www.cadth.ca/sites/default/files/ou-tr/TR0014-multiple-myeloma-protocol-final.pdf']",,,Complete,,,TR0014-000 - OP0547-000
tislelizumabOpens in new tab,(TBC),tislelizumab,[],recurrent or metastatic nasopharyngeal carcinoma,,Pending,,,PC0399-000
tofacitinibOpens in new tab,N/A,tofacitinib,['https://cda-amc.ca/sites/default/files/DRR/2025/SX0757-tofacitinib_Proposed_Scope.pdf'],"Juvenile idiopathic arthritis, idiopathic arthritis",,Pending,01-May-25,,SX0757-000
ibrutinibOpens in new tab,N/A,ibrutinib,['https://cda-amc.ca/sites/default/files/DRR/2025/PX0380-Ibrutinib_Proposed_Scope.pdf'],Hematology,,Received,,,PX0380-000
seladelparOpens in new tab,TBC,seladelpar,[],primary biliary cholangitis,,Pending,,,SR0899-000
dostarlimabOpens in new tab,Jemperli,dostarlimab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0381-Jemperli_DRAFT_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0381-Jemperli_Patient_Clinician_Group_Input.pdf']",Endometrial cancer,,Active,15-Aug-24,,PC0381-000
ribociclibOpens in new tab,Kisqali,ribociclib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0395_Kisqali_Patient_Clinician_Input.pdf'],"Adjuvant treatment of HR-positive, HER2-negative early breast cancer",,Active,19-Dec-24,,PC0395-000
lemborexantOpens in new tab,Dayvigo,lemborexant,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0895-Dayvigo_Patient_Clinician_Group_Input.pdf'],Insomnia,,Active,10-Apr-25,,SR0895-000
delgocitinibOpens in new tab,TBC,delgocitinib,['https://cda-amc.ca/sites/default/files/DRR/2024/SR0875_delgocitinib_Patient_Clinician_Input.pdf'],Chronic hand eczema,,Active,25-Nov-24,,SR0875-000
Multiple MyelomaOpens in new tab,,,"['https://cda-amc.ca/sites/default/files/DRR/2025/PH0068-Multiple_Myeloma.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PH0068%20Consolidated%20Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PH0068%20Consolidated%20Feedback.pdf']",Multiple Myeloma,,Complete,,,PH0068-000
acalabrutinibOpens in new tab,Calquence,acalabrutinib,[],Chronic lymphocytic leukemia (CLL).,,Pending,,,PC0412-000
Multiple MyelomaOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0086_Multiple_Myeloma_proposed%20scope.pdf'],Multiple Myeloma,,Active,,,PH0086-000
Esophageal or Gastroesophageal...Opens in new tab,,,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0061_DRAFT_Report_Gastric_Cancer.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0061_Esophageal_proposed_scope.pdf']",Esophageal or Gastroesophageal Junction Cancer,,Active,,,PH0061-000
Non Small Cell Lung CancerOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0085-NSCLC-EGFR-mutation_revised_scope.pdf'],Non Small Cell Lung Cancer,,Active,,,PH0085-000
Renal cell carcinomaOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0075_Renal_Cell_Carcinoma_proposed_scope.pdf'],Renal cell carcinoma,,Active,,,PH0075-000
Acute Myeloid LeukemiaOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0082_AML_proposed_scope.pdf'],Acute Myeloid Leukemia,,Active,,,PH0082-000
Prostate cancerOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0073_Prostate_Cancer_proposed_scope.pdf'],Prostate cancer,,Active,,,PH0073-000
Hodgkin lymphomaOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0079_Adult_Classical_Hodgkin_Lymphoma_Proposed_Scope.pdf'],Hodgkin lymphoma,,Active,,,PH0079-000
Mantle cell lymphomaOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0087_Proposed_Scope_Mantle_Cell_Lymphoma.pdf'],Mantle cell lymphoma,,Open for Input,,,PH0087-000
risperidoneOpens in new tab,TBC,risperidone,[],"Schizophrenia, adults",,Active,13-Oct-23,,SR0811-000
garadacimabOpens in new tab,TBC,garadacimab,['https://www.cadth.ca/sites/default/files/DRR/2024/SR0860_Patient_and_Clinician_Group_Input.pdf'],Hereditary angioedema  (HAE),,Active,31-Jul-24,,SR0860-000
omaveloxoloneOpens in new tab,Skyclarys,omaveloxolone,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0864-Skyclarys_DRAFT_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0864_Patient_and_Clinician_Input.pdf']",Friedreich’s ataxia,,Active,02-Oct-24,,SR0864-000
Diffuse large B cell lymphoma ...Opens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0078_Large_B_Cell_Lymphoma_Proposed_Scope.pdf'],Diffuse large B,,Active,,,PH0078-000
Multiple myelomaOpens in new tab,,,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0074_Multiple_Myeloma_proposed_scope.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0060_Multiple_Myeloma_Proposed_Scope.pdf']",Multiple myeloma,,Active,,,PH0074-000
dabrafenib trametinibOpens in new tab,TBC,dabrafenib trametinib,"['https://cda-amc.ca/sites/default/files/DRR/2025/PX0375_Dabrafenib_Trametinib_Draft_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0375_Dabrafeninb_trametinib_DPI_Table_draft.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Combined_Review.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Stakeholder_Input.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Supplemental_Material.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PX0375-Dabrafenib-trametini-%20pe-%20LGG_Proposed_Scope.pdf']",Pediatric low grade glioma (ped LGG),,Active,07-Oct-24,,PX0375-000
lazertinib and amivantamabOpens in new tab,Lazcluze and Rybrevant,lazertinib and amivantamab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0392_Lazcluze_Patient_Clinician_Group_Input.pdf'],Locally advanced or metastatic non-small cell lung cancer (NSCLC),,Active,18-Dec-24,,PC0392-000
polatuzumab vedotinOpens in new tab,Polivy,polatuzumab vedotin,['https://cda-amc.ca/sites/default/files/DRR/2024/PC0397-Polivy-Resub_Patient_Clinician_Group_Input.pdf'],Large B-cell lymphoma,,Active,27-Nov-24,,PC0397-000
vorasidenibOpens in new tab,Voranigo,vorasidenib,[],"Astrocytoma or oligodendroglioma, IDH1 or IDH2 mutation",,Active,30-Apr-25,,PC0407-000
fecal microbiotaOpens in new tab,Rebyota,fecal microbiota,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0850-RBX2660-fecal-microbiota_Patient_Clinician_Input.pdf'],"Clostridioides difficile infection, prevention",,Active,03-Jan-25,,SR0850-000
daridorexantOpens in new tab,Quviviq,daridorexant,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0862_Quviviq_Patient_Clinician_Input.pdf'],Insomnia,,Active,05-Dec-24,,SR0862-000
teplizumabOpens in new tab,Tzield,teplizumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0867_Tzield_Patient_Clinician_Input.pdf'],Delay onset of Stage 3 Type 1 Diabetes,,Active,19-Feb-25,,SR0867-000
DupilumabOpens in new tab,Dupixent,Dupilumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0870_Dupixent_Patient_Clinician_Input.pdf'],Chronic  obstructive pulmonary disease (COPD),,Active,11-Dec-24,,SR0870-000
quizartinibOpens in new tab,Vanflyta,quizartinib,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0359-Vanflyta_Patient_Clinician_Group_Input.pdf'],acute myeloid leukemia (AML),,Active,11-Dec-24,,PC0359-000
leuprolide mesylateOpens in new tab,Camcevi,leuprolide mesylate,['https://cda-amc.ca/sites/default/files/DRR/2024/PC0370-Camcevi_Patient_Clinician_Group_Input.pdf'],Prostate cancer,,Active,,,PC0370-000
belzutifanOpens in new tab,Welireg,belzutifan,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0386-Welireg_Patient_Clinician_Group_Input.pdf'],advanced renal cell carcinoma (RCC),,Active,25-Nov-24,,PC0386-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,['https://cda-amc.ca/sites/default/files/DRR/2024/PC0387-Keytruda_Patient_Clinician_Group_Input.pdf'],Advanced or metastatic malignant pleural mesothelioma,,Active,27-Nov-24,,PC0387-000
trastuzumab deruxtecanOpens in new tab,Enhertu,trastuzumab deruxtecan,[],HER2-low or HER2-ultralow breast cancer,,Received,15-May-25,,PC0401-000
cipaglucosidase alfa with migl...Opens in new tab,Pombiliti with Opfolda,cipaglucosidase alfa with miglustat,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0871_cipaglucosidase_alfa_Patient_Clinician_Input.pdf'],Pompe disease,,Active,29-Nov-24,,SR0871-000
dupilumabOpens in new tab,Dupixent,dupilumab,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0876-Dupixent_Patient_Clinician_Input.pdf'],Prurigo nodularis (PN),,Active,20-Dec-24,,SR0876-000
dupilumabOpens in new tab,Dupixent,dupilumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0878_Dupixent_NP_Patient_Clinician_Input.pdf'],Chronic rhinosinusitis with nasal polyps,,Active,18-Dec-24,,SR0878-000
rozanolixizumabOpens in new tab,Rystiggo,rozanolixizumab,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0846-Rystiggo_DRAFT_REC.pdf', 'https://cadth.ca/sites/default/files/DRR/2024/SR0846_Patient_Clinician_Group_Input.pdf']",Generalized myasthenia gravis (gMG),,Active,02-Aug-24,,SR0846-000
MelanomaOpens in new tab,,,['https://cda-amc.ca/sites/default/files/DRR/2025/PH0072-Melanoma_Panel_Scope.pdf'],Melanoma,,Active,,,PH0072-000
osimertinibOpens in new tab,Tagrisso,osimertinib,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0398_Tagrisso_Patient_Clinician_Input.pdf'],Unresectable (stage III) non-small cell lung cancer,,Active,13-Feb-25,,PC0398-000
roflumilastOpens in new tab,Zoryve,roflumilast,[],atopic dermatitis,,Received,16-May-25,,SR0887-000
Small Cell Lung CancerOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0092_SCLC_proposed_scope.pdf'],Small Cell Lung Cancer,,Open for Input,,,PH0092-000
Large B Cell LymphomaOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0088_DLBCL_proposed_scope.pdf'],Large B Cell Lymphoma,,Open for Input,,,PH0088-000
Ovarian CancerOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0089_Ovarian_Cancer_proposed_scope.pdf'],Ovarian Cancer,,Open for Input,,,PH0089-000
Chronic Myeloid LeukemiaOpens in new tab,,,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0091_Ph_CML_proposed_scope.pdf'],Chronic Myeloid Leukemia,,Open for Input,,,PH0091-000
upadacitinibOpens in new tab,Rinvoq,upadacitinib,[],Giant cell arteritis,,Received,16-May-25,,SR0877-000
"vanzacaftor, tezacaftor, deuti...Opens in new tab",Alyftrek,"vanzacaftor, tezacaftor, deutivacaftor",[],"Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older",,Received,09-May-25,,SR0896-000
efanesoctocog alfaOpens in new tab,Altuviiio,efanesoctocog alfa,"['https://cda-amc.ca/sites/default/files/DRR/2025/ST0840-Altuviiio_DRAFT_REC.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/ST0840_Patient_Clinician_Group_Input.pdf']",congenital factor VIII deficiency,,Active,18-Sep-24,,ST0840-000
elafibranorOpens in new tab,Iqirvo,elafibranor,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0865-Iqirvo_DRAFT_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0865_elafibranor_Clinician_Patient_Input.pdf']",Primary biliary cholangitis (PBC),,Active,27-Nov-24,,SR0865-000
nemolizumabOpens in new tab,TBC,nemolizumab,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0869-nemolizumabAD_Patient_Clinician_Group_Input.pdf'],atopic dermatitis,,Active,27-Feb-25,,SR0869-000
guselkumabOpens in new tab,Tremfya,guselkumab,['https://cda-amc.ca/sites/default/files/DRR/2025/SR0882_TremfyaCrohns_Patient_Clinician_Group_Input.pdf'],Crohn’s  disease,,Active,31-Jan-25,,SR0882-000
"relugolix, estradiol, and nore...Opens in new tab",Myfembree,"relugolix, estradiol, and norethindrone acetate",['https://cda-amc.ca/sites/default/files/DRR/2025/SR0885-Myfembree_Patient_Clinician_Group_Input.pdf'],Management of heavy menstrual bleeding associated with uterine fibroids,,Active,04-Feb-25,,SR0885-000
brentuximab vedotinOpens in new tab,N/A,brentuximab vedotin,['https://cda-amc.ca/sites/default/files/DRR/2025/PX0381-Brentuximab_Proposed_Scope.pdf'],Hodgkin lymphoma,,Received,06-May-25,,PX0381-000
"durvalumab, tremelimumabOpens in new tab","Imfinzi, Imjudo","durvalumab, tremelimumab","['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0390_Imfinzi_Draft_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0390_Imfinz_Imjudo_%20Patient_Clinician_Input.pdf']",Metastatic non-small cell lung cancer (NSCLC),,Active,17-Oct-24,,PC0390-000
glofitamabOpens in new tab,Columvi,glofitamab,['https://cda-amc.ca/sites/default/files/DRR/2025/PC0406-Columvi_Patient_Clinician_Group_Input.pdf'],Relapsed or refractory diffuse large B-cell lymphoma,,Active,07-Mar-25,,PC0406-000
Nivolumab and ipilimumabOpens in new tab,Opdivo and Yervoy,Nivolumab and ipilimumab,[],Unresectable or advanced hepatocellular carcinoma (HCC),,Received,22-May-25,,PC0420-000
semaglutideOpens in new tab,Wegovy,semaglutide,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0841-Wegovy%20Resubmission_DRAFT_Rec.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0841_Wegovy_Patient_Clinician_Group_Input.pdf']",Weight management,,Active,27-Nov-24,,SR0841-000
teprotumumabOpens in new tab,Tepezza,teprotumumab,"['https://cda-amc.ca/sites/default/files/DRR/2025/SR0853-Tepezza_DRAFT_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/SR0853-teprotumumab_Patient_Clinician_Input.pdf']","Thyroid Eye Disease (TED), active",,Active,25-Oct-24,,SR0853-000
nemolizumabOpens in new tab,TBC,nemolizumab,['https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0861_nemolizumab_Patient_Clinician_Input.pdf'],Prurigo nodularis (PN),,Active,07-Jan-25,,SR0861-000
pembrolizumabOpens in new tab,Keytruda,pembrolizumab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0383_Keytruda_Draft_Recommendation.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0383-Keytruda_Patient_Clinician_Group_Input.pdf']",Advanced or recurrent endometrial carcinoma,,Active,14-Nov-24,,PC0383-000
durvalumabOpens in new tab,Imfinzi,durvalumab,"['https://cda-amc.ca/sites/default/files/DRR/2025/PC0389_DRAFT_Rec.pdf', 'https://cda-amc.ca/sites/default/files/DRR/2024/PC0389_Imfinzi_Patient__Clinician_Input.pdf']",limited-stage small cell lung cancer (LS-SCLC),,Active,15-Nov-24,,PC0389-000
mepolizumabOpens in new tab,Nucala,mepolizumab,[],chronic obstructive pulmonary disease,,Pending,,,SR0888-000
isatuximabOpens in new tab,Sarclisa,isatuximab,"['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0378_Sarclisa_Draft_Recommendation.pdf', 'https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0378_Sarclisa_Patient_and_Clinician_Group_Input.pdf']",multiple myeloma not eligible for ASCT,,Active,30-Oct-24,,PC0378-000
darolutamideOpens in new tab,Nubeqa,darolutamide,['https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0404-Nubeqa_Patient_Clinician_Group_Input.pdf'],Metastatic castration-sensitive prostate cancer,,Active,28-Apr-25,,PC0404-000
